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Undiagnosed tuberculosis (TB) remains the most common cause of HIV-related mortality, 
including among people living with HIV (PLHIV) starting antiretroviral therapy (ART).  This 
thesis explores opportunities for reducing PLHIV mortality in sub-Saharan Africa. 
 
Firstly, a systematic review of eight Xpert MTB/RIF (Xpert) impact trials found that lack of 
Xpert impact on mortality was mainly due to higher empiric TB treatment rates in 
microscopy versus Xpert arms.   
 
Secondly, the Botswana XPRES trial evaluated the effect of an intervention package 
comprising (1) support for intensified TB case finding (ICF), (2) strengthened tracing to 
support retention, and (3) Xpert replacing sputum-smear microscopy on early (6-month) 
ART mortality.  Strengthened ICF and retention were associated with about 23% lower 6-
month mortality.  No mortality benefit of Xpert replacing microscopy was observed.   
 
Thirdly, to identify PLHIV at highest risk of early ART mortality, CD4-independent and -
dependent scores were derived from XPRES data and externally validated.  Sensitivity of 
CD4-independent score ≥4 in predicting mortality (86%) was twice that of WHO stage 
alone (48%).  Both CD4-independent score ≥4 and CD4-dependent score ≥5 had similar 
sensitivity but higher specificity than WHO-recommended advanced HIV disease criteria 
(i.e., CD4 <200/µL or WHO stage III/IV). 
 
Finally, a TB risk score for PLHIV was derived from XPRES data and validated on three 
external datasets, with the aim of increasing (1) detection of asymptomatic TB, and (2) 
sensitivity to exclude TB prior to TB preventive therapy.  In the external datasets, TB risk 
score ≥2 had higher sensitivity (87–97%) than the WHO four-symptom screening rule (80–





In conclusion, strengthening TB screening and retention in care could reduce early ART 
mortality in sub-Saharan Africa.  In addition, early mortality and TB risk scores could help 
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Chapter 1: Introduction 
 
Globally, about 37.9 million persons are living with HIV, and about 770,000 persons die 
from HIV-related illnesses annually.1  The HIV pandemic disproportionately affects sub-
Saharan Africa; despite holding only 11% of the global population, sub-Saharan Africa is 
home to about 25.6 million (68%) of people living with HIV (PLHIV) and accounts for about 
470,000 (61%) of all HIV-related deaths.1  Undiagnosed tuberculosis (TB) or TB diagnosed 
late in the course of disease remains the most common cause of HIV-related deaths in 
low- and middle- income countries (LMIC), including sub-Saharan Africa.2,3  In the most 
recent meta-analysis of autopsy-confirmed causes of death among hospitalized PLHIV in 
LMIC, about two-fifths (37%) of deaths were due to TB and in nearly half these deaths 
(one-fifth of all deaths), TB was undiagnosed ante mortem.3 
 
Scale-up of antiretroviral therapy (ART) is the most important public health intervention to 
reduce annual HIV-related mortality.4-6  Since 2004, when there were 1.7 million HIV-
related deaths, the annual number of HIV-related deaths has declined by about 55% as 
ART coverage increased from <1% to 62%.7  By 2020, targets of reaching 81% of PLHIV 
with ART were globally endorsed, but many countries will not reach this target.8  Two new 
targets have been proposed for 2030: first, to reach 90% of PLHIV with ART, and second, 
to reduce HIV-related deaths by 90% compared with 2010.9  With an estimated 23.3 
million PLHIV currently receiving ART in 2020, an additional 12-13 million PLHIV will need 
to be enrolled on ART over the next 10 years to reach the 2030 targets.  In addition, 
accelerated declines in HIV-related mortality will be needed to reach 90% HIV mortality 
reduction goals.10,11  Among all ART enrolees, the highest incidence of mortality for both 
adults and children is in the first six months of therapy.12  Therefore, identifying 
interventions to reduce this early mortality on ART remains an urgent public health 





In addition, HIV-associated TB deaths accounted for 251,000 (21%) of the annual 1.2 
million TB deaths in 2018, helping to make TB the leading infectious cause of death 
globally.14  Following the September 2018 United Nations (UN) General Assembly high-
level meeting on TB, world leaders recommitted to ambitious End TB goals, which include 
reducing annual TB deaths by 90% by 2030.14  These ambitious goals can only be achieved 
if significant progress improving TB screening, diagnosis and treatment among PLHIV is 
made.15,16   
 
Therefore, this thesis focuses on evaluating the impact of improved TB screening 
algorithm implementation among PLHIV during early ART, investigates opportunities to 
improve on existing WHO standard eligibility criteria for who needs early ART care 
intensification, and evaluates opportunities to improve TB screening approaches for both 
ART-naïve and -experienced PLHIV with the goal of contributing to HIV and TB pandemic 
control goals by 2030.16 
 
1.1. Early mortality after ART initiation 
 
1.1.1. Incidence and regional variations of early mortality after ART initiation 
In this thesis we define early ART mortality as all-cause mortality within 6 months of ART 
initiation.  However, the time period defining early mortality after ART initiation varies 
across published papers, ranging from 3,17 to 6,18 to 12 months.19  The most recent meta-
analysis of adult (≥15 years old) early mortality on ART in LMIC was published in 2016 and 
included 58 studies that were published between January 2003 and April 2016 focusing on 
mortality within 3 months of ART initiation.17  Key findings were that 3-month mortality 
rates (unadjusted for under-ascertainment of mortality during loss to follow-up (LTFU)) 
were 6% (95% confidence interval (CI), 5-7%) overall, but declined from 7% (95% CI, 6-8%) 
for ART enrolees before 2010 to 4% (95% CI, 3-5%) during or after 2010.17  Point estimates 
of mortality within 3 months of ART initiation varied slightly by region, with point 




America (6.0%), and Asia (5.3%), although 95% CI’s for these point estimates overlapped.  
Published meta-analyses and recent observational studies show that a substantial 
percentage of patients who become LTFU during early ART (20-60% according to recent 
studies)12,20 are found to have died, usually shortly after the missed appointment.  When 
authors made the assumption that 47% of those LTFU within 3 months of ART would have 
died by 3 months, overall 3-month mortality estimates nearly doubled from 6.0% to 
10.6%.17  If we assume that about 70% of 6-month ART mortality occurs within 3 months 
of ART initiation,21 include adjustment upwards for deaths during LTFU that were not 
ascertained, and account for declining early ART mortality over time, a reasonable 
estimate for 6-month mortality on ART for sub-Saharan Africa for the time period 2010–
2016 is about 10%, which is high compared with resource-rich countries where 6-month 
mortality rates under 5% have been reported for the last 10-20 years.22,23 
  
The observation that sub-Saharan Africa has higher early mortality on ART than resource-
rich settings and other LMIC was also noted in a 2010 systematic review and meta-analysis 
of 12-month ART mortality in LMIC, which synthesized data from 50 observational cohort 
studies published during 1996–2010 from program settings in sub-Saharan Africa, Asia, 
and the Americas.19  The meta-analysis adjusted crude mortality estimates upwards to 
account for expected mortality among patients LTFU during the first 12 months of 
therapy.12,20 The meta-analysis reported a global 12-month ART mortality estimate for 
LMIC of 14% (95% CI, 10-20%).19  The meta-analysis, similar to contemporary multi-cohort 
analyses,13,23 reported significant regional variations in 12-month ART mortality, with 12-
month mortality highest in sub-Saharan Africa (17%), followed by Asia (11%), and the 
Americas (7%).   
 
Multiple potential reasons for the higher early mortality on ART in sub-Saharan Africa 
compared with resource-rich settings have been proposed and explored.19,21  An analysis 
by Boulle et al showed that reasons for higher early mortality in sub-Saharan Africa are 




1).22  Boulle and other authors support the interpretation that a combination of factors 
likely account for higher early mortality on ART in sub-Saharan Africa versus resource-rich 
settngs.19,21  A combination of interacting problems including higher disease burden of 
opportunistic infections (OI) like TB in the general population exacerbated by a higher 
prevalence of late presentation for ART initiation among PLHIV, which is often driven by 
socio-economic factors,23,24 are considered to be some key factors driving higher early 
mortality on ART in sub-Saharan Africa compared with resource-rich settings.19,22  These 
findings are supported by autopsy studies, which show that HIV-associated infections, 
especially TB, but often multiple concurrent infections, account for the vast majority of 
early deaths during ART,2 whereas only 30% of classifiable deaths in Europe and North 
America are infection-related.22 
 
Figure 1.1. Comparison of cumulative incidence of mortality up to four years after ART 
start by region, corrected in South Africa for mortality under-ascertainment* 
 
*Taken from Boulle, A et al, PloS Med, 2014.22 Analysis included ART enrolees between 2001-2010. 
Note: Authors estimate good linkage with mortality registers in South Africa and the United States 
to determine LTFU outcomes, and less frequent linkage to mortality registers in European cohorts. 
 
1.1.2. Causes of early mortality after ART initiation 
The most recent meta-analysis of pathological autopsy studies among persons with HIV in 




reported on 3,237 autopsies conducted by 2013; TB was reported as the most common 
cause of death, accounting for 37% of deaths overall.3  Similarly, the only study focused on 
describing autopsy-confirmed causes of early mortality after ART initiation in sub-Saharan 
Africa, which was conducted in South Africa in 2012,25 reported that mycobacterial 
infections (usually Mycobacterium tuberculosis) were  implicated in 69% of early deaths 
during ART.  A more recent autopsy study published in 2016 among PLHIV with CD4 count 
<150 cells/µL who died within 6 months of enrolling in a cluster-randomised trial in South 
Africa reported that 47% of cadavers had evidence of TB (about half untreated 
antemortem), 68% had clinically important bacterial infections, and 12% cryptococcal 
disease, with 59% having two or more infections.2   
 
1.1.3. The persistent problem of early mortality after ART initiation in sub-Saharan 
Africa 
Observational cohort studies among ART enrolees have shown that early mortality 
incidence is largely determined by prevalence of markers for advanced HIV disease at ART 
initiation, such as low CD4 count (e.g. CD4 <50 cells/µL), advanced disease stage (e.g., 
WHO stage IV), low body mass index (BMI <18.5), and severe anaemia (haemoglobin <8 
g/dL).19,26,27  Consequently, as the prevalence of advanced HIV disease among ART 
enrolees has declined over successive annual cohorts in many LMIC due to expanding ART 
access and lower thresholds for ART initiation,28,29 early mortality after ART initiation has 
been reported to decline over time in several countries, including South Africa,30,31 
Botswana,32 Mozambique,21 and in the most recent meta-analysis referenced.17  
 
The trend of increasing median CD4 count at ART initiation and declining early mortality in 
LMIC raises the question whether AIDS-related causes of death, including TB, might be 
declining in importance as a cause of early mortality after ART initiation.33  A recent meta-
analysis to assess the proportion of on-ART mortality due to non-AIDS causes of death 
(e.g. cardiovascular disease, non-AIDS malignancies, and liver disease) synthesized data 




countries and LMIC.33  The meta-analysis reported that non-AIDS causes of death among 
people taking ART accounted for about 53%, 34%, and 19% of deaths in high-income 
countries, LMIC overall, and sub-Saharan Africa specifically.33  Authors hypothesized that 
as median CD4 count at ART initiation has increased among successive annual cohorts of 
patients in the last 20 years in high-income countries, non-AIDS causes of death have 
become proportionally more important.33  Notably, the meta-analysis relied mostly on 
data from verbal autopsies or medical record review, an important limitation.3  In 
addition, the meta-analysis examined causes of death at any time during ART and not only 
in the first 6-12 months of therapy.  However, the author’s hypothesis for high-income 
countries is supported by a multi-country analysis, including data from nearly 50,000 
patients in 212 clinics in Europe, Australia, and the United States, which reported that the 
percentage of deaths due to AIDS-related causes declined from 34% to 22% between 1999 
and 2011 as median CD4 count at ART initiation increased.34    
 
A separate meta-analysis of autopsy studies, which is not yet published as a peer-
reviewed manuscript, included 56 autopsy studies describing over 10,000 autopsies 
conducted between 1984 and 2015.  This meta-analysis evaluated both the trend in 
proportional mortality due to HIV-associated causes, and among those deaths classified as 
HIV/AIDS-associated, the percentage due to TB.35  This meta-analysis showed the 
percentage of deaths due to HIV-associated causes declined from 87% for studies 
conducted pre-2005, to 77% for studies conducted during 2005–2010, and to 70% for 
autopsy studies conducted  during 2011–2015.35  However, TB as a cause of HIV/AIDS-
associated death appeared to increase from 24% in 2005 to 36% in 2015.  Similarly, in the 
meta-analysis by Gupta et al, which evaluated prevalence of TB in pathologic autopsies 
among PLHIV who died in hospital, TB prevalence increased over a time of massive ART 
scale-up rather than decreased.3  These two meta-analyses suggest that while ART scale-
up appears to be reducing mortality due to HIV/AIDS-associated causes, ART scale-up 
appears to have had a lower relative impact on HIV-associated TB mortality.35  A limitation 




time and the non-standard autopsy methods used across the autopsy studies limit ability 
to confidently infer understanding of trends over time.35 
 
In addition, although most studies in sub-Saharan Africa have reported increases in 
median CD4 count at ART initiation over the last 15 years as WHO ART eligibility guidelines 
have shifted towards universal ART eligibility (i.e., test-and-treat), which has been 
recommended since 2015,28,36,37 most studies in sub-Saharan Africa continue to report 
that 15-30% of ART enrolees present late and initiate ART with advanced HIV disease (i.e., 
a CD4 count <200/µL or WHO stage III/IV).  For example, in a recent large multi-year 
review of CD4 count test results (N=864,389) across four high burden sub-Saharan 
countries, the percentage of ART enrolees starting ART with advanced HIV disease (CD4 
<200/µL) remained fairly consistent: 19.4% (95% CI: 18.8-20.1%) in 2012 compared to 
16.1% (95% CI: 16.0-16.3%) in 2016,38 with the proportion of patients diagnosed as having 
advanced HIV disease ranging from 14.5% in Uganda to 29.8% in Cameroon.37,38  This 
shows that even though WHO now recommends test-and-treat,4,39 barriers to early HIV 
testing, linkage to care, and early ART initiation remain in LMIC.40,41  In addition, recent 
studies report that persons presenting to ART clinics with advanced HIV disease are more 
likely to be ART-experienced who have cycled in and out of care with associated 
fluctuations in immune-competence.11  Consequently, improved early ART care and 
improved advanced HIV disease detection and management algorithms, that address risk 
of co-infections including TB, remain a public health priority if 2030 targets of reducing 
AIDS-related deaths are to be met.10,42 
 
1.2. Current WHO-recommended standards for early ART care 
 
Given the clear evidence that ART initiation at earlier disease stages is essential to 
optimize early ART outcomes,4,43 WHO strongly recommends rapid ART initiation for all 
PLHIV after a confirmed HIV diagnosis and clinical assessment, ideally offering ART on the 




delay.44  However, while significant progress has been made in scaling up access to testing 
and linkage to treatment, real-world challenges of achieving early HIV diagnosis,45,46 
linkage to treatment,47 and retention in early pre-ART and ART care,48 especially in certain 
population groups like men,49 youth,50 and those who are asymptomatic at the time of HIV 
diagnosis, remain.51  
 
For example, a 2020 meta-analysis of progress to 90-90-90 targets (i.e., 90% of PLHIV 
aware of their status, 90% of those aware on ART, and 90% of those on ART virally 
suppressed) in sub-Saharan Africa included 92 studies published between 2014 and 
2018.51  Authors did not estimate a pooled estimate of completion of each step in the 
cascade, but rather used an unweighted median achievement of each treatment cascade 
step across studies by age and gender.  PLHIV 15 to 24 years old had lower median 
completion of the treatment cascade (60-49-81), as compared to PLHIV ≥25 years (70-63-
91).  Men also had lower median achievement of the treatment cascade (66-72-85), 
compared to women (79-76-89).51  These differences by age and sex in 90-90-90 cascade 
completion have also been observed across all 13 completed population-based HIV impact 
assessments (PHIAs), which are large nationally representative cross-sectional surveys of 
90-90-90 cascades among PLHIV, in sub-Saharan Africa.52  These persistent challenges 
reaching certain population groups in certain geographies with early diagnosis and linkage 
to treatment, plus the relatively high rates of LTFU during ART in many sub-Saharan 
African settings, resulting in clients cycling in and out of care,11 mean that detecting and 
providing optimal care packages for PLHIV at highest risk of early mortality on ART 
remains a priority.11,44 
 
The WHO currently recommends intensification of care for persons >5 years old starting 
ART with advanced HIV disease as defined by CD4+ T-cell (CD4) count <200 cells/µL or 
WHO stage III/IV (Table 1).44  The intensification of care package, some components of 
which have been shown to reduce mortality in clinical trials,53 include tuberculosis (TB) 




preventive therapy (TPT) for those who screen negative or are diagnosed as not having 
active TB,54 cotrimoxazole prophylaxis,55,56 cryptococcal antigen (CrAg) screening for those 
with CD4 count ≤100/µL and pre-emptive therapy for CrAg-positive people with no 
evidence of meningitis,57 and enhanced adherence counselling57 (Table 1).44 
 
Table 1.1. WHO-recommended components of the package of care for people with 
advanced HIV disease for adults and adolescents* 
 Intervention CD4 cell count 
Diagnosis 
WHO four-symptom TB screening with sputum 
Xpert MTB/RIF as the first test for TB diagnosis 
among symptomatic PLHIV 
Any 
LF-LAM for TB diagnosis among people with signs 
and symptoms of TB 
<100/µL or at any 
count if seriously ill 





Co-trimoxazole prophylaxis  
 
≤350 cells/µL or 
clinical stage 3 or 4  
Any CD4 count in 
settings with high 
prevalence of 
malaria or severe 
bacterial infections.  
 
TB preventive therapy (TPT) Any 
Fluconazole pre-emptive therapy for cryptococcal 





Rapid ART initiation Any 






Tailored counselling to ensure optimal adherence 
to the advanced disease package, including home 
visits if feasible 
<200/µL or at any 
count if seriously ill 
Abbreviations: WHO, World Health Organisation; TB, tuberculosis; PLHIV, people living with HIV; LF-LAM, 
lateral flow urine lipoarabinomannan assay.  
*Taken from the 2017 WHO advanced HIV disease guidelines44 
 
 
1.3. Adherence to WHO-recommended TB screening 
 
In 2008, the WHO launched the three “I”s strategy, namely use of intensified case finding 




up in tandem with ART to reduce morbidity and mortality from TB.58  The ICF strategy 
includes regularly screening all PLHIV for symptoms of TB and implementing TB diagnostic 
and treatment algorithms for those who screen positive.  WHO has recommended a four-
symptom screening questionnaire for current cough, fever, weight loss, or night sweats, to 
be implemented at every clinical visit to identify who requires further TB diagnostic work 
up since 2011.59  The four-symptom screen was initially derived from a meta-analysis of 12 
studies, including approximately 10,000 PLHIV who were predominantly ART-naïve, which 
reported screening sensitivity in detecting culture positive TB of 79%.60  Notably, the goal 
of this initial meta-analysis was to derive a TB symptom screening rule that maximised 
sensitivity in detecting sputum culture-positive TB to facilitate ruling out active TB disease 
and allow subsequent TPT prescription.  A more recent meta-analysis also reported good 
sensitivity (89%) among ART-naïve PLHIV prior to ART initiation.61  
 
However, the TB diagnostic cascade that starts with TB symptom screening is not well 
implemented in LMIC, with loss of patients at all steps of the cascade from TB screening to 
treatment.62,63  Reasons for low compliance with TB screening and ICF algorithms are not 
well understood, but could relate to high patient load making healthcare workers more 
likely to omit key steps in care algorithms, inadequate training and knowledge of the 
guidelines, lack of trust in the accuracy of diagnostics, or deficiencies in monitoring and 
evaluation.16,63-65  Prior to this research, no trial had yet evaluated impact of improving 
adherence to WHO-recommended TB symptom screening and ICF cascade guidelines on 
patient-important outcomes.66 
 
1.4. Adherence to WHO-recommended retention interventions  
 
In sub-Saharan Africa, incidence of mortality among those ART enrolees LTFU is 20-fold 
higher than patients retained on ART, with most mortality occurring soon after the missed 
appointment.67  Several trials have also shown high rates of LTFU among PLHIV with 




itself.68,71-73  WHO recommends intensified counselling and adherence interventions for 
people with advanced HIV disease during early ART based on these data and evidence 
from randomized trials, including the REMSTART trial where weekly home visits were 
provided during the first month of ART.57  However, pre-emptive home visits are not 
widely implemented due to resource limitations.  WHO also recommends rapid tracing for 
patients who miss appointments, initially by phone or through home visit if not reachable 
by phone, which is a retention intervention more widely feasible in sub-Saharan 
Africa.44,74,75  However, prior to this research, no trial had yet included active tracing as 
part of an intervention package to reduce early mortality after ART initiation.76     
 
1.5. Role and impact of Xpert MTB/RIF 
 
In 2009, commercial release of the Xpert MTB/RIF® assay for the GeneXpert® platform 
(Xpert) (Cepheid, Sunnyvale, CA) represented an important advance over sputum smear 
microscopy in diagnosing HIV-associated TB and drug resistant TB, and therefore became 
an important component of the three “I”s strategy.77  With features including a TB 
diagnostic sensitivity among PLHIV of about 79%,78,79 significantly superior to smear 
microscopy (±45%),78 ability to detect rifampicin resistance-conferring mutations, capacity 
to provide results from sputum within 100 minutes, and minimal training requirements, 
Xpert significantly advanced TB diagnostic capability for clinicians managing PLHIV.80  
Consequently, Xpert rollout in high HIV prevalence settings was expected to avert a 
significant portion of TB-related mortality among PLHIV, including those starting ART.81,82  
In the next chapter (chapter 2), results of a systematic review of trials evaluating Xpert 
impact on patient-important outcomes are presented. 
 
1.6. Limitations of WHO advanced HIV disease eligibility criteria 
 
WHO defines advanced HIV disease as CD4 count ≤200/µL or WHO stage III/IV.44  The 




process in developing the 2017 WHO advanced HIV disease guidelines.83  Following the 
consensus process, the definition for advanced HIV disease became the WHO-
recommended eligibility criterion for accessing the advanced HIV disease package of 
care.44  However, no study has systematically attempted to quantify the screening 
accuracy of the WHO advanced disease eligibility criteria in predicting who is at risk of 
early mortality after ART initiation, in terms of sensitivity, specificity, negative predictive 
value (NPV), and positive predictive value (PPV).84  A contrasting approach has sometimes 
been used in resource-rich countries, where internally and externally validated regression-
derived mortality risk scores have been used to define levels of mortality risk, and 
therefore need for intensification of ART care among PLHIV.85,86  Only one previous study 
from Haiti, which was not externally validated, has used regression approaches to create a 
mortality risk score for ART enrolees in a country classified as LMIC.87  However, validated 
risk scores to determine who needs ART care intensification in sub-Saharan Africa, the 
region of the world with the highest early ART mortality rates and the highest number 
(470,000) and percentage (61%) of global annual HIV-related deaths, have not yet been 
developed.1   
 
Within LMIC, another limitation of the WHO advanced disease eligibility criteria is that the 
majority of health facilities providing ART lack access to rapid or point-of-care CD4 
testing.44  In these settings, up to half of adults with a CD4 count <100/µL could be 
categorized as WHO stage I/II, and would be missed by an advanced disease screening 
algorithm that relied on WHO stage alone.53  In addition, a screening tool for advanced 
disease that relies only on CD4 count and WHO disease stage misses the many other 
demographic and clinical predictors associated with early mortality on ART.84  Therefore, 
externally validated clinical screening tools to inform who needs intensification of early 







1.7. Limitations of WHO four-symptom TB screening rule 
 
Currently, the WHO recommends the four-symptom TB screening rule at each clinical visit 
for PLHIV in LMIC, regardless of expected prevalence of active TB or ART status (ART-naïve 
or ART-experienced).88  However, the screening accuracy of the WHO four-symptom 
screening rule varies by population, setting, and ART status, raising the question whether 
a “one-size-fits-all” screening rule is appropriate.89  For example, the most recent meta-
analysis observed that while sensitivity of the WHO four-symptom TB screening rule is 
about 89% among ART-naïve PLHIV, it was only 51% among people on ART due to a higher 
prevalence of asymptomatic TB among stable ART patients.61,90,91  At a time when global 
health donors have committed to reaching over 13 million PLHIV on ART with TPT by 
2021,92 low sensitivity of the WHO four-symptom screening rule for active TB among 
PLHIV on ART warrants consideration of more sensitive screening approaches in order to 
achieve a higher NPV.16   
 
Although new WHO guidelines recommend adding chest radiography to the screening rule 
for PLHIV on ART to increase sensitivity, this comes at the expense of specificity, carries 
significant additional costs and operational challenges, and might hinder rather than 
expedite TPT scale-up in some LMIC settings.61,93  Asymptomatic active TB (i.e., absence of 
self-reported cough, loss of weight, night sweats, and fever) has also been reported in 
other patient groups, including among severely immune compromised PLHIV,94,95 and 
among pre-ART patients without advanced disease in high prevalence settings,96 among 
whom missing asymptomatic active TB can have suboptimal health consequences for 
patients and possibly impede disease control activities.24  Finally, the WHO four-symptom 
screening rule does not allow TB risk differentiation into low-, moderate-, and high-risk 
groups which might inform differentiated models of care.  Therefore, improved TB 





1.8. Structure of the thesis 
 
This thesis is structured in research paper style format.  
 
Chapter 2 is the literature review and has three components.  The first component is a 
published systematic literature review of Xpert impact trials (Research paper 1).  The 
second component is a literature review of existing WHO guidelines for evaluating early 
ART mortality risk and a review of other published risk scores to inform PLHIV mortality 
risk.  The third component is a review of meta-analyses supporting the WHO four-
symptom TB screen and other published risk scores to inform understanding of TB risk 
among PLHIV.  All literature reviews summarize existing scientific evidence to clarify gaps 
in needed research and aim to frame the relevance of thesis research questions and aims 
presented in Chapter 3. 
 
Chapter 4 describes the methodology of how thesis research aims are addressed, 
summarizing the XPRES trial protocol, and outlining analytic methods used in the three 
published research papers in Chapters 5, 6, and 7. 
 
Chapter 5 is the research paper describing XPRES primary objective trial findings, which 
address the first thesis research question (Research paper 2).  Chapter 6 is a research 
paper describing development of a new early ART mortality risk score for use in sub-
Saharan Africa (Research paper 3).  Chapter 7 is a research paper describing development 
of a new TB screening score for use in sub-Saharan Africa (Research paper 4). 
 
Chapter 8 represents the discussion, recommendations and conclusion section of the 
thesis, where key results, contribution to the literature, implications of findings, 





1.9. Role of the candidate 
 
Since 2011, I have played the following roles in the XPRES trial:  (1) conceptualized the 
study; (2) served as a principle investigator (PI) for the study; (3) developed the stepped-
wedge trial design with a retrospective baseline component, (4) wrote the protocol (the 
published version of which is attached as Appendix 1, where I am the first author); (5) 
created all data collection instruments relevant to the thesis, incorporated co-investigator 
feedback, and then finalized the instruments; (6) corresponded with the CDC institutional 
review board (IRB), as well as other ethical oversight bodies; (7) registered the trial at 
ClinicalTrials.gov (NCT02538952); (8) visited Botswana multiple times in 2011 during study 
planning; (9) spent six consecutive months in Botswana during training and site initiation 
for the stepped-wedge trial from May through October 2012; (10) participated in multiple 
monitoring visits during 2013-2015; (11) coordinated weekly conference calls for the 
study, documenting minutes, and tracking action items to ensure study quality and 
protocol compliance; and (12) provided quarterly progress reports to funding oversight 
bodies (the Associate Director of Science Office) at CDC Atlanta. 
 
I led design of the XPRES trial intervention package.  I proposed the need for health 
system strengthening interventions that support implementation of WHO-recommended 
TB screening and retention in HIV-TB care to be part of the package of interventions 
implemented in the XPRES trial.  I proposed this intervention package based on prior 
clinical experience in busy public sector outpatient clinics in South Africa between 2003 
and 2007, as well as operational research conducted in sub-Saharan Africa between 2007 
and 2011.62,98,99 
 
I conducted all analyses included in this thesis.  I wrote the initial drafts of the four 
manuscripts, obtained feedback from co-authors, finalized, and have submitted the 
manuscripts for peer-review, with two manuscripts published, one provisionally accepted 






This research was undertaken while working for the U.S. Centers for Disease Control and 
Prevention (CDC).  XPRES has been supported by the President’s Emergency Plan for AIDS 
Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention.  Disclaimer: 
The findings and conclusions in this thesis do not necessarily represent the official position 










This thesis explores opportunities to reduce early mortality, and mortality in general, 
among PLHIV in sub-Saharan Africa through improved TB case finding and retention 
interventions.  The literature review section contains three parts. 
 
Firstly, a systematic review of trials evaluating Xpert impact on patient-important 
outcomes is presented to frame the contribution for the primary research paper in this 
thesis.  The primary research paper in this thesis evaluates whether a package of health 
system strengthening interventions supporting implementation of WHO-recommended TB 
screening and ICF cascades and retention in HIV-TB care, combined with Xpert roll-out can 
impact early ART mortality compared with standard of care in real-world ART programs in 
sub-Saharan Africa. 
 
Secondly, a literature review is presented that explores different approaches for 
determining who is at risk of early mortality on ART, comparing various published 
approaches with the current WHO-recommended approach. 
 
Thirdly, a literature review is presented that summarizes firstly the meta-analyses 
supporting the WHO four-symptom TB screening rule and secondly summarizes existing 
published clinical scores to help identify PLHIV at risk of prevalent active TB, to frame the 






















Table 2.1. (Research paper Table 1). Study designs of clinical trials with primary or 
secondary aims to estimate impact of Xpert on patient outcomes 
Table 2.2. (Research paper Table 2). Patient outcomes related to the tuberculosis 
diagnostic cascade from clinical trials of Xpert impact 
Table 2.3. (Research paper Table 3). Treatment outcomes assessed in clinical trials 
designed to estimate Xpert impact on patient outcomes 
Table 2.4. (Research paper Table 4). Limitations of clinical trials designed to estimate 
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Compared with smear microscopy, the Xpert MTB/RIF assay (Xpert), with superior accuracy and capacity to
diagnose rifampicin resistance, has advanced tuberculosis (TB) diagnostic capability. However, recent trials of
Xpert impact have not demonstrated reductions in patient morbidity and mortality. We conducted a narrative
review of Xpert impact trials to summarize which patient-relevant outcomes Xpert has improved and explore
reasons for no observed morbidity or mortality reductions. We searched PubMed, Google Scholar, Cochrane
Library and Embase and identified eight trials meeting inclusion criteria: three individually randomized, three
cluster-randomized, and two pre-post trials. In six trials Xpert increased diagnostic yield of bacteriologically-
confirmed TB from sputa and in four trials Xpert shortened time to TB treatment. However, all-cause mortality
was similar between arms in all six trials reporting this outcome, and the only trial to assess Xpert impact on
morbidity reported no impact. Trial characteristics that might explain lack of observed impact on morbidity
and mortality include: higher rates of empiric TB treatment in microscopy compared with Xpert arms, enroll-
ment of study populations not comprised exclusively of populations most likely to benefit from Xpert, and
health system weaknesses. So far as equipoise exists, future trials that address past limitations are needed to
inform Xpert use in resource-limited settings.
Keywords: Clinical trials, Health system weaknesses, Impact, Limitations, Study design, Xpert MTB/RIF
Introduction
In 2009, the commercial release of the Xpert MTB/RIF assay for
the GeneXpert platform (Xpert) represented an important break-
through in the fight against TB. With features including sensitiv-
ity to diagnose culture-positive TB from sputum samples among
persons living with HIV (PLHIV) of about 79%,1 significantly
superior to smear microscopy (45%),2 ability to detect rifampicin
resistance-conferring mutations, capacity to provide results
from sputum within 100 minutes, robustness under varying
temperature and humidity conditions, and minimal training
requirements, Xpert has advanced TB diagnostic capability for
clinicians managing presumptive TB patients in resource-limited
settings, especially those with suspected HIV-associated TB and
persons with suspected drug-resistant TB.3
With ample evidence that undiagnosed TB or TB diagnosed
late in the course of disease is an important cause of death
among persons with HIV,4,5 there was optimism that rapid
scale-up of Xpert in settings with high HIV prevalence, as recom-
mended by WHO,6 would significantly impact key patient out-
comes like morbidity and all-cause mortality.7 For example,
modelling studies predicted that, compared with the status quo
(smear-microscopy), Xpert would avert >100 000 deaths in five
sub-Saharan African countries over 10 years.7 In line with WHO
recommendations and published expert opinion,6,8 several trials
set out to evaluate Xpert impact on patient outcomes, including
morbidity and mortality.9–16 Despite optimism, however, pub-
lished trials of Xpert impact have not yet observed morbidity
and mortality reductions. We conducted a narrative review of
published Xpert impact trials to answer two questions: what
impact has Xpert had on patient-relevant outcomes, and why
have Xpert impact trials not demonstrated morbidity and mor-
tality reductions?
© Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene 2016. This work is written by (a) US
Government employee(s) and is in the public domain in the US.
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We conducted a narrative literature review according to pub-
lished guidelines.17 We searched PubMed, Google Scholar, the
Cochrane Library and Embase from 1 January 2005 to 31
December 2015 for reports published in English with the terms
‘Xpert MTB/RIF assay’ or ‘GeneXpert’ or ‘Xpert’ and ‘impact’ or
‘trial’ or ‘clinical trial’.
Study selection
Studies that met the following criteria were included: 1. the
study was a clinical trial, as defined by the International
Committee of Medical Journals (ICMJ) (i.e., ‘any research study
that prospectively assigned human participants or groups of
humans to one or more health-related interventions to evaluate
the effects on health outcomes’)18; 2. the study included Xpert
in one of the intervention arms or phases; and 3. a stated pri-
mary or secondary aim of the study was to assess Xpert impact
on at least one patient-related outcome.
Studies were excluded if there was no direct comparison
between patients receiving standard of care (sputum micros-
copy) and patients receiving an intervention including Xpert;
therefore, so-called ‘hypothetical trials’, where patients received
both microcopy and Xpert and investigators hypothesized the
impact of Xpert in a scenario where only microscopy was avail-
able, were excluded. In addition, studies in which outcomes of
patients receiving Xpert were compared with historical national
average outcomes when microscopy was standard of care, were
excluded.8 Pre-post trials at the same health facilities, which
compared patient outcomes between pre-Xpert microscopy
phases and post-Xpert rollout phases, were included in the
review, as these trials meet the ICMJ definition of a clinical
trial.18,19
The titles and abstracts of studies identified in the search
were retrieved and assessed by one reviewer who excluded
those that were clearly not relevant. The full texts of remaining
studies were assessed for inclusion by four reviewers, using the
inclusion and exclusion criteria described above.
Data extraction
Data were extracted directly into a spreadsheet that included
the following variables: first and second authors, publication
year, abbreviated study name, setting, design, randomization
level, sample size, study population inclusion criteria, standard
of care, intervention and role of Xpert MTB/RIF in the interven-
tion, key questions related to Xpert MTB/RIF impact on patient
outcomes, and key results including diagnostic yield, time to TB
diagnosis, time to TB treatment, TB treatment initiation rates,
empiric TB treatment initiation rates, loss to follow-up (LTFU)
before TB treatment, TB treatment outcomes, overall treatment
outcomes among all patients enrolled, and predictors of mortal-
ity. In addition, trial limitations as they relate to trial design,
conduct, or health system weaknesses were either abstracted
or postulated based on published data.
Results
Characteristics of studies included
Eight clinical trials, reported in 11 publications, were included
(Table 1). Of the eight trials, six were from sub-Saharan Africa,
one from Brazil, and one from Indonesia. All eight trials were
considered pragmatic (i.e., conducted in routine healthcare set-
tings, with the potential for existing programmatic weaknesses
to impact trial outcomes). Six of the eight trials included a ran-
domization component, while two were pre-post trials.13,16 Of
the six randomized trials, all had two arms or phases, three
were individually randomized,9,14,15 and three were cluster-
randomized.10–12 Of the three cluster-randomized trials (CRT),
one was a parallel group trial,10 one a stepped-wedge trial,11
and one a time-randomized trial at a single clinic,12 where
patients were randomized to receive microscopy or Xpert
depending on which week they attended the clinic. For the three
individually randomized trials, sample sizes were 242, 424, and
1502 patients. For the three CRTs, the number of clusters were:
51 in the time-randomized trial with 1985 patients enrolled, 14
in the stepped-wedge CRT with 24 227 patients enrolled, and 20
in the parallel group CRT with 4656 patients enrolled.
Study populations varied across the eight trials; six enrolled
persons being evaluated for TB,9–13,15 referred to as presump-
tive TB patients in this review, one enrolled HIV-positive patients
starting antiretroviral therapy (ART) regardless of TB symp-
toms,14 and one enrolled presumptive TB patients considered
to be at risk for multi-drug resistant (MDR) TB.16 Six of eight
trials were focused on assessing Xpert impact among adults
(≥18 years at enrollment),9,10,12–15 while two included both
adults and children.11,16 In the control arms, sputum smear
microscopy was used in six trials,9–12,14,16 tracheal aspirate
smear microscopy in one trial,15 and sputum fluorescent smear
microscopy in one trial.13
Xpert impact on TB diagnostic cascade
All eight trials reported diagnostic yield of bacteriologically-
confirmed TB (i.e., the percentage of study enrollees providing
sputum samples who tested positive for TB via either micros-
copy or Xpert). In six of eight trials, Xpert achieved higher diag-
nostic yield than microscopy (Table 2); in these six trials,
compared with microscopy, Xpert increased TB diagnostic yield
by a factor of about 1.6,9 1.2,10 1.5,11 1.5,12 3.0,15 and 1.2,16
respectively.
In the four trials that reported time from sample collection
to result availability among drug-sensitive TB positive cases,
Xpert reduced this time in three trials9,13,15 (Table 2). In these
three trials,9,13,15 Xpert and microscopy tests were performed
on-site (i.e., at the point-of-care), whereas in the trial that
showed no difference in time to result availability, both Xpert
and microscopy tests were performed off-site at a separate
laboratory.14
Six of eight trials reported median time from enrollment or
sputum collection to standard TB treatment initiation among all
patients who started TB treatment, regardless of reason for
starting TB treatment; in four of six trials there was either strong
evidence the median time to treatment was shorter9,11,12 or
A. F. Auld et al.
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Empiric TB treatment rates
(% of enrollees treated for
TB by study end without
bacteriologic confirmation)
Micro % Xpert % p Micro Xpert p Micro Xpert p Micro % Xpert % P Micro % Xpert % p
TB-NEAT9 Presumptive TB patients
(outpatients)
56 15 24 <0.0001 0 (0–6) 0 (0–0) 0.005 1 (0–4) 0 (0–3) 0.0004 42 43 NS 26 17 0.0001
XTEND10,20,29 Presumptive TB patients
(outpatients)





NA 9.7 14.2 <0.001 NA NA NA 11.4 8.1 0.040 17.5d 20.8d NAd 10.4e 9.8e NAe























NA 65.2k 80.2k <0.001k 75.0l 1.0l 0.001l 88.0m 16.0m <0.001m 39.3n 58.5 n <0.001n NA NA NA
ART: antiretroviral therapy; CRT: cluster randomized trial; ICU: intensive care unit; MDR: multidrug resistant; Micro: microscopy; NA: not available; NS: not significant; RCT: randomized controlled trial; RR: rifampicin resistant.
aFollowing study enrollment, sputum samples were obtained from all study enrollees, except in the Zimbabwe RCT where sputa were obtained only from symptomatic ART enrollees. Diagnostic yield represents yield of
bacteriologically-confirmed TB from these sputum samples collected soon after study enrollment.
bIn XTEND, authors reported median time from enrollment to TB treatment only for those who were bacteriologically confirmed as having TB (10 days in microscopy arm vs 7 days in Xpert arm). No p-value was pro-
vided but the text suggests the difference was not statistically significant.
cCalculated from published data: 102 (4.4%) of 2332 presumptive TB patients in the microscopy arm and 54 (2.3%) of 2324 presumptive TB patients in the Xpert arm started empiric TB treatment. No statistical test
was published. However, among TB patients, the percentage with microbiological confirmation was higher in the Xpert than microscopy arms (78.4% vs. 65.0%, p = 0.07).
dCalculated from published data: 2050 (17.5%) of 11 705 presumptive TB patients in the microscopy phase and 2610 (20.8%) of 12 522 presumptive TB patients in the Xpert phase started TB treatment. No published
statistical test.
eCalculated from published data: 906 (7.7%) of 11 705 presumptive TB patients in the microscopy phase and 1 009 (8.1%) of 12 522 presumptive TB patients in the Xpert phase started empiric TB treatment without
microbiology results. 313 (2.7%) of 11 705 presumptive TB patients in the microscopy phase and 216 (1.7%) of 12 522 presumptive TB patients in the Xpert phase started empiric TB treatment with negative microbio-
logical results. No published statistical test.
fAlthough follow-up was for 6 months (182 days) after ART initiation, data presented in this table represent diagnostic yield, time-to-diagnosis, time-to-TB-treatment, TB treatment initiation rates and empiric TB treat-
ment rates in the time from study enrollment to ART initiation.
gCalculated from published data: among all ART enrollees, the percentage given empiric TB treatment was similar between the microscopy arm (31 (15%) of 210) and Xpert arm (23 (11%) of 214). No published statis-
tical test. However, among TB treatment patients, the % treated on empiric grounds was high in both Xpert (54%) and microscopy (69%) arms, p = 0.12.
hIn the microscopy arm, limited use of culture contributed to diagnostic yield estimates as some smear-negative patients had positive culture.
iAlthough follow-up was 182 days, TB incidence risk reported in this analysis was over 3 months (90 days).
jCalculated from published data: 9 (7.8%) 115 ICU presumptive TB patients in the microscopy arm and 4 (3.6%) of 111 ICU presumptive TB patients in the Xpert arm were prescribed empiric TB treatment. No statistical
test published. However, among patients started on TB treatment, empiric TB treatment was higher in the microscopy than Xpert arms (56% vs. 17%, p = 0.015).
kAmong patients at risk for MDR-TB, diagnostic yield of TB increased from 65.2% pre-intervention to 80.2% in the Xpert phase (p < 0.001).
lTime from registration to release of RR TB result declined from 75.0 days to 1.0 days after Xpert implementation, p < 0.001.
mTime from registration to initiation of treatment for RR-TB decreased from a median of 88.0 days to 16.0 days, p < 0.001).




 at Stephen B. Thacker CDC Library on September 19, 2016 http://trstmh.oxfordjournals.org/ Downloaded from 
49
weak evidence it was shorter13 in the Xpert than microscopy
arms (Table 2). In these four trials, Xpert reduced median time
to TB treatment by about 1 day,9 3.3 days,11 4 days12 and 1
day,13 respectively.
In the one trial comparing time to diagnosis of rifampicin
resistant TB and time to second-line TB treatment between
Xpert and culture arms, Xpert reduced time to diagnosis from
75 days to 1 day, and time to second-line TB treatment from 88
days to 16 days (Table 2).16 Xpert was located on-site in the
post-Xpert phase, whereas in the pre-Xpert phase, all culture
and drug susceptibility testing occurred at an off-site laboratory.
In the seven trials reporting percentages of enrollees initiating
drug-sensitive TB treatment by study end,9–15 TB treatment initi-
ation rates were only significantly higher in the Xpert arm in one
trial.12 Across the seven trials, among presumptive TB patients, TB
treatment initiation rates ranged from 12.5 to 81% in the micros-
copy arms and from 10.8 to 85% in the Xpert arms (Table 2).
In the one trial reporting the percentage of enrollees initiat-
ing second-line TB treatment among presumptive MDR TB
patients, the percentage starting second line increased from
39.3% in the microscopy and culture phase to 58.5% in the
Xpert phase (Table 2).16
Among seven trials reporting the percentage of enrollees
receiving empiric TB treatment (i.e., TB treatment based on clin-
ical picture or chest x-ray) by study end, five reported higher
percentages of enrollees receiving empiric TB treatment in the
microscopy than the Xpert arms; in these five trials, Xpert
reduced the percentage of enrollees receiving empiric TB treat-
ment by about 35%,9 48%,10 47%,12 53%,13 and 54%,15
respectively (Table 2).
Xpert impact on patient outcomes
In the two trials reporting the percentage of bacteriologically-
confirmed TB patients LTFU before TB treatment start,9,10 one
trial reported lower LTFU in the Xpert arm (15 vs 8%, p=0.03)9
(Table 3). In the one trial reporting the percentage of rifampicin
resistant TB patients LTFU before second-line TB treatment, the
percentage LTFU before second-line treatment initiation
declined from 52.4 to 31.0% after Xpert rollout (p<0.001).16
Only one trial compared TB treatment morbidity outcomes,
as measured by TB scores and Karnofsky Performance Scores
after TB treatment initiation9; in this trial morbidity scores were
similar between arms (Table 3).
Of eight trials, five reported incidence of unfavorable outcomes
following TB treatment initiation (i.e., LTFU, death, TB-attributable
death, or some combination of these outcomes).9,12,13,20,21
Across the five trials the percentage with unfavorable TB treat-
ment outcomes was similar between microscopy and Xpert
arms (Table 3). In the one trial that compared incidence of
TB-attributable death following TB treatment initiation between
microscopy and Xpert arms, TB-attributable deaths were
reported to be significantly lower in the Xpert than microscopy
phase (2.3 vs 3.8%),21 but there was considerable LTFU (15.9%
in Xpert phase and 16.2% in microscopy phase), limiting ability
to interpret this finding (Table 3).
In all six trials that compared all-cause mortality between
microscopy and Xpert arms,9,10,12–15 no difference in all-cause
mortality was observed at any time point after enrollment
(Table 3). Two trials compared risk of LTFU between Xpert and
microscopy arms13,14 and in one trial LTFU incidence was higher
in the microscopy (10%) than Xpert (2%) arms (p<0.001),13 but
sensitivity analysis suggested this did not affect the conclusion
of no mortality difference between arms (Table 3).
Predictors of outcomes
Five trials reported multivariable models describing predictors of
mortality among trial enrollees. In the four trials that enrolled
presumptive TB patients, being HIV-positive vs HIV-negative
(two trials), being HIV-positive and not on ART vs HIV-negative
(one trial), being HIV-positive with ART status unknown vs being
HIV-positive and not on ART (one trial), and not knowing HIV
status vs being HIV-negative (two trials), were factors predictive
of mortality. In the fourth trial reporting a multivariable model,
which enrolled only HIV-positive patients starting ART, CD4
count <100 cells/µL vs ≥100 cells/µL was predictive of mortality.
Discussion
Across the eight trials reviewed, Xpert generally had a beneficial
impact early in the TB diagnosis and treatment cascade: six of
eight trials reported improvements in yield of bacteriologically-
confirmed drug-sensitive TB among patients who provided spu-
ta, three of four trials reported reduced time to drug-sensitive
TB-diagnosis, four of six trials reported reduced time to drug-
sensitive TB treatment, and five of seven trials reported reduced
rates of empiric drug-sensitive TB treatment in the Xpert com-
pared with the microscopy phase or arm. In addition, in the one
trial examining impact of Xpert on drug-resistant TB treatment
outcomes compared to culture, Xpert achieved remarkable
reductions in time from sputum collection to rifampicin resistant
TB detection, reductions in time to second-line TB treatment,
and reductions in apparent LTFU before second-line TB treat-
ment. However, Xpert had less impact in later stages of the TB
diagnosis and treatment cascade; rates of TB treatment initi-
ation were similar between microscopy and Xpert arms in six of
seven trials, TB treatment outcomes were similar between arms
in all five trials reporting this outcome, and mortality was similar
between arms in all six trials reporting this outcome. There are
several possible reasons related to trial design, trial conduct,
and prevalent health system weaknesses that might help
explain why improvements in outcomes early in the diagnostic
cascade did not translate into observed improvement in final
patient outcomes (Table 4).
Trial design
Higher rates of empiric TB treatment in the microscopy arms
Despite improvements in diagnostic yield of bacteriologically-
confirmed TB in Xpert arms in most trials, higher incidence of
empiric TB treatment in the microscopy arms meant that likeli-
hood of TB treatment by study end was similar between micros-
copy and Xpert arms in most trials, with empiric TB treatment of
culture-positive smear-negative TB patients in the microscopy
arms largely removing any potential for observed Xpert impact
Transactions of the Royal Society of Tropical Medicine and Hygiene
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Table 3. Treatment outcomes assessed in clinical trials designed to estimate Xpert impact on patient outcomes
Study LTFU before TB treatment
among microbiologically-
confirmed TB patients
TB treatment outcomes LTFU and mortality among all study enrollees Mortality predictors
Micro % Xpert % p Outcome Micro % Xpert % p Outcome Micro % Xpert % p
TB-NEAT9 15 8 0.03 LTFU 32 29 NS 3m Mortality 8 8 NS Multivariable analysis:
– HIV-positive vs HIV-negative
– Lower baseline TB score.
2m TB scorea 2 2 NS
2m KPSa 80 90 NS
XTEND10,20,29 14.9b 17b NS Compositec 12.5 11.7 NS 6m Mortality 5.0 3.9 NS Multivariable analysis:
– Known HIV-positive and not on
ART vs HIV-negative
– Not knowing HIV status vs HIV-
negative
– BMI <18.5 vs 18.5–24.9
– Age <30 vs ≥50 years
– Higher number of TB symptoms
Brazil stepped
wedge11,21




– HIV positive vs HIV-negative
– HIV unknown vs, HIV-negative
– Rio vs Manaus
LTFU 16.2 15.9 NSf
TB-mortality 3.8 2.3 SSg
Zimbabwe RCT14 NA NA NA NA NA NA NA 6m Mortality 10 6 NS Multivariable analysis:
– Male sex
– Low CD4 count (<100) vs >100
– TB diagnosed at enrollment before
ART start.
6m LTFU 18 15 NS
6m TB incidence 4 3 NS
6m Death or TB 12 9 NS
South Africa single clinic
CRT12
NA NA NA Compositeh 12.5 12.7 NS 6m Mortality 3.8 3.4 NS NA
Uganda pre-post Trial13 NA NA NA 2m Mortality 17 14 NS 2m Mortality 17 17 NS NA
2m LTFU 10 2 <0.001
South Africa ICU RCT15 NA NA NA NA NA NA NA 1m Mortality 34 27 NS Mortality predictors among all ICU
enrollees (n=341), not just those
randomized:
– Age 24–39 vs <24 years
– HIV-positive and ART unknown vs
HIV-positive not on ART.
– Inotrope use
– APACHE-II score >25 vs <20.
3m Mortality 42 32 NS
Indonesia Pre-post
trial16
52.4i 31.0i <0.001i NA NA NA NA NA NA NA NA NA
ART: antiretroviral treatment; BMI: body mass index; ICU: intensive care unit; KPS: Karnofsky Performance Score; LTFU: loss to follow-up; m: month; NA: not available; NS: not significant; RR: rifampicin
resistant; SS: statistically significant on the basis of an odds ratio with 95 CI excluding 1 (p-value not provided).
aBoth median TB score (2 vs 2, p = 0.85), and median KPS (80 vs 90, p = 0.23) in culture-positive patients, who had started TB treatment, did not differ at 2 months post randomization, or at 6 months.
bIn XTEND, the percentages reported here represent those not starting TB treatment by 28 days after bacteriological TB confirmation.
cComposite poor outcome was death, LTFU, and treatment failure.
dComposite poor outcome was incidence of LTFU, TB-attributable death, other deaths, change of diagnosis, transfer out, or resistance.
ep-value was not provided. Instead, the 95% CI was provided and included 1: 29.6 vs 31.7, OR = 0.93; 95 CI = 0.79–1.08.
fp-value was not provided. In the text, the paper states ‘loss to follow-up was not changed by the intervention (16.2 vs 15.9)’.
gNo p-value was provided. The text states that ‘Adjusted for HIV status, age group and city, the intervention resulted in a 35 decrease in TB-attributed deaths (OR = 0.65, 95CI = 0.44-0.97)’.
hComposite poor outcome was LTFU, death, or TB treatment failure.
iThe percentage of RR TB patients with missing information on RR treatment initiation declined from 52.4 in the baseline phase to 31.0 in the Xpert phase, p < 0.001. No differences in the percentage of
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Table 4. Limitations of clinical trials designed to estimate Xpert impact on patient outcomes





























































TB-NEAT9 L (40% HIV-
negative)
L NL L L NL La Lb <1i 26 L L
XTEND10,29 L (50–55% HIV-
negative)





L NL L NL L N/A Ld >50 NA NA L
Zimbabwe RCT14 NL (100% HIV-
positive)















NL NL L L L N/A NLg 15 31 NA NA
Pre-post trial,
Indonesia16
NL (100% DR TB
suspects)
L L L NL L N/A Lh NA NA L NA
CRT: cluster-randomized trials; DR: drug resistant; HTC: HIV testing and counselling; ICU: intensive care unit; L: stated study limitation applies to this study; LTFU: loss to follow-up; NA: not available; N/A: not
applicable; NL: study limitation does not apply (see corresponding sub-headings in the Discussion section, i.e., Trial design, Trial conduct, and Health system weaknesses for full discussion of limitations noted
in this table); RCT: randomized controlled trial; SOC: standard of care.
aSee Discussion section under Trial design sub-heading for explanation.
b20% LTFU of culture-confirmed TB cases.
cAlthough LTFU before TB treatment was 16% among microbiologically confirmed TB patients, investigators ascertained vital status of nearly all study enrollees by study end.
dHigh incidence of LTFU (about 16% in both SOC and intervention phase).
e16.5% (70/424) of ART enrollees LTFU before 6 months.
f6.7% of study enrollees (32/477) LTFU before study end.
gLess than 4% were LTFU at 90 days.
hMissing data on 2nd line treatment initiation was very high both pre-Xpert (52.4%) and post-Xpert (31.0%). Based on available data, missing data on TB treatment initiation seems equivalent to LTFU before
second-line TB treatment initiation. Overall missing data (probable LTFU) before second-line TB treatment was 42% (267/634) among rifampicin resistant cases.
iStudy enrollees were offered HIV testing and counseling at study enrollment.
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(Table 4).22,23 For example, in the TB-NEAT study,9 of the 68% of
patients with smear-negative tuberculosis in the microscopy
arm, that were later correctly detected by Xpert, 93% were trea-
ted empirically anyway (Table 4). In these trials, an important
driver of empiric TB treatment in the microscopy compared with
the Xpert arms may have been that clinicians administering the
study were not blinded to the diagnostic used and were aware
of the study hypothesis. Therefore, in all study settings, clinicians
would have known firstly that there was a relatively high pre-
test probability of true TB among all patients enrolled, and sec-
ondly that the predictive value of a negative test was lower in
the microscopy arm than the Xpert arm, resulting in higher
empiric TB treatment in the microscopy arm.22
Study populations not exclusively focused on priority populations
Of the eight trials, six enrolled presumptive TB patients, one
HIV-positive adults starting ART and one patients with presump-
tive drug-resistant TB. In the six trials enrolling presumptive TB
patients, HIV prevalence ranged from 8% to 76% (Table 4). The
main advantage of Xpert over smear-microscopy in diagnosing
drug-sensitive TB is ability to diagnose culture-positive smear-
negative TB, which is more common among PLHIV, especially
PLHIV who are significantly immune-compromised,24,25 since
waning immunity is associated with reduced pulmonary immu-
nopathology25 with liberation of lower concentrations of bacilli
into the airways. Therefore, with smear microscopy sensitivity
higher among HIV-negative persons (±69%) than among PLHIV
(±45%),2 one would expect Xpert impact on TB diagnostic yield
and therefore morbidity and mortality to be higher among
exclusively HIV-positive study populations than study popula-
tions including HIV-negative persons.23
The only study to assess Xpert impact among exclusively
HIV-positive persons was by Mupfumi et al. in Zimbabwe. In this
study, other limitations (e.g., very high rates of empiric TB treat-
ment in both arms and small sample size [n=424]), might
explain lack of observed impact. The high rates of empiric TB
treatment observed in the Zimbabwe trial raise the issue that,
although Xpert should increase diagnostic yield of bacteriologic-
ally confirmed TB to a greater extent in HIV-positive than HIV-
negative populations, rates of empiric TB treatment are also
likely to be higher in HIV-positive than HIV-negative popula-
tions.23 Consequently, restriction of Xpert impact trials to exclu-
sively HIV-positive outpatient populations might not, by default,
increase probability of observing Xpert impact on mortality.23
Only one pre-post trial from Indonesia enrolled patients con-
sidered at high risk of MDR TB.16 This trial showed remarkable
impact of Xpert in reducing median time to rifampicin resistant
TB diagnosis (from 75 to 1 day) and in median time to second-
line TB treatment (from 88 to 16 days). In addition, there was a
reduction in LTFU of rifampicin resistant TB patients before
second-line TB treatment initiation. Although there are limited
data on Xpert impact among patients at risk for MDR TB,26 the
reduction in time to diagnosis and appropriate treatment of
rifampicin resistant and MDR TB has potential to reduce trans-
mission and mortality from MDR TB and prevent emergence of
extensively drug-resistant TB.7,26,27 However, patterns of empiric
initiation of second-line TB treatment among patients at risk of
MDR TB also need to be considered when evaluating Xpert
impact.23 It is perhaps surprising that only two of the eight trials
examined Xpert impact among exclusive priority populations for
Xpert rollout (i.e., HIV-positive patients at high risk for TB and
presumptive MDR TB patients).6
Most trials evaluated Xpert impact among outpatients
A recent meta-analysis of autopsy studies in resource-limited set-
tings showed that the majority of deaths among HIV-infected
inpatients that were due to TB (37%), involved disseminated TB
(>85%).4 Although the autopsy meta-analysis among hospitalized
patients is not representative of all deaths among PLHIV, this find-
ing suggests that disseminated TB is a common precursor to
death among patients who die from TB.4 Therefore, restricting trial
enrollees to healthier outpatients, who are unlikely to have disse-
minated TB, in six of eight trials (Table 4), through study exclusion
criteria,9 enrollment at outpatient primary healthcare clinics
(PHCs),10–12 or because study enrollment required sputum produc-
tion,9–14 might have excluded many patients likely to benefit from
early accurate TB diagnosis with Xpert. In these outpatient study
populations, the improvements in time to diagnosis and time to
TB treatment through earlier confirmation of bacteriologically-
confirmed TB with Xpert, might not have resulted in significant
improvements in patient morbidity or mortality outcomes.23
In the two trials that did enroll presumptive TB patients
admitted to hospital (i.e., very ill patients),13,15 other study lim-
itations restrict ability to detect Xpert impact on patient out-
comes. For example, in the Uganda pre-post trial,13 sample size
was small (n=477), empiric TB treatment was higher in the
microscopy phase, a higher proportion of enrollees in the Xpert
phase had ≥1 danger sign, Xpert sensitivity was surprisingly low
among smear-negative TB patients (42%), and patients who
died within three days of admission were excluded from ana-
lysis. In the South African study enrolling intensive care unit pre-
sumptive TB patients,15 only 30% of enrollees were HIV-positive,
and there were higher rates of empiric TB treatment in the
microscopy than Xpert arms.
It should also be noted that, compared with healthier outpa-
tients, sicker patients admitted to hospital with TB symptoms
have higher rates of empiric TB treatment.23,28 Therefore,
among sicker, hospitalized patients, empiric TB treatment might
again replace any benefit associated with Xpert’s improved diag-
nostic sensitivity.23 If future trials were to evaluate Xpert impact
on mortality among hospitalized HIV-positive patients, recent
data suggest that rapid Xpert testing for disseminated TB, espe-
cially Xpert testing of urine, in the intervention arm would be
important in addition to Xpert testing of sputum, which has
become standard of care in many settings.4,28,29
Either not powered to detect a morbidity or mortality outcome
or under-powered to detect these outcomes
Of the eight trials reviewed, only three had primary study aims
of assessing Xpert impact on morbidity or mortality outcomes
(Table 4).9,10,14 TB-NEAT aimed to assess Xpert impact on 2- and
6-month morbidity scores among culture-positive patients who
started TB treatment.9 As described above, the higher incidence
of empiric TB treatment in the microcopy arm probably explains
lack of observed impact of Xpert on morbidity.23 However,
A. F. Auld et al.
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another possible explanation is that, among relatively healthy
outpatients with presumptive TB, a very large sample size would
be needed to detect differences in morbidity scores at 2 and 6
months of TB treatment, raising the possibility, in retrospect,
that the study may have been under-powered.
The XTEND trial aimed to detect a 50% reduction in 6-month
mortality in the Xpert compared with the microscopy arms, based
on preliminary data from a pilot study at two PHCs showing a
potential 74% reduction in mortality.10 However, a recent meta-
analysis of autopsy-confirmed causes of death among PLHIV
suggests that among hospitalized PLHIV, about two-fifths (37%)
of deaths were due to TB, and in nearly half of TB deaths (one-
fifth of all deaths), TB was undiagnosed antemortem. Although
the study population in the autopsy meta-analysis is different to
the XTEND study population, the autopsy meta-analysis suggests
that a more accurate and rapid TB diagnostic like Xpert, through
early, accurate TB diagnosis and subsequent treatment antemor-
tem, might avert about one-fifth (20%) of deaths among persons
with advanced HIV. Among mixed HIV-positive and negative
populations Xpert impact might be lower. More recent trials of TB
diagnostics have assumed 20% reductions in mortality for power
calculations.30 Therefore, XTEND may have over-estimated Xpert
impact mortality in the study population.
In power calculations for the randomized trial from
Zimbabwe,14 investigators assumed a 67% reduction in mortal-
ity and a 58% reduction in TB incidence giving an overall 61%
reduction in mortality or TB in the first six months of ART. Again,
the autopsy meta-analysis suggests the study may have over-
estimated Xpert impact on all-cause mortality in power
calculations.4
Trial conduct
All trials were conducted in a programmatic setting where LTFU
of enrollees is a problem; however, in five of eight trials
LTFU restricted ability to fully interpret key outcomes (Table 4).
LTFU among study enrollees can result in non-differential or dif-
ferential outcome ascertainment error between arms. Non-
differential error in outcome ascertainment between arms can
result in reduced power to detect true differences in morbidity
and mortality, while differential outcome misclassification
between arms can bias study outcomes. It is possible, as was
done for the XTEND trial, to monitor and report LTFU in both
arms, and then through subsequent tracing activities ascertain
final vital status. Such tracing activities help to reduce impact of
LTFU on ability to interpret study outcomes.31
Health system weaknesses
In all the trials reviewed, certain health system weaknesses
probably blunted ability to detect Xpert impact on patient out-
comes (Table 4). Common health system weaknesses included
high prevalence of unknown HIV status at enrollment in four of
five trials reporting this variable (≥15%),10–12,15 and low ART
coverage among known HIV-positive persons in all three trials
reporting this variable (26–31%).9,10,15 Notably, sub-optimal HIV
management (i.e., unknown HIV status, HIV-positive and not on
ART, or HIV-positive with unknown ART status) was predictive of
poor final outcomes in four trials.9,10,15,21 Recent data show
that all PLHIV regardless of CD4 count or disease stage should
start ART to reduce mortality risk.32 Therefore, in an HIV-positive
person not on ART, earlier TB diagnosis and TB treatment
through Xpert rather than microscopy may carry lower health
benefit.23
Another health system-related weakness was high LTFU
before TB treatment in three trials9,10,16 and high LTFU following
TB treatment initiation in four trials.9,12,13,21 LTFU of patients
before they can fully benefit from TB treatment indicated by an
accurate TB diagnosis diminishes Xpert impact. In XTEND, sec-
ondary analysis of trial data showed low compliance with clin-
ical care algorithms following a negative Xpert or microcopy test
(i.e., low adherence to a care plan including chest x-ray, sputum
culture, or hospital referral within 2 weeks of a negative test).33
Improving compliance with the algorithm following a negative
Xpert test might increase impact of the whole Xpert algorithm
on mortality.33 Operational research to identify health system
strengthening interventions that should be implemented in con-
junction with Xpert rollout to maximize Xpert impact could
inform best practices for Xpert scale-up.10
Conclusions
In conclusion, despite improvements in diagnostic yield among
patients who can produce sputa, reductions in time to diagno-
sis, and reductions in time to TB treatment in Xpert compared
with microscopy arms in most trials, Xpert was not shown to
impact the all-important patient outcomes of interest (patient
morbidity or mortality). Trial characteristics related to trial
design, trial conduct, and health system weaknesses might
explain lack of observed impact. The higher rates of empiric TB
treatment in microcopy compared with Xpert arms was a key
feature in most trials that contributed to lack of observed Xpert
impact on mortality. This suggests empiric TB treatment
remains an important strategy for clinicians, especially where
Xpert is not available. So far as equipoise exists, future trials of
Xpert impact, that take into account past trial limitations, would
be helpful to inform Xpert use in resource-limited settings.
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2.3. Literature review of screening approaches to inform intensification of early ART 
care 
 
2.3.1. Introduction: WHO criteria vs. risk score approaches 
 
Although resource-rich countries in North America and Europe have used regression-
derived and externally validated risk scores to help define mortality risk and therefore 
need for ART intensification among PLHIV,86,100 WHO has not yet recommended or used 
this approach to inform eligibility for early ART care intensification packages for LMIC.83  
During the 2016 WHO guideline development process for early ART care intensification 
packages for LMIC, the focus was first on defining “advanced HIV disease” through a 
literature review and Delphi process,101 and secondly on using this advanced HIV disease 
definition as the eligibility criterion for accessing an advanced disease package of care.83   
 
To define advanced HIV disease, the WHO guideline development committee used a two-
stage process.  Firstly, a systematic review was conducted to summarize published 
definitions of advanced HIV disease.  This review revealed a wide range of definitions of 
advanced HIV disease, with CD4 cell count cut-offs ranging from <50 cells/µL to <350 
cells/µL, and a wide range of disease staging classifications (e.g., WHO stage definitions vs. 
CDC stage definitions) and staging cut-offs used.83  Notably, 11 of the 12 studies included 
in the systematic review were from resource-rich countries.83  After the systematic review, 
three rounds of questionnaires were sent to 73 expert respondents in 28 countries.  
Notably, the response rate and percentage of the respondents who agreed with the final 
WHO-recommended definition of advanced HIV disease is not presented in the 
publication, although this percentage should ideally be reported when reporting Delphi 
consensus studies.83,101 
 
Using the advanced HIV disease definition as an eligibility criterion for accessing the 




stage and CD4 count are not the only determinants of early ART mortality, (2) the 
screening accuracy characteristics (e.g., sensitivity and specificity) of the WHO advanced 
disease eligibility criteria in terms of predicting early ART mortality have not been 
systematically assessed, although both advanced WHO stage and low CD4 count are 
known to be strong predictors of early mortality, and (3) rapid CD4 count testing is not 
available in most LMIC clinic settings, with some clinics choosing to prioritise spending of 
limited resources on other tests (e.g., HIV viral load testing during ART follow-up) rather 
than CD4 testing before ART initiation.102  A regression-based risk score development 
approach to developing practical clinical scores could address all three limitations.100,103-105 
 
This section contains a literature review of published regression-based risk scores for 
PLHIV mortality, assesses the strengths and weaknesses of the published studies, and 
discusses the need for externally validated mortality risk scores for PLHIV accessing ART in 
sub-Saharan Africa and in LMIC in general. 
 
2.3.2. Methods: literature search strategy 
 
Search strategy 
MEDLINE®, EMBASE, and the Cochrane library were searched over the time period 
January 1, 2005, to May 31, 2020 for reports published in English with the terms “HIV” or 
“AIDS” or “acquired immune deficiency syndrome”, and “antiretroviral therapy” or 
“treatment”, and “mortality” or “death”, and “risk score” or “clinical score”, and “predict”.  
This literature search was not conducted as a formal systematic review according to 
published Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 
guidelines, which for example, recommend a protocol and multiple reviewers examining 








Studies that met the following criteria were included: (1) the study population 
represented adult or adolescent PLHIV >12 years old, and (2) all-cause mortality was the 
primary outcome of interest or part of a composite primary outcome, and (3) the risk 
score was developed using a statistical approach (e.g., regression-based or machine-
learning approach) rather than other more subjective approaches (e.g., based on author 




Characteristics of studies included 
From a total of 316 published studies that met search criteria, a total of four regression-
based risk score development studies were identified for inclusion based on the study 
inclusion criteria (Table 2.5.).85-87,100  Two studies describe the Veterans Aging Cohort 
Study (VACS) score development.  The VACS score was initially published in 2013100 and 
updated in 2019 (VACS 2.0).85  Both VACS and VACS 2.0 were derived in the U.S.-based 
VACS cohort.  VACS was validated in six and VACS 2.0 in nine appended cohorts from the 
ART Cohort Collaboration (ART-CC) representing PLHIV in care in North America and 
Europe (Table 2.5.).  One study reports the development of the EuroSIDA score, which was 
developed in the EuroSIDA collaboration of 94 health centres in 31 resource-rich 
countries, and validated in the Swiss HIV Cohort Study.86  The only PLHIV mortality risk 
score developed for adults or adolescents in a LMIC, was developed in Haiti from 
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• Veterans Affairs Aging Cohort (VACS) 
represents HIV-positive U.S. Veterans. 
• To be eligible for cohort inclusion, required 
at least one year of ART completed plus 
complete covariates. 
• Among 13,582 men initiating ART in VACS 
between 2000 and 2007, 7823 had a CD4 
cell count at ART initiation as well as HIV-1 
viral load >500 copies/ml in the 3 months 
prior to ART initiation. Among these 7,823, 
6,324 (81%) had complete biomarker 
measurements for regression inclusion. At 1 
year, complete measurements were 
available for 4,932 (85%) of 5794 VACS 
patients who were alive and not lost to 
follow-up.  
• Among patients included:  
o 100% of VACS patients were men.  
o 46% were older than 50. 
o 69% had a CD4 >200.  
o 32% were Hep C co-infected.  
o 45% self-identified as black. 
• Six combined cohorts of ART-CC 
were appended.  
• Eligible cohorts needed to have 
laboratory values of interest and 
report at least 25 deaths in patients 
who met the following criteria: HIV-
positive, ART-naïve, >=18 years old, 
enrolled 2000-2007.  
• Of 5127 ART-CC patients meeting 
inclusion criteria 3,747 (73%) had 
complete measurements at ART 
initiation, varying from 61 to 92% by 
cohort. At 1 year, complete 
measurements were available for 
3,146 (92%) of 3,434 patients alive 
and not lost to follow-up.  
• Among patients included: 
o 72% were men.  
o 15% were older than 50. 
o 84% had a CD4>200.  
o 12% were Hep C co-infected.  


















• Veterans Affairs Aging Cohort (VACS) 
represents aging HIV-positive U.S. Veterans.  
• To be eligible for cohort inclusion: patients 
were ≥18 years old, initiated ART between 
1996 and 2014, and had a visit between 
2000 and 2014.  Excluded 2782 individuals 
who had negative HCV RNA (at any time 
during study period) after previously having 
detectable HCV RNA. ≥1 year of ART 
completed. Any post 1-year visit with 
complete data eligible as starting point of 
follow-up. 75% of visits had complete 
covariate data.   
• Among patients included: 
o 98% were male. 
o Median age was 53.  
o Median CD4 was 435. 
o Median time on ART at randomly 
selected visit was 4.2 years.  
• Nine combined cohorts of ART-CC 
were appended (named: A-I for 
anonymity).  
• To be eligible for cohort inclusion: 
the cohort needed to have 
laboratory values of interest and 
report at least 40 deaths in patients. 
From eligible cohorts, the proportion 
of visit dates with complete 
information varied between 5 and 
82%. Unclear if any patients 
excluded from eligible cohorts. 
 
• Among patients included: 
o 74% were male.    
o Median age was 43. 
o Median CD4 was 500. 











• EuroSIDA is a cohort of >14,000 patients 
with HIV-1 infection in 94 centres from 31 
countries in Europe, Israel and Argentina.  
• Of 14 274 patients within EuroSIDA: 9049 
started ART; 5402 had a CD4 cell count and 
viral load measured 6 months prior to 
starting ART; 5302 had the potential to 
calculate the CD4 cell slope prior to starting 
ART; and 4169 had haemoglobin and BMI 
measured during follow-up.  
• Among patients included: 
o 75% Male.  
o Median age 38. 
o 36% ART-naive.  
o Median CD4 230. 
o 14% non-white.  
• The Swiss HIV Cohort study is a 
prospective population-based cohort 
in Switzerland. 
 
• Eligible to participate if: HIV-positive, 
aged >16 years.  No other data on 
study inclusion data provided.  
Current demographic data provided 
here: http://www.shcs.ch/ 
 
• Among participants included: 
o 70% male.  
o Median age 37. 
o 61% ART-naïve.  
o Median CD4 209. 










Haiti - 6 
clinics 




• Derivation cohort: adults ages 15 to 70 
years starting ART at 6 non-randomly 
selected health facilities in Haiti between 
2007 and 2013. ART initiation 
was based on WHO guidelines at the 
time.† 
• Patients with documented pregnancy at 
time of ART initiation were excluded.  
Multiple imputation was used to account 
for missing covariate and outcome data. 
• Among patients included: 
o 63% female.    
o Median age 36.  
o Median CD4 was 248. 
• Validation cohort: All adults age 15 
to 70 years starting ART in 2012 at 
one non-randomly selected facility. 
ART initiation was based on WHO 
guidelines.†   
 
• Patients with documented 
pregnancy at time of ART initiation 
were excluded. Multiple imputation 
was used to account for missing 
covariate and outcome data. 
• Among patients included: 
o 60% Female.  
o Median age 37  
o Median CD4 was 259 
7,031 1,835 
Abbreviations: VACS, Veterans Aging Cohort Study; HCV, Hepatitis C; ART, antiretroviral therapy; Hep B, Hepatitis B, BMI, Body Mass Index 
*the AIDS Therapy Evaluation Project Netherlands (ATHENA); Cologne-Bonn Cohort, Germany; Royal Free Hospital Cohort, London United Kingdom; Swiss HIV Cohort 
Study; Vanderbilt-Meharry Center for AIDS Research Cohort; and the University of Washington HIV Cohort, Seattle, USA] 
**94 health centres across 31 resource rich countries  










The study populations included in the VACS, VACS 2.0, and EuroSIDA risk score 
development and validation approaches were different to the population included in the 
Haiti score.  The majority of VACS, ART-CC, and EuroSIDA study enrolees were male (70-
100%) and many were Caucasian (26%-86%), whereas in Haiti only 37-40% were male and 
<3% were Caucasian.  Notably both the VACS and VACS 2.0 scores were derived from 
PLHIV who had completed 1 year of ART.  EuroSIDA included observation time before ART.  
Only the Haiti score was derived using covariates present at ART initiation.  Median CD4 
count for participants included in the VACS score derivation was 307/µL, VACS 2.0 
derivation was 435/µL, EuroSIDA derivation was 230/µL, and Haiti score derivation was 
259/µL.  In North American and European cohorts, Hepatitis C co-infection was an 
important comorbidity with prevalence ranging from 18-32%.  Hepatitis C co-infection 
rates are not reported in the Haiti analysis. 
 
Covariate data completeness 
In VACS development only 4,932 (36%) of 13,582 potentially eligible cohort enrolees were 
included in the final regression due to either LTFU or death during the first year of ART or 
missing covariate data.  In development of VACS 2.0, the starting point for ART 
observation for each ART patient was a randomly selected visit with complete covariate 
data with about 75% of visits having complete data.  Overall, 28,390 individuals were 
included in VACS 2.0 development.  In EuroSIDA risk score development, only 4,169 (29%) 
of 14,262 potentially eligible patients were included in the derivation dataset regression 
model due to missing covariate data.  In the Haiti risk score development, 35 
bootstrapped imputations were used to achieve complete covariate data based on the 
rule of thumb of one imputation for every percentage point of missing values for the 
variable with the most missing values.  This implies >35% of observations would have 






Outcome and outcome completeness 
In VACS and VACS 2.0, mortality ascertainment is reported as excellent based on a well-
functioning national mortality register.  The outcome of the EuroSIDA risk score was AIDS 
or death but the mechanism of death ascertainment was not described in the EuroSIDA 
publication.  In Haiti, in the derivation cohort, 21.6% had missing vital status at 1 year; the 
death outcome was reported to the clinic passively by friends or family.  In the validation 
clinic, 45.3% of patients at 1 year had missing vital status.  The authors reported that 
missing vital status was imputed in both derivation and validation datasets because vital 
status was not missing completely at random.   
 
Covariates included in the final scores 
The initial VACS analysis developed a restricted and final VACS score (Table 2.6).  The 
restricted score included only age, CD4 count, and viral load.  The full VACS score included 
11 variables to create 7 score components: age, CD4, HIV viral load, haemoglobin 
concentration, FIB-4 (a four-variable composite score of hepatic function requiring age, 
AST, ALT, and platelet concentration), the estimated Glomerular Filtration Rate (eGFR) (a 
four-variable score requiring creatinine, ethnicity, age, and gender), hepatitis C co-
infection for maximum potential scores of 115 or 164 for the restricted and full VACS 
scores, respectively.  The VACS 2.0 included four additional variables for a total of 15 
variables and 10 score components by adding albumin concentration, white blood cell 
count (WBC), and body mass index (BMI) (height/weight2) to the score.  In addition, VACS 
2.0 maintained all the originally continuous variables in a continuous linear form or 
transformed form appropriate for the non-linear relationship with the outcome.  The 
EuroSIDA score included 10 variables for nine score components: age, prior CDC-defined 
AIDS diagnosis, CD4 count, CD4 slope, anaemia category, BMI, prior ART use, whether 
currently taking ART, and Injection Drug Use (IDU) history for a total possible score of 
6.43. The Haiti score included five variables and score components: sex, WHO stage, CD4 






Table 2.6. Comparison of published risk scores for mortality among PLHIV 





















visit >1 year ART 
Time updated variables 
Variables at ART 
initiation 
Sex             Female 0 
             Male 1 
Age (years) <50 0 0 Continuous (age 
30-75 years = 
32-59 points 
  0.027/year      
  50-64 23 12         
  >65 44 27         
Prior Diagnoses of AIDS    No 0 WHO st.1-3 0 
       Yes** 0.19 WHO st.4 2 
 CD4 
(cells/µL) 
>500 0 0 
Continuous (10-
900 cells/µL = 
55-32 points) 
>=350 0 
>250 0 350-499 10 6 
200-349 10 6 201-350 0.62 
100-199 19 10 
51-200 1.46 
101-250 1 
50-99 40 28 51-100 2 
<50 46 29 <=50 2.44 <=50 3 
CD4 slope at time point of interest   
 <-25 0.49     
       
 -25 to +25 0     
       
 >25 0.18     
 HIV-1 RNA 
(copes/ml) 




        
500-
100,000 
11 7         
>100,000 25 14         
Haemoglobin 
(g/dL) 
>14   0 
Continuous (9-
16 g/dL = 58-42 
points) 
No anaemia 0     
12-13.9   10 Mild 0.68     
10-11.9   22 Severe 1.02     
<10   38         
FIB-4* 
<1.45   0 
Continuous (0.5-
7.5 = 41-61 
points) 




6         
>3.25   25         
eGFR 
(ml/min)* 
>60   0 Continuous (0-
100 = 53-44 
points; 120-180 
= 46-60 points) 
        
45-59.9   6         
30-44.9   8         
<30   26         
Hepatitis C co-infection 
(current) 
  
5 51 if yes         
Active TB 
disease 
           No 0 
      Yes 2 
Albumin     
  
Continuous (2-
5g/dL = 65-39 




    
  
Continuous (2.5-
11 = 43-55 
points)         
BMI     
  
Continuous (15-
35 = 62-41 
points) 
<18 0.8     
18.1-25 0     
>25 minus 0.29     
Weight  
          <50 3 
          50-60 1 






    
  
 
Yes 0     
         No minus 0.39     
Taking ART        Any 0     
         None 1.24     
Route of presumed HIV Acquisition   
Any except 
IDU 0     
         IDU 0.25     
Theoretical maximum 
score 
115 164    6.43   9 
Abbreviations: eGFR, estimated glomerular filtration rate; VACS, Veterans Aging Cohort Study; BMI, body 
mass index; ART, antiretroviral therapy; TB, tuberculosis; AIDS, Acquired Immune Deficiency Syndrome. 
*FIB-4: (years of age * AST)/(platelets in 109/l * square root of ALT); eGFR: 186.3 *(serum creatinine ^-
1.154) * (age^-0.203) * (0.742 for women) * (1.21 if black). 
**CDC criteria from 1993 MMWR (Center for Disease Control. 1993 revised classification system) 
†The restricted score was a shorter version of the full VACS score generated to assess improved feasibility of 
a less complex score 
 
 
AUROC curve values for final risk score 
The area under the receiver operating characteristic (AUROC) curve values for the 
restricted VACS, full VACS score, VACS 2.0, and Haiti scores in the validation datasets were 
0.78, 0.82, 0.83, and 0.69, indicating acceptable (0.7-0.79), good (0.8-0.89), or poor (<0.7) 
discrimination respectively (Table 2.7).  The EuroSIDA analysis did not provide AUROC 
values.  Specific cut-offs for early ART care intensification, and associated sensitivity, 
specificity, NPV, and PPV were not suggested. 
 
Table 2.7. Discrimination of risk score in derivation and validation datasets 
  
Tate et al, 2013 
Tate et al, 
2019 
Mocroft et al 
McNairy et 
al  
   Restricted VACS VACS 2.0 EuroSIDA Haiti 
Number of primary outcomes           
Derivation  656 656 7,293 658* 242† 
Validation  86 86 722 897** 50† 
AUROC       
Derivation   0.72 0.78 0.805 Not provided 0.73 
Validation   0.78 0.82 0.831 Not provided 0.69 
Abbreviations: AUROC, Area under the receiver operating characteristic 
*388 of the events were new AIDS defining illnesses (59.0%) and 270 patients (41.0%) died 
**Patients progressed to a new AIDS-defining illness or death (17.4%), of which 494 were new AIDS-defining 
events (55.1%) 







2.3.4. Discussion  
 
Based on this literature review, no externally validated risk scores for early ART mortality 
in LMIC have been published.  The only internally validated score developed was from 
Haiti.  No regression-based risk scores have been developed for sub-Saharan Africa, the 
region of the world with the highest early ART mortality and largest annual number of 
HIV-related deaths.84  
 
Lack of mortality risk scores for LMIC, including sub-Saharan Africa 
The seven-clinic study from Haiti is the only LMIC regression-based study published to 
date reporting early ART mortality score development and internal validation among 
PLHIV.87  However, the Haiti study has several limitations including: (1) the score has not 
been validated widely within Haiti (1 clinic) or outside Haiti, (2) the score was developed 
using a routine electronic medical record (EMR) system with significant missing covariate 
data (>35%), and (3) the primary outcome of early mortality on ART was not well-
ascertained and is therefore falsely low (due to unascertained mortality among PLHIV 
LTFU), introducing outcome ascertainment error, with 1-year vital status in the derivation 
and validation datasets missing in 21.6% and 45.3%, respectively.87   
 
In addition, the authors used multiple imputation to address missing covariate and 
outcome data, which introduces at least non-differential measurement and outcome 
ascertainment error.  Because the authors did not describe the patterns of missing data, it 
is challenging to understand why the missing at random assumption was considered 
reasonable.  Multiple imputation is only acceptable if the missing at random or missing 
completely at random assumptions hold.  If data were missing not at random (i.e., the 
propensity for data to be missing were related to the value of the data points that were 
missing), multiple imputation could have led to differential measurement error (i.e., 




likely to be missing than high CD4 counts the missing at random assumption would not 
hold and multiple imputation would be inappropriate.110  
 
One small study in which a non-regression-based clinical score was piloted in 2 clinics in 
Zimbabwe between 2008 and 2010111 is not summarized in detail  here because it does 
not meet inclusion criteria, deviates from standard risk score development approaches,107-
109 and was not used again either within Zimbabwe or outside to our knowledge.111  In this 
analysis, authors implemented a literature review to obtain adjusted hazard ratios for 
author-selected risk factors for mortality during ART, and then used the median adjusted 
hazard ratio across studies identified as the clinical score; however, neither the literature 
review methodology nor the rationale for this approach is clearly presented.111 
 
Limitations of clinical scores generated for resource-rich settings 
The VACS, VACS 2.0, and EuroSIDA scores have a number of strengths including: (1) 
development using a regression-based approach, (2) wide external validation in cohorts 
from resource-rich settings outside the cohorts in which they were developed, (3) well-
described methodology, (4) large sample size, and (5) in the case of the VACS scores, 
accurate mortality ascertainment.  However, both scores also have several limitations.  
Firstly, the scores were generated for cohorts with demographic and clinical 
characteristics that are currently markedly different from all or almost all LMIC settings, 
with participants tending to be older, male, self-identify as white, live in resource-rich 
settings, and have additional comorbidities such as hepatitis C co-infection.  Such 
characteristics are different to the majority of ART enrolees in LMIC who are almost 
exclusively non-white, more likely to be female, live in resource-poor settings, and have 
different comorbidities (e.g., are more likely overall to have TB disease instead of Hepatitis 
C co-infection).  While the VACS score has been validated in multiple resource-rich cohorts 
such as ART-CC,85,100 a younger, healthier population of PLHIV enrolled in the U.S. Military 
HIV Natural History Study (NHS),104 female, multi-race/ethnic ART-experienced PLHIV in 




not been validated as a predictor of mortality outside resource-rich settings like the U.S. 
and Europe.  A Kenyan study did report that VACS was correlated with biomarkers of 
inflammation among hospitalized PLHIV in Kenya, however, there was no attempt to 
validate VACS as a predictor of mortality in this setting.114  
 
Other limitations of VACS, VACS 2.0, and EuroSIDA include: (1) none of these scores is 
focused on the time period after ART initiation or re-initiation, with VACS score 
development starting after 1 year of ART and EuroSIDA including the pre-ART time period; 
(2) the large percentage of potentially eligible PLHIV that were dropped from the 
derivation regression (>50%) due to either death or LTFU in the first year of ART (VACS), or 
missing covariate data (VACS and EuroSIDA); (3) the outcome of the EuroSIDA score was a 
combination score of both death or AIDS (CDC 1993 definition), and (4) complexity of the 
score, with VACS, VACS 2.0, and EuroSIDA requiring ≥10 variables, including some 
complicated joint scores (e.g., FIB-4 and eGFR), in the case of VACS 2.0, use of continuous 
variables, and in the case of EuroSIDA, use of scores with decimal points.  The complexity 
of these scores would require an online calculator or built-in electronic medical record 
algorithm that is not yet widely available in LMIC.85,86,100 
 
Proof of concept 
Despite the limitations of VACS, VACS 2.0, EuroSIDA, and Haiti scores, these scores do 
raise the important point that mortality risk is not determined solely by a limited number 
of HIV biomarkers (such as CD4 count and WHO stage).84,105  In the VACS score the 
demographic variable of older age, and in the Haiti score, the demographic variable of 
male gender, carry important additional risk information for the clinician managing the 
patient.  As McNairy et al note, many clinicians in LMIC know that male gender and other 
non-HIV-specific biomarkers like anaemia are important predictors of death and 
morbidity, but importantly are not prompted by existing HIV care algorithms to use this 
information to intervene.84  Per WHO guidelines, the focus remains on WHO stage and 




easier to use lateral flow assays are in development.44  As the WHO guidelines and 
published reports suggest, up to 50% of those with a CD4 count <100 cells/µL could be 
classified as having WHO stage I or II and therefore missed by an advanced HIV disease 




In summary, these data and prior proof-of-concept mortality risk scores suggest that 
either through absent CD4 testing, or through lack of clinical scores that incorporate 
wholistic risk factors for on-ART mortality in sub-Saharan Africa, such as male gender and 
haemoglobin concentration, clinicians are likely missing a substantial percentage of clients 
requiring intensification of early ART care.  Therefore, a clinical scoring system suitable for 
sub-Saharan Africa that: (1) takes into account both HIV and non-HIV-specific risk factors 
for mortality, allowing a more precise approach to early ART care, (2) is feasible and easy 
to use in settings that both have or lack CD4 testing capacity, and (3) has similar or 
superior screening accuracy (i.e., sensitivity, specificity) in predicting early mortality on 
ART compared with current WHO advanced HIV disease eligibility guidelines, is needed to 





2.4. Literature review of TB screening approaches for HIV-positive people 
 
2.4.1. Introduction: WHO four-symptom TB screen vs. clinical score approach 
 
WHO currently recommends a four-symptom TB screening rule (i.e., for cough, weight 
loss, night sweats or fever) to determine which PLHIV need investigation for active TB and 
which are eligible for immediate TB preventive therapy (TPT).88  The WHO four-symptom 
TB screening rule is recommended for LMIC regardless of expected prevalence of active 
TB, setting (e.g., high or low TB burden settings), or ART status (ART-naïve or ART-
experienced).88  This introductory section describes briefly the development process for 
the WHO four-symptom TB screening rule and its strengths and limitations.  Subsequently, 
a literature review of alternative approaches to TB screening among PLHIV using clinical 
scores is provided to summarize existing literature and assess gaps in needed research. 
 
WHO four-symptom screening rule 
WHO has recommended the four-symptoms TB screening rule since 2011 following the 
individual patient data meta-analysis by Getahun et al, which included studies published 
up to and including 2008.  A new meta-analysis of studies examining screening accuracy of 
the four-symptom rule was conducted by Hamada et al in 2018 including published 
studies during January 1, 2011 and March 12, 2018.  Both meta-analyses also assessed the 
added value of chest radiography (CXR) in terms of TB symptom screening rule accuracy.  













Table 2.8. Comparison of WHO TB symptom screening rule meta-analyses from 2011 and 
2018 
  
Getahun et al, 2011 
- An individual patient data meta-
analysis 
Hamada et al, 2018 
- A meta-analysis of published 
summary data 
Study aim 
To find the screening rule with the highest 
possible sensitivity and lowest possible 
negative likelihood ratio for ruling out TB 
disease (without any predetermined cut-off 
points). 
To assess screening accuracy of the 
WHO four-symptom TB screen by ART 
status and effect of adding CXR on 
screening accuracy. 
Eligibility criteria for 
inclusion 
(1) collected sputum specimens from PLHIV 
regardless of signs or symptoms; (2) used 
mycobacterial culture of at least one specimen 
to diagnose TB; and (3) collected data about 
signs and symptoms. 
(1) collected sputum or any specimens 
(e.g., urine, blood, or fine-needle 
aspirates from lymph nodes) from PLHIV 
regardless of signs or symptoms; (2) 
excluded case-control studies 
Calendar time 
represented 
2000-2008 Jan 1, 2011 through March 12, 2018 
Number of studies 
considered 
2119 screened, 53 full text reviewed, 14 met 
inclusion criteria (6 published, 8 unpublished) 
4615 screened, 195 reviewed for 
eligibility, 21 included in review 
Numbers of studies 
included 
12 included in final meta-analysis 
18 studies in final meta-analysis (7 with 
disaggregated ART status; 11 were 
among PLHIV not on ART) 
Number of 
candidate variables 
159 (159 different symptoms were included in 
at least 2 of 12 studies) 
Only the 4 WHO-recommended 




5 symptoms: current cough, haemoptysis, 
fever, night sweats, and weight loss. 




TB patient: any PLHIV with >=one sputum 
specimen culture positive for MTB. No TB: 
sputum cultures were negative for MTB and 
participants were judged not to have TB in 
original study. Excluded from the analysis: (1) 
patients receiving ATT or TPT at enrolment; (2) 
patients AFB smear positive, but culture grew 
nontuberculous mycobacteria; and (3) patients 
AFB smear positive or scanty, but sputum 
culture negative. 
TB patient: Active TB was defined as 
tuberculosis diagnosed with 
bacteriological confirmation by use of 
culture or Xpert MTB/RIF of any 
specimens. 
Type of populations 
2 studies: SA gold miners; 5 studies: 
community TB prevalence survey; 5 studies 
clinic population (3 were among pre-screened 
PLHIV). 
20 studies in clinic settings; 1 in prisons; 
none in community; none in miners* 
TB case finding 
approach 
3 studies exclusively used liquid media to 
culture specimens, two studies used both solid 
and liquid media, and seven studies exclusively 
used solid media.  
All studies collected sputum specimens. 
Four studies collected additional 
specimens: fine-needle aspirates from 
individuals with enlarged peripheral 
lymph nodes; non-respiratory samples 
(e.g., ascitic, cerebrospinal and pleural 
fluid, blood, stool, fine-needle aspirate, 
and bone marrow) as clinically indicated; 
and blood from all participants. 16 of 
the included studies used culture alone, 
and the other studies used both culture 






Data from 4 studies used to assess effect on 
accuracy 
Data from 12 studies used to assess 
effect on accuracy 
Countries 
represented  
Zambia, Zimbabwe (2 studies), Cambodia (3 
studies), Thailand, Vietnam, South Africa (5 
studies), Ethiopia,   
Malaysia, South Africa (10 studies), 
Ethiopia, Ghana, Swaziland, Zambia, 
Kenya, Cameroon, Vietnam, Uganda. 
Analytic approach 
1-of-n rules: 23 candidate rules identified.  M-
of-n not considered because sensitivity was 
key feature prioritized. 
Main aim was to assess the performance 
of the 4-symptom screen, not to assess 
candidate variables 
Statistics 
Bivariate random-effects meta-analysis 
(BREMA) and the hierarchical summary 
relative operating characteristic (HSROC) 
curve. 
When at least four studies were 
available, bivariate random-effects 
models were used to estimate both 
pooled sensitivity and specificity 
together. If <4 studies were available, 
meta-analyses using univariate random-
effects logistic-regression models were 
used separately for sensitivity and 
specificity. 
Stratified analyses 
To examine how (1) setting, and (2) individual 
factors affect screening accuracy. The study 
examined variations in accuracy parameters 
and used odds ratios to compare relative 
likelihood of true positives and true negatives 
between groups.   
To examine variation in accuracy by ART 
status and pregnancy status.  10 studies 
included people on ART (range: 0.14%-
92.3%); 7 gave results stratified by ART 
status.  11 studies - no ART enrolees. 
Number needed to 
screen (NNS) 
Evaluated NNS in hypothetical populations 
with varying TB prevalence rates of size 1000. 
 Not provided. 
Missing data 
Complete case analysis. About 15% 
observations missing covariate data. 
Complete case analysis. >30% who 
underwent symptom screening were 
excluded because of their inability to 




Median age 34 (27-41).  Overall median CD4 
among 9,626 PLHIV was 248 (IQR: 107-409). 
Among 8,148 PLHIV included in meta-analysis, 
median CD4 was 94 (IQR 33-215) in those with 
TB vs. 229 (IQR 94-391) in those with no TB. 
Median CD4 was 272 cells per μL (IQR 
202–337) in 21 studies included in the 
review.  Median CD4 across 18 studies 
included in the meta-analysis not 
provided. 
Sample size (n) 
8,148 PLHIV of 10,057 total PLHIV, taken from 
9 of 12 studies had outcome and 5 symptoms 
of interest. 
15,427 PLHIV in 18 studies included in 
the final meta-analysis. 
Prevalence of TB  557 (5.8%) of 9,626 PLHIV 1559 (10.1%) of 15,427 
Abbreviations: PLHIV, people living with HIV; ART, antiretroviral therapy; TB, tuberculosis; ATT, anti-tuberculosis 
treatment; TPT, TB preventive therapy; AFB, acid-fast bacilli;  CXR, chest radiography; WHO, world health 
organisation; NNS, number needed to screen to detect one TB case; IQR, inter-quartile range; MTB, 
Mycobacterium tuberculosis 
*One study was considered to be at high risk of selection bias because it had included only people with HIV who 
required acute admission to hospital.  Seven studies were considered to be of high concern for applicability, three 
of which included only pregnant or lactating women,  one of which included only patients admitted to hospital, 
and three of which included only participants with low CD4 cell counts or those with advanced HIV clinical disease 
(WHO stage 3 or 4).  Three studies were considered to be at risk of bias either because types of specimens 
obtained for tuberculosis diagnosis differed between patients, or because a substantial proportion of participants 
who underwent symptom screening were excluded because of their inability to produce sputum or had missing 






Notably, the Getahun meta-analysis was designed to first derive the four-symptom 
screening rule and then assess the screening rule accuracy with and without chest 
radiograph in a variety of settings, whereas the key purpose of the Hamada meta-analysis 
was to assess the screening accuracy of the four-symptom screening rule and changes if 
CXR is added to the screening algorithm.  Both studies are well-described with large 
sample sizes and wide representation from LMIC.  However, two weaknesses of the 
Getahun analysis are that: (1) the TB outcome was dependent on a sputum culture and 
this relies on (a) ability to produce sputum, and (b) the assumption that the screening rule 
is designed to detect pulmonary TB, and (2) the screening accuracy is not stratified by ART 
status because all participants were pre-ART.  In contrast, in the Hamada meta-analysis: 
(1) TB diagnosis was not purely reliant on sputum culture although most studies still 
required patients to produce sputum, and (2) screening accuracy results were stratified by 
ART status.  Missing covariate data of 15% in the Getahun analysis, and missing covariate 
or outcome data (>30%) in the Hamada analysis are limitations of both studies.   
 
However, the three biggest limitations of both meta-analyses and by definition the WHO-
recommended four-symptom TB screening rule are that: (1) by developing a screening 
tool that relies purely on symptoms, all asymptomatic TB will be missed, (2) screening 
accuracy characteristics (e.g., sensitivity and specificity) vary by setting and patient 
population, and yet the screening rule derived (either positive or negative for the 
symptom screen) is a one-size fits all approach regardless of setting, PLHIV population, or 
use-case scenario, and (3) by stratifying risk into two categories, this does not allow 
opportunity to derive differentiated TB-HIV algorithms more precisely suitable to the 
continuum of risk present in the PLHIV population served. 
 
The importance of asymptomatic TB 
Asymptomatic TB, as shown by national TB prevalence surveys115 as well as observational 
cohorts studies,61 is relatively common in several settings and populations.  Firstly, as is 




settings, asymptomatic TB is common among PLHIV on ART and therefore a WHO 
symptom screen will not be a sensitive screening tool in this population.61,90,91  Notably, 
sensitivity of the WHO four-symptom screen was only 51% among PLHIV on ART versus 
89% among ART-naïve PLHIV in the Hamada meta-analysis (Table 2.9).  There are at least 
two key reasons why asymptomatic TB was relatively more common among ART-
experienced versus ART-naïve PLHIV who were included in the Hamada meta-analysis.  
Firstly, PLHIV on ART represent a pre-screened population, where the four WHO 
symptoms should have been assessed at each pre-ART and ART visit over the course of 
care, progressively reducing the relative contribution of undiagnosed symptomatic TB and 
increasing the relative contribution of undiagnosed asymptomatic TB in the population 
screened.61  This is well illustrated by the Getahun analysis where sensitivity of the WHO 
four-symptom TB screen in previously unscreened PLHIV was 88% but dropped to 41% 
among those who had been previously screened (Table 2.9).60  Secondly, PLHIV who are 
stable on ART are likely to have higher CD4 counts with higher immune competence and 
are more likely to have an indolent course of disease possibly with intermittent 
symptoms.90  The lower sensitivity of the WHO four-symptom screening rule among PLHIV 
with higher CD4 counts is also well-illustrated by the Getahun meta-analysis where odds 
of a true positive screen result using the WHO four-symptom screening rule was about 6-

















Table 2.9. Summary of key results from the 2011 and 2018 meta-analyses informing 
four-symptoms screening rule recommendations 
Getahun et al, 2011 Hamada et al, 2018 
TB prevalence 5.8% (557/9,626) 1559 (10.1%) of 15,427 
% Patients WHO four-symptom screening rule +ve 49.80% Median 68.0%  (IQR 37.0–86.4) 
Not on ART 49.80% 71.2% (IQR: 46.7–87.1) 
On ART N/A 29.7% (IQR: 14.3–45.7) 
WHO four -symptom screening rule accuracy 
Not on ART* 
Pooled sensitivity (95% CI)** 78.9 (58.3–90.9) 89.4% (83.0–93.5) 
Pooled specificity (95% CI)** 49.6 (29.2–70.1) 28.1% (18.6–40.1) 
On ART 
Pooled sensitivity (95% CI) N/A 51.0% (28.4–73.2) 
Pooled specificity (95% CI) N/A 70.7% (47.8–86.4) 
WHO four-symptom screening rule or CXR +ve accuracy 
Not on ART 
Pooled sensitivity (95% CI) 90.6% (66.7–97.9) 94.3% (76.2–98.8) 
Pooled specificity (95% CI) 38.9% (12.8–73.3) 20.1% (7.6–43.8) 
On ART 
Pooled sensitivity (95% CI) N/A 84.6% (69.7–92.9) 
Pooled specificity (95% CI) N/A 29.8% (26.3–33.6) 
Variations by setting 
Screened in clinical setting 
Pooled sensitivity (95% CI) 90.1% (76.3–96.2) 81.7% (61.2-92.7)§ 
Pooled specificity (95% CI) N/A 38.8% (18.4-64.1)§ 
Not previously screened 
Pooled sensitivity (95% CI) 88.0% (76.1–94.4) N/A 
Pooled specificity (95% CI) N/A N/A 
Screened in community setting 
Pooled sensitivity (95% CI) 67.1% (41.7–85.3) N/A 
Pooled specificity (95% CI) N/A N/A 
Previously screened for TB 
Pooled sensitivity (95% CI) 40.5% (16.6–69.9) N/A 
Pooled specificity (95% CI) N/A N/A 
Variations at the patient-level Age >=33 (1.43);  
Male (1.26),  
CD4 <200 (6.38); 
 CXR abnormal (1.36) 
Individual level factors predictive of increased 
sensitivity (odds ratio for true positive screen) 
N/A 
Changes in NPV by TB prevalence WHO symptom rule only WHO symptom rule only (plus CXR)† 
Not on ART     1% TB prevalence 99.60% 99.6%  (99.7%) 
5% TB prevalence 97.70% 98.0% (98.5%) 
10% TB prevalence 95.30% 96.0% (97.0%) 
20% TB prevalence 90.00% 91.4% (93.4%) 
On ART     1% TB prevalence N/A 99.3% (99.5%) 
5% TB prevalence N/A 96.5% (97.4%) 
10% TB prevalence N/A 92.8% (94.6%) 
20% TB prevalence N/A 85.2% (88.6%) 
 Changes in NNS by TB prevalence 1% TB prevalence 62 
5% TB prevalence 12 
10% TB prevalence 6 
20% TB prevalence 3 
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; NPV, negative predictive value; CXR, chest radiography; NNS, number 
needed to screen to detect one case 
*Getahun analysis no participants were on ART
**Significant heterogeneity between studies in the sensitivity and specificity of the four-symptoms screen
† In this table, the figure in brackets indicates the NPV when CXR is added.  Overall NPV increased 0.9% with addition of CXR.
††Participants with CD4 cell count ,200 cells/ml had 6.4 times the odds of a true-positive screen (95% CI 2.9–14.2).




In addition, asymptomatic active TB can be present among severely immune compromised 
PLHIV,94,95 and among pre-ART patients without advanced disease in high prevalence 
settings,96 among whom missing asymptomatic active TB can have suboptimal health 
consequences for patients and impede disease control activities.24 
 
Secondly, both meta-analyses reported significant heterogeneity in WHO four-symptom 
screening rule by study, which is a proxy for setting.  The variations by setting are well 
illustrated in the Getahun meta-analysis, where the WHO four-symptom screening rule 
sensitivity varied from 90.1% in clinical settings to 67.1% in community settings, because 
at the time the study was published prevalence of healthier PLHIV and therefore 
asymptomatic TB disease was more common in community settings.  Similarly, sensitivity 
varied by pre-screened versus screened populations and by CD4 count as described above.  
By definition, key parameters like number needed to screen (NNS) and NPV depend on the 
underlying prevalence of TB.  Notably, NPV of the WHO four-symptom screening rule 
when a 20% TB prevalence was assumed was only 91.4% and 85.2% among ART-naïve and 
ART-experienced PLHIV, respectively.  This indicates the challenge that in high prevalence 
settings, higher numbers of PLHIV with active TB could potentially be prescribed TB 
preventive therapy, when a full course of TB therapy is required, with implications for 
emerging TB drug resistance.16  Although Hamada et al and new WHO guidelines 
recommend possibly adding chest radiography to the screening rule for PLHIV on ART to 
increase sensitivity and NPV, this comes at the expense of lower specificity, carries 
significant additional costs and operational challenges, provides only modest overall NPV 
increase (0.2% at 1% TB prevalence), and therefore might not facilitate TPT scale-up in 
many LMIC settings.61,93   
 
Thirdly, a screening rule that only classifies patients into two categories (WHO screen 
positive versus negative), does not allow more precise understanding of TB risk, which 





One approach to overcoming all three limitations might be to derive a clinical score based 
on easily available variables in LMIC clinic settings that are not purely dependent on TB 
symptoms and for which cut-offs can be tailored to setting, patient population, use-case 
scenario, and to inform differentiated TB-HIV care.  Therefore, we searched the literature 
to better understand the availability of clinical TB screening rules and their potential 
suitability for LMIC, especially in sub-Saharan Africa. 
 
2.4.2. Methods: literature search strategy 
 
Search strategy 
MEDLINE®, EMBASE, and the Cochrane library were searched over the time period 
January 1, 2005, to May 31, 2020 for reports published in English with the terms 
“Tuberculosis” or “tuberculosis” or “TB”, and “HIV” or “acquired immune deficiency” or 
“AIDS”, and “score” or “clinical score”, and “screen”, and “validate” or “validation” or 
“predict” or “risk” or “prognostic”.   
 
Study selection 
Published peer-reviewed studies that met the following criteria were included: (1) the 
study population represented adult or adolescent PLHIV >12 years old, and (2) active TB 
disease was the outcome of interest, whether microbiologically confirmed or clinically 





Characteristics of studies included 
A total of six studies describing six clinical scores for TB risk among PLHIV were identified 
that met inclusion criteria from five countries: Thailand, Vietnam, Ethiopia, Guinea Bissau, 




scores as the second screening test among patients initially screening positive with the 
WHO four-symptom TB-screen, and one score (TBScore) was trialled as both an initial 
screen and second-step screen in two separate studies.  The time period of the studies 






























TB case finding 
approach 
Prevalen

















5 health centres in Oromia 
region, Ethiopia.  All PLHIV 
study enrolees were ART-
naïve, >=18 yo, submitted 
>=1 sputum sample at 
enrolment, provided 
written consent, were not 
already on ATT for >2 
weeks, and were WHO 
screen +ve. All PLHIV were 
pre-ART. Median CD4 was 
212 (119–321). 
625 





TB (at baseline or within 3 
months after enrolment). 
Participants with clinically 
diagnosed TB (defined as 
subjects who were 
prescribed ATT without 
microbiological 
confirmation) at baseline 
or within 3 months of 
enrolment were excluded 
from statistical analysis. 
At inclusion, 
participants were 
requested to submit 



















Variables significant at 
p<0.3 were considered 
candidate variables. 
Backward stepwise 
regression cut-off at 
p<0.05. 





Nanta et al, 
2011119 
Thailand first step 2009-2011 
2 hospitals in a region of 
Thailand, with the PLHIV 
patient population drawn 
from outpatient ART and TB 
clinics and inpatient wards. 
PLHIV were >=18 yo. Not 
eligible if had IPT or ATT 
within 1y. 66.5% were on 
ART. Enrolled also from TB 
clinics, implying many were 
referred for TB 
investigation. 29% had 
CD4<200. 
257 
TB defined as any of: 
smear +ve, culture +ve, 
compatible histology, 
clinical or radiological 
response to TB Rx.  TB 
investigations were part 
of routine care through 2 










collections for AFB 





Variables significant at 




elimination was used 
for second stage 
analysis to identify 
independent predictors. 







Vietnam first step 2009-2010 
1 HIV clinic in Vietnam. 
Cross sectional. PLHIV 
outpatients were 
consecutively enrolled, 
>=15, and lived in District 6. 
PLHIV were excluded if 
screened in last 3 m or on 
ATT.  57.9% were on ART. 
22% with CD4<200.  
397 
Pulmonary TB (PTB) case 
was defined as a subject 
with at least one sputum 
culture positive for M. 
tuberculosis. 
Two sputum samples 
(home and clinic), 
for culture, smear, 
DST. Chest x-rays 
and TST performed 











with clinical significance 
in multivariable model. 
Examined combinations 
of chosen covariates 




















PLHIV enrolled were >15 
years old, patients seeking 
health care for cough, 
weight loss and/or 
expectoration within the 
Bandim Health Project 
(health + demographic 
surveillance area). PLHIV 
were pre-ART. CD4 data not 
provided. 17% of HIV+ had 
BMI <18.  
164 
Patients were smear +ve 
PTB if ≥1 sputum smear 
was +ve for AFB. Patients 
with a -ve sputum smear, 
but with clinical signs, 
symptoms and CXR 
changes considered TB-
related, were classified as 
smear -ve PTB if no 
improvement with 
antibiotics and the 
physician initiated ATT. 
Sputum collection 
for AFB microscopy, 
chest radiography 
16.5% Complete 















first step 2014 
HIV Clinic of Hospital 
Nacional Simão Mendes in 
Bissau, Guinea-Bissau. 
PLHIV enrolled were newly 
diagnosed; >=15; not 
pregnant and not on TB 
treatment in last year. 
Median CD4 183 among TB 
patients and 300 among 
non-TB patients. About one 
third with CD4<200. 
164 
The final TB diagnosis was 
established based on the 
following: TB = sputum 
positive for AFB OR 
sputum positive for Xpert 
OR clinical judgement OR 
X-ray findings not 
resolved after a short 
course of antibiotics, 




Newly diagnosed HIV 
patients with a 
Tbscore >=2 were 
asked to produce 
sputum if they were 
able to for Xpert, 
smear microscopy 
and CXR. Newly 
diagnosed HIV 
patients with score 
<2 + TST>5mm had 
CXR, +- Antibiotic 
trial, + second CXR.  
13.4% 




due to Ebola 
outbreak and 
logistical 
reasons. 31 of 
164 lost to 
follow-
up/screening. 
Not applicable since the 
















Prospective cohort at 2 
hospital-based and 2 
community health centre 
clinics. PLHIV enrolled 
were: ≥18 years old, 
included three groups 
(newly HIV diagnosed, pre-
ART care, or on-ART 
groups); had not received 
ATT in previous 3 months; 
and there were no CD4 
count criteria for 
enrolment.  Median CD4: 
378 (IQR 228-543). About 














confirmed TB within 6 
months of enrolment 
visit. 
≥1 Spot sputum 
sample for all 
enrolees regardless 




subsequent visits if 
“high risk”**; Xpert 
for all sputum 














Abbreviations:  ART, antiretroviral therapy; TB, tuberculosis;  WHO, world health organisation; SA, South Africa;  AFB, acid fast bacilli;  CXR, chest radiography; PTB, 






Among the six study populations, three (Ethiopia and the two TBScore studies from 
Bissau) included only pre-ART118,121,122 adult patients and three (Thailand, Vietnam, and 
South Africa studies) included a mix of both pre-ART and ART patients.119,120,123  Some 
measure of CD4 count distribution among PLHIV was provided in five studies, with 22% to 
50% of PLHIV having a CD4<200/µL.  Sample size ranged from 164 to 1,048.  The 
prevalence of active TB in the populations screened ranged from 7.0% to 25.7% (Table 
2.10).   
 
TB outcome and case finding approach 
The TB outcome definition varied across the studies; four (Thailand, two TBScore studies 
from Bissau, and South Africa studies) used either a clinical or microbiologically confirmed 
diagnosis of TB as the outcome of interest, while two (Ethiopia and Vietnam studies)118,120 
used only microbiologically confirmed TB from sputum and other samples.  Five studies 
focused on pulmonary TB and only one (Ethiopia study) focused on either pulmonary or 
extra-pulmonary TB.118  Four studies (Ethiopia, Vietnam, initial TBScore study from Bissau, 
and South Africa study) collected sputum from all enrolees; in the follow-up TBScore study 
from Bissau, study enrolees only provided sputum if the TBScore was >=2;122 and in one 
study (Thailand study) it is unclear whether all enrolees provided a sputum for 
microbiological assessment as TB diagnosis was done in routine settings.119 
 
Covariates assessed 
Across the six studies and scores, a large number of potential predictors of prevalent 
active TB were considered as candidate predictors, with a total of 39 categories of 
symptoms across the studies evaluated (Table 2.11).  Some categories (e.g., WHO TB 
symptoms and comorbidities), had multiple levels (e.g., 14 symptoms were considered in 
the Thailand study and 11 in the Vietnam study, while five comorbidities in addition to HIV 
infection were considered in the Thailand study).  Approaches to categorizing the 




in the Thailand study, (categorized as <18 and <16 in the TBscore studies from Bissau), and 
categorized as <18.5, 18.5-24.9, and ≥25 in the South Africa study.  Sometimes predictors 
in one study were considered part of the outcome definition in other studies.  For 
example, a CXR suggestive of TB was considered a predictor in the Vietnam study, but was 
considered to define clinical TB in the three studies where a clinical diagnosis of TB was 




































Table 2.11. Summary of covariates assessed in published clinical TB risk scores among PLHIV 





































Age Yes Yes Yes Yes 
Sex 
Yes Yes Yes No Yes Male 
Female 
Residence 












Yes Yes No No No 
Yes 
No 
Prior TB in HH  
Yes No No No No Yes 
No 
Household size No Yes No No 
Smoking 
Yes No Yes No Yes Yes 
No 
Alcohol 
Yes No Yes No Yes Yes 
No 
IDU 
No No Yes No No Yes 
No 
Khat 
Yes No No No No Yes 
No 
Employment 








Yes No No No Yes 





Yes No No No No 1 or 2 






w Cough 2.1 1 6.16 3 Yes 0.7 NP Yes 1 1 1 Yes 
Fever 
chills 
>=1w 6.95 3 
Yes 
2.64 NP No Yes 







Yes 1.22 NP No Yes 








e  0.94 NP Dyspnoea 1 1 1 
Chills  1.98 NP 
Chest 
pain 1.36 NP 
Chest 
pain 1 1 1 
4 others considered 
Yes >1 




No No No No 
Yes 
Comorbidities 








No Yes No 
Yes 
(Auscult
ation) 1 1 
On IPT 
Yes No No No Yes Yes 
No 
On CPT 
Yes Yes No No Yes Yes 
No 
ART status 
Yes Yes No Yes On ART 
Not on ART 6.37 3 2.34 3 
Hospitalization 












n) 1 1 No 
Temperature 
No No No 
Yes 
(>37) 1 1 
No 
Karnofsky score  
Yes 
(<=80










1 1 1 No 
Yes  






2) 3.99 2 
No 
Yes 
(<18) 1 1 1 
Yes 
18.5-
24.9 2.23 2 
Yes 
(<16) 1 1 1 
Yes 
(<18.
5) 6.79 6 






















µL) 1.4 1 
Haematocrit No Yes No No No 
Platelet count No Yes No No No 
WBC No Yes No No No 
AFB +ve No No Yes 32.04 NP No No 
TB-CXR No No Yes 4.28 NP No No 
Abbreviations: AOR, adjusted odds ratio; TB, tuberculosis, IDU, injection drug use; ART, antiretroviral 
therapy; IPT, isoniazid preventive therapy; CPT, co-trimoxazole preventive therapy; MUAC, mid-upper arm 
circumference; BMI, body mass index; TST, tuberculin skin test; WBC, white blood cell count; AFB, acid fast 
bacilli; CXR, chest x-ray; PLHIV, people living with HIV; symp., symptoms 
*AORs not provided for the TBScore analyses.
86 
Statistical approaches to score development 
Four of the six studies (Ethiopia, Thailand, Vietnam, and South Africa) used a logistic 
regression approach to identify predictors in univariate analysis (Table 2.10).  Two of these 
four studies indicated that candidate predictor variables with p<0.3 (Ethiopia) and p<0.25 
(Thailand study) in univariate analysis were eliminated as candidate variables.  Of these 
four studies, three used a backward multivariable stepwise regression approach as the 
final step to select chosen variables for the score, sequentially eliminating variables with 
the highest p-value until only those with p<0.05 were retained.  Five of six studies 
generated numeric scores for TB risk, whereas one (Vietnam) only provided screening 
accuracy for a variety of combinations of variables.  Among the five studies with numeric 
scores, one (Ethiopia) assigned a single point for each selected variable regardless of 
coefficient, two re-scaled multivariable model coefficients (Thailand and South Africa), 
and two (the TBScore studies from Bissau) did not present the regression approach and 
assigned a single point to each of the final chosen variables.  Only the South Africa study 
assessed the possibility of non-linear relationships between continuous predictors and log 
odds outcome. 
Screening accuracy and validation approaches 
None of the six studies and scores included an external validation component.  Only the 
South Africa study used a temporal internal validation approach, splitting the dataset into 
derivation and validation components based on the median enrolment date and showing 
score performance in both derivation and validation datasets. 
Predictive accuracy 
AUROC of the first-step screening scores were 0.58-0.62, 0.77 (at TBScore II ≥3), and 0.92 
in the Vietnam, follow-up TBScore study from Bissau, and Thailand studies, respectively, 
indicating poor (<0.7), acceptable (0.7-0.79), or outstanding (>0.9) discrimination, 
respectively (Table 2.12).  AUROC of the second step screening scores were 0.52 (at 




South Africa, and Ethiopia, studies, respectively, indicating poor (<0.7) or acceptable (0.7-
0.79) discrimination.  Only the Ethiopian second-step score and Vietnam first-step score 
compared discrimination and screening accuracy of the score versus the WHO standard, 
with similar or slightly better discrimination of the score versus the WHO standard.  In the 
Vietnam first step screening score, the sensitivity could be increased from the WHO 
standard of 50% to 100% by adding additional screening variables, and NPV from 94% with 
the WHO score to 100%.  By definition, any second step score is going to have lower 
sensitivity and lower NPV compared with the WHO screening criteria. 
 
Table 2.12. Screening accuracy of the TB risk scores  























  *Second step 
**First 
step 










137 137 66 28 28 27 27 22 22 110 









0.92 0.58-0.62 0.57 
>=3: 0.52  
>=4: 0.53 
>=2: 0.50  
>=3: 0.62 





Sensitivity NP NP NP 43-100% 50% 
>=3: 93%  
 >=4: 78% 
>=2: 85%  
>=3: 74% 
>=3: 96% 100% 
>=3: 92%   
>=7: 67% 
Specificity NP NP NP 24-79% 64% 
>=3:12%  
>=4: 29% 
>=2: 15%  
>=3: 50% 
>=3: 37% 15% 
>=3: 34%   
>=7: 74% 
PPV 
  ≤1: PPV 
(7.8%); 
2-3: PPV  
(27.5%); 








NP 6-11% 10%     >=3: 23% NP  
NPV 
92% at <=1; 
72% at 2-3, 
and 44% at 
>=4 
94% NP 91-100% 94% 
>=3: 89%  
>=4: 87% 
>=2: 84%  
>=3: 91% 
>=3: 98% NP 
>=3: 97%    
>=7: 95% 
Abbreviations: NP, not provided by the referenced study; AUROC, area under the receiver operating 
characteristic curve; PPV, positive predictive value; NPV, negative predictive value; WHO, World Health 
Organisation; SA, South Africa 
*Second step screen is an additional screening rule after a PLHIV has screened positive for one of the four 
WHO TB symptoms 







Simplicity and feasibility of score in LMIC 
In general, all the scores included available variables in LMIC clinics such as TB symptoms, 
clinical measures (e.g., Karnofsky score), temperature, anthropometric measurements 
(e.g., body mass index, mid-upper arm circumference), and widely available blood tests 
(e.g., haemoglobin concentration measurements).  However, some scores included 
variables that were more subjective and open to interpretation (e.g., TBScore and TBScore 
II included findings from chest auscultation), and the other four scores (Ethiopia, Thailand, 
Vietnam, and South Africa) included the need for CD4 testing, which is not yet widely 




Overall, the six studies and six clinical TB risk scores had a number of limitations that mean 
the scores are not easily generalizable outside the study populations included.  Three 
main limitations are common across the studies: (1) lack of external validation, (2) the 
potential for biased score generation, and (3) use of either variables that are subjective or 
not rapidly available in LMIC settings.   
 
The need for external validation 
Per published guidelines for generating predictive models and scores, external validation 
in cohorts different to the cohort in which the model and score were developed is 
important to assess the generalizability of the predictive model and score and therefore 
utility in settings outside of that in which it was developed.124  Only one study (the South 
Africa study by Hanifa et al) used a temporal internal validation approach to build 
confidence in the model and clinical score, but this falls short of external validation in 







The potential for generating biased scores 
The study population used for clinical score generation plays an important role in 
determining which variables will be selected for the clinical score and also the screening 
accuracy characteristics.  For example, two studies from South East Asia (Thailand and 
Vietnam studies), at initial glance have similar study populations (adult PLHIV outpatients, 
some of whom are on ART, with 22-29% having a CD4 count <200/µL).  However, the 
prevalence of active TB was markedly different (25.7% in the Thailand study and 7% in the 
Vietnam study).  On deeper examination it is clearer that those enrolled in the Thailand 
study were already suspected of having TB and had been referred for investigation, 
whereas those in the Vietnam study represented a less biased study population.  
Therefore, although the Thailand study is presented as a first-step screening tool, it is in 
fact a second step screening tool for prevalent active TB among those already reporting 
symptoms of TB.  If the Thailand screening tool were applied as a first screening step in 
another population of PLHIV, it would possibly not perform as well as it did in the 
somewhat biased primary study population.  In particular, whether the Thailand screening 
tool is an accurate screening tool in a population of both symptomatic and asymptomatic 
individuals cannot be ascertained from the data presented. 
 
Variable inclusion suitable and feasible in LMIC  
Another limitation of the studies is use of either subjective or difficult to obtain variables 
in LMIC for the clinical score.  The initial and follow-up TBScore studies from Bissau used a 
13 variable score (TBScore I) with two main challenges.  Firstly, a 13-variable score 
represents a large number of variables to ask a busy HCW from a LMIC setting to gather 
during routine care.  Currently, it is challenging to support HCWs to screen for just the 
four WHO TB symptoms in LMIC.  For example, the percentage of eligible PLHIV 
appropriately screened for all four WHO TB symptoms has been reported as 59% in SA,63 
61% in Mozambique,62 4% in Kenya (4%),125 and 36% in Cote d’Ivoire98 in recent years.  
Reasons for low adherence with TB screening protocols are not well understood, but could 




of access to monitoring data, and possibly lack of prompts, either as part of an electronic 
medical record or on a routine paper form, to screen for TB.  Overall, the lesson learned is 
that the screening tool needs to be very simple.  Secondly, the TBScore includes more 
subjective variables like abnormal findings on auscultation and “anaemic eyes”, which 
leave room for non-standard capture of variables for the risk score.  The other four scores 
(Ethiopia, Thailand, Vietnam, and South Africa scores) all require a CD4 variable, with CD4 
not widely available yet in LMIC settings, although a lower cost lateral flow assay to 
determine CD4 <200 cells/µL is in development. 
   
First step vs. second step screening 
Recent WHO guidelines,88 the recent WHO TB symptom screening meta-analyses,61 and 
recent expert opinion16 all express some level of concern about inability of the WHO TB 
symptom screen to detect asymptomatic TB and therefore increasingly sub-optimal 
sensitivity and NPV, especially among PLHIV on ART.  By definition, any second step 
screening approach after the initial WHO four-symptom TB screen is going to have a lower 
sensitivity and lower NPV than the WHO four-symptom screening rule alone, which does 
not alleviate the currently most pressing concern emerging in TB screening literature.  Of 
the three first-step screening scores, none are suitable for wide scale-up for reasons 
already discussed: related to the Thailand score, lack of external score validation, 
potentially biased derivation study population, and dependence on CD4 limit its use; 
related to the Vietnam score, lack of external validation and inclusion of CD4 and chest x-
ray as potential variables in the score; and related to the TBScore study, lack of external 
validation, use of a complex 13-level score, inclusion of more subjective variables 
(auscultation and anaemic eyes) in the score. 
 
Statistical approach 
Notably only one study (South Africa study) examined the potential for non-linear 
relationships between continuous predictors and the log odds of outcome using a 




novel cut-offs for continuous variables not derived from the data.  Recently, the superior 
ability of machine learning models to account for non-linear relationships between the 
continuous predictors and the outcome of interest has been highlighted as a potential 
advantage of machine learning approaches versus traditional generalised linear regression 
models.  No clinical TB score has yet been derived using the advantages of machine 
learning approaches, which is a potential area for future research.127,128 
 
Other TB screening approaches 
Other TB screening approaches, such as use of blood tests for C-reactive protein (CRP) in 
the initial129 or second-step screening approach after a positive WHO symptom screen and 
trial of antibiotics130 have also been published.  Most attempts at using CRP as the initial 
TB screening test have shown high sensitivity.  For example, in one study from KwaZulu-
Natal South Africa, sensitivity of both the CRP screening test (>5 vs ≤5) and WHO four-
symptom TB screen was 91%,129 but the CRP test was more specific than the WHO four-
symptom TB screen (59% vs. 37%).  However, while other studies have reported that CRP 
as an initial screening test (>10 vs ≤10) had high sensitivity, in some of these prior studies, 
sensitivity of the CRP screening test was lower than the WHO four-symptom screen 
standard of care,131 and in other studies CRP was considered to have little benefit as a 
screening tool versus the four-symptom screening tool due to no improvement in 
accuracy or discrimination.132  One study suggested CRP added value as a second step 
screening tool after a positive WHO four-symptom screen and trial of antibiotics, but not 
as an initial screening test.130  While lower cost point-of-care CRP screening tests are 
available, this test is not yet widely available in LMIC.131  In addition, debate about the CRP 
cut-off and location in the TB screening algorithm continues,130 and most studies have 
advocated use of CRP to increase specificity rather than sensitivity.131  Future inclusion of 
CRP in clinical scores could yield important additional information rather than using CRP as 







In summary, there is no externally validated, feasible, and flexible initial clinical score for 
TB among PLHIV, including those on ART, which can be used to either improve sensitivity 
and NPV, or increase specificity and PPV, compared with the WHO four-symptom TB 
screening rule, depending on the use-case scenario.  Use-case scenarios where improved 
sensitivity in detecting asymptomatic TB and high NPV would be prioritized include: (1) at 
the point of HIV care or ART enrolment where undiagnosed TB prevalence is relatively 
high and intensified TB case finding to reduce TB-related mortality is the focus, and (2) 
prior to provision of TPT (i.e., among ART-naïve or ART-experienced PLHIV who have not 
yet received TPT).16  Use-case scenarios where higher specificity and PPV might be 
prioritized would be among those PLHIV stable on ART who have received TPT and among 
whom improving cost-effectiveness of TB screening approaches (i.e., lowering the NNS) 
would be a higher public health priority.  In addition, there has been little focus stratifying 
TB risk among PLHIV to inform differentiated TB-HIV care algorithms for sub-Saharan 
Africa.  A new externally validated screening tool that addresses this gap could be very 
useful in sub-Saharan Africa, where early ART mortality due to undiagnosed TB remains 
high, global efforts to scale-up TPT to >13 million PLHIV are ongoing, and resource-
limitations demand investigation of opportunities to improve efficiency through 














The overarching aim of this thesis was to investigate opportunities to reduce early 
mortality on ART specifically, and HIV-TB mortality more broadly, among PLHIV in sub-
Saharan Africa, through improved approaches to TB screening, diagnosis, and retention in 
HIV care. 
 
3.2. Specific research questions 
 
To meet this over-arching aim, I specifically aimed to address the following research 
questions: 
 
1. Compared with standard of care in Botswana, what is the impact of the following 
package of interventions on early (6-month) adult ART mortality rates: (1) 
additional support for ICF, (2) intensified tracing for patients missing clinic 
appointments to return them to care, and (3) Xpert replacing sputum-smear 
microscopy.  
Note: this was a co-primary objective of the Botswana Xpert Package Rollout Evaluation 
using a Stepped-wedge design (XPRES) trial (ClinicalTrials.gov: NCT02538952).18 
 
2. Compared with the current WHO advanced disease eligibility criteria for early ART 
care intensification, can predictive clinical scores tailored for settings that (a) do 
not have access to rapid CD4 count testing, and (b) do have access to rapid CD4 
count testing, better predict who is at risk for early (6-month) ART mortality and 





3. Can a predictive clinical score, developed using easily available covariates in 
resource-constrained clinic settings in sub-Saharan Africa, predict TB risk among 
PLHIV better than the current WHO four-symptom screening rule? 
 




In 2018, Botswana was ranked 94 out of 189 countries on the human development index 
(HDI),133 with a Gross Domestic Product (GDP) per capita of about $15,000 making it an 
upper middle-income country, with economic growth since independence in 1966 fuelled 
by significant mineral (diamond) wealth, good governance, prudent economic 
management, and a relatively small population of slightly more than two million.134  Most 
of the population (71%) reside in urban centers and life expectancy in 2020 was estimated 
at 69.9 years.135 
 
Botswana has the third highest prevalence of HIV-infection among adults aged 15-49 
globally (22%), however comprehensive and effective treatment programs have reduced 
HIV/AIDS-related deaths substantially from 17,000/year in 2004 to 4,800/year in 2018.136  
In 2020, Botswana’s progress to 90-90-90 is estimated at 91-92-95, making it one of the 
first countries in the region estimated to have reached 90-90-90 targets.1 
 
In 2018, overall TB incidence was estimated at 275 (95% CI, 213-345) per 100,000 
population and incidence of HIV-associated TB in the total population was estimated at 
148 (95% CI, 114-186) per 100,000 population, with incidence rates steadily declining 
since 2000 (Figure 1).  Therefore, about half of TB cases in Botswana are estimated to be 
among PLHIV.  Multi-drug resistant TB is estimated to be low (13/100,000 population) but 




2008).16,137  Annually there are an estimated 560 deaths from TB among HIV-negative 
persons and 1,200 deaths from TB among HIV-positive persons.     
 
Figure 3.1. Estimated total TB incidence (green), new and relapse TB cases notified 
(black), and HIV-positive TB incidence (red) in Botswana — 2000–2018* 
 
*Taken from the most recent WHO Botswana Country Profile report.138 
 
The Botswana National TB Programme was established in 1975.  National guidelines since 
2011 have placed significant emphasis on coordinated TB-HIV services, although in most 
cases TB treatment clinics are run separately from HIV treatment clinics in terms of 
location of the clinic or timing of the clinic if the TB and HIV treatment clinics are co-
located on the same health facility grounds.  Laboratory diagnosis using sputum smear 
microscopy was the mainstay of TB identification for PLHIV prior to rollout of Xpert as the 
first line TB diagnostic starting in 2012.  Although TB culture using mycobacterial growth 
indicator tubes was available at the central National TB Reference Laboratory in 
Gaborone, culture was seldom requested in practice for PLHIV suspected of having TB 
(i.e., those PLHIV who screened positive for one of cough, fever, loss of weight, or night 
sweats).18  Chest radiography was recommended for TB-symptomatic PLHIV who tested 




in 2012.  Our XPRES study activated the first 13 Xpert devices in service of PLHIV in a 
phased manner as described in Chapter 4.  Nurse practitioners, in addition to medical 
doctors, are allowed to initiate and monitor TB treatment.  Since 1993 Botswana adopted 
directly observed therapy for all patients for the entire TB treatment period, with 
community healthcare workers supporting direct observed therapy implementation 
where possible and implementation of direct observed therapy affected by logistical 
challenges (e.g., cost of transport for the patients, work load for healthcare providers).139 
 
3.3.2. South Africa 
 
For the second and third thesis research questions, data from three prospective clinical 
cohorts from South Africa were used to validate the clinical scores derived from the XPRES 
dataset.  The three cohorts are: (1) TB Fast Track (TBFT) trial enrolees from Gauteng, 
Limpopo, and North West Provinces in South Africa, which represents a homogenous ART-
naïve population with advanced HIV disease;117 (2) prospective cohort data for XPHACTOR 
enrolees from Gauteng province, South Africa, which represents a predominantly stable, 
long-term ART population;123 and (3) prospective cohort data from the Western Cape, 
South Africa, which represents an ART-naïve population in a very high TB incidence 
setting.140 
 
In 2018, South Africa was ranked 113 out of 189 countries on the human development 
index (HDI), with a Gross Domestic Product (GDP) per capita of about $12,000 making it a 
middle-income country.141  Economic growth has stagnated recently with rising 
unemployment (27%) and significant socio-demographic inequalities in wealth across the 
population of about 57.8 million.  Most of the population (67%) resides in urban centers 
and life expectancy in 2020 was estimated at 63.9 years.142 
 
In 2018, overall TB incidence was estimated at 520 (95% CI, 373-691) per 100,000 




population, with incidence rates rising between 2000 and 2008 and then declining since 
2009.138  Over half of TB cases in South Africa are estimated to be among PLHIV.  Multi-
drug resistant TB is estimated to be 19/100,000 population.  Annually there are an 
estimated 21,000 HIV-negative TB deaths and 42,000 HIV-positive TB deaths. 
 
Figure 3.2. Estimated total TB incidence (green), new and relapse TB cases notified 
(black), and HIV-positive TB incidence (red) in South Africa — 2000–2018* 
 
 
3.4. Key challenges facing the Botswana national ART programme at the time of 
XPRES  
 
As described above, Botswana is one of the worst affected countries by the HIV pandemic 
with nearly one in four adults living with HIV.  To respond to the national HIV epidemic, 
the Government of Botswana launched its national antiretroviral therapy (ART) program 
called “Masa”, which means “a new dawn” in Setswana, on January 21, 2002.  After 12 
years of scale-up, by the end of 2014, the Masa program had expanded to more than 302 
healthcare facilities and the number of patients ever initiated on ART had reached 
247,856, of which 229,133 were in the public sector.  At the time of XPRES trial initiation 




during ART and from TB-HIV care cascades were considered important challenges facing 
the Masa program.32  For example, in an observational cohort study of 226,030 adult 
patients starting ART during 2002–2013, mortality (uncorrected for mortality among ART 
enrolees LTFU) during the first three months of ART was 11.8 per 100 person-years (95% 
CI, 0.98-1.04), but dropped to 1.0 per 100 person-years (95% CI, 0.98-1.04) among PLHIV 
in the time period after one year of completed ART.32  In addition, LTFU during the first 
year of ART was 14.9 per 100 person-years (95% CI, 14.7-15.1) overall, and LTFU rates 
among ART enrolees was observed to have increased from 7.7 per 100 person-years for 
ART enrolees in 2003 to 22.5 per 100 person-years for ART enrolees in 2011.32  In addition, 
in the only pathological autopsy evaluating causes of death among adult PLHIV in 
Botswana in 2002, 38% of deaths were due to TB, and 90% of TB cases had both 
pulmonary and extra-pulmonary disseminated TB.143  These challenges were important in 




Chapter 4. Methods 
 
This Chapter describes methodology used to answer the three thesis research questions 
described in Chapter 3.  A summary of the XPRES trial methods is provided in section 4.1. 
with additional details provided in the published manuscript in Chapter 5 and the 
published protocol, which can be found as Appendix 1.  An overview of analytic methods 
used to develop and validate the early ART mortality risk scores is provided in section 4.2., 
and analytic methods used to develop and validate the TB risk score for PLHIV in section 
4.3. 
 
4.1. XPRES trial summary 
 
4.1.1. Primary trial objectives 
 
In 2012, as a pilot for Botswana’s national Xpert MTB/RIF (Xpert) rollout plans, I designed 
a study called the Xpert Package Rollout Evaluation using a Stepped-wedge design (XPRES) 
trial.18  XPRES had two co-primary objectives.  The XPRES co-primary objective reported in 
this thesis, and the first key research question for this thesis as described in Chapter 3, 
was to evaluate the impact of a package of interventions comprising (1) additional support 
for TB screening and intensified TB case finding (ICF) algorithms, (2) active tracing for 
patients missing clinic appointments to support retention, and (3) Xpert replacing sputum-
smear microscopy, on early (6-month) antiretroviral therapy (ART) mortality.18  The other 
XPRES co-primary objective, which aimed to compare diagnostic sensitivity of the new 
Xpert-based TB diagnostic algorithm with that of the sputum-smear-microscopy-based 







4.1.2. Secondary trial objectives 
 
Two secondary XPRES trial objectives are also reported in this thesis as follows: (1) to 
evaluate impact of the TB screening, retention, and Xpert package on 12-month ART 
mortality compared with standard of care, and (2) to evaluate impact of Xpert compared 
with smear microscopy on all-cause, adult, 6-month ART mortality. 
 
4.1.3. XPRES Study design  
 
The XPRES stepped-wedge cluster randomised trial (CRT) design with a retrospective 
baseline component is illustrated in Figure 4.1.  XPRES was conducted at 22 clinics 
purposively chosen to be representative of HIV care and treatment clinics in Botswana.  All 
HIV clinic enrolees >12 years old, except for PLHIV who were incarcerated, were eligible 
for inclusion in the study in three phases: a retrospective standard of care (SOC), 
prospective enhanced care (EC), and prospective EC plus Xpert (EC+X) phase (Figure 4.1.).  
EC and EC+X phases were implemented as a stepped-wedge trial.  Participants in the EC 
phase received SOC plus components 1 (strengthened ICF) and 2 (active tracing) of the 
intervention package, and participants in the EC+X phase received SOC plus all three 




















4.1.4. Study design rationale 
 
A pragmatic stepped-wedge cluster-randomised trial design with a retrospective 
component was chosen for the following reasons.  A cluster-randomised design (i.e., for 
the EC vs. EC+X comparison) was chosen because Xpert device activation was most 
feasibly achieved for an entire district TB laboratory, which often served more than one 
health facility; this fact made an individually randomised controlled trial design less 
desirable.144  A stepped-wedge rather than parallel-group design was chosen because: (1) 
at the time, according to WHO guidance77 and Ministry of Health guidelines,137 the Xpert 
device was expected to be beneficial for both patients and providers, and therefore it was 
considered ethically sub-optimal to implement a parallel group cluster-randomised trial, 
where certain district TB laboratories and their associated clinics were denied access to 
Xpert for an extended period of time,78,145 (2) the phased rollout of Xpert provided 
logistical advantages, because it meant that a single site activation team, in charge of 
training and activation of the Xpert device, could sequentially initiate all study sites,145 (3) 
the need for only a single site activation team reduced projected study cost, and (4) in a 
real-world setting, the sequential rollout of an intervention allows lessons learned during 
earlier steps to be applied during later steps.   
 
The primary study question, however, was addressed through a pre versus post 
comparison (i.e., a comparison of 6-month ART mortality between SOC and EC+X phases).  
The main reasons a pre- versus post-design was chosen related to sample size, Ministry of 
Health preferences concerning speed of Xpert rollout, funding availability, desire for a 
more pragmatic study design to increase generalizability of findings related to the primary 
study question, and opportunity to address a different study question than other Xpert 
trials.146  As described in the sample size section below (4.1.11), we estimated a possible 
40% impact of the Xpert package versus standard of care on early ART mortality.  To 
observe a 40% difference in 6-month mortality rates within a stepped-wedge trial would 
have required a very large and lengthy EC and EC+X prospective cohort enrolment.  This 
was not feasible because: (1) the MOH preferred the 13 Xpert devices be rolled out as 




accuracy;81 and (2) there was insufficient funding for a stepped-wedge trial of the needed 
size to detect a >40% reduction in all-cause mortality (>10,000 prospective trial enrolees).  
In addition, since investigators wanted the study findings related to intervention package 
impact on mortality to be generalizable to other settings in sub-Saharan Africa, a 
pragmatic design was needed and the pre-requisite for a pragmatic trial is that the 
standard of care arm or phase needs to reflect true standard of care.147  Prospectively 
enrolling the standard of care cohort would likely alter the true standard of care as it did 
in many other Xpert impact evaluation trials.148  In Chapter 8, Section 8.2.2., the thesis 
provides more detail on why investigators consider the XPRES trial design a pragmatic 
design.  In addition, by implementing three phases, XPRES was positioned to answer a 
question other Xpert trials were not expressly designed to answer, namely what is the 
impact of the Xpert package of interventions (i.e., strengthened TB screening, retention, 
and Xpert rollout) on early ART mortality?18  As a secondary trial objective, the trial aimed 
to examine, using data from the stepped-wedge portion of the trial, representing a 
controlled, strengthened health system with high completion of both smear microscopy 
and Xpert diagnostic algorithms, whether Xpert provided additional benefit in terms of 
patient-important outcomes.  However, similar to most trials,149,150 XPRES was powered to 
meet the primary study objective (i.e., the pre versus post comparison of 6-month ART 
mortality between SOC and EC+X phases) and was not powered to answer this secondary 
objective due to the timeline and funding limitations described above.149,150 
 
4.1.5. Cluster eligibility criteria 
 
A cluster was defined as an HIV care and treatment clinic.  Twenty-two clusters, located at 
five district hospitals and 17 primary healthcare facilities, were purposively selected to: (1) 
be representative of HIV treatment clinics in Botswana, and (2) have new ART initiation 
rates sufficient to meet sample size requirements (all clinics had >8 new ART enrolees per 







Figure 4.2. Location of 13 Xpert devices in service of 22 study clinics 
 
 
4.1.6. Study enrolee eligibility criteria 
 
At these 22 clusters, individual patients were eligible for study enrolment if they were new 
HIV clinic attendees, regardless of TB treatment status, and not prisoners at the time of 
the first HIV clinic visit.  For the XPRES primary outcome trial analysis, only those study 
enrolees who newly started ART at or after study enrolment and were >12 years old at 
ART initiation were included.18 
 
4.1.7. Randomisation and masking 
 
The selected 22 clusters received TB diagnostic services from 13 laboratories (Figure 4.1.). 
Because some of the study clinics used the same TB diagnostic laboratory, full Xpert, ICF, 
and retention package activation was planned to be simultaneous for these clinic 
consortiums (Figure 4.11).  After obtaining ethical approvals and agreement to participate 




the study statistician randomly selected one of the rollout permutations.18  Participants, 
investigators and health facilities were not blinded to their phase of enrolment because it 
was considered unfeasible and also ethically sub-optimal to blind health care providers 





At the 22 clusters, per Botswana national guidelines during the time period of the study 
(July 2010 through June 2015), all study participants in all phases were eligible for ART 
initiation if they had a CD4 count ≤350 cells/µL, were diagnosed as having WHO stage 
III/IV, or were pregnant or breastfeeding.152  All study participants received clinical care 
and follow-up appointments according to MOH guidelines, with follow-up schedules 
described as Additional File 2 of the trial manuscript in Chapter 5. 
 
Standard of care phase 
Enrolment in the retrospective SOC phase was through chart abstraction of eligible adult 
patients who started ART between July 2010 and the end of July 2012 (Figure 4.1.) 
(Appendix 1 and 2).18  The SOC phase enrolees received HIV care according to national 
guidelines, limited ICF, infrequent active tracing due to resource limitations, and sputum-
smear microscopy for presumptive TB patients.   
 
Intervention phases EC and EC+X 
Prospective EC enrolment started in August 2012 and was complete by January 2013.  
Prospective EC+X enrolment occurred from October 2012 through March 2014 according 
to the stepped-wedge design (Figure 4.1.).  At enrolment, after written informed consent 
procedures were followed, standard baseline and follow-up questionnaires were 
completed as described in Appendices 1 and 2.  EC phase participants received SOC 
supplemented by two components of the Xpert, ICF, and retention package (i.e., 
additional support for ICF and intensified tracing) combined with sputum-smear 




components of the Xpert, ICF, and retention package (i.e., additional support for ICF, 
intensified tracing, and Xpert in place of sputum-smear microscopy) (Figure 4.3.).  All 
interventions were activated at the cluster-level for the benefit of all clients receiving care 
at the clinic.  Figure 4.3 below summarises the key differences between the SOC and 
intervention phases.   
 
Figure 4.3. Comparison of interventions introduced in the EC and EC+X phases 
Intervention 
component 
Standard of Care (SOC)* Enhanced Care  (EC) EC + Xpert (EC+X) 
TB screening and ICF Weak Strengthened Strengthened 




Infrequent Strengthened Strengthened 
TB Diagnostic Smear microscopy Smear microscopy Xpert 
Abbreviations:  ICF, intensified TB case finding 
 
EC and EC+X participants were followed for 12 months, or until the end of TB treatment, 
whichever was later. The final follow-up visits for EC+X enrolees were in June 2015. 
 
Interventions 
The ICF and active tracing interventions were strengthened through four key mechanisms: 
(1) additional human resources (study nurses) to support implementation, (2) additional 
training for clinic and laboratory personnel, (3) use of checklists and job aids to 
standardize implementation, and (4) regular supervisory visits to track adherence to ICF 





Regarding the ICF intervention, implementation of the WHO 4-symptom TB screening rule 
(i.e., screening for cough of any duration, fever, loss of weight, and night sweats) was 
recommended for all enrolees at each clinic visit in the SOC, EC, and EC+X phases, but 
implementation was strengthened in the EC and EC+X phases.  In all phases, clients were 
considered symptomatic if they screened positive for one or more of the four TB 
symptoms.  In all phases, at least two same-day, on-the-spot (spot) sputum samples were 
recommended for collection from symptomatic clients.  As part of strengthened ICF in the 
EC and EC+X phases, a previously published job-aid was used by study nurses to inform 
the patient how to collect quality sputum samples.  Prior to the EC phase, laboratory 
personnel at the 13 laboratories serving the 22 clusters received refresher training on 
Ziehl-Neelsen staining for sputum-smear microscopy and, prior to the EC+X phase, 
laboratory personnel were trained for Xpert implementation.  In all phases, sputum test 
results were returned to the clinics, with clinicians responsible for informing the patients. 
In the SOC phase, the patient was informed of a TB diagnosis at the next scheduled clinic 
appointment.  In the EC and EC+X phases, study nurses were trained to work with 
laboratories to ensure the turnaround time from sample collection to result return to the 
clinic was ≤4 days for sputum-smear microscopy and ≤2 days for Xpert testing.  In the EC 
and EC+X phases, nurses were trained to inform patients of positive TB diagnoses the 
same day via phone, or if unreachable by phone, by active tracing to the household. 
Indicators monitoring implementation of the ICF cascade were collected and used to 
inform supervision visits (see Additional file 3 of Chapter 5, a table summarizing the 
indicators) 
 
Per national guidelines, clients ≥1 day late for an HIV clinic appointment should be traced 
through phone and home visit starting the day after the missed visit.  However, 
programme reports showed this tracing was infrequently implemented in the SOC phase 
due to lack of human and financial resources.  Implementation of the active tracing policy 
was strengthened in the EC and EC+X cohorts.  In the EC and EC+X phases, a patient 
locator form was used to document telephone numbers and home addresses for 




home visits, facilitated by checklists, were used in attempts to return clients, who had 
missed clinic appointments, to care.  The key HIV care retention indicator used for 
monitoring purposes was the rate of loss to follow-up (LTFU) per 100 person-years (see 
Additional file 3 of Chapter 5, a table summarizing the indicators).  LTFU was defined as 
being >60 days late for a scheduled appointment, per Botswana guidelines. 
 
4.1.9. Primary trial outcome 
 
In XPRES, intensive efforts were implemented to ascertain true mortality outcomes among 
trial participants.  All-cause mortality was either reported passively to clinics by friends or 
family of the decedents or, if a client was considered lost to follow-up, telephonic tracing, 
home visits, and if tracing was unsuccessful, review of the national mortality register, 
were conducted, with further details provided in Chapter 5 and in the published protocol 
(Appendix 1). 
 
4.1.10. Sample size 
 
To estimate power for the comparison of all-cause 6-month mortality in the SOC versus 
EC+X cohort, the approach of Moulton et al, suitable for stepped-wedge trial designs, was 
chosen because these power estimates were more conservative than those derived from a 
pre-post sample size calculation.149  Per this approach, published formulae for the 
comparison of two rates in an unmatched parallel group CRT153 were adapted to the 
stepped-wedge design as follows: 
 
where  is the standard normal deviate corresponding to the upper tail probability of  
and  is the probability of a Type II error; c  is the number of clusters (study facilities) per 
arm, where, since this is a stepped-wedge trial involving 22 clinics, 22/2 was used;149 is 
the estimated true 6-month ART mortality rate in the SOC phase;  is the estimated true 
mortality rate in the EC+X phase;  is the average number of person-years per clinic in the 




two since each patient commits 6 months of follow-up time to the analysis;  is average 
number of person-years per clinic in the intervention phase, conservatively estimated as 
the harmonic mean of person-years contributed by each study site in EC+X, again 
assuming 6 months of follow-up time per participant;149  is the estimated between-
cluster coefficient of variation of the true rates in both the SOC and EC+X phases, 
estimated as 0.2;149  is the standard normal deviate corresponding to the upper tail 
probability of  where is the probability of a Type I error.    
 
Since a log-rank test statistic for intervention effect calculated for a simulated stepped-
wedge trial (  will generally always be lower than the corresponding statistic for 
a parallel group trial, because allocation ratios of patients to intervention or control status 
for parallel group trials remain equal while for stepped-wedge trials they are usually 
unequal, except at the mid-point of the stepped-wedge design, the z-score in the stepped-
wedge trial formula ( above) was divided by a published estimate of  (i.e., 1.2) 
prior to extrapolating the z-score to a power estimate.149  Similarly, for Type 1 error of 5%, 
instead of assuming a  of 1.96, an inflated estimate of 2.352 was used, per published 
precedent.149   
 
Prior to study start, available data from Botswana suggested that the documented all-
cause early mortality rates in the first 6 months of ART among adults were about 15 
deaths per 100 person-years,154 which was similar to estimates from a meta-analyses of 
18 programs in LMIC with active tracing programs (14.7/100 PY).23  Since Botswana data 
and available meta-analyses suggested about 40% of deaths among PLHIV were due to 
undiagnosed TB or TB diagnosed late, and given that interrupting ART during the first 6 
months of therapy by missing clinic appointments increases mortality risk;67,155 it was 
considered reasonable that the Xpert package plus the tracing intervention might reduce 
mortality by about 40%.143,156  To provide >80% power to detect a ≥40% reduction in all-
cause 6-month ART mortality between the two SOC and EC+X groups, assuming SOC 
mortality was ≥10/100 person-years, a 24-month SOC phase enrolment period (N=12,144) 




Figure 4.4. Power to detect a 40% and 50% difference in all-cause 6-month ART mortality 
between SOC and EC+X cohorts over a range of pre-ART SOC mortality rates 
 




4.1.11. Laboratory procedures  
 
Sputum collection 
Implementation of the WHO four-symptom TB screening rule (i.e., screening for cough of 
any duration, fever, loss of weight, and night sweats)60 was recommended for all enrolees 
at each clinic visit in the SOC, EC, and EC+X phases, but implementation was strengthened 
in the EC and EC+X phases.  Implementation of four-symptom TB screening and all 
components of the ICF cascade were strengthened by situating one additional study nurse 
at each study facility, additional training for the health facility in ICF cascades, provision of 
checklists and job aides, and supportive supervision and mentorship.  In all phases, clients 
were considered symptomatic if they screened positive for one or more of the four TB 




recommended for collection from symptomatic clients.  As part of strengthened ICF in the 
EC and EC+X phases, a previously published job-aid was used by study nurses to inform 
the patient how to collect quality sputum samples.18  In addition, where feasible, EC and 
EC+X enrolees were asked to return to the clinic on the second day after screening 
symptom-positive for TB to provide a morning sputum sample and third on-the-spot 
sputum sample primarily to meet other study objectives not covered in this thesis. 
 
Laboratory procedures 
Prior to the EC phase, laboratory personnel at the 13 laboratories serving the 22 clusters 
received refresher training on Ziehl-Neelsen staining for sputum-smear microscopy and, 
prior to the EC+X phase, laboratory personnel were trained for Xpert implementation.  
Two spot sputa were sent to the on-site or peripheral district TB lab for: (1) smear 
microscopy, and (2) Xpert, if the Xpert device had been activated by that time.  The other 
sputum samples were sent to the national TB reference lab to meet other study objectives 
not covered in this thesis (Appendix 1). 
 
Xpert activation 
Training for GeneXpert operators consisted of a three-day curriculum.  The training 
covered the theoretical basis of the Xpert test, how to operate the instrument, 
interpretation of results, troubleshooting, and GeneXpert maintenance (daily, weekly, and 
monthly).  GeneXpert operators were provided a standard operating procedure (SOP) 
manual to serve as a reference for GeneXpert operation.  The third day of the training was 
hands-on operational training and all trainees had to pass a competency test before 
testing patient specimens from study sites.  The GeneXpert was initially installed by a local 
GeneXpert vendor who provided calibration and maintenance services during the study, 
Xpert cartridge sales, and cartridge delivery services. 
 
Air conditioning units were also installed with each GeneXpert to ensure control of room 
temperature.  Uninterruptible power supply (UPS) systems were installed with each 




analysis during power grid outages.  Xpert cartridges were procured through the same 
vendor at $18 per cartridge at the time, which included the cost of the cartridge, central 
warehousing, and delivery to sites when requested.157 
 
Turn-around times 
In all phases, sputum test results were returned to the clinics, with clinicians responsible 
for informing the patients.  In the SOC phase, the patient was informed of a TB diagnosis 
at the next scheduled clinic appointment.  In the EC and EC+X phases, study nurses were 
trained to work with laboratories to ensure the turnaround time from sample collection to 
result return to the clinic was ≤4 days for sputum-smear microscopy and ≤2 days for Xpert 
testing.  In the EC and EC+X phases, nurses were trained to inform patients of positive TB 
diagnoses the same day via phone, or if unreachable by phone, by active tracing to the 
household. 
 
4.1.12. Data collection and management  
 
Paper trial data collection forms (Appendix 2) were completed by study nurses, evaluated 
for completeness and consistency by study nurse supervisors, and then transported 
securely to Gaborone CDC Botswana offices, where data were double-entered into Clindex 
Clinical Trial Software (Fortress Medical Systems, Inc).  The data entry software included 
completeness and consistency checks.  Missing data and inconsistencies were corrected 
where possible through liaison with study nurses at the sites, with corrections made to 
paper forms, and corrections signed by both study nurses and study nurse supervisors.   
 
4.1.13. Trial statistical analysis 
 
For the primary outcome analysis, time at risk for ART enrolees started on the day of ART 
initiation and ended at 6 months of follow-up after ART initiation, or at the time of death, 
LTFU, or transfer out if these events were before 6 months of ART follow-up.  Crude and 
multivariable Cox proportional hazards regression models, with a random effect for clinic, 




Secondary objective analyses were conducted to: (1) compare 12-month ART mortality 
between SOC and EC+X phases, and (2) compare 6-month ART mortality rates between 
cohorts EC and EC+X.18  For the latter I used analytic methods described by Moulton et al, 
fitting Cox proportional hazards models to the data with the underlying time frame being 
time since August 2012 (initiation month for the stepped-wedge component of the trial), 
fixed effect for intervention arm (Xpert device activation), and a random effect for 
clinic.149  I also implemented several sensitivity analyses to assess robustness of primary 
trial findings to different analytic approaches which are described in the trial manuscript 
in Chapter 5. 
 
4.1.14. Ethical considerations 
 
Ethical approvals for this study were obtained from the U.S. Centers for Disease Control 
and Prevention (CDC) Institutional Review Board (IRB) C, the Health Research and 
Development Division of the Health Research and Development Committee (HRDC) in 
Botswana, the University of Pennsylvania IRB No.4, and the London School of Hygiene & 
Tropical Medicine (LSHTM) Observational/Interventions Research Ethics Committee 
(LSHTM ethics reference number: 11779).  All ethical approvals are provided as Appendix 
3.  All consent procedures were approved by the ethical review committees.  For the SOC 
cohort, a waiver of informed consent for chart abstraction was granted in accordance with 
45CFR 46.116 (d).  Written informed consent was obtained from all EC and EC+X enrolees.  
XPRES is registered at ClinicalTrials.gov (trial registration no. NCT02538952). 
 
4.2. Early ART mortality risk score development 
 
I used data from the EC and EC+X phases of the XPRES trial to derive two clinical scores to 
help clinicians identify those at highest risk of early ART mortality and therefore in need of 
ART care intensification.18  The first clinical score assumes CD4 is unavailable at ART 
initiation (i.e., a CD4-independent score) and the second clinical score assumes CD4 count 
is available (i.e., a CD4-dependent score).  I considered the XPRES EC and EC+X cohorts as 




mortality or major differences in other cohort characteristics between EC and EC+X phases 
as described in Chapter 5.  I split the cohort temporally at the mid-point date of ART 
initiation and used the first 50% of XPRES EC and EC+X cohort enrolees to derive a 
parsimonious, multivariable, logistic regression prognostic model for 6-month all-cause 
ART mortality, and the second 50% to internally validate the model.124,126  I used data from 
the TB Fast Track (TBFT) trial in South Africa (SA) to externally validate the derived clinical 
scores.117  I then compared screening accuracy in terms of sensitivity, specificity, positive 
predictive value (PPV), and negative predictive value (NPV) of the derived clinical scores 
with existing WHO eligibility criteria for advanced disease and ART care intensification 
(i.e., CD4 <200/µL or WHO stage III/IV).  Full details of the analytic approach are provided 
in the manuscript in Chapter 6. 
 
4.3. Development of a risk score for TB among PLHIV  
 
I again used data from the from the EC and EC+X phases of the XPRES trial to derive the TB 
clinical score.18  The outcome of interest was prevalent active TB, defined as a new clinical 
or microbiological diagnosis of TB within the first 6 months after HIV clinic and XPRES trial 
enrolment.123  In this analysis, I split the XPRES cohort data into 11 southern and 11 
northern clinics to serve as an internal derivation and validation datasets, respectively.  I 
used a geographical split rather than a temporal split because, although there was no 
difference in overall new TB case finding between EC (5%) and EC+X (6%) phases, the 
percentage of TB diagnoses that were microbiologically confirmed was higher in the EC+X 
(65%) than EC (51%) phases.  I used two different but complementary modelling 
approaches to generate a parsimonious TB clinical risk score comprised of variables easily 
available in a resource-constrained clinic setting: (1) logistic regression models, and (2) 
random forest machine learning models. Random forest machine learning models are 
particularly useful for identifying important non-linear associations between predictors 
and outcomes.127  Having derived the clinical score, I then used data from three other 
settings to validate the derived clinical score: (1) prospective cohort data for XPHACTOR 
study enrolees from Gauteng province, South Africa, which represents a predominantly 




Gauteng, Limpopo, and North West Provinces in South Africa, which represents a 
population with advanced HIV disease not taking ART;117 and (3) prospective cohort data 
from the Western Cape, SA, which represents an ART-naïve population in a very high TB 
incidence setting.140  I compared screening accuracy of our derived clinical scores with 
existing WHO TB symptom screening criteria for active TB among PLHIV in each of these 
populations.  
 
4.4. Random forest model 
 
A random forest modelling approach, which is a type of machine learning, was used to 
supplement the traditional logistic regression approach to score development because of 
its relative strength in ability to identify important non-linear relationships between 
covariates and categorical outcomes.127,158   
 
A random forest model is built from many decision trees 
The random forest model consists of multiple decision trees that attempt to sequentially 





Figure 4.5. A decision tree with two nodes with classification informed by covariates x 
and y (taken from Zhou et al)159 
 
To develop a single decision tree, the best split at each node is assessed by evaluating 
which cut-off gives the most homogenous classifications (i.e., lowest Gini impurity or 
highest Gini Gain according to published formulae).159  Random forest packages available 
in R software (R Core Team (2017). R Foundation for Statistical Computing, Vienna, 
Austria) try every possible split to find the split that gives the least Gini impurity or 





Figure 4.6. Example of splits for covariate x tried to evaluate "best" split with lowest 
Gini impurity 
 
In training a decision tree, multiple nodes are formed until it is no longer possible to 
further split the homogenous group based on available data.  This occurs when all possible 
splits are equally good and have a Gini Gain of 0.  The “leaves” of the decision tree can 
then be classified (e.g., green, red, and blue in Figure 4.5). 
 
Bootstrap aggregating or bagging 
A random forest model combines predictions from multiple trees through a process of 
sampling with replacement a certain number of training datasets, with each sample 
representing a random sample of two-thirds of all observations from the full dataset.  A 
decision tree is then trained on each sampled dataset as described earlier.  This process is 
repeated a certain number of times to create a certain number of trees (usually 200-1000 
trees).160  Finally, the predictions from the individual decision trees are aggregated into 
either a “majority vote” (if the outcome is categorical like the TB outcome), or an average 
(if the outcome is a continuous variable).   
 
Feature bagging 
Random forests also have a parameter that controls how many covariates to try when 




algorithms that help modelers identify the right number of covariates (referred to as the 
mtry feature in Chapter 7) to randomly select and use for decision tree formation.  By 
using subsets of the covariates rather than all covariates, this injects randomness that 
makes the individual trees more unique and reduces correlations between the trees, 
which improves the random forest predictions overall on validation datasets.  In this way 
random forests are designed to reduce the problem of over-fitting on the training dataset 
that is inherent in single decision tree modelling approaches.   
 
Variable importance 
A key reason I supplemented standard logistic regression modelling with the random 
forest machine learning approach was to understand the importance of each covariate in 
its ability to split patients into homogenous groups (i.e., those with TB versus those 
without).  Random forest models allow this evaluation of variable importance by assessing 
the mean decrease in Gini impurity associated with each variable included in a random 
forest model.  The mean decrease in impurity is the average of a variable’s total decrease 
in node impurity, weighted by the proportion of samples reaching that node in each 
individual tree in the random forest.  Therefore, high mean decrease in Gini indicates 
higher variable importance (i.e., the variable was on average important in splitting nodes 
into groups that had TB versus did not have TB).158  Further description of this modelling 













Table 5.1. (Research paper Table 1) Demographic and clinical characteristics of XPRES 
participants at antiretroviral therapy initiation 
Table 5.2. (Research paper Table 2) Primary and secondary study outcomes—
comparison of mortality rates between study phases 
Table 5.3. (Research paper Table 3) Methods of new TB diagnosis immediately before 
ART and in the first 6 months of ART in the SOC, EC, and EC+X phases of XPRES 
 
Figure 5.1. (Research paper Fig. 1) Study design for the Xpert Package Rollout Evaluation 
using a Stepped-wedge design (XPRES). Abbreviations: SOC, standard of care phase; EC, 
enhanced care phase; EC+X, enhanced care plus Xpert phase 
Figure 5.2. (Research paper Fig. 2) Trial profile 
Figure 5.3. (Research paper Fig. 3) Kaplan-Meier curves showing cumulative 6-month 
mortality among ART enrollees in SOC, EC, and EC+X phases 
Figure 5.4. (Research paper Fig. 4) Intensified TB case finding (ICF) cascade among ART 
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Abstract
Background: Undiagnosed tuberculosis (TB) remains the most common cause of HIV-related mortality. Xpert MTB/
RIF (Xpert) is being rolled out globally to improve TB diagnostic capacity. However, previous Xpert impact trials
have reported that health system weaknesses blunted impact of this improved diagnostic tool. During phased
Xpert rollout in Botswana, we evaluated the impact of a package of interventions comprising (1) additional support
for intensified TB case finding (ICF), (2) active tracing for patients missing clinic appointments to support retention,
and (3) Xpert replacing sputum-smear microscopy, on early (6-month) antiretroviral therapy (ART) mortality.
Methods: At 22 clinics, ART enrollees > 12 years old were eligible for inclusion in three phases: a retrospective standard
of care (SOC), prospective enhanced care (EC), and prospective EC plus Xpert (EC+X) phase. EC and EC+X phases were
implemented as a stepped-wedge trial. Participants in the EC phase received SOC plus components 1 (strengthened
ICF) and 2 (active tracing) of the intervention package, and participants in the EC+X phase received SOC plus all three
intervention package components. Primary and secondary objectives were to compare all-cause 6-month ART
mortality between SOC and EC+X and between EC and EC+X phases, respectively. We used adjusted analyses,
appropriate for study design, to control for baseline differences in individual-level factors and intra-facility correlation.
Results: We enrolled 14,963 eligible patients: 8980 in SOC, 1768 in EC, and 4215 in EC+X phases. Median age of ART
enrollees was 35 and 64% were female. Median CD4 cell count was lower in SOC than subsequent phases (184/μL in SOC,
246/μL in EC, and 241/μL in EC+X). By 6months of ART, 461 (5.3%) of SOC, 54 (3.2%) of EC, and 121 (3.0%) of EC+X enrollees
had died. Compared with SOC, 6-month mortality was lower in the EC+X phase (adjusted hazard ratio, 0.77; 95% confidence
interval, 0.61–0.97, p= 0.029). Compared with EC enrollees, 6-month mortality was similar among EC+X enrollees.
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Conclusions: Interventions to strengthen ICF and retention were associated with lower early ART mortality. This new
evidence highlights the need to strengthen ICF and retention in many similar settings. Similar to other trials, no additional
mortality benefit of replacing sputum-smear microscopy with Xpert was observed.
Trial registration: Retrospectively registered: ClinicalTrials.gov (NCT02538952)
Keywords: Tuberculosis, Xpert MTB/RIF, Intensified tuberculosis case finding, Mortality
Background
In resource-limited settings, tuberculosis (TB) remains
the most common cause of death among people living
with HIV (PLHIV), including those starting antiretroviral
therapy (ART), and is commonly undiagnosed at the
time of death [1, 2]. Death from undiagnosed TB or TB
diagnosed late is a key reason early (6-month) ART mor-
tality rates remain significantly higher in sub-Saharan
Africa (SSA) than resource-rich settings [2–4]. All data
point towards a critical need to improve TB case finding
among PLHIV starting ART.
In 2011, following World Health Organization (WHO)
endorsement of Xpert MTB/RIF® (Xpert) as the first-line
TB diagnostic test for symptomatic PLHIV [5], the
Botswana Ministry of Health (MOH) and partners initi-
ated planning for a phased national Xpert rollout [6].
Review of available program data for new HIV care
enrollees showed that many components of the intensi-
fied TB case finding (ICF) cascade, especially compliance
with the WHO-recommended 4-symptom TB screening
rule, and early retention in HIV care, should be
strengthened in order for Xpert to have maximum bene-
fit [7]. Weaknesses in the health system that have re-
sulted in poor completion of the TB diagnostic and
treatment cascade and sub-optimal retention in HIV
care, have been cited as important reasons for lack of
observed Xpert impact on PLHIV mortality in similar
settings [8, 9]. Therefore, Botswana used the Xpert roll-
out as an opportunity to strengthen ICF and retention in
early HIV care through rollout of a package of services
[6]. The intervention package has three components: (1)
additional support for ICF, (2) intensified tracing for pa-
tients missing clinic appointments to return them to
care, and (3) Xpert replacing sputum-smear microscopy.
No trial has yet evaluated impact of Xpert combined
with strengthened health systems on mortality [8–10]. We
evaluated impact of the Xpert, ICF, and retention package
versus standard of care on early ART patient mortality.
Methods
Study design
We conducted a multi-center, stepped-wedge cluster
randomized trial (CRT) with a retrospective baseline
component called the Xpert Package Rollout Evaluation
using a Stepped-wedge design (XPRES) trial. A stepped-
wedge rather than parallel group design was chosen be-
cause the Xpert, ICF, and retention package was ex-
pected to be beneficial for patients and the trial was part
of a national rollout [6].
Participants
A cluster was defined as an HIV care and treatment
clinic. Twenty-two clusters, located at five district hospi-
tals and 17 primary healthcare facilities, were purpos-
ively selected to (1) be representative of HIV treatment
clinics in Botswana and (2) have new ART initiation
rates sufficient to meet sample size requirements (see
Additional file 1, providing text on clinic selection cri-
teria). At these 22 clusters, individual patients were eli-
gible for study enrollment if they were new HIV clinic
attendees, regardless of TB treatment status, and not
prisoners at the time of the first HIV clinic visit. The
study aimed to enroll or offer enrollment to all eligible
HIV clinic attendees in three consecutive phases: (1) a
retrospective standard of care (SOC) phase, (2) a pro-
spective enhanced care (EC) phase, and (3) a prospective
EC plus Xpert (EC+X) phase (Fig. 1). For this pre-
defined protocol analysis, only those study enrollees who
newly started ART at or after study enrollment and were
≥ 12 years old at ART initiation were included [6].
Randomization and masking
The selected 22 clusters received TB diagnostic services
from 13 laboratories (Fig. 1). Because some of the study
clinics used the same TB diagnostic laboratory, full
Xpert, ICF, and retention package activation was
planned to be simultaneous for these clinic consortiums
(Fig. 1). After obtaining ethical approvals and agreement
to participate in the study from MOH at a central level
and MOH management at the selected facilities, the
study statistician randomly selected one of the rollout
permutations [6].
Procedures
At the 22 clusters, per Botswana national guidelines dur-
ing the time period of the study (July 2010 through June
2015), all study participants in all phases were eligible for
ART initiation if they had a CD4 count ≤ 350 cells/μL,
were diagnosed as having WHO stage III/IV, or were
pregnant or breastfeeding [11]. All study participants
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received clinical care and follow-up appointments accord-
ing to MOH guidelines (see Additional file 2, a table sum-
marizing standard clinical care follow-up).
Standard of care phase
Enrollment in the retrospective SOC phase was through
chart abstraction of eligible adult patients who started
ART between July 2010 and the end of July 2012 (Fig. 1)
[6]. The SOC phase enrollees received HIV care accord-
ing to national guidelines, limited ICF, infrequent active
tracing due to resource limitations, and sputum-smear
microscopy for presumptive TB patients.
Intervention phases EC and EC+X
Prospective EC enrollment started in August 2012 and
was complete by January 2013. Prospective EC+X enroll-
ment occurred from October 2012 through March 2014
according to the stepped-wedge design (Fig. 1). EC phase
participants received SOC supplemented by two compo-
nents of the Xpert, ICF, and retention package (i.e., add-
itional support for ICF and intensified tracing) combined
with sputum-smear microscopy. EC+X phase partici-
pants received SOC supplemented by all three compo-
nents of the Xpert, ICF, and retention package (i.e.,
additional support for ICF, intensified tracing, and Xpert
in place of sputum-smear microscopy). All interventions
were activated at the cluster-level for the benefit of all
clients receiving care at the clinic. EC and EC+X
participants were followed for 12 months, or until the
end of TB treatment, whichever was later. The final
follow-up visits for EC+X enrollees were in June 2015.
Interventions
The ICF and active tracing interventions were strength-
ened through four key mechanisms: (1) additional human
resources (study nurses) to support implementation, (2)
additional training for clinic and laboratory personnel, (3)
use of checklists and job aids to standardize implementa-
tion, and (4) regular supervisory visits to track adherence
to ICF and tracing checklists.
ICF intervention
Implementation of the WHO 4-symptom TB screening
rule (i.e., screening for cough of any duration, fever, loss
of weight, and night sweats) [12] was recommended for
all enrollees at each clinic visit in the SOC, EC, and
EC+X phases, but implementation was strengthened in
the EC and EC+X phases. In all phases, clients were con-
sidered symptomatic if they screened positive for one or
more of the four TB symptoms. In all phases, at least
two same-day, on-the-spot (spot) sputum samples were
recommended for collection from symptomatic clients.
As part of strengthened ICF in the EC and EC+X phases,
a previously published job-aid was used by study nurses
to inform the patient how to collect quality sputum sam-
ples [6]. Prior to the EC phase, laboratory personnel at
Fig. 1 Study design for the Xpert Package Rollout Evaluation using a Stepped-wedge design (XPRES). Abbreviations: SOC, standard of care phase;
EC, enhanced care phase; EC+X, enhanced care plus Xpert phase
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the 13 laboratories serving the 22 clusters received re-
fresher training on Ziehl-Neelsen staining for sputum-
smear microscopy, and prior to the EC+X phase, labora-
tory personnel were trained for Xpert implementation.
In all phases, sputum test results were returned to the
clinics, with clinicians responsible for informing the pa-
tients. In the SOC phase, the patient was informed of a
TB diagnosis at the next scheduled clinic appointment.
In the EC and EC+X phases, study nurses were trained
to work with laboratories to ensure the turnaround time
from sample collection to result return to the clinic was
≤ 4 days for sputum-smear microscopy and ≤ 2 days for
Xpert testing. In the EC and EC+X phases, nurses were
trained to inform patients of positive TB diagnoses the
same day via phone, or if unreachable by phone, by ac-
tive tracing to the household. Indicators monitoring im-
plementation of the ICF cascade were collected and used
to inform supervision visits (see Additional file 3, a table
summarizing the indicators) [7].
Active tracing intervention
Per national guidelines, clients ≥ 1 day late for an HIV
clinic appointment should be traced through phone and
home visit starting the day after the missed visit. How-
ever, program reports showed this tracing was infre-
quently implemented in the SOC phase due to lack of
human and financial resources. Implementation of the
active tracing policy was strengthened in the EC and
EC+X cohorts. In the EC and EC+X phases, a patient lo-
cator form was used to document telephone numbers
and home addresses for intensified tracing activities to
support retention. Up to five telephone calls and two
home visits, facilitated by checklists, were used in at-
tempts to return clients, who had missed clinic appoint-
ments, to care. The key HIV care retention indicator
used for monitoring purposes was the rate of loss to
follow-up (LTFU) per 100 person-years (see Additional
file 3, a table summarizing the indicators). LTFU was de-
fined as being > 60 days late for a scheduled appoint-
ment, per Botswana guidelines.
Objectives and outcomes
The study had two primary objectives. The primary ob-
jective reported here is the non-randomized comparison
of all-cause 6-month ART mortality among adult ART
enrollees (≥12 years old) between the SOC and EC+X
phases [6]. The second primary objective, which aimed to
compare diagnostic sensitivity of the new Xpert-based TB
diagnostic algorithm with that of the sputum-smear-
microcopy-based algorithm, will be reported separately ac-
cording to diagnostic accuracy study reporting guidelines.
Secondary objectives reported in this paper include (1)
the comparison of 12-month ART mortality between SOC
and EC+X phases and (2), within the randomized
stepped-wedge trial, the comparison of all-cause, adult, 6-
month ART mortality between the EC and EC+X phases.
We implemented intensive efforts to ascertain true
mortality outcomes among participants. Deaths and date
of death were either passively reported to the clinic by
friends or relatives of the deceased participant, or ac-
tively ascertained if the client had missed an appoint-
ment or was considered LTFU [13]. Initial efforts to
ascertain outcomes of clients who missed an appoint-
ment or were LTFU included phone outreach to the cli-
ent or contact and home visits. For participants in the
SOC phase, these efforts started after data entry was
complete which was always > 12months after ART initi-
ation. In the EC and EC+X phases, this outreach started
immediately after the missed appointment, in an attempt
to return the client to care. For all clients unreachable
by phone or home visit who met the LTFU definition,
vital status was ascertained through national Death
Registry review. By law, since 1969, all deaths need to be
registered in the Death Registry, which is maintained by
the Civil and National Registration Office.
Sample size
As described previously [6], to obtain conservative sam-
ple size estimates, we used the approach of Moulton
et al., suitable for stepped-wedge trial designs, to esti-
mate required sample sizes to meet the primary study
objective comparing 6-month ART mortality rates be-
tween SOC and EC+X phases [14]. Funding limitations
restricted the number of clinics that could be included
in the study to 22. A between-cluster coefficient of vari-
ation of 0.2 was used based on review of the literature of
similar stepped-wedge trials [14]. Monthly HIV clinic
(cluster) size was derived from reported program ART
enrollment rates in the SOC phase and varied between
clinics (average, 23 ART enrollees/month; range, 8–46/
month). Prior to study start, available data from
Botswana suggested that all-cause, adult, 6-month ART
mortality rates were about 15 deaths per 100 person-
years [3, 15]. To provide > 80% power to detect a ≥ 40%
reduction in all-cause 6-month ART mortality between
the two groups, assuming SOC mortality was ≥ 10/100
person-years, a 24-month SOC phase enrollment period
(N = 12,144) and an 18month EC+X phase enrollment
period (N = 6348) were chosen.
Statistical analysis
For the primary outcome analysis, time at risk for ART
enrollees started on the day of ART initiation and ended
at 6 months of follow-up after ART initiation, or at the
time of death, LTFU, or transfer out if these events were
before 6 months of ART follow-up. Crude and multivari-
able Cox proportional hazards regression models, with a
random effect for clinic, were used to assess the effect of
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intervention status (SOC vs EC+X) on time to death [6].
Per a pre-specified analysis plan, age at ART initiation,
sex, pregnancy status, and baseline CD4 count were a
priori covariates to be included in the multivariable
model. Hemoglobin at ART initiation [16], ART regimen
[17], and weight at ART initiation [16] were included in
the multivariable model because of their importance as
predictors of mortality in this and other analyses.
Pre-specified secondary analyses were conducted to
(1) compare 12-month ART mortality between SOC
and EC+X phases and (2) compare 6-month ART
mortality rates between cohorts EC and EC+X [6].
For the latter, we used analytic methods described by
Moulton et al., fitting Cox proportional hazards
models to the data with the underlying time frame
being time since August 2012 (initiation month for
the stepped-wedge component of the trial), fixed ef-
fect for intervention arm (Xpert device activation),
and a random effect for clinic [14]. The proportional-
ity assumption was checked using visual methods and
the Grambsch and Therneau test.
Per the pre-specified analysis plan, plausible interac-
tions between the intervention effect and other covari-
ates, including CD4 count at ART initiation, were
examined by comparing models with and without inter-
actions using the likelihood ratio test. Per the pre-
specified analysis plan, the primary time-to-event ana-
lytic approaches comparing SOC versus EC+X and EC
versus EC+X mortality rates assigned follow-up time to
the phase in which the participant started ART because
the interventions were expected to have maximum im-
pact around the time of ART initiation. However, two
pre-specified sensitivity analyses of this approach were
planned. The first sensitivity analysis censors follow-up
time for ART enrollees at the time of cross-over be-
tween phases, while the second assigns follow-up time
to contemporary intervention phases when cross-over
occurs, through use of a time-dependent covariate [18].
In addition, per a third pre-specified sensitivity analysis,
an inverse probability weighting approach was used to
account for non-enrollment in the EC and EC+X phases
of the study. Separate adjusted logistic regression models
for hospital versus clinic enrollees were used to predict
the probability of being enrolled in the study. Patients
consenting to enrollment were up-weighted by the in-
verse of the calculated enrollment probability. An ad-
justed logistic regression approach was used to estimate
inverse probability weights to lower the likelihood of
bias given the possibility of non-random enrollment in
the EC and EC+X phases [19]. All analyses were con-
ducted using STATA 14 or 16 (StataCorp, 2009, Stata
Statistical Software, Release 14 and 16, College Station,




Across the 22 study clinics, there were 528 months of
enrollment in the SOC phase (mean 24/clinic), 120
months in the EC phase (mean 5.5/clinic), and 299
months of enrollment in the EC+X phase (mean 13.6
months/clinic) (Fig. 2). All 10,047 eligible patients for
the SOC phase were enrolled. Among the 2703 and
5834 patients eligible for the EC and EC+X phases, re-
spectively, 1794 (66%) and 4247 (73%) consented to en-
rollment. The main reason eligible clients were not
enrolled prospectively is that they left the clinic before
they could be offered enrollment. The demographic and
clinical characteristics of clients consenting to enroll-
ment were very similar to the characteristics of clients
not enrolled (see Additional file 4, a table comparing
characteristics of those enrolled versus not enrolled).
We excluded from this analysis patients who transferred
into the clinic on ART (n = 1067), were < 12 years old at
ART initiation (n = 22), or did not start ART during
follow-up (n = 36) (Fig. 2). In total, 8980, 1768, and 4215
patients were included in the SOC, EC, and EC+X
phases for analysis, respectively.
Baseline characteristics
Among all study enrollees included in the analysis, me-
dian age was 35 (interquartile range (IQR) 29–42) at
ART initiation and the percentage female was 64% and
these characteristics were similar between phases
(Table 1). Among female enrollees, the percentage who
were pregnant at the time of ART initiation was lower
in the SOC phase (16%) than EC (23%) and EC+X (32%)
phases. Among all enrollees, median weight (58.4 kg)
and median hemoglobin (11.7 g/dL) were similar be-
tween phases. However, median CD4 count at ART ini-
tiation was lower in the SOC phase (184 cells/μL) than
in the EC (246 cells/μL) and EC+X (241 cells/μL) phases.
In addition, the percentage of enrollees with mild or
moderate anemia per WHO criteria was higher in the
SOC phase (56%) than EC (48%) and EC+X phases
(46%). Tenofovir (combined with lamivudine or emtrici-
tabine and efavirenz or nevirapine) was less commonly
prescribed as first-line ART in the SOC (78%) compared
with the EC (93%) and EC+X (96%) phases.
Primary outcome: 6-month ART mortality in SOC versus
EC+X
By 6months after ART initiation, 461 (5.3%) of enrollees
in the SOC phase had died compared with 121 (3.0%) of
enrollees in the EC+X phase. Six-month ART mortality
rates were 11.4 deaths per 100 person-years in the SOC
phase versus 6.3 deaths per 100 person-years in the
EC+X phase (Table 2). Compared with the SOC phase,
6-month mortality was lower in the EC+X phase in
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unadjusted analysis (hazard ratio (HR) 0.58, 95% CI
0.48–0.71, p < 0.001) (Fig. 3, Table 2). After controlling
for potential confounders, including age, sex, pregnancy
status, weight, CD4 count, hemoglobin, and ART regi-
men, 6-month mortality remained lower in the EC+X
phase compared with the SOC phase (adjusted HR, 0.77,
95% CI 0.61–0.97, p = 0.029).
Intervention effect size was similar across CD4 strata
(see Additional file 5, a figure showing cumulative mor-
tality incidence stratified by CD4 count at ART initi-
ation). In addition, effect size was robust to sensitivity
analyses that censored follow-up time at the time of
transition between phases or assigned follow-up time to
contemporary intervention phases using a time-
dependent covariate (see Additional file 6, a table show-
ing these sensitivity analyses). Effect size was robust to
sensitivity analysis using an inverse probability weighting
approach to account for non-enrollment in EC and
EC+X phases (see Additional file 7, a table showing
these sensitivity analyses).
Secondary outcomes: 12-month ART mortality in SOC
versus EC+X
By 12months after ART initiation, 551 (6.5%) of SOC
versus 137 (3.7%) of EC+X phase enrollees had died.
Twelve-month mortality rates were 7.3/100 person-years
in the SOC versus 4.6/100 person-years in the EC+X
phase. Compared with the SOC phase, 12-month mor-
tality was lower in the EC+X phase in both unadjusted
(HR 0.58, 95% CI 0.48–0.70, p < 0.001) and adjusted
(AHR 0.76, 95% CI 0.61–0.95, p = 0.014) analyses
(Table 2). Intervention effect size was robust to sensi-
tivity analyses (see Additional files 6 and 7, tables
showing sensitivity analyses).
Secondary outcomes: 6-month ART mortality in EC versus
EC+X
By 6 months of ART follow-up among ART enrollees
in the EC phase, 54 (3.2%) of enrollees had died. Six-
month mortality rates were similar between the EC
(6.5/100 person-years) and EC+X phases (6.3/100
person-years) in both unadjusted and adjusted pre-
specified analyses (AHR 1.13, 95% CI, 0.63–2.03),
where all follow-up time was assigned to the phase in
which the patient started ART (Table 2). In sensitivity
analyses comparing EC vs. EC+X 6-month mortality
rates, the AHR was 0.90 (95% CI 0.42–1.95) when EC
enrollee follow-up time was censored at the time of
EC+X cross-cover, and 0.79 (95% CI 0.41–1.50) when
EC enrollee follow-up time in the EC+X phase was
assigned to the EC+X phase using a time-dependent
variable (see Additional file 6, a table showing sensi-
tivity analyses).
Fig. 2 Trial profile
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Table 1 Demographic and clinical characteristics of XPRES participants at antiretroviral therapy initiation
SOC EC EC+X
(N = 8980) (N = 1768) (N = 4215)
n %/median (IQR) n %/median (IQR) n %/median (IQR)
Age (years)a
n, median, (IQR) 8969 35 (30–43) 1768 34 (29–42) 4215 34 (29–41)
Gender
Female 5624 63% 1194 68% 2797 66%
If female, pregnant?
Yes 927 16% 271 23% 903 32%
Weight (kg)b
Median (IQR) 8351 57.9 (50.5–66.6) 1765 58.6 (51.3–67.8) 4209 59.4 (52.5–68.7)
Weight (kg)
< 45 kg 871 10% 160 9% 318 8%
45–60 kg 3971 48% 817 46% 1910 45%
> 60 kg 3509 42% 788 45% 1981 47%
Baseline CD4 (cells/μL)c
Median (IQR) 8675 184 (100–241) 1765 246 (148–310) 4180 241 (132–321)
Baseline CD4 (cells/μL)
< 50 1061 12% 132 7% 370 9%
50 to < 100 1109 13% 161 9% 371 9%
100 to < 200 2660 31% 366 21% 928 22%
200 to < 350 3456 40% 947 54% 1928 46%
350 to < 500 246 3% 93 5% 334 8%
≥ 500 143 2% 66 4% 249 6%
Baseline hemoglobin (g/dL)d
Median (IQR) 7869 11.5 (10.0–13.0) 1678 11.9 (10.4–13.3) 3911 12.0 (10.6–13.3)
Hemoglobin categorye
Severe anemia 426 5% 68 4% 109 3%
Mild/moderate anemia 4399 56% 805 48% 1810 46%
No anemia 3044 39% 805 48% 1992 51%
TB treatment at ART initiation
Yes 423 5% 85 5% 251 6%
Regimenf
TDF/XTC/EFV or NVP 6998 78% 1615 93% 4000 96%
AZT/3TC/EFV or NVP 1045 12% 94 5% 107 3%
D4T/3TC/EFV or NVP 151 2% 2 0% 4 0%
Other 784 9% 26 1% 54 1%
Abbreviations: SOC standard of care phase, EC enhanced care phase, EC+X enhanced care plus Xpert phase, IQR interquartile range, TDF tenofovir, XTC either
lamivudine or emtricitabine, EFV efavirenz, NVP nevirapine, ddI didanosine, ABC abacavir, LPV/r lopinavir/ritonavir, AZT zidovudine, 3TC lamivudine, D4T stavudine
a11 ART enrollees in the SOC cohort had unknown age but were documented to be adult in the ART chart
b629 (7%), 2 (0.2%), and 6 (0.1%) had missing weights at ART initiation in the SOC, EC, and EC+X phases, respectively
c305 (3%), 3 (0.2%), and 35 (0.8%) had missing CD4 in the SOC, EC, and EC+X phases, respectively. For each enrollee, the CD4 count taken closest to the date of
ART initiation in the 12 months before ART start was used
d1111 (12%), 90 (5%), and 304 (7.2%) had missing hemoglobin in the SOC, EC, and EC+X phases, respectively. For each enrollee, the hemoglobin taken closest to
the date of ART initiation in the 12 months before ART start was used
eAnemia severity was classified according to World Health Organization criteria as follows: no anemia, hemoglobin level of ≥ 13.0 g/dL for men, ≥ 12.0 g/dL for
non-pregnant females, and ≥ 11.0 g/dL for pregnant females; mild/moderate anemia, 8.0 to < 13.0 g/dL for men, 8.0 to < 12.0 g/dL for non-pregnant women, and
7.0 to < 11.0 g/dL for pregnant women; and severe anemia, < 8.0 g/dL for males and non-pregnant females and < 7.0 g/dL for pregnant women
f2 (0%), 31 (2%), and 50 (1%) had missing ART regimen in the SOC, EC, and EC+X phases, respectively
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TB screening and diagnosis
Among SOC, EC, and EC+X phase enrollees respect-
ively, 359 (4%), 44 (2%), and 122 (3%) were diagnosed
with TB and had started TB treatment prior to arrival at
the HIV treatment clinic. Therefore, in the SOC, EC,
and EC+X phases, 8621, 1724, and 4093 patients were
eligible for TB symptom screening before ART initiation.
Among these patients eligible for TB symptom screening
before ART initiation in the SOC, EC, and EC+X phases,
1700 (20%), 1724 (100%), and 4093 (100%) were
screened for at least one TB symptom and 1243 (14%),
1724 (100%), and 4093 (100%) were screened for all four
TB symptoms, respectively (Fig. 4). Within the SOC
phase, ART enrollees were more likely to be screened
Table 2 Primary and secondary study outcomes—comparison of mortality rates between study phases
ART enrollees Deaths (n)a Rate/100PYb Crude HRc (95% CI) p AHRcd (95% CI) p
Primary outcome: 6-month ART mortality in SOC versus EC+X phase
SOC 8980 461 11.4 1.00 – – 1.00 – –
EC+X 4215 121 6.3 0.58 (0.48–0.71) < 0.001 0.77 (0.61–0.97) 0.029
Secondary outcomes: 12-month ART mortality in SOC versus EC+X phase
SOC 8980 551 7.3 1.00 – – 1.00 – –
EC+X 4215 137 4.6 0.58 (0.48–0.70) < 0.001 0.76 (0.61–0.95) 0.014
6-month ART mortality in EC versus EC+X phasee
EC 1768 54 6.5 1.00 1.00
EC+X 4215 121 6.3 1.07 (0.62–1.84) 0.800 1.13 (0.63–2.03) 0.690
Abbreviations: SOC standard of care phase, EC enhanced care phase, EC+X enhanced care plus Xpert phase, PY person-years, HR hazard ratio, AHR adjusted hazard
ratio, CI confidence interval, XPRES Xpert Package Rollout Evaluation using a Stepped-Wedge design
aRepresents deaths observed among all ART enrollees by the time point specified
bRepresents unadjusted 6- and 12-month ART mortality rates among all ART enrollees in each phase of the study. For mortality rates among ART enrollees
included in the adjusted analyses, see Additional file 6
cAll Cox proportional hazards regression models included a random effect for clinic
dAdjusted for the following characteristics at ART initiation: age, sex, pregnancy status, weight, CD4 count, hemoglobin, and ART regimen. Adjusted analysis
comparing SOC versus EC+X mortality rates included 7184 SOC enrollees with 350 deaths within 6 months and 424 deaths within 12months, and 3861 EC+X
enrollees with 93 deaths within 6months and 108 deaths within 12 months
eAnalysis restricted to randomized stepped-wedge portion of the trial, fitting a Cox proportional hazards regression model to the data with the underlying time
frame beginning August 2012 (the start of EC enrollment), and including a fixed effect for monthly changes in mortality rates during the first 6 months of ART.
Adjusted analysis comparing EC versus EC+X mortality rates included 1653 EC enrollees with 43 deaths within 6 months and 3861 EC+X enrollees with 93 deaths
within 6 months
Fig. 3 Kaplan-Meier curves showing cumulative 6-month mortality among ART enrollees in SOC, EC, and EC+X phases
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for at least one TB symptom if they had lower weight
and lower CD4 count at ART initiation (see Add-
itional file 8, a table showing predictors of being
screened for TB in the SOC cohort).
Among SOC, EC, and EC+X enrollees eligible for
screening, 525 (6%), 514 (30%), and 1249 (31%) screened
positive for at least one TB symptom and 199 (2%), 237
(14%), and 688 (17%) provided a sputum sample for TB
diagnosis (Fig. 4). Ultimately, 129 (1%), 86 (5%), and 244
(6%) enrollees in the SOC, EC, and EC+X phases were
newly diagnosed with TB and started TB treatment be-
fore ART initiation or during the first 6 months of ART.
The number of pulmonary TB diagnoses in the SOC
(n = 123), EC (n = 68), and EC+X (n = 198) phases that
were confirmed microbiologically was 22 (18%), 35
(51%), and 129 (65%), respectively (Table 3).
Early ART LTFU
By 6months after ART initiation, cumulative LTFU inci-
dence, uncorrected by subsequent mortality ascertain-
ment efforts, in the SOC, EC, and EC+X phases, was 4%,
1%, and 1%, respectively (see Additional file 9, a table
summarizing these cumulative LTFU incidence percent-
ages). Compared with 6-month LTFU rates in the SOC
phase (8.3/100 person-years), rates of 6-month LTFU
were lower in the EC (1.2/100 person-years) and EC+X
(1.6/100 person-years) phases in both unadjusted and
adjusted analyses (see Additional file 10, a table compar-
ing LTFU rates between SOC, EC, and EC+X phases).
Discussion
In Botswana, compared with SOC, interventions to
strengthen WHO-recommended TB symptom screening
and ICF algorithms combined with active tracing to sup-
port retention were associated with increased TB case
finding and lower early ART mortality. No additional
mortality benefit of replacing sputum-smear microscopy
with Xpert was observed.
Although implementation of the WHO-recommended
4-symptom TB screening rule as the first step in ICF al-
gorithms among PLHIV starting ART has been recom-
mended since 2011 along with TB-HIV care continuum
retention interventions including active tracing [20], no
study has yet reported on the potential impact on mor-
tality of strengthening systems to implement these
guidelines [7]. Although the observed reduction in all-
cause mortality between SOC and subsequent EC and
EC+X phases represents a pre- versus post-comparison,
rather than a randomized comparison, and is therefore
at risk of residual confounding, the study has a number
of strengths that suggest ICF and retention interventions
did independently contribute to observed mortality
impact. Firstly, the reduction in all-cause mortality
remained statistically significant after adjusting for key
Fig. 4 Intensified TB case finding (ICF) cascade among ART enrollees in SOC, EC, and EC+X phases. Abbreviations: SOC, standard of care phase,
EC, enhanced care phase, EC+X, enhanced care plus Xpert phase
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covariates. Secondly, the improvements in TB screening,
TB case finding, and uncorrected LTFU rates between
SOC and subsequent EC and EC+X phases were large,
providing credence that these interventions were a driver
behind observed mortality reductions. Thirdly, very high
ascertainment of the primary early ART mortality out-
come improves ability to interpret observed mortality
changes. Fourthly, the intervention effect size and statis-
tical significance were robust to several sensitivity ana-
lyses. Therefore, these findings represent important
additional evidence in support of current WHO ICF and
retention guidelines, and support continued or add-
itional investment from donors to strengthen health sys-
tems to implement these guidelines for all HIV clinic
enrollees [9].
Although it was widely anticipated that introduction of
the new more sensitive TB diagnostic test (Xpert) in
place of sputum-smear microscopy would independently
reduce mortality among PLHIV, this study and six of the
seven previously reported Xpert impact trials have not
observed any independent impact of Xpert versus
sputum-smear microscopy on mortality [8, 21]. In the
one trial that did observe Xpert impact on mortality, the
mortality benefit was restricted to clients with advanced
HIV disease (WHO stage III/IV) [21]. Furthermore, pro-
gram data have clearly shown that leaks in the ICF cas-
cade before a TB diagnostic test is implemented,
especially failure to implement the WHO-recommended
4-symptom TB screen, may be largely responsible for
unacceptably high rates of mortality due to undiagnosed
TB among PLHIV engaged in care in sub-Saharan Africa
[22, 23].
Per WHO guidelines, screening for the four TB symp-
toms (i.e., current cough, weight loss, night sweats, or
fever) should occur at every clinical care encounter for
PLHIV as the initial step in ICF to improve detection
and treatment of HIV-associated TB [20]. The recom-
mendation is based on a high sensitivity of the 4-
symptom screening rule (89.4%) in detecting culture-
positive pulmonary TB disease among ART-naïve
PLHIV [24]. However, low compliance in implementing
the 4-symptom TB screen at or prior to ART initiation
has been consistently observed in many high burden
TB-HIV countries in sub-Saharan Africa, including
South Africa (59%) [23], Mozambique (61%) [25], Kenya
(4%) [26], and Cote d’Ivoire (36%) [22]. Similarly, in
XPRES, failure to implement TB screening before ART
was the most “leaky” part of the ICF cascade in the SOC
phase, with only 30% screened before ART. Improving
the coverage of TB symptom screening from 30% in the
SOC to 100% in the EC and EC+X phases was the main
driver behind improved TB case detection from 1% in
SOC to 5–6% in EC and EC+X phases and therefore ap-
pears to have been a key driver behind the declines in
early ART mortality between SOC and subsequent EC
and EC+X phases.
Reasons for low compliance with TB screening proto-
cols in the SOC phase are not well understood, but
Table 3 Methods of new TB diagnosis immediately before ART and in the first 6 months of ART in the SOC, EC, and EC+X phases of
XPRES
SOC phase EC phase EC+X phase
n % n % n %
Pulmonary TB
Microbiologically confirmed pulmonary TB (smear microscopy in SOC and EC, Xpert during EC+X) 22 18 23 34 113 57
Microbiologically confirmed pulmonary TB through culturea (missing or negative smear and Xpert) 0 0 12 18 16 8
Clinical diagnosis of pulmonary TB with negative sputum test (negative smear, Xpert, or culture documented) 6b 5 6d 9 17f 9
Clinical diagnosis of pulmonary TB with no documented sputum test result 95c 77 27e 40 52g 26
Sub-total pulmonary TB 123 100 68 100 198 100
All TB
Pulmonary TB total 123 95 68 79 198 81
Extra-pulmonary TB total 6 5 18 21 46 19
Total 129 100 86 100 244 100
Abbreviations: SOC standard of care, EC enhanced care, EC+X enhanced care plus Xpert, TB tuberculosis, XPRES Xpert Package Rollout Evaluation using a
Stepped-wedge design
aTo meet other study objectives related to estimation of diagnostic accuracy of the smear microscopy-based and Xpert-based TB diagnostic algorithms, one spot
sputum and the morning sputum were sent to the National TB Reference Laboratory (NTRL) for liquid culture in mycobacteria growth indicator tubes (MGIT). The
liquid culture results were also returned to the clinics, although average turnaround times exceeding 49 days were expected per existing standard of care
b5 (83%) of 6 had documentation that x-ray findings were suggestive of pulmonary TB
c13 (14%) of 95 had documentation that x-ray findings were suggestive of pulmonary TB
d3 (50%) of 6 had documentation that x-ray findings were suggestive of pulmonary TB
e16 (59%) of 27 had documentation that x-ray findings were suggestive of pulmonary TB
f8 (47%) of 17 had documentation that x-ray findings were suggestive of pulmonary TB
g20 (38%) of 52 had documentation that x-ray findings were suggestive of pulmonary TB
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could have related to high patient load making health-
care workers more likely to omit key steps in care algo-
rithms, inadequate training and knowledge of the
guidelines, or deficiencies in monitoring and evaluation
[27]. In the SOC phase, having more advanced disease at
ART initiation (i.e., having a lower weight and CD4
count) was associated with higher odds of being
screened for TB, suggesting that healthcare workers
were triaging the clients to receive TB screening based
on perception of disease stage. This finding might fit
with a clinic experiencing high patient volume and
HCW’s rushing through patient consultations in order
to complete their clinical duties within available business
hours. Our intervention of providing additional nurses
to implement the TB screening, additional training, and
additional supervision increased the percentage of ART
enrollees screened for TB from 30% to 100%.
Notably, although the percentage of enrollees screen-
ing positive for ≥ 1 TB symptom who provided ≥ 1 spu-
tum sample increased from 38% in the SOC phase to
46% and 55% in the EC and EC+X phases, respectively,
collection of sputum samples remained a challenge even
in the EC phases. This low compliance with sputum col-
lection guidelines has been observed in multiple settings
[23, 27], with potential reasons being patient hesitance
to provide a sputum sample for stigma-related reasons,
true inability to provide a sputum sample, and HCW-
related reasons such as feeling overloaded, or lack of
confidence in the laboratory sample transport and diag-
nostic system [23]. Further research and interventions to
improve this component of the cascade are needed. In
addition, this finding supports calls for improved
sputum-independent diagnostic tests for TB.
A key reason that prior Xpert impact trials have gener-
ally not observed independent Xpert impact on mortality
is that higher rates of empiric TB treatment among cli-
ents with TB symptoms but a negative sputum-smear
microscopy result replaced any potential benefit of
Xpert’s improved diagnostic sensitivity in detecting
culture-positive TB [28, 29]. Similarly in our study, al-
though Xpert implementation was the driver behind in-
creased microbiological confirmation of TB diagnoses in
the EC+X versus EC phase (65% vs. 51%), there was no
significant difference in percentage of ART enrollees
newly treated for TB (6% vs. 5%). However, as reported
previously, Xpert was the driver behind reduced median
time from sputum collection to TB treatment in the
EC+X phase (6 days) versus the EC phase (22 days) [30].
Although no independent effect of Xpert on 6-month
mortality was observed in our study, two features of the
study suggest, similar to findings of a recent meta-
analysis of Xpert impact trials [31], that we cannot confi-
dently rule out the possibility of modest independent
Xpert impact: (1) our study was not powered to detect a
difference between EC and EC+X 6-month mortality
and (2) the sensitivity analyses comparing EC vs. EC+X
6-month mortality rates generated AHRs of 0.90 (p =
0.793) and 0.79 (p = 0.472), which could possibly point
to a modest Xpert impact our study was under-powered
to detect.
In ART programs in resource-limited settings, ob-
served LTFU from early ART is common, with an aver-
age of 20% LTFU by 12months of follow-up [32, 33].
Mortality rates among LTFU ART patients are high [33].
The percentage of LTFU clients found to have died by
the time of tracing ranges from 20 to 60% [13, 33]. In
our study, 41% of patients LTFU in the first 6 months of
ART in the SOC phase had died by 6 months of follow-
up. Accumulating data show that among LTFU patients
who have died by the time of tracing, mortality rates are
highest shortly after the last clinic visit, the majority (>
90%) die from illness rather than other causes (e.g.,
trauma), and the majority had some opportunity for
clinical intervention at the last visit [33]. In addition, six
previous trials, which aimed to evaluate Xpert impact on
patient-important outcomes, have reported that LTFU
of patients with bacteriologically confirmed TB, either
before or during TB treatment, almost certainly reduces
the potential impact of improved TB case finding on
mortality [8].
The reductions in LTFU achieved in EC and EC+X
phases compared with the SOC phase are likely due to a
combination of factors, including the strengthened tra-
cing intervention, additional training and nurses, and
possibly reduced incidence of missed visits due to inter-
current illness from undiagnosed TB [34]. The intensi-
fied tracing intervention might be particularly helpful in
maintaining a personalized partnership with clients
struggling with adherence to clinic visit schedules for a
variety of reasons to ensure minimal interruption in
ART pill taking [34]. These data support the underlying
principle that supportive services to retain patients in
HIV care are an essential component of both the ICF
and HIV treatment cascade.
The absence of an interaction between CD4 count at
ART initiation and intervention package effect size sug-
gests that ICF and retention interventions could be im-
portant for all new HIV clinic enrollees, not just those
with advanced disease as defined by WHO (CD4 count
< 200 copies/ml) [35]. Therefore, although median CD4
count at ART initiation is increasing in many countries,
including Botswana [36], with most countries having
adopted WHO universal HIV treatment guidelines, these
data support current WHO recommendations that high-
quality implementation of ICF and retention interven-
tions remains important for HIV clinic enrollees.
This study has a number of strengths and limitations.
Strengths include the large sample size, accurate
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ascertainment of the primary mortality outcome, and
implementation in a real-world programmatic setting,
which improves generalizability of findings. Limitations
include the fact that the primary objective relies on an
adjusted pre-post analysis that is subject to residual con-
founding, and that data from the SOC phase were col-
lected retrospectively. In the SOC phase, TB screening
or sputum sample collection may sometimes have been
implemented but not documented. While retrospective
data collection in the SOC phase increases the likelihood
of missing covariate data, it also ensures that the type of
care received by clients in the SOC phase truly repre-
sents the care provided prior to implementation of the
EC and EC+X interventions. While EC and EC+X phases
were of different duration, our study results show good
compliance with ICF algorithm implementation and im-
pressive active tracing impact on LTFU throughout EC
and EC+X phases, indicating no discernable lag time
needed for these interventions to reach maximum po-
tential. In addition, good implementation of Xpert in the
EC+X phase is evidenced by the increase in the percent-
age of TB cases that were microbiologically confirmed in
EC+X versus EC phases, and in the shorter time from
sputum collection to TB treatment in EC+X versus EC
phases, with these results consistent with several prior
Xpert impact trials [8]. Notably, while these data support
effectiveness of the ICF and retention intervention in re-
ducing early ART mortality, future economic evaluation
would be needed to explore cost-effectiveness.
Conclusions
In summary, a health system strengthening intervention
to improve compliance with WHO-recommended TB
symptom screening and ICF algorithms, combined with
active tracing to support retention of HIV and HIV-TB
co-infected patients in care through the early period of
ART, was associated with significant reductions in early
ART mortality and should be considered for scale-up. In
addition, similar to most other trials of Xpert impact on
mortality, replacing sputum-smear microscopy with
Xpert was not associated with a mortality reduction.
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5.1. Published research paper supplementary material 
Additional file 1 - Text: Selection criteria for study clinics 
XPRES study clinics were purposively selected to be representative of ART clinics in 
Botswana, while also ensuring sample sizes could be reached. Clinic characteristics that 
were taken into account have been previously published and included: 
• All 22 clinics had at least one year’s experience in providing ART services.
• 21 of 22 sites had ART enrolment rates >8 ART patients per month (mean 23/month;
range 8-46/month) according to routine program data.  These enrolment rates were
anticipated to meet study sample size requirements. One site had an unknown
enrolment rate at study initiation (Gantsi), but enrolment rates of eight ART
enrolees/month were observed during study conduct.
• The study clinic with initially unknown ART enrolment rates (Gantsi) was selected
because it was thought to have a high prevalence of MDR TB among HIV clinic
enrolees and MOH believed these patients would benefit from early rollout of the
Xpert device.
• Accessibility to either onsite or off-site TB laboratories was representative of HIV care
and treatment centres in Botswana
• All sites were implementing the microscopy-based TB diagnostic algorithm prior to
study initiation.
• All sites had the ability to perform testing, or to transport specimens for, haematology,




Table 5.4. (Research paper additional file 2) Clinical follow-up of clients in SOC, EC, and 
EC+X phases (2010-2015) 
Pre-ART, CD4 >350 3 monthly Weight, CD4, TB screen 
ART 
ART start Weight, CD4, TB screen, ALT/AST if NVP-
based regimen, Hb if AZT-based regimen, 
Hepatitis B screen, creatinine if TDF-based 
regimen 
2 weeks Weight, TB screen, ALT/AST if NVP-based 
regimen, Hb if AZT-based regimen 
1 month Weight, TB screen, ALT/AST if NVP-based 
regimen, Hb if AZT-based regimen 
3 months Weight, TB screen, ALT/AST if NVP-based 
regimen, Hb if AZT-based regimen, Viral 
load, creatinine if TDF-based regimen 
6months Weight, TB screen, ALT/ASTa if NVP-based 
regimen, Hb if AZT-based regimen, Viral 
load, CD4 
Quarterlyb Weight, TB screen, Viral load and CD4 6 
monthly, creatinine if TDF-based regimen 6 
monthly 
Abbreviations: CD4, CD4 cell count; TB, tuberculosis; ALT, alanine transaminase; AST, 
aspartate aminotransferase; NVP, nevirapine; AZT, zidovudine; TDF, tenofovir;    
aRoutine ALT/AST not required after 6 months but may be requested by the clinician 
depending on the clinical situation.  
bFor those patients started on PI-based regimens, baseline and 12-monthly glucose 














Table 5.5. (Research paper additional file 3) - Table: Indicators used to assess 
implementation of TB ICF and retention in the HIV care cascade 
 
Indicators used to monitor the intensified TB case finding (ICF) cascade 
 Indicator Denominator and Numerator 
1 % of ART enrolees 
screened for ≥1 WHO-
recommended TB 
symptom before or on 
the day of ART initiation 
Denominator:  
The number of ART enrolees eligible for TB symptom 
screening (i.e., are not already diagnosed with TB). 
Numerator: 
The number of ART enrolees with documented 
screening for ≥1 of four WHO-recommended TB 
symptoms (cough, loss of weight, fever, night sweats) 
before or on the day of ART initiation 
2 % of ART enrolees 
screened for all four 
WHO-recommended TB 
symptoms before or on 
the day of ART initiation 
Denominator: Same as in #1 
Numerator: 
The number of ART enrolees with documented 
screening for all four WHO-recommended TB 
symptoms (cough, loss of weight, fever, night sweats) 
before or on the day of ART initiation 
3 % of ART enrolees 
screening positive for ≥1 
of four WHO-
recommended TB 
symptoms before or on 
the day of ART initiation 
Denominator: Same as in #1 
Numerator: 
The number of ART enrolees screening positive for ≥1 
of four WHO-recommended TB symptoms before or 
on the day of ART initiation.  
4 % of ART enrolees having 
a sputum sample 
analysed at the lab to 
diagnose TB 
Denominator: Same as in #1 
Numerator: 
The number of ART enrolees having a sputum sample 
sent for analysis on or before the date of ART 
initiation.  
5 % of ART enrolees newly 
diagnosed with either 
extra-pulmonary or 
pulmonary TB 
Denominator: Same as in #1 
Numerator: 
The number of ART enrolees newly diagnosed with TB 















Indicators used to monitor loss to follow-up from ART 
 Indicator Denominator and Numerator 
1 Rate of uncorrecteda LTFU 
from ART during the first 6 
months of ART 
Denominator:  
Person-years of follow-up starting on the day of ART 
initiation and ending at the event of interest, which 
would be the date of last attended follow-up 
appointment for those LTFU, date of death, date of 
transfer out or departure from the study, or 6 months of 
follow-up if still alive and on ART at 6 months after ART 
initiation. 
Numerator: 
The number of clients meeting the definition of LTFU 
within the first 6 months of ART (i.e., >60 days late for 
the next scheduled appointment). 
aMortality ascertainment efforts among all patients meeting the LTFU definition were 































Table 5.6. (Research paper additional file 4) Comparison of demographic and clinical 
characteristics between prospective study enrolees in the EC and EC+X phases and 
eligible clients declining enrolment  
  
EC EC+X Declined Enrolment in 
Prospective Cohorts 
(N=1,768) (N=4,215) (N=2,439)a 
 n %/median (IQR) n %/median (IQR) n %/median (IQR) 
Age        
n, Median, (IQR) 1,768 34 (29-42) 4,215 34 (29-41) 2,439 34 (28-41) 
Missing 0 0% 0 0% 0 0% 
Gender       
Female 1,194 68% 2,797 66% 1,650 68% 
If female, pregnant?       
Yes 271 23% 903 32% 580 35% 
Weight (Kg)       
Median (IQR) 1,765 58.6 (51.3-67.8) 4,209 59.4 (52.5-68.7) 2,246 60.3 (52.8-69.5) 
Missing 3 0.20% 6 0.10% 193 8% 
Weight (Kg)       
<45 kg 160 9% 318 8% 177 8% 
45-60 kg 817 46% 1,910 45% 931 41% 
>60 kg 788 45% 1,981 47% 1,138 51% 
Baseline CD4 (cells/µL)       
Median (IQR) 1765 246 (148-310) 4,180 241 (132-321) 2,367 242 (139-322) 
Missing 3 0.20% 35 0.80% 72 3% 
Baseline CD4 (cells/µL)       
<50 132 7% 370 9% 195 8% 
50-<100 161 9% 371 9% 212 9% 
100-<200 366 21% 928 22% 517 22% 
200-<350 947 54% 1,928 46% 1,081 46% 
350-<500 93 5% 334 8% 206 9% 
≥500 66 4% 249 6% 156 7% 
Baseline Haemoglobin 
(g/dL) 
    
  
Median (IQR) 1,678 11.9 (10.4-13.3) 3,911 12.0 (10.6-13.3) 2,169 11.9 (10.5-13.2) 
Missing 90 5% 304 7.20% 270 11% 
Haemoglobin category       
Severe anaemia 68 4% 109 3% 73  3% 
Mild/moderate anaemia 805 48% 1,810 46% 1,017  47% 
No anaemia 805 48% 1,992 51% 1,079  50% 
Abbreviations: SOC, standard of care phase; EC, enhanced care phase; EC+X, enhanced care plus Xpert 
phase; IQR, interquartile range; 
aNote that a total of 2,496 patients declined to enrol.  However, of these patients, 57 were <12 at the time 
of first presentation to the clinic and were therefore ineligible for this analysis and are not included in the 
column of clients declining enrolment to facilitate comparisons with EC and EC+X cohorts.  Of all 2,439 
clients >=12 at first presentation to the study clinic, 2,430 (99.6%) were documented to have started ART by 
the end of the prospective cohort enrolment period (March 31, 2014). The mean percentage of patients 







Fiesearch paper additional file 5) Cumulative 6-month ART mortality stratified by SOC, EC, and EC+X phases among (a) enrollees with CD4 
<200 cells/μL, (b) CD4 ≥200 cells/μL* 
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Table 5.7. (Research paper additional file 6) Table of sensitivity analyses of primary and secondary study outcomes - 
comparison of mortality rates between study phases. 
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Table 5.8. (Research paper additional file 7) Table of sensitivity analyses of prim
ary and 
secondary study outcom




een study phases. 
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Table 5.9. (Research paper additional file 8) Table of predictors of being screened for at 




(N=1,700) ORa 95% CI 
p-
value 










Female 4,402 81% 1,056 19% 1.00 
Male 2,519 80% 644 20% 1.07 (0.91-1.25) 0.445 
If female, pregnant?c 
No 3621 80% 914 20% 1.00 
Yes 781 85% 142 15% 0.72 (0.53-0.99) 0.041 
Weight (Kg)d 
<45 kg 589 72% 228 28% 1.00 
45-60 kg 3,057 79% 823 21% 0.70 (0.57-0.84) 
<0.001 
>60 kg 2,922 83% 609 17% 0.54 (0.42-0.69) 
Baseline CD4e 
<50 744 76% 230 24% 1.00 
50-<200 2,879 80% 730 20% 0.82 (0.69-0.97) 
<0.001 
200-<350 2,754 81% 630 19% 0.74 (0.59-0.93) 
350-<500 184 79% 49 21% 0.86 (0.55-1.35) 
≥500 120 88% 17 12% 0.46 (0.25-0.84) 
Haemoglobinf 
severe anaemia 292 75% 96 25% 1.00 
mild/moderate anaemia 3312 79% 859 21% 0.79 (0.58-1.07) 
0.285 
no anaemia 2400 80% 593 20% 0.75 (0.47-1.19) 
Abbreviations: OR, Odds Ratio; CI, confidence interval; IQR, inter-quartile range; XPRES, Xpert Package 
Rollout Evaluation using a Stepped-wedge design 
aAll logistic regression models specified a random effect for clinic. The P-value reported is that associated 
with the overall model’s likelihood chi-square test statistic.  
bOdds ratio of being screened for TB associated with being 10 year’s older. Likelihood ratio test for 
departure from linearity (p=0.574). Age was missing for 10 (0%) of those not screened and 1 (0%) of those 
screened 
cRestricted to female ART patients only 
dWeight was missing for 353 (5%) of those not screened and 40 (2%) of those screened 
eCD4 was missing for 240 (3%) of those not screened and 44 (3%) of those screened  
fHaemoglobin was missing for 917 (13%) of those no screened and 152 (10%) of those screened 
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Table 5.10. (Research paper additional file 9) Comparison of 6-month ART outcomes 
before versus after efforts to ascertain accurate primary mortality outcome status 
among clients LTFU by study phase 
Before Ascertainment of  
Outcomes of Clients LTFU 
After Ascertainment of 
Outcomes of Clients LTFU 
SOC 6 month ART Outcomes 
n N % n N % 
Alive 7,956 8,980 89% 8,125 8,980 90% 
Dead 322 8,980 4% 461 8,980 5% 
LTFU 336 8,980 4% 28 8,980 0% 
Transfer Out 366 8,980 4% 366 8,980 4% 
Unable to Continue 0 8,980 0% 0 8,980 0% 
EC 6 month ART Outcomes 
Alive 1,585 1,768 90% 1,594 1,768 90% 
Dead 53 1,768 3% 54 1,768 3% 
LTFU 10 1,768 1% 0 1,768 0% 
Transfer Out 76 1,768 4% 76 1,768 4% 
Unable to Continue 44 1,768 2% 44 1,768 2% 
EC+X 6 month ART Outcomes 
Alive 3,613 4,215 86% 3,641 4,215 86% 
Dead 119 4,215 3% 121 4,215 3% 
LTFU 31 4,215 1% 1 4,215 0% 
Transfer Out 325 4,215 8% 325 4,215 8% 
Unable to Continue 127 4,215 3% 127 4,215 3% 
Abbreviations: SOC, standard of care; EC, enhanced care; EC+X, enhanced care plus Xpert; 
LTFU, loss to follow-up (>60 days late for last scheduled appointment). 
Table 5. 11. (Research paper additional file 10) Table show
ing differences in rates of 
uncorrected loss to follow
-up in the first 6 m
onths of ART betw
een SO




Chapter 6: Results | Risk score to inform who needs intensification of ART 
(Research Paper 3) 
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Table 6.1. (Research paper Table 1) Comparison of characteristics of antiretroviral therapy 
enrolees between internal derivation, internal validation, and external validation datasets 
Table 6.2. (Research paper Table 2) Univariable and multivariable logistic regression analysis in 
the derivation dataset (N = 2,838) 
Table 6.3. (Research paper Table 3) Multivariable model and clinical score generation from the 
derivation dataset (N = 2,838) 
Figure 6.1. (Research paper Figure 1) Study profile 
Figure 6.2. (Research paper Figure 2) Model A (excluding CD4) development and performance in 
the internal derivation and validation datasets respectively 
Figure 6.3. (Research paper Figure 3) Model B (including CD4) development and performance in 
the internal derivation and validation datasets respectively 
Figure 6.4. (Research paper Figure 4) CD4-independent and CD4-dependent clinical score cards 
Figure 6.5. (Research paper Figure 5) Sensitivity, Specificity, PPV, and NPV of clinical score in 
predicting 6-month mortality in XPRES dataset (N=5,553) and external validation TB Fast Track 
Dataset (N=1,077) for Models A (excluding CD4) and B (including CD4) 
Figure 6.6. (Research paper Figure 6) Distribution of risk scores and 6-month mortality risk in the 
XPRES dataset (N=5,553) and external validation TB Fast Track Dataset (N=1,077) for Models A 
(excluding CD4) and B (including CD4) 
Figure 6.7. (Research paper Figure 7) Survival curves stratified by risk scores in the XPRES 
dataset (N=5,553) and external validation TB Fast Track Dataset (N=1,077) for Models A 
(excluding CD4) and B (including CD4) 
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Abstract 
Background: Clinical scores to determine early (6-month) antiretroviral therapy (ART) 
mortality risk have not been developed for sub-Saharan Africa (SSA), home to 70% of 
people living with HIV. In the absence of validated scores, WHO eligibility criteria (EC) for 
ART care intensification are CD4 <200/µL or WHO stage III/IV. 
Methods: We used Botswana XPRES trial data for adult ART enrollees to develop CD4-
independent and -dependent multivariable prognostic models for 6-month mortality. 
Scores were derived by rescaling coefficients. Scores were developed using the first 50% 
of XPRES ART enrollees and their accuracy validated internally and externally using South 
African TB Fast Track (TBFT) trial data. Predictive accuracy was compared between scores 
and WHO EC. 
Results: Among 5,553 XPRES enrollees, 2,838 were included in the derivation dataset; 68% 
were female and 83 (3%) died by 6 months. Among 1,077 TBFT ART enrollees, 55% were 
female and 6% died by 6 months. Factors predictive of 6-month mortality in the derivation 
dataset at p<0.01 and selected for the CD4-independent score included: male gender (2 
points), ≥1 WHO tuberculosis symptom (2 points), WHO stage III/IV (2 points), severe 
anemia (hemoglobin <8g/dL) (3 points), and temperature >37.5˚C (2 points). The same 
variables plus CD4 <200/µL (1 point) were included in the CD4-dependent score. Among 
XPRES enrollees, a CD4-independent score of ≥4 would provide 86% sensitivity and 66% 
specificity, whereas WHO EC would provide 83% sensitivity and 58% specificity. If WHO 
stage alone was used, sensitivity was 48% and specificity 89%. Among TBFT enrollees, the 
CD4-independent score of ≥4 would provide 95% sensitivity and 27% specificity, whereas 
WHO EC would provide 100% sensitivity but 0% specificity. Accuracy was similar between 
CD4-independent and -dependent scores. Categorizing CD4-independent scores into low 
(<4), moderate (4-6), and high-risk (≥7) gave 6-month mortality of 1%, 4%, and 17% for 
XPRES and 1%, 5%, and 30% for TBFT enrollees. 
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Conclusions: Sensitivity of the CD4-independent score was nearly twice that of WHO stage 
in predicting 6-month mortality and could be used in settings lacking CD4 testing to inform 
ART care intensification. The CD4-dependent score improved specificity versus WHO EC. 
Both scores should be considered for scale-up in SSA. 
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Background  
Over the last 16 years, the scale-up of HIV treatment globally has reached over 24.5 
million people living with HIV (PLHIV) with lifesaving antiretroviral therapy (ART), resulting 
in declines in both HIV-associated mortality and HIV incidence [1-3]. However, each year 
there are still about 770,000 global AIDS-related deaths, with 470,000 (61%) of these 
deaths occurring in sub-Saharan Africa (SSA) [1]. To reduce AIDS-related mortality, the 
global community is striving to reach 2030 targets of ensuring at least 90% of PLHIV are on 
ART [4], which will require ART enrollment for an additional 10 million of the 37.9 million 
PLHIV globally, about two-thirds of whom live in sub-Saharan Africa (SSA) [1]. Mortality 
rates during ART are highest in the first 6 months of therapy, and these early ART 
mortality rates continue to be highest in SSA [5, 6]. If 2030 goals of reducing AIDS-related 
mortality by 90% compared with 2010 are to be met, substantial progress needs to be 
made in addressing early ART mortality in SSA [5, 6], where 20-40% of new ART enrollees 
still initiate ART with relatively advanced HIV disease [7, 8]. 
To achieve these mortality reductions, efficient use of available resources through 
differentiated service delivery (DSD) models to provide tailored, patient-centered care, 
will be needed [9, 10]. The World Health Organization (WHO) currently recommends 
intensification of care for persons >5 years old starting ART with advanced HIV disease as 
defined by CD4+ T-cell (CD4) count <200 cells/µL or WHO stage III/IV [8]. The 
intensification of care package, which has been shown to reduce early mortality [11], 
includes cotrimoxazole prophylaxis, tuberculosis (TB) screening with subsequent TB 
treatment or TB preventive therapy, cryptococcal antigen (CrAg) screening with pre-
emptive therapy for eligible CrAg-positive people, and enhanced adherence counseling. 
However, the majority of health facilities providing ART in low- and middle-income 
countries (LMIC) lack access to rapid or point-of-care (POC) CD4 testing [8]. In these 
settings, up to half of adults with a CD4 count <100/µL could be categorized as WHO stage 
I/II, and would be missed by an advanced disease screening algorithm that relied on WHO 
stage alone [11]. In addition, a screening tool for advanced disease that relies only on CD4 
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count and WHO disease stage misses the many other demographic and clinical predictors 
associated with early ART mortality [9]. To date, most analyses evaluating eligibility for 
DSD models have focused on identifying stable patients for de-escalation of care [9]. Only 
one analysis from Haiti has evaluated a clinical score for determining who needs 
intensification of early ART care and this was not externally validated [12]. 
Therefore, we evaluated whether a clinical score derived from easily available covariates 
at ART initiation in resource-constrained clinic settings could better predict who is at risk 
for early (6-month) ART mortality than the current WHO advanced disease eligibility 
criteria. We developed clinical scores to help predict early ART mortality risk for two 
scenarios: (1) a scenario where on-site/rapid off-site CD4 testing is not available as is the 
case for the majority of ART clinics in LMIC, and (2) a scenario where on-site/rapid off-site 
CD4 testing is available. 
Methods 
We used data from the Xpert Package Rollout Evaluation using a Stepped-wedge design 
(XPRES) trial to derive the two clinical scores to help clinicians identify those at highest risk 
of early ART mortality and therefore in need of ART care intensification [13]. The first 
clinical score assumes CD4 is unavailable at ART initiation (i.e., a CD4-independent score) 
and the second clinical score assumes CD4 count is available (i.e., a CD4-dependent score). 
We used the first 50% of XPRES cohort enrollees to derive a prediction model, and the 
second 50% to internally validate the model. We then used data from the TB Fast Track 
(TBFT) trial in South Africa (SA) to externally validate the derived clinical scores [14]. We 
compared screening accuracy of our derived clinical scores with existing CD4-based WHO 
eligibility criteria for advanced disease and ART care intensification. 
XPRES study design and participants for prediction tool development 
XPRES was a multi-center, stepped-wedge cluster randomized trial with a retrospective 
baseline component conducted at 22 health facilities, including five hospitals and 17 
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clinics, that were purposively selected to be representative of HIV treatment clinics in 
Botswana [13]. In the prospective, stepped-wedge portion of the trial, all non-
incarcerated, consenting, ART-naïve, HIV-positive persons, regardless of TB treatment or 
symptom status, presenting to the study clinics between August 2012 and end of March 
2014, were eligible for enrollment. Only adolescents and adults (aged ≥12 years old), were 
included in this analysis. 
XPRES procedures 
Per Botswana national guidelines during the time period of the study, all XPRES study 
participants were eligible for ART initiation if they had a CD4 count ≤350 cells/µL, were 
diagnosed as having WHO stage III/IV events, or were pregnant or breastfeeding [15]. All 
study participants received clinical care and follow-up appointments per Ministry of 
Health (MOH) guidelines (see Additional file 1, a table summarizing standard clinical care 
follow-up). 
Interventions 
The prospective XPRES cohort was recruited within two phases of the stepped-wedge trial. 
In the first phase, all prospective XPRES participants received two enhanced care 
interventions in addition to standard of care: (1) additional support for intensified TB case 
finding, and (2) intensified tracing for patients missing clinic appointments. In the second 
phase, the Xpert® MTB/RIF assay (Cepheid; Sunnyvale, California) (Xpert) was initiated in 
place of sputum smear microscopy for TB diagnosis. We have previously shown that there 
was no significant difference in 6-month ART mortality between the two prospective 
phases of XPRES [16]. Enrollment and follow-up procedures are described in a 
supplementary appendix (see Additional file 2, text summarizing follow-up procedures). 
XPRES participants were followed for 12 months, or until the end of TB treatment, 
whichever was later. The final follow-up visits for XPRES enrollees were in June 2015. 
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Development and temporal validation of the prediction model 
A clinically useful prediction model should demonstrate accurate prediction of the 
outcome in data other than that in which the model was developed. Therefore, we split 
the XPRES dataset in a 1:1 ratio using the mid-point of enrollment at each of the 22 study 
clinics to create the derivation dataset (the first 50% of enrollees) and the temporal 
validation dataset (the second 50% of enrollees) [17].  
Outcome 
The outcome of interest for both the XPRES trial and this analysis was early (6-month) ART 
mortality. We implemented intensive efforts to ascertain true mortality outcomes among 
participants, with deaths and date of death either passively reported to the clinic by 
friends or relatives or actively ascertained if the client had missed an appointment or was 
considered LTFU (>60 days late for a scheduled appointment) [18]. Initial efforts to 
ascertain outcomes of clients who missed an appointment by ≥1 day included up to five 
phone calls to the client or contact and up to two home visits. In addition, for all clients 
unreachable by phone or home visit who met the LTFU definition, vital status was 
ascertained through national Death Registry review. By law, since 1969, all deaths need to 
be registered in the Death Registry, which is maintained by the Botswana Civil and 
National Registration Office. Available data shows Death Registry data completeness to be 
high [16].    
Candidate predictor variables 
We selected candidate predictor variables for potential inclusion in the predictive model 
based on prior publications, and the need for variables to be reproducible, objective, and 
readily available in resource-constrained clinic settings [19]. We considered variables 
known to be associated with mortality including age, sex (coded as male, pregnant female, 
and non-pregnant female [20]), education level, employment status, smoking history, 
prior TB treatment, number of WHO TB symptoms, weight, body mass index (BMI) 
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(weight/height2), hemoglobin level, CD4 count, temperature at ART initiation in degrees 
Celsius, and respiratory rate at ART initiation [20-23].  
Within the derivation dataset, we performed univariable analyses assessing the 
association of each variable with risk of mortality using logistic regression. Because follow-
up of all XPRES and TBFT enrollees was complete with true ascertainment of 6-month 
mortality outcomes, 6-month risk was preferred to rate [16]. Continuous variables were 
assessed for non-linearity with log odds of death using fractional polynomials, as well as 
by comparing Akaike’s Information Criteria and Bayesian Information Criteria between 
models with linear or fractional polynomial terms. Where non-linearity was observed, the 
appropriate fractional polynomial terms were included in the logistic regression. We also 
examined scatter plots of linear and transformed continuous variables and risk of 
mortality to assess inflexion points which might inform appropriate categorization of 
continuous variables.  
For the multivariable analysis, a complete case analysis, whereby observations with 
missing data for key variables were dropped, was chosen because few data (<10%) were 
missing. To generate a parsimonious multivariable model, we used a stepwise backward 
elimination approach, starting with all candidate variables and excluding variables 
sequentially if p>0.01 using both automatic and manual approaches. We also explored 
how findings changed using a forward stepwise addition approach. Where two or more 
predictors were highly correlated, only one was selected, to simplify the prognostic 
model. We created two multivariable models: one in which CD4 was purposefully 
excluded and one in which CD4 count was included as a candidate variable to reflect 
situations where CD4 is either unavailable or available at the clinic. Plausible interactions 
between covariates (e.g., between CD4 and age) were assessed using the likelihood ratio 
test. 
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In both the derivation and temporal validation datasets, we assessed multivariable model 
calibration, (i.e., the agreement between probability of 6-month mortality predicted by 
the model and observed probability of TB within quantiles of predicted risk) graphically in 
a calibration plot [17], and statistically using the Hosmer-Lemeshow test. We also 
assessed discrimination, the ability of our model to differentiate patients who died by 6 
months of ART vs. those who did not, using the area under the receiver-operating 
characteristic (AUROC) curve, also referred to as the C-statistic or C-index. AUROC values 
of 0.7 to 0.79, 0.8±0.89, and >0.9 are respectively considered acceptable, excellent and 
outstanding discrimination [24]. 
Two final multivariable models were used to generate the two clinical scores (i.e., the 
CD4-independent and CD4-dependent scores). For these models, continuous variables 
were categorized in a clinically meaningful manner based on their functional form and 
information from the published literature. Each beta coefficient from this logistic 
regression model was then rescaled to generate a clinical score by dividing each 
coefficient by the smallest positive model coefficient and rounding to the nearest integer. 
The total number of points was summed for each participant to calculate their total 
clinical score. 
External validation of risk scores 
To externally validate the clinical risk score, we used data collected independently from 
the TBFT trial from SA [14].  TBFT was an open-label cluster-randomized controlled trial, 
recruiting individuals from 24 primary health-care clinics in SA. All outpatient, HIV-positive 
adults (aged ≥18 years) with CD4 counts <150/μL, no TB treatment in the past 3 months, 
and no ART in the last 6 months were eligible. In the intervention clinics, participants were 
classified by a study algorithm as having high, medium, or low TB risk. High TB risk patients 
(i.e., those with positive lateral flow urine lipoarabinomannan assay [LF-LAM], BMI <18.5, 
or hemoglobin <10 g/dL) started TB treatment immediately followed by ART 2 weeks later. 
Medium TB risk participants (i.e., those with ≥1 WHO TB symptom only) were 
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recommended to have symptom-guided TB investigation. Low TB risk patients (no TB 
symptoms or high-risk criteria) were recommended to start ART immediately. The primary 
outcome was all-cause mortality at 6 months after enrollment. We restricted this analysis 
to intervention arm participants, for whom key variables such as temperature at 
enrollment were available, and to those patients who started ART, since the outcome of 
interest was mortality within the first 6 months of ART. The median time from trial 
enrollment to ART start in the intervention arm was 21 days. Participants were enrolled in 
TBFT between December 19, 2012, and December 18, 2014. The clinical risk score for 
mortality was calculated by assigning the same ‘points’ to variables as for the derivation 
cohort.  
For both the XPRES cohort (combined derivation and validation datasets), and the TBFT 
datasets, we explored how sensitivity, specificity, positive predictive value (PPV), negative 
predictive value (NPV), and AUROC curve values varied with increasing clinical score in 
terms of predicting 6-month mortality and compared this screening accuracy and 
discrimination performance with the WHO eligibility criteria for advanced disease. Three 
risk groups were created to visualize increasing 6-month ART mortality risk with increasing 
clinical score, and the percentage of ART enrollees falling into each risk group. Kaplan-
Meier (K-M) curves were used to visualize rates of early mortality within the three risk 
groups. 
All analyses were conducted using STATA 16 (StataCorp, 2009, Stata Statistical Software, 
Release 16, College Station, TX).  The study is reported in concordance with TRIPOD 
guidance for multivariable prediction models (see Additional file 3, a table with the 
TRIPOD checklist).  
Ethics approval and consent to participate 
Ethical approval for each of the source studies was obtained from the relevant ethics 
committees in the country of data collection and from the trial sponsors. All participants 
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provided informed written consent, or where the enrollee could not read or write, 
witnessed verbal informed consent. Ethical approvals for XPRES were obtained from the 
U.S. Centers for Disease Control and Prevention (CDC) Institutional Review Board (IRB) C, 
the Health Research and Development Division of the Health Research and Development 
Committee (HRDC) in Botswana, and the University of Pennsylvania IRB No.4. All consent 
procedures were approved by the ethical review committees. Written informed consent 
was obtained from all prospective XPRES enrollees. XPRES is registered at ClinicalTrials.gov 
(trial registration no. NCT02538952). Oversight of study initiation and quarterly review of 
implementation was conducted by the Office of the Associate Director of Science at CDC 
Atlanta.  
TBFT was approved by the research ethics committees of the University of the 
Witwatersrand and the London School of Hygiene & Tropical Medicine, and the South 
African Medicines Control Council. All participants provided written or witnessed verbal 
informed consent. This trial was registered with the ISRCTN registry, ISRCTN35344604, 
and the South African National Clinical Trials Register, DOH-27-0812-3902.  
Results 
From the XPRES cohort, 5,553 eligible ART enrollees with complete data for candidate 
predictors were included in the analysis (Fig 1). Overall, 150 (3%) of 5,553 ART enrollees 
died within 6 months of ART initiation.  
160
Fig 1. Study profile 
161
Internal derivation and temporal validation datasets 
From the XPRES cohort, the internal derivation (N=2,838) and temporal validation 
(N=2,715) datasets were created (Table 1). Key characteristics including median age (34), 
percentage female (66-68%), median CD4 (240-245/µL), and 6-month mortality (2.5-2.9%), 
were similar between internal XPRES derivation and validation datasets (Table 1). 
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Table 1: Comparison of characteristics of antiretroviral therapy enrollees between internal derivation, internal validation, and external 
validation datasets  
Internal Derivation Dataset 
(N=2,838) 
Internal Validation Dataset 
(N=2,715) 
External Validation Dataset  
(TB Fast Track, SA; N=1,077)* 
Demographics n (median or %) n (median or %) n (median or %) 
Age, years, median (IQR) 2,838 33.8 (28.6-40.9) 2,715 34.0 (28.6-41.4) 1,077 38.0 (32.0-44.0) 
Female, n, %   1,938 68% 1,779 66% 590 55% 
If Female, Pregnant, n, % 520 27% 551 31% 0 0% 
Marital status  Married/Civil Union 300 11% 265 10% 
Single 2,441 86% 2,346 86% 
Widowed/Divorced 97 3% 104 4% 
Smoking History (ever smoked), n, % 517 18% 551 20% 238 22% 
Currently Employed, n, % 1,270 45% 1,286 47% 
Education None 196 7% 200 7% 
Primary 687 24% 596 22% 
Secondary 1,734 61% 1,641 60% 
Higher 221 8% 278 10% 
HIV/TB history 
Previous TB treatment Yes 277 10% 262 10% 
WHO TB Symptoms 
Cough Yes 495 17% 547 20% 463 43% 
Weight loss Yes 599 21% 555 20% 797 74% 
Fever Yes 259 9% 245 9% 314 29% 
Night sweats Yes 273 10% 253 9% 348 32% 
Number of WHO TB symptoms 0 1,975 70% 1,911 70% 230 21% 
1 427 15% 349 13% 285 26% 
2 202 7% 216 8% 226 21% 
3 141 5% 137 5% 178 17% 
4 93 3% 102 4% 158 15% 
Clinical Characteristics 
WHO stage III/IV, n, % 354 12% 307 11% 
CD4 Median (IQR) 2,838 245 (143-315) 2,715 240 (134-319) 1,077 72 (36-110) 
Weight Median (IQR) 2,838 58.8 (51.8-68.2) 2,715 59.7 (52.8-69.0) 1,077 57.9 (50.8-67.0) 
BMI Median (IQR) 2,838 21.5 (18.9-24.9) 2,715 21.6 (19.1-25.0) 1,077 21.3 (18.8-25.0) 
Hemoglobin Median (IQR) 2,838 11.9 (10.4-13.2) 2,715 12.0 (10.7-13.4) 1,077 11.3 (9.7-13.0) 
Temperature Median (IQR) 2,838 36.2 (35.8-36.5) 2,715 36.2 (35.8-36.6) 1,077 36.4 (36.0-36.7) 
Respiratory rate Median (IQR) 2,838 19 (18-20) 2,715 19 (18-20) 
Mortality within 6 months 
Cumulative incidence 83 2.9% 67 2.5% 60 6% 
Time to death 83 50 (25-105) 67 46 (16-87) 60 55 (30-112) 
Abbreviations: IQR, interquartile range; TB, tuberculosis; WHO, World Health Organization; CD4, CD4+ T-cell count; TB, tuberculosis; BMI, body mass index; SA, South Africa 
a TBFT study enrollees in the intervention arm who started ART  
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Development of regression model 
Table 2 summarizes the results of univariable and multivariable logistic regression model 
development.  Although age (linear continuous variable), history of smoking, weight 
(linear continuous variable), BMI (linear continuous variable), and respiratory rate (linear 
continuous variable) were associated with 6-month mortality in univariable analysis, these 
variables were eliminated in the stepwise backward elimination approach due to p-values 
in multivariable analysis >0.01. 
The final multivariable Model A (which simulated the situation where CD4 is unavailable) 
included sex, number of WHO TB symptoms, WHO disease stage, hemoglobin 
concentration (continuous, linear term), and temperature (modelled as two transformed 
terms following output from the multivariable fractional polynomial analysis) (Table 2). In 
the final multivariable model B (which simulated the situation where CD4 is available), the 
same variables included in Model A, plus CD4 were included (Table 2).  
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Table 2: Univariable and multivariable logistic regression analysis in the derivation dataset (N = 2,838) 
Alive/TF by 6 months of ART 
(N=2,755) 
Died by 6 months of ART 
(N=83) 
Unadjusted Model A – adjusted model 
excluding CD4 
Model B – adjusted model 
including CD4 
n N Median(IQR)/%  n  N Median(IQR)/% OR 95% CI P AOR 95% CI p AOR 95% CI p 
Demographics 
Age, years (for every 10-year increase) 2,755 34 (29-41) 83 39 (31-49) 1.44 (1.19-1.73) <0.001 
Sex and pregnancy status Pregnant 517  520  99% 3  520  1% 1.00  --  -- 1.00  --  -- 1.00  --  -- 
Female non-pregnant 1,379  1,418  97% 39 1,418  3% 4.87 (1.66-14.3) 0.004 2.45 (0.76-7.88) 0.133 2.04 (0.68-6.09) 0.201 
Male 859  900  95% 41 900  5% 8.23 (2.72-24.91) <0.001 5.47 (1.49-20.17) 0.011 4.35 (1.27-14.88) 0.019 
Marital status Married/civil union 292  300  97% 8  300  3% 1.00  --  -- 
Single 2,367  2,441  97% 74  2,441  3% 1.14 (0.65-2) 0.646 
Widowed/Divorced 96  97  99% 1  97  1% 0.38 (0.05-3.14) 0.369 
Smoking History  Never 2,262  2,321  97% 59  2,321  3% 1.00  --  -- 
Current/ex-smoker 493  517  95% 24  517  5% 1.87 (1.11-3.15) 0.019 
Employed Employed 1,233  1,270  97% 37  1,270  3% 1.00  --  -- 
Unemployed 1,522  1,568  97% 46  1,568  3% 1.01 (0.68-1.48) 0.971 
Education None 188  196  96% 8  196  4% 1.00  --  -- 
Primary 664  687  97% 23  687  3% 0.81 (0.36-1.85) 0.610  
Secondary 1,687  1,734  97% 47  1,734  3% 0.65 (0.31-1.39) 0.265  
Higher 216  221  98% 5  221  2% 0.54 (0.23-1.26) 0.300  
HIV/TB history 
Previous TB treatment No 2,489  2,561  97% 72  2,561  3% 1.00  --  -- 
Yes 266  277  96% 11  277  4% 1.43 (0.74-2.77) 0.290 
Number of WHO TB symptoms 0 1,955  1,975  99% 20  1,975  1% 1.00  --  -- 1.00  --  -- 1.00  --  -- 
1 407  427  95% 20  427  5% 4.80 (2.8-8.23) <0.001 3.39 (1.88-6.09) <0.001 3.16 (1.84-5.43) <0.001 
2 188  202  93% 14  202  7% 7.28 (3.58-14.8) <0.001 4.03 (1.82-8.92) 0.001 3.64 (1.63-8.12) 0.002 
3 or 4 205  234  88% 29  234  12% 13.83 (9.04-21.13) <0.001 5.05 (3.31-7.7) <0.001 4.68 (2.93-7.48) <0.001 
Clinical Characteristics 
WHO Stage I/II 2,441  2,484  98% 43  2,484  2% 1.00  --  -- 1.00  --  -- 1.00  --  -- 
III/IV 314  354  89% 40  354  11% 7.23 (3.87-13.52) <0.001 2.57 (1.32-4.99) 0.005 2.47 (1.24-4.89) 0.010 
CD4 (per 10-cell increase)a 2,755 249 (149-317) 83 98 (41-218) 0.94 (0.9-0.98) 0.002 0.98 (0.95-1.01) 0.211 
Weight (per 1 kg increase)  2,755 59 (52-68) 83 51 (45-60) 0.96 (0.93-0.98) 0.001 
BMI (per 1-unit increase)  2,755 21.6 (19.0-25.0) 83 19.0 (17.0-21.8) 0.86 (0.79-0.94) 0.001 
Hemoglobin (per 1g/dL increase) 2,755 11.9 (10.5-13.3) 83 9.9 (8.5-11.7) 0.69 (0.61-0.79) <0.001 0.73 (0.65-0.81) <0.001 0.74 (0.67-0.81) <0.001 
Temperature (per 1 ˚C increase) b 2,755 36.2 (35.8-36.5) 83 36.5 (36.0-37.0) 2.09 (1.47-2.96) <0.001 1.26 (0.96-1.65) 0.092 1.25 (0.94-1.67) 0.127 
Respiratory rate (per 1 breath/min increase)  2,755  18 (18-20)  83 20 (18-22) 1.02 (1.01-1.04) 0.009 
Abbreviations: ART, antiretroviral therapy; TF, transfer-out; CI, confidence interval; WHO, World Health Organization; BMI, body mass index; OR, odds ratio; AOR, adjusted odds ratio; IQR, inter-quartile range 
a Due to non-linearity in the association between CD4 and log odds of death, CD4 was modelled as two terms (term 1 = X-.2432641563 and term2 = X*ln(X)+.3438800025 if e(sample), where  X = CD4/1000). Output 
shown is for the linear term.  The p-value associated with each CD4 term was <0.001. 
b Due to non-linearity in the association between temperature and log odds of death, temperature was modelled as two terms (term 1 = temperature^3-47148.67774 and term 2 = temperature^3*ln(temperature)-
169123.2696) . Output shown is for the linear term.  The p-value associated with each squared term for temperature was <0.001. 
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Internal validation of final regression models 
The Hosmer-Lemeshow statistics for Model A (excluding CD4) on both the derivation 
(p=0.381) and validation (p=0.210) datasets indicated good model fit (see Additional file 4, 
table showing results of Hosmer-Lemeshow tests).  Similarly, the calibration curves (Fig 2) 
indicate adequate prediction performance for the 10 risk groups in terms of predicted 
number of deaths within 6 months of ART versus observed number of deaths. In addition, 
the AUROC curve values for the derivation (0.874) and validation (0.822) datasets 
indicated excellent discrimination (Fig 2). 
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Fig 2: Model A (excluding CD4) development and performance in the internal derivation and validation datasets respectively 
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The Hosmer-Lemeshow statistics for model B (including CD4) on both the derivation 
(p=0.735) and validation (p=0.677) datasets also indicated good model fit (see Additional 
file 4, table showing results of Hosmer-Lemeshow tests), with calibration curves (Fig 3) 
indicating adequate prediction performance for the 10 risk groups. However, in the 
highest risk group (risk group 10), Model B over-estimated mortality risk in the validation 
dataset, with 48 deaths predicted but only 34 observed (see Additional file 4, table 
showing results of Hosmer-Lemeshow tests).  In addition, the AUROC curve values for the 
derivation (0.887) and validation datasets (0.836) indicated excellent discrimination (Fig 
3). 
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Fig 3: Model B (including CD4) development and performance in the internal derivation and validation datasets 
respectively 
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Transformation from regression model to clinical score 
We used WHO advanced disease classifications for WHO stage (stage III or IV), and CD4 
count (<200 cells/µL). Anemia severity in adults was classified according to WHO criteria 
as follows [25]: no anemia was defined as hemoglobin ≥13.0 g/dL for men, ≥12.0 g/dL for 
non-pregnant females, and ≥11.0 g/dL for pregnant females; mild/moderate anemia was 
defined as 8.0–<13.0 g/dL for men, 8.0–<12.0 g/dL for non-pregnant females, and 7.0-
<11.0 g/dL for pregnant females; and severe anemia was defined as <8.0 g/dL for males 
and non-pregnant females and <7.0 g/dL for pregnant females. Temperature was 
classified as ≤37.5˚C versus >37.5˚C based on the observed distribution of mortality risk as 
measured temperature increased, and a common definition of a low-grade fever or higher 
(>37.5˚C) [26]. The multivariable model with categorization of these continuous variables 
in the derivation dataset is presented in Table 3.
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Table 3: Multivariable model and clinical score generation from the derivation dataset (N = 2,838).
Predictor - Model A (excluding CD4) Predictor - Model B (including CD4) 




coefficient Score AOR 95% CI 
p-
value ß coefficient Score 
Sex and pregnancy 
status 
Female (pregnant)  1.00 -- --  -- 0  1.00 -- --  -- 0 
Female (non-pregnant) 1.94 (0.58-6.50) 0.283 0.66 1 1.71 (0.53-5.52) 0.373 0.53 1 
Male 3.54 (0.95-13.26) 0.060 1.26 2 2.93 (0.82-10.44) 0.097 1.08 2 
Number of WHO 
TB symptoms 
0  1.00 -- --  -- 0  1.00 -- --  -- 0 
≥1 3.65 (2.24-5.97) <0.001 1.30 2 3.33 (2.06-5.38) <0.001 1.20 2 
WHO Stage I/II  1.00 -- --  -- 0  1.00 -- --  -- 0 
III/IV 2.72 (1.42-5.20) 0.003 1.00 2 2.55 (1.32-4.92) 0.005 0.94 2 
Temperature at 
enrollment 
≤37.5°C  1.00 -- --  -- 0  1.00 -- --  -- 0 
>37.5°C 3.39 (1.65-6.96) 0.001 1.22 2 3.37 (1.56-7.26) 0.002 1.21 2 
CD4 count ≥200/µL -- -- -- -- N/A  1.00 -- --  -- 0 
<200/µL -- -- -- -- N/A 2.05 (1.20-3.50) 0.009 0.72 1 
Anemia Statusa 
No anemia  1.00 -- --  -- 0  1.00 -- --  -- 0 
mild/moderate anemia 5.03 (2.57-9.87) <0.001 1.62 2 4.58 (2.37-8.84) <0.001 1.52 3 
Severe anemia 9.42 (3.43-25.89) <0.001 2.24 3 8.02 (3.04-21.14) <0.001 2.08 4 
Abbreviations: AOR, adjusted odds ratio; CI, confidence interval; WHO, World Health Organization. 
aAnemia severity was classified according to World Health Organization criteria as follows: no anemia, hemoglobin level of ≥13.0 g/dL for men, ≥12.0 g/dL for 
non-pregnant females, and ≥11.0 g/dL for pregnant females; mild/moderate anemia, 8.0–<13.0 g/dL for men, 8.0–<12.0 g/dL for non-pregnant women, and 
7.0-<11.0 g/dL for pregnant women; and severe anemia, <8.0 g/dL for males and non-pregnant females and <7.0 g/dL for pregnant women. 
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Model A, categorized in this way, retained statistically excellent discrimination in both 
derivation (AUROC 0.867) and validation datasets (AUROC 0.818), and the Hosmer-
Lemeshow statistic p-values were 0.269 in the derivation and 0.334 in the validation 
datasets indicating good calibration. Similarly, Model B AUROC statistics were 0.874 in the 
derivation and 0.830 in the validation datasets, with Hosmer-Lemeshow statistic p-values 
of 0.367 and 0.307 in the derivation and validation datasets respectively, indicating good 
model fit. The clinical scores that could be used in clinic settings to identify those at risk of 
early 6-month mortality, depending on availability of CD4 count, are illustrated in Fig 4. 
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Fig 4: CD4-independent and CD4-dependent clinical score cards 
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External validation of risk scores 
The clinical score for each predictor was generated and the possible range for the total 
score was 0 to 11 for Model A and 0 to 13 for Model B (see Additional file 5, tables 
showing performance of clinical scores).  Fig 5 shows the performance of the two clinical 
scores at different cut-offs, in terms of sensitivity, specificity, negative predictive value 
(NPV), positive predictive value (PPV), and percentage of enrollees screened into ART care 
intensification. For the CD4-independent clinical score derived from Model A, (Fig 5) 
among XPRES enrollees, a clinical score of ≥4 would screen in 36% of ART enrollees into a 
care intensification pathway, providing 86% sensitivity and 66% specificity in detecting 
those at risk for early mortality, whereas the WHO advanced disease eligibility criteria 
(CD4 <200/µL or WHO stage III/IV) would screen in 44% of ART enrollees, providing 83% 
sensitivity and 58% specificity. Notably, if the WHO advanced disease eligibility criterion of 
WHO stage III/IV only was used since CD4 is unavailable, 12% of ART enrollees would be 
screened into an ART care intensification pathway, with only 48% sensitivity in detecting 
6-month mortality and 89% specificity. Among TBFT enrollees, the clinical score of ≥4
would screen in 74% of ART enrollees, providing 95% sensitivity and 27% specificity in 
detecting early mortality, versus the WHO advanced disease eligibility criteria which 
would screen in 100% of ART enrollees, with 100% sensitivity but 0% specificity. 
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Fig 5: Sensitivity, Specificity, PPV, and NPV of clinical score in predicting 6-month mortality in 
XPRES dataset (N=5,553) and external validation TB Fast Track Dataset (N=1,077) for Models A 
(excluding CD4) and B (including CD4) 
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For the CD4-dependent clinical score derived from Model B, a clinical score of ≥5 would 
screen in 38% of ART enrollees into a care intensification pathway, providing 92% 
sensitivity and 63% specificity in detecting those at risk for early mortality. Among TBFT 
enrollees, the clinical score of ≥5 would screen in 81% of ART enrollees, providing 88% 
sensitivity and 20% specificity in detecting early mortality. 
The AUROC for CD4-independent (0.845) and -dependent (0.852) clinical scores remained 
high for XPRES enrollees but was low for TB FT enrollees (0.568 for CD4-independent and 
0.569 for CD4-dependent scores) (see ≤: figure of AUROC for clinical score performance). 
For the CD4-independent clinical score, risk scores were grouped into low (<4), moderate 
(4-6), and high-risk categories (≥7) (Fig 6), with 6-month low, moderate, and high risk 
group incidence percentages being 1%, 4%, and 17% among XPRES enrollees and 1%, 5%, 
and 30% among TBFT enrollees.  Similarly, for the CD4-dependent clinical score, risk 
scores were grouped into low (<5), moderate (5-8), and high risk categories (≥9) (Fig 6), 
with 6-month low, moderate, and high risk group mortality percentages being 0%, 4%, and 
18% for XPRES enrollees and 3%, 5%, and 16% for TBFT enrollees. Fig 7 shows K-M failure 
curves of mortality over the first 6 months of ART according to the low, moderate, and 
high-risk groups, indicating that specific populations of moderately high- and high-risk 
groups, in high need of care intensification, were differentiated by the respective clinical 
scores. 
Fig 6: Distribution of risk scores and 6-month mortality risk in the XPRES dataset (N=5,553) 
and external validation TB Fast Track Dataset (N=1,077) for Models A (excluding CD4) and B 
(including CD4) 
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Fig 7: Survival curves stratified by risk scores in the XPRES dataset (N=5,553) and external 




A CD4-independent clinical score designed for settings where CD4 is unavailable at ART 
intitiation with a cut-off score of ≥4 was largely as sensitive in screening in persons at risk 
of death by 6 months as the current WHO advanced disease eligibility criteria, and nearly 
twice as sensitive as WHO eligibility criteria that would rely on WHO stage alone. 
Compared with the CD4-based WHO advanced disease eligibility criteria, the CD4-
independent clinical score had higher specificity and would screen 8-26% fewer ART 
enrollees into intensified care pathways, suggesting the screening tool could also increase 
efficiency of investments in DSD models for advanced disease. Therefore, in the many 
settings in SSA that lack access to rapid CD4 testing, the CD4-independent clinical score 
should be considered for scale-up to facilitate early ART care intensification, with the 
potential for reductions in early ART mortality [11]. In addition, in those settings where 
CD4 is available, using the CD4-dependent clinical score with a cut-off score of ≥5 could 
increase both sensitivity and specificity over WHO advanced disease eligibility criteria, 
with the potential to both reduce early ART mortality and improve efficiency of DSD 
algorithms. To our knowledge, these are the first externally validated clinical scores for 
ART care intensification generated for SSA [9]. 
In contrast to current WHO guidelines, which recommend only the use of CD4 count and 
WHO HIV disease staging to identify patients at high risk for morbidity and mortality, our 
composite risk score provides both more comprehensive and specific information on the 
magnitude of risk for each patient by integrating additional objective variables into the 
assessment [9]. The additional variables included in our score are both clinical and 
demographic. The clinical variables of WHO TB symptom screen, temperature, and anemia 
severity are known to be associated with serious comorbidities that significantly increase 
early mortality risk, while the demographic variables in the scores (the gender variable of 
male, female non-pregnant, and female pregnant) captures important generalizable 
differences in early mortality risk in SSA, which are due to both psychosocial and biological 
factors [27, 28]. Our risk scores are careful to be simple (5 or 6 variables assessed), use 
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objective covariates rather than variables that are more open to interpretation, and use 
variables that should be available, or could easily be made available, at the POC in LMIC. 
The measured hemoglobin level is more available in LMIC than POC CD4, although scale-
up of CD4 testing is needed and ongoing. Available POC hemoglobin measurement devices 
tend to be durable, easy to use, and have shown good accuracy in LMIC [29, 30], probably 
because to date these devices have been less expensive than currently available POC CD4 
systems and are useful for non-HIV-related care (e.g., <$100/POC hemoglobin 
measurement device and $0.75/test [31] vs. about $7,430/POC CD4 device and about 
$8.70/test [32]). Both CD4 testing and hemoglobin testing are important at the point of 
care, and less expensive POC CD4 lateral flow assays and transcutaneous 
spectrophotometry solutions for hemoglobin level measurement may become available in 
the future [33-35]. 
Additional advantages of developing clinical scores with a variety of cut-offs is that it 
allows programme managers to choose cut-offs with associated screening accuracy
characteristics, allowing programme managers to choose cut-offs based on funding
availability, by trading sensitivity for improved specificity [9]. 
Another potential advantage of the combined clinical score over the WHO advanced 
disease criteria is the ability to differentiate three risk groups (low, moderate, and high), 
with the highest risk group having 6-month mortality rates of 16–30% versus 0–3% in the 
low and 4–5% in the moderate risk groups. While all patients with moderate or high 
scores might benefit from a standardized outpatient intensified early ART care, patients in 
the highest risk group might be candidates for additional interventions to help navigate 
the relatively complex time of early ART. During this time, clinicians need to rapidly search 
for, diagnose, or rule out co-morbidities, and both choose and time appropriate therapies, 
all within the context of ART-driven immune reconstitution [36, 37]. Our clinical score 
could be used to inform a clinical trial of such interventions. 
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Moderate to severe anemia was a stronger predictor than CD4 count and overall was the 
strongest predictor of early ART mortality in our cohort, similar to other studies in SSA [21, 
38, 39]. Anemia is the most common hematological complication of HIV disease among 
PLHIV [40] and develops through several mechanisms including direct HIV infection of 
hematopoietic progenitor cells, dysregulated erythropoiesis through indirect effects of 
proinflammatory cytokines, and through anemia of chronic disorders (ACD), which is 
thought to be the most common pathway [41]. ACD is driven by hepatic expression of 
hepcidin, an acute phase reactant that causes iron to be diverted from the circulation and 
sequestered within cells of the reticuloendothelial system through down-regulation of 
ferroportin channels [42]. TB also drives ACD through this hepcidin-ferroportin-interaction 
[42, 43]. In turn, sequestration of iron inside macrophages and T-cells might support both 
intracellular mycobacterial growth [39, 42] and HIV viral replication [44], showing the 
potential for rapid worsening of HIV, TB, and severe hepcidin-driven anemia. Therefore, 
although ART is the most important treatment of HIV-associated anemia, early treatment 
of any associated co-infections is crucial [39]. In a separate analysis, we show that 
moderate to severe anemia was also predictive of active TB infection in the XPRES cohort, 
similar to other analyses [39]. Given the strong association between moderate to severe 
anemia, early mortality, and active TB, which is the most common cause of early mortality 
in SSA [45], the scores associated with observed moderate-severe anemia in this analysis 
(2–4 points) appropriately bring the total clinical score very close to the threshold for ART 
care intensification. Per current WHO guidelines, care intensification should include 
further investigations for TB, especially disseminated TB, through use of the urine TB-LAM 
assay and Xpert MTB/RIF [39, 43, 46, 47].  
Another notable finding is that measured temperature at >37.5˚C at ART initiation was 
strongly predictive of early ART mortality, independent of the WHO TB symptom screen 
for fever or night sweats, which was also predictive of mortality. This indicates the 
importance of objective measures of fever in addition to patient history [23]. Notably 
some of the key inflammatory cytokines that drive hepcidin release and fever are the 
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same (e.g., interleukin (IL)-6, tumor necrosis factor which stimulates IL-6 release, 
interferons, and microbial-derived Toll-like receptors) are important for both pathways 
[42, 48]. Disseminated undiagnosed TB or TB diagnosed late is the most common 
infectious cause of death among PLHIV in sub-Saharan Africa, accounting for about 40% of 
deaths [45]. However, a recent autopsy study of causes of death among new HIV clinic 
enrollees in SA, found that 59% of decedents had evidence of two or more concurrent 
infections [49]. Most bacterial infections were due to common pathogens, such as 
Klebsiella spp., Salmonella spp., H. influenzae, and S. aureus, while cryptococcal infection 
was found in 13% [49]. Targeting an antimicrobial package of interventions to patients 
who screen positive for our proposed clinical scores, such as the package of interventions 
recommended by WHO or trialed in the REALITY trial (continuous trimethoprim–
sulfamethoxazole, ≥12 weeks of isoniazid–pyridoxine (once active TB is ruled out), 12 
weeks of fluconazole, 5 days of azithromycin, and a single dose of albendazole) could 
significantly reduce mortality for patients who screen positive [11].  
The prognostic importance of male gender in predicting mortality was correlated with 
older age and smoking history in our model, and we chose to include the single gender 
variable rather than two additional variables (age ≥55 and smoking) in the CD4-dependent 
clinical score to make the most parsomnoius clinical score and because male gender is a 
more generalizable predictor of poor outcomes in SSA [28, 50, 51]. However, if ART 
programmes in SSA are able in the future to achieve earlier testing, ART initiation, and 
better adherence for male and non-pregnant female PLHIV, it is likely gender and 
pregnancy status could become less important predictors, while predictors like smoking 
and older age will become more important [50]. Although smoking is not part of the 
clinical score, this article provides additional evidence for the need for tobacco smoking 
reduction programmes for PLHIV, separate or included in early ART care intensification
algorithms, to minimize not only the risk of ischemic cardiovascular diseases but also the 
risk of malignancies and bacterial infections, including TB [52]. 
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Strengths of this study include the use of data from prospective cohorts nested within 
clinical trials, meaning there was minimal missing covariate data and strong ascertainment 
of the primary outcome of interest (6-month ART mortality). Additional strengths include 
the high screening accuracy in both the XPRES and TBFT cohorts, from two geographically 
separate cohorts, with very different cohort characteristics (e.g., XPRES enrollees 
represent general outpatient ART enrollees while TBFT enrollees had homogenously low 
CD4 counts (<150/µL)). Notably, while in the XPRES cohort 6% of ART enrollees were 
newly diagnosed and treated for TB, in the TBFT cohort 62% were  treated for TB through 
a risk-based TB-treatment algorithm [14], suggesting that the risk score is likely to be 
generalizable across a wide range of new ART enrollee cohorts. Limitations include that 
the risk score has not yet been validated in a cohort enrolled under HIV test-and-treat 
guidelines, something which is planned in the near future. Other limitations include the 
fact that while the gender and pregnancy variable is relevant in SSA and many resource-
limited settings, it is not generalizable to cohorts in resource-rich settings like the U.S. and 
Europe, where males often have better outcomes than female ART enrollees. Although 
the specificity of the clinical scores is superior to the WHO advanced disease eligibility 
criteria, a substantial percentage of ART enrollees (36-38% in the XPRES cohort) would be 
screened into receiving an advanced disease care package, which would require a 
monitoring system to assess implementation fidelity. In addition, these screening tools 
were validated in clinical trial cohorts that received relatively intensive TB screening and 
treatment services, and therefore those that died did so despite access these services.   
Conclusions 
In conclusion, where CD4 testing is not available in similar LMIC, especially in SSA, the 
CD4-independent risk score should be strongly considered for scale-up to facilitate early 
ART care intensification, with the potential for significant reductions in early ART mortality 
if targetted individuals are provided with evidence-based care packages [11]. For clinics 
where CD4 count is available, use of the CD4-dependent clinical score could improve both 
sensitivity and specificity over WHO advanced disease eligibility criteria, with the potential 
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to reduce early ART mortality and improve efficiency of DSD algorithms. Finally, further 
research to understand best management of ART enrollees enrolled in the highest-risk 
categories is warranted to further explore mortality reduction interventions. Together 
these actions could help drive progress to AIDS 2030 goals of zero AIDS deaths in the 
region of the world with the highest HIV/AIDS-associated mortality. 
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6.1. Research paper supplementary material 
Table 6.4. (Research paper additional file 1) Table showing HIV care clinical follow-up of 
clients in the Botswana XPRES cohort (2010-2015) 
Pre-ART, CD4 >350 3 monthly Weight, CD4, TB screen 
ART 
ART start Weight, CD4, TB screen, ALT/AST if NVP-based 
regimen, Hb if AZT-based regimen, Hepatitis B 
screen, creatinine if TDF-based regimen 
2 weeks Weight, TB screen, ALT/AST if NVP-based 
regimen, Hb if AZT-based regimen 
1 month Weight, TB screen, ALT/AST if NVP-based 
regimen, Hb if AZT-based regimen 
3 months Weight, TB screen, ALT/AST if NVP-based 
regimen, Hb if AZT-based regimen, Viral load, 
creatinine if TDF-based regimen 
6months Weight, TB screen, ALT/ASTa if NVP-based 
regimen, Hb if AZT-based regimen, Viral load, 
CD4 
Quarterlyb Weight, TB screen, Viral load and CD4 6 
monthly, creatinine if TDF-based regimen 6 
monthly 
Abbreviations: CD4, CD4 cell count; TB, tuberculosis; ALT, alanine transaminase; AST, 
aspartate aminotransferase; NVP, nevirapine; AZT, zidovudine; TDF, tenofovir;    
aRoutine ALT/AST not required after 6 months but may be requested by the clinician 
depending on the clinical situation.  
bFor those patients started on PI-based regimens, baseline and 12-monthly glucose 
(random or fasting) and total cholesterol/triglycerides are recommended. 
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Additional file 2, Text showing XPRES enrolment and follow-up procedures 
At prospective cohort enrolment, research staff administered a standardized 
questionnaire, which captured demographic characteristics including age, sex, and 
pregnancy status, as well as clinical characteristics, including the WHO TB symptom 
screening rule for any current cough, fever, night sweats or weight loss, WHO HIV disease 
stage, height and weight, temperature in degrees centigrade, the most recent 
haemoglobin level, and the most recent CD4 count. As part of the trial intervention to 
strengthen ICF, all patients symptomatic for TB were encouraged to provide at least two 
same-day, on-the-spot (spot) sputum samples. Laboratory personnel had received 
refresher training on Ziehl-Neelsen staining for sputum-smear microscopy and Xpert 
implementation. In all phases, sputum test results were returned to the clinics within 4 
days for sputum-smear microscopy and 2 days for Xpert testing. Study nurses were 
trained to inform patients of positive TB diagnoses the same day via phone, or if 
unreachable by phone, by active tracing to the household. As part of the active tracing 
intervention, for all patients ≥1 day late for a clinic appointment, study nurses conducted 
up to five telephone calls and two home visits in attempts to return these clients to care. 
XPRES participants were followed for 12 months, or until the end of TB treatment, 
whichever was later. The final follow-up visits for XPRES enrolees were in June 2015. 
Table 6.5. (Research paper additional file 3) Tripod checklist for prediction model 
development and validation 
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Table 6.6. (Research paper additional file 4) Table showing Hosmer-Lemeshow tests for 
calibration of final models A (CD4 excluded) and B (CD4 included) 
Additional file 4a: Hosmer-Lemeshow test for calibration of final model – Model A (CD4 
excluded) 
Derivation Dataset Validation Dataset 
Death Death 
Decile N Cut off* Observed** Predicted† Decile N Cut off* Observed** Predicted† 
1 285 0.0034 1 0.7 1 272 0.0031 0 0.7 
2 283 0.0045 0 1.1 2 271 0.0042 3 1 
3 284 0.0057 0 1.4 3 273 0.0053 0 1.3 
4 284 0.007 1 1.8 4 270 0.0066 1 1.6 
5 283 0.0091 0 2.3 5 272 0.0085 3 2 
6 284 0.0131 3 3.1 6 271 0.0122 5 2.8 
7 284 0.021 5 4.7 7 272 0.0189 2 4.1 
8 284 0.0345 8 7.6 8 271 0.031 6 6.7 
9 284 0.0689 20 13.6 9 272 0.0619 10 11.9 
10 283 0.7517 45 46.6 10 271 0.5941 37 42.6 
Total 2838 83 83 2715 67 75 
Derivation dataset Hosmer-Lemeshow chi2(8) = 8.56, p=0.3807 
Validation dataset Hosmer-Lemeshow chi2(8) = 10.91, p=0.2069 
* Upper boundary of predicted risk
**Observed = observed number dying within 6 months of ART initiation
†Predicted = expected number dying within 6 months of ART initiation
Additional file 4b: Hosmer-Lemeshow test for calibration of final model – Model B (CD4 
included) 
Derivation Dataset Validation Dataset 
Death Death 
Decile N Cut off* Observed** Predicted† Decile N Cut off* Observed** Predicted† 
1 284 0.0026 0 0.6 1 272 0.0025 1 0.5 
2 284 0.0036 0 0.9 2 271 0.0034 1 0.8 
3 284 0.0046 0 1.2 3 272 0.0044 1 1.1 
4 284 0.0059 1 1.5 4 271 0.0057 1 1.4 
5 284 0.0084 3 2 5 272 0.0078 2 1.8 
6 284 0.0123 1 2.8 6 271 0.0113 3 2.5 
7 284 0.0193 5 4.4 7 272 0.0177 3 3.9 
8 284 0.0325 7 7.1 8 271 0.0322 7 6.5 
9 284 0.0704 15 13.4 9 272 0.068 14 12.7 
10 284 0.807 52 50.1 10 271 0.7138 34 47.5 
2840 84 84 2715 67 79 
Derivation dataset Hosmer-Lemeshow chi2(8) 5.21, p=0.7345 
Validation dataset Hosmer Lemeshow chi2(8) = 5.73, p=0.677 
* Upper boundary of predicted risk
**Observed = observed number dying within 6 months of ART initiation
†Predicted = expected number dying within 6 months of ART initiation
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Table 6.7. (Research paper additional file 5) Tables showing performance of clinical 
score in derivation and validation datasets for Models A (excluding CD4) and B (including 
CD4) 
Additional file 5a: Performance of clinical score in derivation and validation datasets – 
Model A (excluding CD4) 























months % Died 
0 236 1 0% 293 1 0% 0 0 0 
1 434 - 0% 415 2 0% 45 0 0% 
2 573 - 0% 569 2 0% 65 0 0% 
3 564 7 1% 490 8 2% 167 3 2% 
4 367 11 3% 371 4 1% 183 10 5% 
5 263 11 4% 214 9 4% 279 15 5% 
6 203 16 11% 186 15 8% 282 15 5% 
7 81 8 19% 66 10 15% 34 11 32% 
8 92 20 38% 80 13 16% 16 6 38% 
>=9* 25 9 27% 31 3 10% 6 0 0% 
 Total 2838 83 2715 67 1,077 60 
*In derivation dataset, 11, 11, and 3 patients had scores of 9, 10, and 11, with 6, 3, and 0 deaths
respectively. In XPRES validation dataset, 14, 15, and 2 had scores of 9, 10, and 11 with 0, 2, and 1 deaths
respectively.  No scores >9 were observed in the TBFT dataset.
Additional file 5b: Performance of clinical score in derivation and validation datasets – 
Model B (including CD4) 























months % Died 
0 198  1 1% 257 1 0% 0 0 0 
1 381 - 0% 361 1 0% 0 0 0 
2 296 - 0% 305 2 1% 45 0 0% 
3 413  1 0% 413 2 0% 65 0 0% 
4 451  2 0% 351 2 1% 100 7 7% 
5 358  9 3% 348 8 2% 198 10 5% 
6 228  12 5% 226 7 3% 54 5 9% 
7 195  9  5% 166 9 5% 277 17 6% 
8 149  14 9% 131 11 8% 282 12 4% 
9 82  12 15% 67 9 13% 56 9 16% 
10 67  17 25% 63 12 19% 
11 8  3  38% 11 - 0%
>=12 12  3  25% 16 3 19% 
 Total 2838 83 2715 67 1,077 60 
*In derivation dataset, 9 and 3 patients had scores of 12 and 13, with 3, and 0 deaths respectively. In XPRES
validation dataset, 14 and 2 had scores of 12 and 13 with 2 and 1 deaths respectively.  No scores >9 were
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Table 7.1. (Research paper Table 1) Comparison of derivation and validation datasets (internal  
and external)*  
Table 7.2. (Research paper Table 2) Univariable and multivariable logistic regression analysis in 
the derivation dataset (N = 2,771) 
Table 7.3. (Research paper Table 3) Multivariable model and clinical score in the derivation 
dataset (N = 2,771). 
Figure 7.1. (Research paper Fig 1) Study profile 
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Abstract 
Background: Among people living with HIV (PLHIV), more flexible and sensitive 
tuberculosis (TB) screening tools capable of detecting TB are needed to reduce morbidity 
and mortality from undiagnosed TB, facilitate prudent scale-up of TB preventive therapy 
(TPT) to over 13 million PLHIV by 2021, and allow for differentiated HIV-TB care.  
Methods: We used Botswana XPRES trial data for adult HIV clinic enrolees to develop a 
parsimonious multivariable prognostic model for active prevalent TB using both logistic 
regression and random forest machine learning approaches. A clinical score (CS) was 
derived by rescaling final model coefficients. The CS was developed using southern 
Botswana XPRES data and its accuracy validated internally, using northern Botswana data, 
and externally using three diverse cohorts of antiretroviral therapy (ART)-naïve and ART-
experienced PLHIV enrolled in XPHACTOR, TB Fast Track (TBFT), and Gugulethu studies 
from South Africa. Predictive accuracy of the CS was compared with the World Health 
Organisation (WHO) four-symptom TB screen. 
Results: Among 5,418 XPRES enrolees, 2,771 were included in the derivation dataset; 
median CD4 was 240/µL, and 189 (7%) had undiagnosed prevalent TB. Among XPHACTOR, 
TBFT, and Gugulethu cohorts, median CD4 was 400/µL, 73/µL, and 167/µL, and prevalence 
of TB was 5%, 10%, and 18%, respectively. Factors predictive of TB in the derivation 
dataset and selected for the CS included: male gender (1 point), ≥1 WHO TB symptom (7 
points), smoking history (1 point), temperature >37.5˚C (6 points), body mass index 
<18.5kg/m2 (2 points), and severe anaemia (haemoglobin <8g/dL) (3 points). Sensitivity 
using the WHO four-symptom TB screen was 73%, 80%, 94% and 94% in XPRES, 
XPHACTOR, TBFT and Gugulethu cohorts, respectively, but increased to 88%, 87%, 97%, 
and 97%, when a CS of ≥2 was used. Negative predictive value (NPV) also increased 1%, 
0.3%, 1.6%, and 1.7% in XPRES, XPHACTOR, TBFT, and Gugulethu cohorts, respectively 
when the CS of ≥2 replaced the WHO four-symptom TB screen. Categorizing risk scores 
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into low (<2), moderate (2-10), and high-risk categories (>10) yielded TB prevalence of 1%, 
1%, 2%, and 6% in the lowest risk group and 15%, 22%, 26%, and 32% in the highest risk 
group for XPRES, XPHACTOR, TBFT, and Gugulethu cohorts, respectively. At CS ≥2 the 
number needed to screen ranged from 5.0 in Gugulethu to 11.0 in XPHACTOR. 
Conclusions: The simple and feasible CS allowed improved sensitivity and NPV, which 
could facilitate reductions in mortality from undiagnosed TB and safer administration of 
TPT during proposed global scale-up efforts. Differentiation of risk by CS cut-off allows 




Tuberculosis (TB) remains the most common cause of death among people living with HIV 
(PLHIV), causing 251,000 HIV-associated TB deaths in 2018, with over 95% of these deaths 
in low- and middle-income countries (LMIC) [1]. Among PLHIV who die from TB, TB is 
commonly undiagnosed at the time of death [2,3]. The World Health Organization (WHO) 
recommends a four-symptom TB screening rule (i.e., for cough, weight loss, night sweats 
or fever) to determine which PLHIV need investigation for active TB and which are eligible 
for immediate TB preventive therapy (TPT) [4]. The WHO four-symptom TB screening rule 
is recommended for LMIC regardless of expected prevalence of active TB, setting (e.g., 
high or low TB incidence settings), or antiretroviral therapy (ART) status (ART-naïve or 
ART-experienced) [4].  
However, screening accuracy of the WHO four-symptom screening rule varies by 
population, setting, and ART status, raising the question whether a “one-size-fits-all” 
screening rule is appropriate. For example, a recent meta-analysis observed that while 
sensitivity of the WHO four-symptom TB screening rule is about 89% among ART-naïve 
PLHIV, it was only 51% among people on ART due to a higher prevalence of asymptomatic 
TB among stable ART patients [5-7]. At a time when global health donors have committed 
to reaching over 13 million PLHIV on ART with TPT by 2021 [8], low sensitivity of the WHO 
four-symptom screening rule for active TB among PLHIV on ART warrants consideration of 
more sensitive screening approaches [9]. Although new WHO guidelines recommend 
adding chest radiography (CXR) to the screening rule for PLHIV on ART to increase 
sensitivity and negative predictive value (NPV), this comes at the expense of specificity, 
carries significant additional costs and operational challenges, and might hinder rather 
than expedite TPT scale-up in some LMIC settings [5,10].  Asymptomatic active TB can also 
be present among severely immune compromised PLHIV [11], and among pre-ART 
patients without advanced disease in high prevalence settings [12], among whom missing 
asymptomatic active TB can have suboptimal health consequences for patients and 
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impede disease control activities [13]. Finally, the WHO four-symptom screening rule does 
not allow TB risk differentiation into low-, moderate-, and high-risk groups which might 
inform differentiated models of care. 
Therefore, we aimed to develop a predictive clinical score based on variables commonly 
available in resource-contained clinics, to define a range of cut-offs, with associated 
screening sensitivity, specificity, NPV, positive predictive value (PPV), and number needed 
to screen (NNS) to detect one person with active TB. 
Methods 
We used data from the Xpert Package Rollout Evaluation using a Stepped-wedge design 
(XPRES) trial conducted in Botswana to derive the predictive TB clinical score [14]. We split 
XPRES cohort data geographically into 11 southern and 11 northern clinics to serve as an 
internal derivation and validation datasets, respectively. We used two different but 
complementary modelling approaches to generate a parsimonious TB clinical risk score 
comprised of variables easily available in a resource-constrained clinic setting: (1) logistic 
regression models, and (2) random forest machine learning models. Random forest 
machine learning models are particularly useful for identifying important non-linear 
associations between predictors and outcomes because the modelling approach does not 
rely on assumptions of average linear or curvilinear associations [15]. Having derived the 
clinical score, we then used data from three other settings to validate the derived clinical 
score: (1) prospective cohort data for XPHACTOR study enrolees from Gauteng province, 
South Africa (SA), which represents a predominantly stable, long-term ART population 
[16]; (2) cluster-randomised trial data from the TB Fast Track (TBFT) trial from Gauteng, 
Limpopo, and North West Provinces in SA, which represents a population with advanced 
HIV disease not taking ART [17]; and (3) prospective cohort data from the Western Cape, 
SA, which represents an ART-naïve population in a very high TB incidence setting [18]. We 
compared screening accuracy of our derived clinical scores with existing WHO TB 
symptom screening criteria for active TB among PLHIV in each of these populations.  
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XPRES study design and participants for prediction tool development 
XPRES was a stepped-wedge cluster-randomised trial (CRT) with a retrospective baseline 
component conducted at 22 health facilities, including five hospitals and 17 clinics, that 
were purposively selected to be representative of HIV treatment clinics in Botswana [14]. 
In the prospective, stepped-wedge portion of the trial, all non-incarcerated, consenting, 
ART-naïve, HIV-positive persons, regardless of TB treatment or symptom status, 
presenting to the study clinics between August 2012 and end of March 2014, were eligible 
for enrolment. Only adolescents and adults (aged ≥12 years old), who did not present at 
the study clinic with a TB diagnosis, were included in this analysis. 
XPRES procedures 
Per Botswana national guidelines during the time period of the study, all XPRES study 
participants were eligible for ART initiation if they had a CD4 count ≤350 cells/µL, were 
diagnosed as having WHO stage III/IV, or were pregnant or breastfeeding [19]. All study 
participants received clinical care and follow-up appointments per Ministry of Health and 
Wellness guidelines, which included WHO TB symptom screening at the first and all 
subsequent clinic visits (see S1, table). 
Interventions 
The prospective XPRES cohort was recruited within two phases of the stepped-wedge 
trial. In the first phase, all prospective XPRES participants received two enhanced care 
interventions in addition to standard of care (SOC): (1) additional support for intensified 
TB case finding, and (2) intensified tracing for patients missing clinic appointments. In the 
second phase, the Xpert MTB/RIF assay was initiated in place of sputum smear microscopy 
for TB diagnosis. We have previously shown that there was no significant difference in TB 
case finding between the first and second prospective phases of XPRES (5% vs. 6%), 
although the prevalence of microbiologically confirmed TB was higher in the post-Xpert 
study phase (51% vs. 65%) [20]. Enrolment and follow-up procedures are described in a 
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supplementary appendix (S2, text). XPRES participants were followed for 12 months, or 
until the end of TB treatment, whichever was later. The final follow-up visits for XPRES 
enrolees were in June 2015. 
Development and internal validation of the prediction model 
A clinically-useful prediction model should demonstrate accurate prediction of the 
outcome in data other than that in which the model was developed. Therefore, we split 
the XPRES dataset in an approximately 1:1 ratio into southern clinics (n=11) and northern 
clinics (n=11) with southern clinics serving as the derivation dataset and northern clinics as 
the model validation dataset [21].  
Outcome 
The outcome of interest for this analysis was new diagnosis of active TB (clinical or 
microbiologically confirmed), within 6 months of arrival at the HIV treatment clinic. In this 
manuscript, this outcome is referred to as undiagnosed prevalent TB at arrival at the HIV 
treatment clinic [16,22,23]. Active TB during this initial 6 month post-clinic enrolment 
period is considered prevalent rather than incident TB based on prior clinical cohort data 
showing that 87% of active TB cases identified in months 0-6 after HIV clinic enrolment, 
could have been diagnosed at the HIV clinic enrolment visit [23]. In addition, data from 
Zimbabwe show that the mean duration of smear-positivity prior to TB diagnosis amongst 
HIV-positive adults to be 18±33 weeks [22]. Precedent for this approach and definition has 
been previously published [16].  We implemented intensive efforts to ascertain true active 
TB disease among participants with TB case finding procedures previously published and 
provided in supplementary appendix S2 (text) [14,20]. 
Candidate predictor variables 
We selected candidate predictor variables for potential inclusion in the predictive models 
based on prior publications, and the need for variables to be reproducible, objective, and 
readily available in resource-constrained clinic settings [24]. We considered variables 
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known to be associated with active TB including age, sex, marital status, education level, 
employment status, previous/current work as a miner, smoking history, prior TB 
treatment, history of a TB contact in the last 24 months, presence and number of WHO TB 
symptoms, body mass index (BMI) (weight/height2), haemoglobin concentration, CD4 
count, temperature at ART initiation in degrees Celsius, and respiratory rate at enrolment 
visit [16,25-27]. We included BMI rather than weight as a candidate variable as a better 
marker of nutritional status [28]. 
Logistic regression model approach 
Within the derivation dataset, we performed univariable logistic regression analyses 
assessing the association of each variable with risk of prevalent active TB. Continuous 
variables were assessed for non-linearity with log odds of TB using multivariable fractional 
polynomial models, as well as by comparing Akaike’s Information Criteria (AIC) and 
Bayesian Information Criteria (BIC) between models with linear or fractional polynomial 
terms. Where non-linearity was observed, the appropriate fractional polynomial terms 
were included in the logistic regression. We also examined scatter plots of untransformed 
and transformed continuous variables and risk of mortality to assess inflexion points 
which might inform appropriate categorization of continuous variables.  
For the multivariable logistic regression analysis, a complete case analysis was chosen 
because few data (<10%) were missing. To inform generation of a parsimonious 
multivariable model, we used a stepwise backward elimination approach, starting with all 
candidate variables and excluding variables sequentially if p>0.01 using both automatic 
and manual approaches.  Prior regression derived scores used p-value cut-offs of >0.05 
[16,29,30]; however, there is no accepted standard p-value cut-off for backward or 
forward stepwise variable elimination approaches [24].  Because we aimed to generate a 
parsimonious model, to increase feasibility of the practical clinical score in LMIC clinic 
settings, we used a >0.01 cut-off in line with recommendations from Royston et al [24,31]. 
We also explored how findings changed using a forward stepwise addition approach. 
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Where two or more predictors were highly correlated, only one was selected, to simplify 
the prognostic model. Plausible interactions between covariates (e.g., between gender 
and BMI [32]) were assessed using the likelihood ratio test.  
Random forest model approach 
We first built a random forest model with all 15 possible candidate variables that were 
included in the backward stepwise elimination approach. We fit the model using the 
randomForest R package with 1,000 trees. We used the bestmtry function to identify the 
optimum number of variables to be randomly included in each of the 1000 trees. We used 
this model to order the 15 variables according to importance in predicting TB as measured 
by both the mean decrease in accuracy and mean decrease in Gini for each variable [33]. 
We compared results with the logistic regression to assess if potentially important 
discriminatory variables had been eliminated in the backward stepwise regression. To 
assess any potentially important loss of discrimination through eliminating variables to 
create a parsimonious model, and to assess potential differences in discriminatory 
capacity between model approaches, we compared area under the receiver-operating 
characteristic (AUROC) curve values, between logistic regression and random forest 
models in scenarios where all 15 variables were modelled and a scenario where a 
parsimonious model was chosen. Information from the backward stepwise regression and 
random forest modelling was used to generate the final parsimonious model. 
Internal validation of parsimonious model 
In both the derivation and validation datasets, we assessed multivariable logistic 
regression model calibration graphically in a calibration plot [21], and statistically using 
the Hosmer-Lemeshow test. We also assessed discrimination using the AUROC values. 
AUROC values of 0.7 to 0.79, 0.8 to 0.89, and >0.9 are respectively considered acceptable, 
excellent and outstanding discrimination [34]. 
Clinical score generation 
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The final multivariable model was used to generate a practical clinical score. For these 
models, continuous variables were categorized in a clinically meaningful manner based on 
their functional form and information from the published literature. Each beta coefficient 
from this logistic regression model was then rescaled to generate a clinical score by 
dividing each coefficient by the smallest positive model coefficient and rounding to the 
nearest integer. The total number of points was summed for each participant to calculate 
their total clinical score. 
External validation of risk scores 
To externally validate the clinical risk score, we used data collected independently from 
the XPHACTOR cohort [16], TBFT trial [17], and Gugulethu cohort [18]. Characteristics of 
these studies as relate to setting, clinic types, eligibility criteria, dates of enrolment, ART 
eligibility criteria, TB symptoms screening, TB case finding approaches, and definition of 
active prevalent TB for this analysis, are described in Supplementary Table 3 (S3, table). 
For both the XPRES cohort (combined derivation and validation datasets), and the three 
validation datasets, we explored how sensitivity, specificity, PPV, NPV, and AUROC curve 
values varied with increasing clinical score in terms of predicting active prevalent TB and 
compared this screening accuracy and discrimination performance with the current WHO 
TB symptom screening rule. Three risk groups were created to visualize increasing active 
prevalent TB risk with increasing clinical score, and the percentage of ART enrolees falling 
into each risk group. The NNS to detect one TB case was compared between WHO TB 
symptom screening rules and a range of clinical score cut-offs. 
All logistic regression and clinical score validation analyses were conducted using STATA 
16 (StataCorp, 2009, Stata Statistical Software, Release 16, College Station, TX).  All 
Random Forest Plot analyses and analyses to assess the mean decrease in Gini associated 
with candidate predictor variables were done with R version 3.6.1. (R Core Team (2017). R 
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Foundation for Statistical Computing, Vienna, Austria). The study is reported in 
concordance with TRIPOD guidance for multivariable prediction models (S4, Table). 
Ethical review 
Ethical approval for each of the source studies was obtained from the relevant ethics 
committees in the country of data collection and from the trial sponsors. All participants 
provided informed written consent, or where the enrolee could not read or write, 
witnessed verbal informed consent. Ethical approvals for XPRES were obtained from the 
U.S. Centers for Disease Control and Prevention (CDC) Institutional Review Board (IRB) C, 
the Health Research and Development Division of the Health Research and Development 
Committee (HRDC) in Botswana, and the University of Pennsylvania IRB No.4.  XPHACTOR 
was was approved by the ethics committees at the University of the Witwatersrand, 
University of Cape Town, and the London School of Hygiene & Tropical Medicine. TBFT 
was approved by the research ethics committees of the University of the Witwatersrand 
and the London School of Hygiene & Tropical Medicine, and the South African Medicines 
Control Council. The Gugulethu prospective cohort study was approved by the research 
ethics committees of the University of Cape Town, and the London School of Hygiene & 
Tropical Medicine.  
Results 
From the XPRES cohort, 5,418 eligible adult (≥12 years old) study enrolees with complete 
data for candidate predictors were included in the analysis (Fig 1). Overall, 318 (6%) of 
5,418 enrolees had undiagnosed prevalent active TB at HIV clinic registration and study 
enrolment.  
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Fig 1. Study profile 
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Internal derivation and temporal validation datasets 
From the XPRES cohort, the internal derivation (N=2,771) and validation (N=2,647) 
datasets were created (Table 1). Key characteristics including median age (34 years), 
percentage female (67-68%), median CD4 (240-249/µL), and prevalence of active TB at 
enrolment (5-7%), were similar between XPRES derivation and validation datasets (Table 
1). 
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Dataset (SA, XPHACTOR: 
N=1807) 
External Validation 
Dataset (TBFT, SA: N=793) 
External Validation Dataset 
(Gugulethu Cohort, CT, SA: 
N=488) 
Demographics n (median or %) n (median or %) n (median or %) n (median or %) n (median or %) 
Age (years)  n, median (IQR) 2,771 34.3 (28.8-41.3) 2,647 33.5 (28.3-40.8) 1,807 40.0 (34.0-47.0) 793 38.0 (32.0-45.0) 488 33.6 (27.9-40.7) 
Female, n, % 1,862 67% 1,790 68% 1,290  71% 424  53% 310  64% 
If Female, Pregnant, n, % 499 27% 568 32% 0   0% 0   0% 0   0% 
Marital status, n, % Married/Civil Union 306 11% 242 9% 
Single 2,353 85% 2,322 88% 
Widowed/Divorced 112 4% 83 3% 
Smoking history (ever), n, % 466 17% 575 22% 388  21% 180  23% 185  38% 
Employed, n, % 1467 53% 1023 39% 
Education, n, % None 154 6% 235 9% 
Primary 637 23% 614 23% 
Secondary 1,689 61% 1,597 60% 
Higher 291 11% 201 8% 
Ever a miner, n, % 124 4% 143 5% 
HIV/TB history 
Previous TB treatment, n, % 232 8% 169 6% 
TB contact in last 24 months, n, % 266 10% 230 9% 
WHO TB symptoms, n, % 
Cough 533 19% 466 18% 364  20% 424  53% 243  50% 
Weight loss 533 19% 577 22% 243  13% 621  78% 331  68% 
Fever 262 9% 223 8% 105  6% 269  34% 139  28% 
Night sweats 257 9% 243 9% 135  7% 297  37% 199  41% 
Number of WHO TB symptoms, n, % 0 1979 71% 1837 69% 1,299  72% 133  17% 67  14% 
1 349 13% 397 15% 384  21% 173  22% 127  26% 
2 200 7% 203 8% 136  8% 191  24% 135  28% 
3 136 5% 134 5% 41  2% 145  18% 121  25% 
4 107 4% 76 3% 17  1% 151  19% 38  8% 
Duration of WHO symptoms  n, median (IQR) 792 60 (30-120) 810 60 (21-150) 
Clinical Characteristics 
CD4+ T-cell Count (cells/µL) n, median (IQR) 2,771 240 (131-314) 2647 249 (151-321) 1807 400 (246-600) 793  73 (34-109) 488  167 (95-231) 
Weight (kg)** n, median (IQR) 2,771 59 (52-69) 2647 60 (53-69) 793  57 (50-66) 488  64 (56-73) 
BMI (kg/m2) n, median (IQR) 2,771 21.8 (19.2-25.4) 2647 21.5 (18.9-24.7) 1807 25.0 (21.4-29.3) 793  20.9 (18.6-24.5) 488  23.5 (20.9-27.1) 
Haemoglobin g/dL n, median (IQR) 2,771 11.9 (10.5-13.3) 2647 12.0 (10.7-13.4) 1,807  13.1 (11.8-14.3) 793  11.1 (9.6-12.8) 488  12.0 (10.6-13.4) 
Temperature (˚C) n, median (IQR) 2,771 36.2 (35.8-36.7) 2647 36.1 (35.7-36.5) 793  36.3 (36.0-36.6) 
Respiratory rate (breaths/min) n, median (IQR) 2,771 20 (18-21) 2647 18 (17-20) 
New TB Diagnosis 
Cumulative prevalent active TB, n, % 189 6.8% 129 4.9% 83  4.6% 77  9.7% 90  18.4% 
Cumulative incidence microbiologically confirmed TB, n, % 96 3.5% 64 2.4% 62  3.4% 77  9.7% 90  18.4% 
Time to diagnosis of prevalent TB (days) n, median (IQR) 189 16 (7-35) 129 19 (4-48) 
Abbreviations: SA, South Africa; CT, Cape Town; WHO, World Health Organization; TB, tuberculosis; BMI, body mass index; IQR interquartile range*Where variable is blank, the data were not 
collected, or not provided from the source study for this analysis 
**BMI was used as the covariate for nutritional status rather than weight (weight was not considered as an independent predictor)  
212
Variable importance in logistic regression and random forest models 
Table 2 summarizes the results of univariable and multivariable logistic regression model 
development. Although age (linear continuous variable), education level achieved, 
prior/current work as a miner, previous TB treatment, and respiratory rate (transformed 
variable), were associated with prevalent TB in univariable analysis, these variables were 
eliminated in the stepwise backward elimination approach due to p-values in 
multivariable analysis >0.01. 
Rankings of variable importance as measured by size of beta coefficient in the logistic 
regression model and by mean decrease in Gini in the random forest model, were similar 
with respect to presence or absence of WHO TB symptoms, temperature, and BMI, with 
these variables in the top three most important predictors (Fig 2, Supplementary 
Appendix 5). Notably, the transformed term of BMI, which was eliminated in the 
backwards stepwise logistic regression at p=0.408, was considered the second most 
important variable according to mean decrease in Gini approach (52.766) and third most 
important in terms of size of the logistic regression beta coefficient (1.617). Given the 
importance of BMI in the variable ranking approach, importance in the published 
literature, and availability in resource-constrained clinics, BMI was retained in final 
multivariable model (Table 2). The final multivariable model included sex, smoking history, 
presence/absence of ≥1 WHO TB symptom, BMI (as a transformed term per the 
multivariable fractional polynomial (MFP) analysis), temperature (modelled as two 
transformed terms per the MFP analysis), and haemoglobin concentration (continuous, 
linear term) (Table 2).  
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Fig 2: Random forest model variable importance ranking by mean decrease in accuracy and mean decrease in Gini in the derivation dataset 
(N=2,771) 
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Table 2: Univariable and multivariable logistic regression analysis in the derivation dataset (N = 2,771) 
Not Diagnosed with TB 
(N=2,582) 
Diagnosed with TB within 
6 months (N=189) 
Unadjusted Final Adjusted Regression 
OR 95% CI p-value AOR 95% CI p-value 
Demographics n Median(IQR)/% n Median(IQR)/% 
Age, years (for every 10 year increase) 34 (29-41) 38 (32-44) 1.24 (1.15-1.33) <0.001 
Sex Female      1,768  95% 94 5% 1.00  -- --  1.00  -- --  
Male         814  90% 95 10% 2.20 (1.63-2.95) <0.001 1.91 (1.27-2.88) 0.002 
Marital status Married/civil union         288  94% 18 6% 1.00  -- --  
Single      2,190  93% 163 7% 1.19 (0.71-2) 0.508 
Widowed/Divorced         104  93% 8 7% 1.23 (0.44-3.41) 0.690 
Smoking History (ever smoked) No      2,165  93% 154 7% 1.00  -- --  1.00  -- --  
Yes - ever smoked         417  89% 50 11% 1.82 (1.56-2.12) <0.001 1.44 (1.12-1.85) 0.004 
Employed Employed      1,370  93% 97 7% 1.00  -- --  
Unemployed      1,212  93% 92 7% 1.07 (0.71-1.62) 0.742 
Education None         137  89% 17 11% 1.00  -- --  
Primary         588  92% 49 8% 0.67 (0.38-1.18) 0.166 
Secondary      1,576  93% 113 7% 0.58 (0.35-0.95) 0.030 
Higher   281  97% 10 3% 0.29 (0.14-0.58) <0.001 
Ever a miner No      2,478  94% 169 6% 1.00  -- --  
Yes         104  84% 20 16% 2.82 (2.04-3.9) <0.001 
HIV/TB history 
Previous TB treatment No   2,381  94% 158 6% 1.00  -- --  
Yes         201  87% 31 13% 2.32 (1.43-3.78) 0.001 
Any TB contact in last 24 months No      2,339  93% 180 7% 1.00  -- --  
Yes         243  91% 24 9% 1.33 (0.83-2.14) 0.233 
Number of WHO symptoms 0    1,936  98% 43 2% 1.00  -- --  
>=1         646  82% 146 18% 10.18 (6.79-15.26) <0.001 6.91 (4.55-10.49) <0.001 
Clinical Characteristics 
CD4 (per 10-cell increase)      2,582  247 (139-316) 189 151 (57-255) 0.96 (0.94-0.97) <0.001 
Weight (per 1 kg increase)a      2,582  59.4 (52.3-69.2) 189 53.7 (47.0-62.0) 0.97 (0.95-0.99) 0.001 
BMI (per 1 unit increase)b      2,582  21.9 (19.4-25.5) 189 19.4 (17.2-22.3) 0.90 (0.83-0.97) 0.004 0.98 (0.93-1.05) 0.612 
Haemoglobin (per 1g/dL increase)      2,582  12.0 (10.6-13.3) 189 10.6 (9.2-12.3) 0.76 (0.69-0.83) <0.001 0.78 (0.7-0.86) <0.001 
Temperature at enrolment (per 1 ˚ Celsius increase)c     2,582  36.2 (35.8-36.6) 189 36.4 (36.0-37.1) 2.13 (1.57-2.88) <0.001 1.46 (1.18-1.81) <0.001 
Respiratory rate (breaths/min)d      2,582   20 (18-20)   189 20 (18-22) 1.03 (1.01-1.05) 0.010 
Abbreviations: TB, tuberculosis; CI, confidence interval; WHO, World Health Organization; BMI, body mass index; OR, odds ratio; AOR, adjusted odds ratio; IQR, inter-quartile range;  
a Due to correlation with BMI, weight was not included in the stepwise backward regression. 
b Due to non-linearity in the association between BMI and log odds TB, BMI was modelled as a transformed term from the MFP analysis (transformed BMI =X^-.5-.666749355, where: X = BMI/10). Output shown is 
for the single linear term to facilitate interpretation of average BMI effect (i.e., higher BMI associated with lower TB risk). In the backward stepwise regression, the p-value associated with BMI term was 0.4077 at 
point of elimination. Given the importance of BMI as a predictor in the Random Forest model (2nd most important predictor), ease of availability of this variable in almost all resource-limited clinics, and importance 
of BMI in published literature, BMI was retained in the final adjusted model. 
c Due to non-linearity in the association between temperature and log odds TB, temperature was modelled as two transformed terms (term 1 = temperature -36.12674419; term 2 = temperat^2-1305.141645). 
Output shown is for the single linear term to facilitate interpretation of average temperature effect (i.e., higher temperature associated with higher TB risk).  In the backward stepwise regression, the p-value 
associated with each transformed term was 0.005 and 0.004 respectively. 
d Due to non-linearity in the association between respiratory rate (RR) and log odds TB, RR was modelled as a transformed term from the MFP analysis (transformed term = X^-1-5.170636738, where: X = RR/100). 
Output shown is for the single linear term to facilitate interpretation of average RR effect (i.e., higher respiratory rate associated with higher TB risk).  In the backward stepwise regression, the p-value associated 
with the transformed term was 0.0251 at the point of elimination from the model.
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Internal validation of final multivariable regression model 
For the derivation dataset, the Hosmer-Lemeshow statistic for the TB prediction model 
(p=0.135, see S6, table), and the calibration curve (Figure 3), indicated good model fit. 
Although the Hosmer-Lemeshow statistic for the internal validation dataset (p=0.0001) 
indicated lack of fit with over-estimation of prevalent TB, with 169 cases of prevalent TB 
predicted versus 129 observed, (1) the Hosmer-Lemeshow test is sensitive to sample size 
and our sample size is large, and (2) the calibration curve (Fig 3) indicated adequate 
prediction performance for the 10 risk groups. In addition, the AUROC curve values for the 
derivation (0.8391) and validation datasets (0.7991) indicated excellent, and borderline 
excellent discrimination, respectively (Fig 3). 
Fig 3: Logistic regression model development and performance in the internal derivation and validation datasets respectively 
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Comparison of regression and random forest discrimination  
Comparison of discriminatory performance between 15-covariate and 6-covariate 
parsimonious models (Fig 4), indicated very little loss of discrimination by eliminating nine 
of the covariates from the predictive model, building confidence in the final multivariate 
model. Similarly, although the random forest approach had far superior discrimination on 
the derivation dataset versus the logistic regression approach, both modelling approaches 
had similar discrimination in the internal validation dataset (Fig 4). 
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Fig 4: Comparison of area under the receiver operating characteristic curves by modelling approach (logistic regression vs. random forest), 














Ratio  95% CI  p‐value  β coefficient  Score 
WHO TB symptoms  no symptoms   1.00  ‐‐   ‐‐  
>=1 symptom  7.00  (4.66‐10.52)  <0.001  1.95  7 
Sex  Female   1.00  ‐‐   ‐‐  
Male  1.35  (0.88‐2.08)  0.173  0.30  1 
Smoker  Never   1.00  ‐‐   ‐‐  
Ever smoked  1.32  (1.03‐1.7)  0.030  0.28  1 
Haemoglobin  >=8 g/dL   1.00  ‐‐   ‐‐  
<8 g/dL  2.50  (1.28‐4.85)  0.007  0.91  3 
Temperature  <=37.5   1.00  ‐‐   ‐‐  
>37.5 5.53  (3.5‐8.72)  <0.001  1.71  6 
BMI  >=18.5   1.00  ‐‐   ‐‐  










Fig 5: Clinical score for predicting tuberculosis among people living with HIV 
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External validation of risk scores 
The clinical score for each predictor was generated and applied to each external dataset, 
where the possible range for the total score was 0 to 20 (see S8, table).  Fig 6 shows the 
performance of the clinical score at different cut-offs, in terms of sensitivity, specificity, 
NPV, PPV, and percentage of clinic enrolees that would be offered a TB test.  Across the 
four datasets, a clinical score of ≥7 would give similar sensitivity and specificity to the 
WHO four-symptom TB screening rule. Moving the clinical score to ≥2 would give superior 
sensitivity versus the WHO four-symptom TB screening rule, but with some loss of 
specificity. For example, sensitivity in detecting prevalent active TB using the WHO four-
symptom TB screening rule was 73%, 80%, 94% and 94% in XPRES, XPHACTOR, TBFT and 
Gugulethu cohorts, respectively, but this increased to 88%, 87%, 97%, and 97%, when a 
clinical score of ≥2 was used. However, specificity would decline from 73%, 70%, 18%, and 
16% if the WHO  four-symptom TB-screen was used to 55%, 58%, 13%, and 12% if the 
clinical score of ≥2 was used. Similarly, the percentage of patients offered a TB test per the 
WHO four-symptom TB screening rule would be 30%, 32%, 83%, and 86% in the XPRES, 
XPHACTOR, TBFT and Gugulethu cohorts, respectively, but this increases to 45%, 42%, 
87%, and 88% if a clinical score of ≥2 is used.     
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Fig 6: Clinical risk scores and associated sensitivity, specificity, negative predictive value, 
and positive predictive value for tuberculosis across four study cohorts 
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Notably, when the XPHACTOR dataset was restricted to clients on ART for >3 months, the 
clinical score retained high sensitivity and specificity (see S9, figure). For example, at 
clinical score ≥2, sensitivity was 80% and specificity 60%, versus WHO four-symptom 
screening criteria which provided 69% sensitivity and 72% specificity.    
The NPV of the WHO 4-symptom TB screen was 97.7%. 98.6%, 96.2%, and 92.5% in the 
XPRES, XPHACTOR, TBFT, and Gugulethu cohorts, increasing to 98.7%, 98.9%, 97.8%, and 
94.2% when the clinical score at cut-off ≥2 was used reflecting a 1%, 0.3%, 1.6%, and 1.7% 
increase in NPV.   
When restricting the XPRES and TBFT cohorts to those who died within 6 months of clinic 
enrolment, the clinical score at a cut-off of ≥2 had superior sensitivity to the WHO four-
symptom TB screen in predicting TB in the XPRES cohort (94% vs. 79%), and similar 
sensitivity in the TBFT cohort (100% vs. 100%) (see S10, figure). However, specificity of the 
clinical score at ≥2 was inferior to that of the WHO 4-symptom TB screen in both XPRES 
(16% vs. 31%) and TBFT (3% vs. 8%) cohorts. 
Overall, the clinical score had superior discrimination in the XPRES and XPHACTOR 
datasets than in the TBFT and Gugulethu cohorts (Figure 7). The XPRES and XPHACTOR 
cohorts were more similar with respect to median baseline CD4 count (245/µL in XPRES 
and 400/µL in XPHACTOR) compared with TBFT and Gugulethu cohorts (73/µL in TBFT and 
167/µL in Gugulethu cohorts) (table 1). Similarly, XPRES and XPHACTOR cohorts were 
more similar with respect to baseline prevalence of active prevalent TB (6% in XPRES and 
5% in XPHACTOR) compared with TBFT and Gugulethu cohorts (10% in TBFT and 18% in 
Gugulethu cohort).     
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Fig 7: Clinical score discrimination according to area under the receiver operating characteristic curve by study cohort 
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Risk scores were grouped into low (<2), moderate (2-10), and high-risk categories (>10) 
(Fig 8). Prevalence of active TB among enrolees in low, moderate, and high risk groups was 
1%, 3%, and 15% among XPRES enrolees, 1%, 11%, and 22% among XPHACTOR enrolees, 
2%, 8%, and 26% for TBFT enrolees, and 6%, 19%, and 32% for Gugulethu cohorts, 
respectively, indicating a differentiation of prevalent TB risk by the respective clinical 
scores.  
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Fig 8: TB risk stratification into low, moderate, and high-risk groups by study cohort 
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Number needed to screen to diagnose one TB case 
In the cohorts with the highest prevalence of active TB (TBFT and Gugulethu), a clinical 
score with cut-off of ≥2 would give a marginally higher NNS to diagnose one TB case 
compared with the four-symptom WHO screen (Fig 9); the NNS increased from 8.6 to 9.3 
in TBFT and from 4.7 to 5.0 in Gugulethu cohorts. In contrast, in cohorts with lower 
prevalence of active prevalent TB (XPPRES and XPHACTOR), the NNS increased to a larger 
extent (from 5.0 to 9.3 in XPRES, and from 6.9 to 11.0 in XPHACTOR). The NNS in the 
highest risk group (clinical score >10) was uniformly low being 3.0, 4.5, 3.9, and 3.1 in 
XPRES, XPHACTOR, TBFT, and Gugulethu cohorts, respectively. If the NNS threshold was 
set at about 5.0, this would correspond to clinical scores of about ≥9-10 in XPRES, 
XPHACTOR, and TBFT cohorts, but ≥2 in the Gugulethu cohort.      
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Fig 9: Number needed to screen to detect one case of active tuberculosis by clinical score 
cut-off and by study cohort 
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Discussion 
This study is the first to derive and externally validate an initial clinical score for active TB 
among both ART-naïve and ART-experienced PLHIV that does not rely solely on WHO TB 
symptom screening, and allows flexibility in choosing the desired sensitivity, specificity, 
NPV, PPV, and NNS across a range of cut-offs, depending on the setting, use-case scenario, 
and population served. In addition, the screening tool can be used to reduce the likelihood 
of missing asymptomatic TB, which could help reduce morbidity and mortality due to late 
or absent TB diagnosis in some settings, as well as reduce TPT prescription to PLHIV 
needing a full TB treatment course. Similarly, the screening tool’s differentiation of three 
risk groups can be used to inform differentiated care in LMIC clinic settings, which could 
improve efficiency and potentially impact morbidity and mortality. Finally, the different 
modelling approaches provide unique insight into covariate predictor importance and 
practical ways machine learning can be helpful in predicting TB. 
While five previous studies have generated clinical scores for TB among PLHIV, three were 
designed as a second step after screening positive using the WHO four-symptom TB 
screening rule [16,30,37], and two generated a relatively complex score (13 signs and 
symptoms), were focused on ART-naïve patients only in Bissau, and lack external 
validation [38,39]. Our tool is careful to use widely available variables in LMIC settings 
with external validation in three different cohorts. The only blood test needed for our 
score is haemoglobin concentration. Point of care (POC) haemoglobin measurement 
devices are widely available, durable, easy to use, have good accuracy [40,41], are useful 
for non-HIV-related care, and are inexpensive[42]. In addition, the importance of severe 
anaemia as a predictor of active TB, as well as the biological mechanism (i.e., hepcidin-
driven iron sequestration in the reticuloendothelial system), has been well-described 
[43,44]. Another routinely available variable in LMIC clinic settings, measured temperature 
at >37.5˚C, was also independently predictive of TB, indicating the importance of objective 
measures of fever in addition to patient history [45].  
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A key advantage of the clinical score over the WHO four-symptom screening tool is that 
the score can be used by programme managers to choose the desired cut-off with
associated sensitivity, specificity, NPV, PPV, and NNS. For example, among people starting 
or re-starting ART, among whom mortality risk from undiagnosed disseminated TB 
remains relatively high, a more sensitive screening tool could help reduce morbidity and 
mortality [2,46]. Notably, in the XPRES cohort, sensitivity of detecting TB at the initial HIV 
clinic visit among those who died within 6 months of clinic enrolment increased from 79% 
with the WHO four-symptom rule to 94% with our clinical score at cut-off ≥2, suggesting 
the potential for improved early case finding with possible morbidity and mortality 
reductions [13,20].  
In addition, with support from global health donors, many countries are embarking on 
ambitious TPT scale-up for PLHIV, with the majority of targeted TPT recipients being long-
term stable ART patients [8]. Following the 2018 United Nations high-level meeting on TB, 
the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) committed to reaching >13 
million PLHIV with TPT by 2021 [8]. Although increases in NPV by using a clinical score cut-
off of ≥2 instead of the WHO four-symptom TB screen are modest, ranging from 0.3% to 
1.7%, use of the clinical score cut-off of ≥2 during the proposed TPT scale-up for PLHIV 
could potentially avoid 39,000 to 221,000 PLHIV with active TB being prescribed TPT. 
Missed active TB increases morbidity and mortality risk for the patient, but also increases 
risk of isoniazid-resistant TB, which is associated with worse treatment outcomes and may 
be transmitted to others [9,47]. Our simple screening rule approach to increasing 
sensitivity and NPV would be much less expensive and logistically challenging than the 
current WHO recommendation to consider adding CXR to the WHO symptom screen 
[10,48]. In addition, the NPV increase associated with adding CXR to the WHO screening 
rule of 0.9% is similar to the NPV increase gained by our much simpler and less costly 
clinical score at cut-off ≥2 (0.3-1.7%) [5].  
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Another potential advantage of the clinical score is that the cut-off can be tailored to the 
use-case scenario [49]. As described above, for clients at ART enrolment, re-enrolment, or 
being assessed for TPT eligibility, ruling out active TB is a high priority and therefore high 
sensitivity and NPV are desired and a cut-off of ≥2 could be chosen. However, for stable 
patients on long-term ART who have completed a course of TPT, a screening rule cut-off 
with higher specificity and therefore higher PPV could be chosen to lower the NNS and 
improve efficiency and cost-effectiveness [16,50,51].   
The clinical score could also facilitate differentiated TB care based on TB risk [52]. Firstly, 
the clinical score is relatively simple and could be used by community healthcare workers 
in the community [52], with community-based care models for HIV and TB increasingly 
important to decongest health facilities during the COVID-19 pandemic [53]. Secondly, the 
score could facilitate identifying which new or long-term ART patients should be 
prioritized for dedicated adherence and retention resources to ensure completion of the 
TB diagnostic and treatment cascade, with loss to follow-up from HIV-TB care a common 
problem in LMIC [20,54,55]. Similarly, prioritization of limited on-site GeneXpert 
diagnostics can be informed by the clinical score to increase cost-effectiveness of POC 
Xpert use [56]. Finally, diagnostic and therapeutic algorithms could be stratfied by risk 
groups, with more aggressive TB case finding and treatment approaches appropriate for 
highest risk groups (e.g., sputum culture, urinary diagnostics, abdominal sonography, or 
empiric TB treatment) [17].  
A strength of the analysis is the dual modelling approach of logistic regression and use of 
random forest machine learning to build confidence in the final practical clinical score for 
use in LMIC clinic settings. A key strength of the random forest approach, is that, similar to 
other machine learning approaches, it is better able to capture non-linear relationships 
between predictors and outcomes compared with well-established generalised linear 
regression models [15], because random forest models are not dependent on making 
assumptions of average linear or curvilinear associations between covariates and 
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outcomes. Among machine learning models, random forest models are particularly strong 
at predicting categorical outcomes like our TB outcome [57]. For example, despite using 
the fractional polynomial transformed BMI variable in the logistic regression backward 
stepwise elimination approach, it was eliminated from the parsimonious model at p>0.01. 
In contrast, the importance of BMI in discriminating prevalent active TB using the mean 
decrease in Gini analysis indicated the importance of BMI in its ability to accurately split 
groups of patients into those who have or do not have prevalent active TB across the 
1,000 decision trees examined in our random forest model. The high ranking of BMI 
according to mean decrease in Gini indicates the significant decrease in average, weighted 
decision tree node purity that occurred when BMI was removed from the possible list of 
predictor variables [57]. 
Our analysis also indicates some of the weaknesses of machine-learning approaches. 
Firstly, although the random forest model is superior to single decision trees in reducing 
the likelihood of over-fitting to the training data [57], we observed extremely high 
discrimination of the random forest model on the training data and a significant drop in 
discrimination on the validation data. This highlights the importance of a stringent 
validation approach [15]. Notably the most widely available training resources and 
publications use a random 75%:25% split to create training and validation datasets for 
random forest models [33], but we purposefully split the dataset into northern and 
southern clinics in Botswana with a 50%:50% split, which is in line with more stringent 
validation approaches that help better assess generalizability of predictive models [15,21]. 
This joint approach of using multiple modelling approaches, using the strength of one 
approach to examine and account for weaknesses of another, represents a new and useful 
contribution to the TB screening literature in line with emerging expert guidance [58,59].  
Additional strengths of this study include the use of data from high quality prospective 
cohorts, meaning there was minimal missing covariate data and strong ascertainment of 
the primary outcome of interest (prevalent active TB). Additional strengths include the 
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high screening accuracy in the three external validation cohorts, XPHACTOR, TBFT, and 
Gugulethu cohorts, representing three geographically separate cohorts, with very 
different cohort characteristics, in very different settings. Limitations include that the risk 
score has been validated in cohorts in SSA and may not be generalizable to cohorts in 
resource-rich settings like the U.S. and Europe. Another limitation is that the approaches 
to TB case finding were different across the four cohorts and that for the XPRES and 
XPHACTOR cohorts a clinical definition of TB was included in the TB outcome definition, 
whereas for TBFT and Gugulethu cohorts, results of enrollment sputum collection for TB 
culture and Xpert were used to define the TB outcome. However, model results did not 
change significantly when we restricted the TB outcome in XPRES and XPHACTOR datasets 
to microbiologically confirmed TB [16].  
Another limitation is that in XPRES, sputum samples for microbiological diagnosis were 
only obtained from symptomatic XPRES enrolees at enrolment and during follow-up.  
Although the intensive TB symptom and ICF cascades during repeat visits during six 
months of follow-up in XPRES make it less likely that active TB disease was missed over 
the course of 6 months of follow-up [23], persistantly asymptomatic TB disease would 
have been missed. In addition, in the XPHACTOR dataset, 45% of study participants were 
excluded from the validation dataset due to missing haemoglobin, and in the TBFT dataset 
29% were excluded because they could not produce sputum for culture at trial enrolment. 
Comparisons of available patient characteristics between persons excluded versus 
included in the validation datasets did not indicate notable differences, but additional 
validation exercises in contemporary cohorts with complete covariates are warranted to 
further build confidence in the risk score. 
In conclusion, this new, simple TB screening clinical score for PLHIV, which is appropriate 
for both ART-naïve and ART-experienced PLHIV, and which incorporates but does not rely 
on the WHO four-symptom screening rule, is a timely addition to practical tools available 
for clinicians and programme managers in LMIC. The clinical score improves on the WHO
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four-symptom screening rule’s capacity to detect asymptomatic TB, carrying potential 
associated morbidity, mortality, and TB transmission reduction benefits. The clinical score 
provides improved sensitivity and NPV over the WHO four-symptom TB screen, which is 
needed ahead of intensive global TPT scale-up efforts. Finally, the range of clinical scores 
allows clinicians and programme managers to differentiate patient care and choose cut-
offs based on the use-case scenario and availability of resources to improve precision and 
quality of patient-centered care.    
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7.1. Research paper supplementary material 
Table 7.4. (Research paper supplementary appendix 1 (S1)) - Table of HIV care clinical 
follow-up for clients in the Botswana XPRES cohort (2010-2015) 
Pre-ART, CD4 >350 3 monthly Weight, CD4, TB screen 
ART 
ART start Weight, CD4, TB screen, ALT/AST if NVP-
based regimen, Hb if AZT-based regimen, 
Hepatitis B screen, creatinine if TDF-based 
regimen 
2 weeks Weight, TB screen, ALT/AST if NVP-based 
regimen, Hb if AZT-based regimen 
1 month Weight, TB screen, ALT/AST if NVP-based 
regimen, Hb if AZT-based regimen 
3 months Weight, TB screen, ALT/AST if NVP-based 
regimen, Hb if AZT-based regimen, Viral load, 
creatinine if TDF-based regimen 
6months Weight, TB screen, ALT/ASTa if NVP-based 
regimen, Hb if AZT-based regimen, Viral load, 
CD4 
Quarterlyb Weight, TB screen, Viral load and CD4 6 
monthly, creatinine if TDF-based regimen 6 
monthly 
Abbreviations: CD4, CD4 cell count; TB, tuberculosis; ALT, alanine transaminase; AST, 
aspartate aminotransferase; NVP, nevirapine; AZT, zidovudine; TDF, tenofovir;    
aRoutine ALT/AST not required after 6 months but may be requested by the clinician 
depending on the clinical situation.  
bFor those patients started on PI-based regimens, baseline and 12-monthly glucose 
(random or fasting) and total cholesterol/triglycerides are recommended. 
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Supplementary Appendix 2 (S2): XPRES Enrolment, TB Case Finding, and Follow-up 
Procedures  
At prospective cohort enrolment, research staff administered a standardized 
questionnaire, which captured demographic characteristics including age, sex, and 
pregnancy status, as well as clinical characteristics, including the WHO TB symptom 
screening rule for any current cough, fever, night sweats or weight loss, WHO HIV disease 
stage, height and weight, temperature in degrees centigrade, the most recent 
haemoglobin level, and the most recent CD4 count.  
As part of the trial intervention to strengthen ICF, all patients symptomatic for TB were 
encouraged to provide at least two same-day, on-the-spot (spot) sputum samples. In 
addition, if feasible for the patient, a morning sputum the day after screening positive for 
TB symptoms was recommended along with a 3rd spot sputum upon arrival at the clinic. A 
previously published job-aid was used by study nurses to inform the patient how to collect 
quality sputum samples.  Laboratory personnel at the 13 laboratories serving the 22 
clusters received refresher training on Ziehl-Neelsen staining for sputum-smear 
microscopy and Xpert implementation. When all four sputum samples were available, the 
morning sputum sample and second spot sputum sample for all symptomatic clients were 
sent to the national TB reference laboratory (NTRL) for culture using mycobacteria growth 
indicator tubes (MGIT). 
In all phases, sputum test results were returned to the clinics within 4 days for sputum-
smear microscopy and 2 days for Xpert testing. Study nurses were trained to inform 
patients of positive TB diagnoses the same day via phone, or if unreachable by phone, by 
active tracing to the household. As part of the active tracing intervention, for all patients 
≥1 day late for a clinic appointment, study nurses conducted up to five telephone calls and 
two home visits in attempts to return these clients to care. XPRES participants were 
followed for 12 months, or until the end of TB treatment, whichever was later. The final 
follow-up visits for XPRES enrolees were in June 2015. 
Table 7.5. (Research paper supplem
entary appendix 3 (S3)) - Table com
paring XPRES and 
external validation datasets 
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Table 7.6. (Research paper supplementary appendix 4 (S4)) - Table of TRIPOD checklist: 
prediction model development and validation 
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Table 7.7. (Research paper supplem
entary appendix 5 (S5)) - Table of im
portance of 





Table 7.8. (Research paper supplementary appendix 6 (S6)) - Hosmer-Lemeshow test for 
calibration of final tuberculosis prediction model 
Derivation Dataset Validation Dataset 
Prevalent TB Prevalent TB 
Decile N 
Cut 
off* Observed** Predicted† Decile N 
Cut 
off* Observed** Predicted† 
1 278 0.0111 2 2.6 1 265 0.0113 3 2.5 
2 277 0.0137 2 3.4 2 265 0.0138 4 3.3 
3 277 0.0162 5 4.1 3 265 0.016 0 3.9 
4 277 0.0191 1 4.9 4 264 0.0189 2 4.6 
5 277 0.0231 4 5.8 5 265 0.0232 6 5.5 
6 277 0.0299 6 7.2 6 265 0.031 10 7 
7 277 0.0551 19 10.8 7 264 0.063 15 11.4 
8 277 0.1099 27 23 8 265 0.1063 12 22.7 
9 277 0.1881 38 39.8 9 265 0.1684 13 35.2 
10 277 0.8484 85 87.4 10 264 0.8629 64 72.8 
Total 2771 189 189 2647 129 169 
Derivation dataset Hosmer-Lemeshow chi2(8) = 12.39, p=0.1348 
Validation dataset Hosmer-Lemeshow chi2(8) = 31.39, p=0.0001 
* Upper boundary of predicted risk
**Observed = observed number diagnosed with active TB within 6 months of clinic enrolment
†Predicted = expected number diagnosed with active TB within 6 months of clinic enrolment
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Figure 7.10. (Supplem




odelled as a transform
ed 
versus linear variable and prevalent active TB 
Figure 7.11. (Research paper supplem
entary appendix 8 (S8)) - Table of perform
ance of 
the TB prediction clinical score in derivation and validation datasets 
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Figure 7.12. (Research paper supplementary appendix 9 (S9)) - Figure 
of sensitivity, specificity, negative predictive value, positive predictive 
value, of TB clinical score versus WHO 4-symptom TB screening rule 
among ART-experienced clinic attendees 
(XPHACTOR, n=1612) 
Figure 7.13. (Research paper supplementary appendix 10 (S10)) - Figure of sensitivity, 
specificity, negative predictive value, positive predictive value of clinical score versus 




Chapter 8. Discussion, Recommendations, and Conclusions 
This thesis aimed to explore opportunities for reducing rates of early mortality on ART, as 
well as mortality in general, among PLHIV in sub-Saharan Africa.  I endeavoured to do this 
through a systematic review of existing literature of Xpert impact trials, review of early 
ART care intensification algorithms and TB screening rules among PLHIV, as well as by 
designing and analysing results from the XPRES stepped-wedge trial, and using XPRES trial 
data to develop and externally validate new early ART care intensification scores and a TB 
screening score suitable for sub-Saharan Africa.  This chapter provides a summary of the 
key results from the above work in section 8.1., shows how the key findings contribute to 
the existing scientific literature with associated implications of the new evidence in 
section 8.2., examines the limitations and strengths of the methods used in section 8.3., 
provides a short reflective commentary and some practical lessons learned in section 8.4., 
and ends with a summary set of recommendations and conclusions in sections 8.5. and 
8.6., respectively. 
8.1. Summary of key results 
Systematic review of Xpert impact trials 
Our systematic review of Xpert impact trials conducted between January 2005 and 
December 2015 was the first systematic review of Xpert impact trials and explored 
potential reasons for lack of observed impact of Xpert versus smear microscopy on patient 
morbidity and mortality outcomes.146  Key reasons for lack of observed impact related to 
high rates of empiric TB treatment in microscopy arms and enrolment of study 
populations not comprised exclusively of those most likely to benefit from Xpert.  In 
addition, a high frequency of health system weaknesses resulting in losses from TB-HIV 
care cascades in both microscopy and Xpert arms were observed which might have 
blunted potential impact of the improved diagnostic tool. 
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XPRES trial primary and secondary outcome analyses 
XPRES was designed to address gaps in scientific literature that other Xpert impact trials 
could not or had not addressed.18  Specifically, XPRES was designed to address health 
system weaknesses resulting in “leaky” TB case finding and TB-HIV care cascades at the 
design stage and ensure these weaknesses were addressed in addition to rollout of the 
new diagnostic device to achieve maximum impact on HIV-TB mortality.18  Through the 
XPRES three-phase design, which compared historical standard of care, with enhanced 
care (EC), and EC plus Xpert (EC+X) phases, XPRES showed that interventions to 
strengthen implementation of WHO-recommended four-symptom TB screening and ICF 
algorithms combined with active tracing to support retention were key drivers behind 
increased TB case finding and lower early ART mortality.  Similar to other Xpert impact 
trials, no independent mortality benefit of replacing sputum-smear microscopy with Xpert 
was observed.161   
Risk score to inform risk of early mortality on ART 
To assess further opportunities for reducing early ART mortality, the thesis reviewed how 
current definitions for WHO advanced HIV disease eligibility criteria (i.e., CD4 <200/µL or 
WHO stage III/IV) were derived and then used to inform intensification of care algorithms, 
as well as the limitations associated with this approach.  The literature review also 
examined published clinical scores for early ART care intensification, most of which were 
prepared for resource-rich settings.  I then used XPRES trial data to derive, and TB Fast 
Track trial data to externally validate, a clinical score potentially generalizable to sub-
Saharan Africa for who needs intensification of early ART care.  Key findings were that 
both the CD4-independent and -dependent early ART care intensification scores have 
potential advantages over the current WHO standard of care, which recommends ART 
care intensification for those with advanced HIV disease.  Key advantages of the clinical 
scores over WHO advanced disease eligibility criteria include: (1) superior screening 
accuracy in predicting risk for early ART mortality, (2) independence from the requirement 
for availability of rapid on-site or near-site CD4 count testing, which is not yet widely 
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available in sub-Saharan HIV clinics, and (3) additional ability to inform differentiated care 
algorithms by categorizing patients into low-, moderate-, and high-risk groups.  
Risk score to predict active TB among PLHIV 
Similarly, building on the main XPRES trial findings, which highlight the importance of 
implementing a sensitive TB screening tool versus addition of a sensitive TB test (Xpert) to 
case finding algorithms, I conducted a literature review of meta-analyses supporting WHO 
recommendations for the WHO four-symptom TB screen, and emerging limitations of this 
TB symptom screen, especially its inability to detect asymptomatic TB.  I then used XPRES 
trial data to derive, and XPHACTOR, TB Fast Track, and Gugulethu study data to externally 
validate, a flexible, initial TB clinical score for ART-naïve and ART-experienced PLHIV in 
sub-Saharan Africa that is capable of screening in asymptomatic TB, and can be used to 
prioritize either increased sensitivity and NPV or increased specificity and PPV depending 
on the setting and use-case scenario.  In addition, by stratifying risk into low-, moderate- 
and high-risk groups, the new TB clinical score also provides opportunity to design 
differentiated models of care to maximize impact of available resources.   
The section below describes how these findings complement existing literature in seven 
important ways with new insights and implications. 
8.2. New evidence and insights from the literature review, XPRES trial, and risk score 
analyses 
Firstly, the Xpert systematic review and XPRES trial results add to the existing published 
literature in at least three areas: (1) the importance of health system strengthening 
interventions to address “leaky” ICF and HIV-TB retention cascades to reduce all-cause 
early ART mortality and a public health intervention package for how to approach this; (2) 
the need for pragmatic trial designs for future novel TB diagnostic trials in LMIC, especially 
the importance of assessing at the design stage in what ways the standard of care trial 
arm needs to represent true standard of care rather than an “enhanced” version of 
existing care; and (3) the relative importance of simple sensitive screening tools that 
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prompt clinicians to consider risk of early death and risk of TB and prompt empirical action 
where needed, in addition to the need for better and more accessible diagnostic tests.   
The risk score analyses to generate the externally validated early ART mortality risk score 
for sub-Saharan Africa, and the externally validated active TB risk score for both ART-naïve 
and ART-experienced PLHIV, flowed directly from insights gleaned from the Xpert impact 
systematic review and XPRES trial on the relative importance of sensitive screening tools, 
and represent the fourth and fifth contributions to the literature discussed below. 
Sixth, a hybrid modelling approach that harnessed the strengths of both traditional 
generalized linear regression models and new machine learning approaches was used to 
generate a TB risk score among PLHIV, with possible implications for future prognostic 
research in the field of TB.   
Finally, the seventh contribution of the thesis is that lessons learned from the literature 
reviews including the Xpert systematic review, the XPRES trial, and the risk score analyses 
highlight the importance of considering the operational capacity of HIV and TB clinics in 
sub-Saharan Africa, where the majority of clinics are under-resourced and operate within 
weak health systems.  Within these under-resourced clinic environments, interventions to 
(1) strengthen the health system to do the basics right, and (2) provide simple, feasible
screening tools and care algorithms, can potentially have a bigger impact on mortality 
than introducing new diagnostic tools, which are often not tailor-made for LMIC settings.  
Simple innovations to screening tools, through improving the clinician’s understanding of 
holistic risk, and informing differentiated early ART and TB management algorithms, can 
maximize impact of available resources through a more precise and feasible public health 
approach. 
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8.2.1. The importance of health system strengthening interventions to address “leaky” 
ICF and HIV-TB retention cascades 
Although implementation of the WHO-recommended four-symptom TB screening rule as 
the first step in ICF algorithms among PLHIV starting ART has been recommended since 
2011 along with TB-HIV care continuum retention interventions,162 and although large 
numbers of studies report on the challenge of “leaky” TB-HIV care continua,163 no study 
has yet reported on the potential impact on mortality and other patient-relevant 
outcomes of strengthening systems to implement existing WHO guidelines for TB 
screening, ICF and TB-HIV care retention.66  Below I summarize the extent of the problem 
of leaky TB-HIV care cascades, potential reasons for these weaknesses in the health 
system, and then how XPRES provides evidence on how to feasibly address these 
challenges with ultimate improvements in TB case finding and reduced mortality. 
Increasing awareness of the “leaky” TB-HIV cascade problem 
A key theme of the Xpert impact systematic review was the high frequency with which 
health system weaknesses affected both the SOC and intervention arms and patient 
outcomes in all eight trials.  Common indicators of health system weaknesses included (1) 
the high frequency with which Xpert impact trial enrolees were unaware of their HIV 
status (with ≥15% of enrolees unaware of their status in four of five trials reporting this 
variable),69,71,164,165 and (2) low ART coverage among known HIV-positive persons in all 
three trials reporting this variable (26%‒31%).68,69,165  Notably, sub-optimal HIV 
management (i.e., unknown HIV status, HIV-positive and not on ART, or HIV-positive with 
unknown ART status) were predictive of poor final outcomes in four trials.68,69,73,165  
Another health system-related weakness was high LTFU before TB treatment in three 
trials68-70 and high LTFU following TB treatment initiation in four trials.68,71-73 
While several meta-analyses have been published describing the problem of patient loss 
at various steps of the TB diagnostic and care cascade, most meta-analyses have focused 
on overall TB diagnostic cascades regardless of HIV status,166,167 some have focused on 
individual steps within the cascade (e.g., pre-treatment loss to follow-up among 
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microbiologically confirmed TB cases),166 and some have focused on specific types of TB 
(e.g., multi-drug resistant TB).168  However, a systematic review and meta-analysis aiming 
to quantify the relative drop-off at each step in the ICF and TB treatment cascade among 
PLHIV in LMIC has not yet been reported.   
A recent attempt to create a TB screening, diagnostic, and treatment cascade among 
PLHIV using data from South Africa’s electronic tuberculosis register reported that only 
52% of estimated total PLHIV with active TB successfully completed TB treatment with 
losses from the cascade estimated as follows: 3% of PLHIV never visiting a health facility, 
15% not receiving a TB diagnosis despite visiting a facility, 11% not starting TB treatment 
despite having a TB diagnosis, and 19% not completing TB treatment despite starting 
therapy.163  Notably, this analysis back-calculated the number of PLHIV accessing a 
diagnostic test as equal to bacteriologically confirmed TB cases via microscopy or Xpert 
divided by the respective TB test sensitivity.  Therefore, in this analysis the 15% loss 
among TB-HIV co-infected patients at the diagnostic step was attributed to persistent use 
of less sensitive TB diagnostic tests alone (i.e., use of smear microscopy rather than 
Xpert),163 which is unlikely to reflect the reality of LMIC clinics where TB symptom 
screening among PLHIV is poorly performed.    
Sub-optimal implementation of the TB symptom screening step 
A wealth of published literature shows that implementing the TB symptom screening step 
in the ICF cascade is commonly omitted in many high burden TB-HIV countries in sub-
Saharan Africa.  Low completion of the four-symptom TB screening step has been 
observed in South Africa through an ancillary study nested within the XTEND trial where 
only an estimated 59% of symptomatic persons attending the XTEND primary healthcare 
clinics during 2012–2013 reported being asked about any TB symptom or reporting their 
own TB symptoms voluntarily to the attending healthcare worker.63  Similarly, as part of 
nationally representative adult ART programme evaluations in Mozambique (30 clinics) 
and Cote d’Ivoire (35 clinics) capturing data on ART enrolees during 2004–2007, TB 
symptoms were only asked about and documented in 61%62 and 36%98 of ART enrolees, 
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respectively, despite national guidelines recommending TB symptom screening at each 
clinic visit.  In a recent report of 90,454 PLHIV attending HIV clinics in western Kenya 
between 2015 and 2016, 44% of PLHIV were screened for TB symptoms in <90% of their 
clinical encounters.169  Similarly, in a recent study from South Africa which aimed to 
quantify the percentage of TB cases missed by primary healthcare clinics, authors 
estimated that 63–79% of TB patients with TB symptoms were missed, with 39% of TB 
cases missed because they were never screened for TB symptoms.170  In a 2012 survey of 
47 clinics in 26 countries, only 38% of sites reported they were using symptom-based 
screening to identify PLHIV in need of TB diagnostic tests.171 
In XPRES, failure to implement TB screening before ART initiation was the most “leaky” 
part of the ICF cascade in the standard of care phase, with only 30% screened before ART. 
Improving the coverage of TB symptom screening from 30% in the SOC to 100% in the EC 
and EC+X phases was the main driver behind improved TB case detection from 1% in SOC 
to 5-6% in EC and EC+X phases, and therefore appears to have been a key driver behind 
the declines in early ART mortality between SOC and subsequent EC and EC+X phases.   
Sub-optimal sputum sample collection from symptomatic patients 
Another leaky part of the TB screening, case finding, and treatment cascade from the SOC 
phase of XPRES and highlighted in the literature is the persistently low percentage of 
persons with TB symptoms that provide sputum for diagnosis, either because 
symptomatic persons are not asked for sputum samples or because they are unable to 
produce sputum.63,64,170  For example, through a secondary analysis of the XTEND trial, 
only 23% of persons with TB symptoms attending the XTEND primary healthcare clinics 
reported being asked to provide a sputum sample.63  In addition, in a South African study 
which aimed to quantify the percentage of TB cases missed by primary healthcare clinics, 
authors estimated that 38–48% of microbiologically-confirmed TB patients were missed 
because the symptomatic patients were not asked to provide sputum samples during the 
clinic visit.170  In addition, a certain percentage of symptomatic PLHIV will be unable to 
produce sputum spontaneously and sputum induction equipment and personnel trained 
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in their use are not widely available in LMIC clinic settings.169  For example, in XPRES, 
although the percentage of enrolees screening positive for at least one TB symptom who 
provided one or more sputum samples increased from 38% in the SOC phase to 46% and 
55% in the EC and EC+X phases, respectively, collection of sputum samples remained a 
challenge even in the EC phases mainly because symptomatic patients indicated they were 
unable to produce sputum.   
Pre-treatment loss and poor completion of TB treatment among PLHIV 
The meta-analysis of pre-treatment loss to follow-up among microbiologically confirmed 
TB patients reported that 18% of patients with a TB diagnosis are lost before treatment 
initiation in Africa.166  Similarly, high LTFU before TB treatment was reported in three 
Xpert impact trials.68-70  In the South African TB diagnosis and treatment cascade analysis 
using the electronic TB registers, authors estimated that 19% of TB-HIV patients do not 
complete TB treatment.163  Similarly, four Xpert impact trials reported high rates of failing 
to complete TB treatment among patients diagnosed and starting treatment.68,71-73 
Reasons for poor completion of the TB screening and treatment cascade 
Potential reasons for poor completion of the TB investigation and care cascade can be 
classified as healthcare worker-related, patient-related, and public health management-
related.  In terms of healthcare worker-related reasons, lack of healthcare worker 
knowledge and training in TB case finding algorithms,172,173 high workload and lack of 
motivation,173,174 lack of confidence in the laboratory sample transport and diagnostic 
system,175 and lack of supervision or mentorship, have been commonly cited reasons.63  In 
terms of patient-related barriers to completing the TB diagnostic and treatment cascades, 
stigma,65 long wait times,173 logistical barriers such as cost of transport and family care 
responsibilities,176 and poor treatment of patients by healthcare workers,163,177,178 are 
commonly reported reasons.  At the public health system level, weaker district 
management teams with irregular monitoring and support for healthcare workers and 
health facility management,179 as well as vertical rather than integrated TB-HIV care 
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models,180 have been associated with lower completion of TB case finding and care 
cascades. 
High rates of loss to follow-up during early ART  
In addition to poor implementation of the TB screening, diagnosis, and treatment cascade, 
there are many meta-analyses documenting drop-offs in the HIV diagnosis, treatment 
initiation, retention, and viral suppression cascade.51,181,182  Recent data from the Joint 
United Nations Programme on HIV/AIDS (UNAIDS) show that the drop between those 
aware of their status and those on ART (i.e., between the first and second 90) accounts for 
the largest drop-off in the 90-90-90 cascades in Africa (e.g. southern and eastern Africa 
90-90-90 estimates are currently 85-79-87, indicating 85% of PLHIV are aware of their
status, 79% of those diagnosed are on ART, and 87% of those on ART are virally 
suppressed).  In addition, most recent studies show that LTFU after ART initiation rather 
than before ART initiation is increasingly the driver for drop-offs in the second 90 with 
patients cycling in and out of ART.11  Notably, LTFU rates during ART are highest in the first 
few months after ART initiation, with an average of 20% LTFU by 12 months of follow-
up.12,183  In addition, mortality rates among patients lost from early ART care are high with 
most patients dying soon after the missed appointment.12  The percentage of LTFU clients 
found to have died by the time of tracing ranges from 20-60%.12,20  Similarly in XPRES, 41% 
of patients LTFU in the first 6 months of ART in the SOC phase had died by 6 months of 
follow-up.161   
Few trial interventions shown to comprehensively address leaky TB-HIV care cascades 
Although the problems of the leaky TB screening and HIV retention cascades are well 
documented, and reasons for poor completion of the TB-HIV care cascades have been 
widely investigated, few trials have evaluated the impact of strengthening both TB 
screening and retention on patient-important outcomes like morbidity and mortality. 
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XPRES suggests that strengthened TB symptom screening could be associated with 
improved outcomes 
Firstly, although the WHO four-symptom screen has been recommended by WHO since 
2011, impact of implementing the four-symptom TB screen on patient-relevant outcomes 
has not yet been reported.  Although the XPRES trial has several limitations, including the 
pre-post design for the primary mortality outcome, XPRES showed that strengthening 
implementation of the WHO four-symptom TB screen appeared to drive increased TB case 
finding with associated reductions in early ART mortality.44,60,61,88 
As described in Chapter 5, and in the limitations section (Section 8.3.1.), the pre-post 
design is not an experimental design and therefore provides weaker evidence than a true 
experimental design such as a parallel group CRT.144  For example, Sanson-Fisher et al, 
describe the evidence generated from a pre-post study design as providing only moderate 
evidence that a change has occurred, weak evidence that any change observed was due to 
the intervention, and moderate evidence that the degree of change is significant.144  In 
contrast, evidence from a parallel group CRT would be classified as “strong” for all three 
categories noted above.144  Pre-post study designs are weaker than parallel group 
randomised trial designs because pre-post designs are inherently at risk for residual 
confounding.  Therefore, in XPRES, the difference in 6-month ART mortality rates between 
SOC and EC+X phases, might be explained by unmeasured confounders.  Two potential 
unmeasured confounders include WHO stage and background trends of other factors over 
time.  WHO stage was not included in the adjusted analysis per the pre-specified analysis 
plan, because 61% of patients in the SOC cohort had missing WHO stage data.  Other 
variables including CD4 count, weight, and haemoglobin concentration at ART initiation, 
variables which were ≥90% complete in the SOC cohort and EC+X cohort, were used to 
control for disease stage at ART initiation, but these variables might not have fully 
controlled for disease stage.32  In addition, background trends in factors such as declining 
national TB incidence over time (as shown in Chapter 3) might have contributed to 
declining risk of PLHIV mortality over time resulting in residual confounding affecting the 
pre-post analysis.      
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In addition, the 95% confidence interval associated with the adjusted hazard ratio (0.77) 
comparing SOC versus EC+X 6-month ART mortality rates was 0.61–0.97.  Therefore, if an 
important unmeasured confounder exists (e.g., WHO stage or declining trends in TB risk 
over time), and if it were possible to add the unmeasured confounder into the adjusted 
analysis, it is possible that the new adjusted hazard ratio would be closer to 1.0 and the 
new 95% confidence interval would include 1.0. 
XPRES did observe large changes in the percentage of new ART enrolees screened with the 
WHO four-symptom TB screen between SOC and EC+X phases (30% versus 100%).  
However, as described in Section 8.3.1., it is still possible that clinicians in the SOC phase 
did the TB screening but did not document the screening, which would introduce 
measurement error.  In addition, the change in new TB case finding between phases, from 
1% in the SOC to 6% in the EC+X phase, was relatively large, but this change might partly 
be explained by clinicians failing to document TB cases in the SOC cohort.   
In addition, the findings from the XPRES trial pertain to new, non-incarcerated, adult (>12 
years old) ART enrolees during 2010-2015 at the 22 study facilities, which were 
purposively selected to be representative of HIV treatment health facilities in Botswana 
(see section 5.1.).  During this time, adult PLHIV were only eligible for ART if the CD4 count 
was ≤ 350 cells/µL, or WHO stage was III or IV, or the client was pregnant or 
breastfeeding.  If a client did not meet these criteria, the client often was managed in pre-
ART care at separate smaller health facilities referred to as health posts, with quarterly 
CD4 count monitoring.  When the CD4 count fell below 350 cells/µL, or WHO stage III/IV 
was reached, or the client became pregnant, the client was referred to an HIV treatment 
clinic.  Therefore, all enrolees in the SOC, EC, and EC+X cohorts represent PLHIV who had 
survived from the time of diagnosis until the time of ART eligibility.  Although each study 
population (SOC, EC, and EC+X) would have been equally affected by any survivor bias, 
meaning comparisons between phases in the primary outcome paper (Chapter 5) remain 
internally valid to the population studied, care should be taken to generalize findings to 
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PLHIV populations at the time of HIV diagnosis.  Currently, the standard of care is that all 
PLHIV are eligible for ART, with many newly diagnosed PLHIV starting ART on or near to 
the date of HIV diagnosis.      
Therefore, additional contemporary evaluations of the intervention in the XPRES cohort, 
using a stronger study design (e.g., parallel group randomised CRT), are ideally needed to 
confirm the findings from the XPRES trial.  However, investigators designing a parallel 
group CRT to evaluate effectiveness of the same interventions thought to be effective in 
XPRES (i.e., improved TB screening, and strengthened active tracing), would need to 
carefully address (1) the issue of equipoise (since TB screening and active tracing are 
already recommended by WHO and most ministries of health in sub-Saharan Africa), and 
(2) the Hawthorne effect (i.e., the possibility that the standard of care arm would
experience a change in TB screening and retention practices due to health worker, and 
possibly study enrolee, awareness of the study hypothesis).   
Need for deployment of new diagnostics, such as Xpert, as part of a holistic package 
As Xpert has been rolled out globally, reaching over 122 countries and with more than 16 
million tests performed since 2011, and given the lack of observed impact of Xpert versus 
smear microscopy in terms of reducing morbidity and mortality in trials to date, there 
have been several papers calling for Xpert to be rolled out alongside health system 
strengthening interventions.163,184  For example, in a paper by Albert et al in 2016, authors 
explored practical lessons learned from Xpert rollout.184  Authors argued that Xpert rollout 
and impact had been hampered by lack of a “complete solution package (notably 
comprehensive training, quality assurance, and implementation plans)” and insufficient 
focus on “effective linkage to care of diagnosed patients” with Xpert impact “blunted by 
weak health systems”.184  However, Sun et al used a modelling analysis to explore any 
differential impact weak health systems might have on Xpert- compared with microscopy-
based diagnostic cascades.185  In this analysis, similar to our Xpert impact trial review,146 
Sun et al showed that the biggest driver in minimizing impact of Xpert versus smear 
microscopy was the rates of empiric TB treatment, with higher rates of empiric TB 
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treatment eliminating potential impact of the improved diagnostic tool (Xpert).185  From 
this analysis by Sun et al, any differential impact of strengthened health systems to correct 
“leaky” TB-HIV cascades that would result in increased Xpert versus microscopy impact on 
patient-important outcomes appeared to be minimal.     
However, most authors agree that health system strengthening interventions that address 
the drop-offs throughout the TB screening, diagnosis, and treatment cascade, regardless 
of TB diagnostic used, should be prioritised by TB programme managers and global 
oversight bodies like WHO even as new diagnostics like Xpert are rolled out.163,186,187 
Therefore, the XPRES trial results fill an important research gap by providing proof of 
concept data that strengthening facility-based TB symptom screening and diagnostic 
cascades prior to rollout of novel diagnostic devices like Xpert, can have significant 
independent benefit for patients served, in addition to any additional synergistic effect a 
strengthened cascade might afford the new diagnostic.184,185 
XPRES adds useful evidence for active tracing to support retention during early ART 
WHO guidelines for management of advanced HIV disease cite the REMSTART trial as the 
key evidence that adherence interventions need to be part of the package of care for 
PLHIV starting ART with advanced HIV disease.57  REMSTART was an individually 
randomised trial among PLHIV with CD4 <200/µL comparing standard clinic-based care 
versus standard of care plus an intervention package.  Prior to enrolment in both the 
standard of care and intervention arms, all participants were screened for TB with Xpert 
testing of sputum samples.  In the intervention arm (referred to as standard care plus 
community support), PLHIV received two additional interventions: (1) weekly home visits 
for the first 4 weeks from lay counsellors who had received a two-week training and used 
a checklist to document each home-based care interaction.  During the weekly visit, the 
lay counsellors delivered adherence support, monitored for signs and symptoms of 
disease progression or toxicity, and referred the client to the clinic if needed; and (2) 
screening for serum cryptococcal antigen combined with antifungal therapy for patients 
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testing antigen positive.  In addition, a second Xpert test was provided to intervention arm 
enrollees at 6 weeks after ART initiation in Tanzania clinic enrollees among those not 
diagnosed with TB at enrollment.   
At 12 months of follow-up all-cause mortality was 13% in the intervention arm and 18% in 
the standard of care group, with the 28% relative reduction in all-cause 12-month 
mortality statistically significant (p=0.004).  Authors attributed about half of the mortality 
reduction to antifungal treatment for those with positive cryptococcal antigenemia and 
half of the mortality reduction to the home-based adherence counselling.57 
XPRES adds important evidence to that contributed by the REMSTART trial.  While the 
REMSTART community-based adherence and retention intervention was well-costed and 
considered relatively inexpensive ($42.60/participant in Tanzania and $45.77/participant 
in Zambia), these costs which are equivalent to about 56% of a person-year’s supply of the 
current WHO-recommended first-line ART regimen for adults (about $75/person/year) are 
not insignificant,188 pre-emptive home visits are not possible for all new ART enrolees, and 
pre-emptive home visits are not widely implemented due to the complexity of engaging 
new cadres, community-facility linkages, transport to people’s homes, and resource 
limitations.189  WHO also recommends rapid tracing for patients who miss appointments, 
initially by phone or through home visit if not reachable by phone, which is a retention 
intervention more widely feasible in sub-Saharan Africa.44,74,75  XPRES adds evidence in 
support of the active tracing intervention since prior to this research, no trial had yet 
included active tracing as part of an intervention package to reduce early ART mortality.76   
In addition, the most recent meta-analysis of supportive interventions to improve 
retention on ART in LMIC included evidence from seven trials including REMSTART.189  
Among the other six trials, two required directly observed daily medication taking at 
home,190,191 one required lay counsellor support through home visits,192,193 one required 
community adherence clubs,194 and two required either daily195 or weekly196 visits by the 
patient to the health facility for directly observed therapy and clinical check-ups.  
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Therefore, the evidence provided by XPRES showing effectiveness of the retention 
intervention, comprised of facility-based, nurse-led counselling and telephonic and home 
tracing if a patient missed an appointment, with associated 82-95% reductions in LTFU 
rates, is an important addition to the available supportive retention interventions for 
PLHIV starting ART, with increasing relevance as phone coverage increases.    
Why the XPRES health system strengthening intervention appears to have worked 
Although the observed reduction in all-cause mortality between SOC and subsequent EC 
and EC+X phases of XPRES represents a pre- versus post-comparison, rather than a 
randomised comparison, and is therefore at risk of residual confounding, the study has 
strengths that suggest ICF and retention interventions did independently contribute to 
observed mortality impact.  These strengths include the multivariable analysis to control 
for known confounders, the large improvements in TB screening, TB case finding, and 
uncorrected LTFU rates between SOC and subsequent EC and EC+X phases which provide 
credence these interventions were drivers behind observed mortality reductions, the high 
ascertainment of the primary early ART mortality outcome, and robustness of pre-
specified primary outcome analyses to several sensitivity analyses.  
As described in Chapter 5, the health system strengthening intervention in XPRES had four 
over-arching components: (1) additional human resources (study nurses) to support 
implementation, (2) additional training for clinic and laboratory personnel, (3) use of 
checklists and job aids to standardize implementation, and (4) regular supervisory visits to 
track adherence to ICF and tracing checklists.  These four components directly address 
many of the underlying health facility-related and district health system-level reasons for 
leaks in the TB case finding and TB-HIV care cascades as described earlier (Table 8.1). 
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Table 8.1. XPRES health system strengthening components that addressed the 
underlying causes of missed steps in the TB and HIV care cascades 
Reason for poor 
completion of 
recommended TB and HIV 
cascade of care  




High workload causing 
healthcare workers to miss 
components of care 
implementation173,174 
HSS component #1:  
One additional nurse per site to focus on TB case 
finding and TB-HIV retention cascade.  Average 
nurse salary about $11,400/year.197 
Lack of healthcare worker 
knowledge and training in 
TB case finding 
algorithms172,173 
HSS component #2: 
Additional training at study start on TB case-
finding algorithms. 
Lack of confidence in the 
laboratory sample 
transport and diagnostic 
system175 
HSS component #2 and #3: 
HSS component #3 was the provision of job aids 
and checklists as well as clarifying (1) who was 
responsible for monitoring completion of each 
part of the cascade and (2) expected turnaround 
times for sample transport and analysis for 
smear microscopy and Xpert diagnostic tests.   
Rudeness/lack of support 
for patients at the 
clinic163,177,178 
All HSS components #1-4.  
HSS component #4 was that each study nurse 
was directly supervised by a study nurse 
supervisor who regularly reviewed data including 
TB diagnostic cascade and HIV care cascade 
completion indictors. 
Lack of supervision or 
mentorship63 
HSS component #4 as described above. 
Public health 
system level 
Irregular monitoring and 
support for healthcare 
workers and health facility 
management179 
HSS component #4 as described above. 
Non-integration of TB and 
HIV care systems 
TB screening, diagnosis, referral for TB treatment 
and monitoring during ART and TB treatment 
were the responsibility of the same nurse based 
at the HIV study clinic.  Although the TB clinic 
was often not co-located, one healthcare 
provider was monitoring completion of both 
cascades. 
Abbreviations: HSS, health system strengthening 
Notably, our study did not specifically address patient-specific barriers to completion of TB 
and HIV care cascades (e.g., by providing money for transport or other incentives), but by 
introducing new healthcare workers, conducting new training, providing job aids and 
check lists for healthcare workers, and conducting supportive supervision for the new 
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nurses at the sites, and given the overall 82-95% reduction in LTFU rates that occurred 
between SOC and EC phases of XPRES, it seems likely that patients enrolled in XPRES EC 
phases found the care provided patient-centred and patient-friendly, although XPRES did 
not collect quantitative or qualitative data on patient perceptions of care provided. 
Important considerations before scale-up of public health interventions 
Multiple factors need to be considered prior to scale-up of any public health 
intervention.10  At the planning or policy-making stage, rigorous evaluation of the 
scientific evidence supporting effectiveness of the public health intervention, its cost and 
cost-effectiveness, feasibility, and acceptability are key considerations.10  As described in 
this section, and in the limitations section (Section 8.3.1.), XPRES does not provide 
definitive evidence that scaling up health system strengthening interventions to improve 
implementation of TB screening and active tracing to support retention will with certainty 
reduce early ART mortality in sub-Saharan Africa.  However, as described above, there is a 
wealth of literature beyond XPRES that supports the need for health system strengthening 
to appropriately address “leaky” ICF and HIV-TB retention cascades, and both ICF58 and 
active tracing to support retention44 are already recommended by WHO guidelines.  As 
stated in Chapter 5, a limitation of the XPRES trial analysis is that it was not paired with a 
formal cost-effectiveness analysis, although a retrospective cost-effectiveness analysis has 
been proposed.  As described above, the health system strengthening interventions were 
feasible in the Botswana health system within the XPRES research context, and acceptable 
to healthcare workers at the XPRES trial health facilities.  However, Botswana is classified 
as an upper middle-income country, whereas the majority of countries in sub-Saharan 
Africa are middle- or lower-income countries.133,134  Any decision to scale up a public 
health intervention should be accompanied by a detailed strategic plan, documentation of 
financial considerations, monitoring plans, additional evaluations, and the future vision for 
sustainability.10  Therefore, the data in the XPRES trial in Chapter 5 and the related 
information presented in this thesis could be used to inform discussions about scale-up of 
health system strengthening interventions to improve TB screening and retention, but 
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should be considered along with other data relating to effectiveness, cost-effectiveness, 
feasibility and acceptability of the interventions.10    
8.2.2. The importance of considering the need for truly pragmatic designs for future 
novel TB diagnostic trials in LMIC 
Increasingly trialists are asked to consider at the design stage the extent that a proposed 
intervention trial needs to be pragmatic (i.e., undertaken in the “real world” with the 
intent of assessing whether the intervention will be effective in the setting it is designed 
for) or explanatory (i.e., undertaken in an idealised setting, to give insight into efficacy in a 
carefully controlled research environment).71,147,198,199  A recent systematic review of Xpert 
impact trials (currently under review and published as a pre-print)148 argues that a key 
reason Xpert impact trials have not observed impact on mortality is because the standard 
of care arm represented an enhanced care arm (similar to the EC phase in XPRES) rather 
than a true SOC arm (such as the SOC phase in XPRES).  Here we explore this perspective, 
assess how XPRES uniquely provides both pragmatic and explanatory trial components 
and insights, and discusses implications for future novel TB diagnostic and universal 
treatment trials. 
Which Xpert impact trials were truly pragmatic? 
The first step in considering whether a trial should be pragmatic or explanatory, even 
before scoring the nine components of the Pragmatic-Explanatory Continuum Indicator 
Summary 2 (PRECIS-2) scoring tool (see table 8.2. below), is to carefully consider the aim 
of the trial.  For example, a truly pragmatic Xpert impact trial would be appropriate for a 
study question that aims to assess whether Xpert replacing sputum microscopy in an 
unchanged health system, which is largely a weak health system in LMIC, has independent 
impact on mortality.  While this was the key question for the seven previous Xpert impact 
trials that assessed Xpert impact on mortality outcomes,68,69,71,72,82,165,200 the XTEND trial 
was the closest to implementing a truly pragmatic design and therefore answering the 
question raised.  Firstly, unlike five68,72,82,165,201 of the other six studies, XTEND was careful 
not to include additional TB diagnostic tests such as chest radiography or culture on top of 
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microscopy that went beyond standard care in the standard of care arm.  Secondly, XTEND 
was designed to minimise study-related changes to routine TB-HIV care in standard of 
care and intervention arms aside from Xpert introduction in the intervention arm, with 
primary mortality outcomes ascertained at 6 months through reports from participant-
nominated contacts, clinic staff, and national vital statistic database review, whereas 
some form of system strengthening was present in both standard of care and intervention 
arms in all other six trials.148       
Notably, although the trial considered the “most pragmatic” from the recent Xpert impact 
trial review published as a pre-print by Ochodo et al,148 is the stepped-wedge trial by 
Trajman et al, from Brazil, in our own Xpert impact trial review, we did not consider that 
this trial truly assessed impact on all-cause or even TB-attributed mortality among any 
easily describable group of study enrolees for four reasons.  Firstly, Trajman et al 
acknowledge that rates of loss to follow-up from both trial arms of patients starting TB 
treatment were very high (16% LTFU in both trial phases), and there was no mortality 
ascertainment among those LTFU through national mortality registry review.  Mortality 
among patients lost to follow-up from TB treatment are high,202 and therefore there is 
almost certainly outcome miss-classification in this trial.  Secondly, when authors compare 
the composite outcome (death, LTFU, transfer, or suspicion of TB drug resistance) 
between study phases, these percentages were not different between phases (29.6% in 
intervention vs. 31.7% in control phase).  Thirdly, the trial-specified study population was 
patients being investigated for TB (presumptive TB patients) whereas the mortality 
outcome reported is for those who started TB treatment with no way of assessing 
potential selection bias introduced by this restricted outcome analysis.  Fourthly, the 
assignment of a death as due to TB among TB patients, which authors reported as being 
different between arms (2.3% vs. 3.8%) was based on clinician-reported cause of death 
data on death certificates, the completeness and accuracy of which is not discussed and 
known to be sub-optimal in most LMIC settings.35  However, the trial does have a 
pragmatic design, and indicates the challenges of using data from pure pragmatic designs 
to understand trial outcomes and their associated policy implications.  
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Contribution of XPRES trial design to Xpert impact trial literature 
XPRES had both pragmatic and explanatory components to its design.  In our published 
protocol, we proposed that XPRES was primarily a pragmatic trial because the primary 
XPRES study question is answered by a pragmatic study design.  Firstly, the SOC phase 
represents a true standard of care (i.e.,  historical data untouched by study-related 
procedures or interventions that might have strengthened standards of care) which is the 
pre-requisite for any truly pragmatic trial.147  Secondly, XPRES specifies that the 
intervention is a package that includes both health system strengthening and Xpert 
replacing smear microscopy.  By specifying that health system strengthening is part of the 
intervention package, XPRES addresses the importance of considering pragmatism in trial 
design directly.  For example, if the SOC versus EC+X comparison was characterized as a 
pragmatic approach to understanding purely the impact of Xpert replacing sputum smear 
microscopy on standard of care (i.e., the same question that XTEND quite successfully 
addressed as described above), XPRES would represent a very poorly designed pragmatic 
trial to answer this question, because significant health system strengthening 
interventions were invested to support rollout of the Xpert device.  Instead at the design 
stage, and inherent to the name of the XPRES trial, the intervention was described as a 
combination of health system strengthening interventions to support Xpert rollout.18  In 
this respect, XPRES was similar to other published pragmatic trials, which frequently 
include complex interventions, sometimes consisting of several interacting 
components and often involving the skills and experience of one or more health care 
professionals to deliver the intervention.198  
Four components of the PRECIS-2 score evaluate whether health system strengthening, 
which is separate from the specified trial intervention, have pushed the trial towards the 
explanatory side of the pragmatic trial continuum.  Each of the nine PRECIS-2 components 
are given a score between 1 and 5, with scores closer to 1/5 indicating the trial feature is 
more explanatory and scores closer to 5/5 indicating the trial feature is more pragmatic.  
These four components are: component 4, which examines the degree to which the 
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intervention package requires additional resources to implement; component 5, which 
examines how flexible the investigators aim to be in allowing study clinics to determine 
the operationalization of the intervention; component 6, which evaluates what measures 
are in place to ensure adherence to intervention algorithms; and component 7, how 
closely participants are followed up.  For the XPRES primary study question (comparing all-
cause 6-month ART mortality between SOC and EC+X enrolees), because there was limited 
health system strengthening outside the pre-specified intervention package for 
comparison with true SOC, and after evaluating eligibility criteria, recruitment, setting, 
primary outcome, and primary analysis approaches, I believe that the XPRES design should 
be considered largely pragmatic (Table 8.2.).203 
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Table 8.2. Evaluating XPRES on the pragmatic vs. explanatory trial continuum 
PRECIS-2 Criteria Primary XPRES study question 
- Comparison of all-cause 6-month ART mortality between SOC and EC+X
ART enrolees (non-randomised)
Secondary XPRES study question 
- Comparison of all-cause 6-month ART mortality between EC
and EC+X ART enrolees
Aim 
To answer the question whether the package of health system 
strengthening interventions to support TB screening and TB-HIV care 
retention combined with Xpert replacing sputum smear microscopy can 
impact all-cause 6-month mortality compared with true SOC. 
To assess within a strengthened health system whether Xpert is 




Rationale: The study population eligibility criteria very closely reflected the patient population attending the study clinics.  Only those new HIV 
clinic enrolees who were incarcerated were excluded from the study (<0.5%).  As described in the limitations section, some study enrolees 
were referred to the XPRES study clinics after a period of pre-ART care and represent a partially pre-screened population with some patients 
already taking TB treatment upon arrival at the study clinics. 
2.Recruitment
Score: 4 
Rationale: All new HIV clinic enrolees in the retrospective SOC phase were included in the SOC cohort.  In the EC phases, all new HIV clinic 
enrolees were eligible but about 30% left the clinic before they could be offered enrolment.  In comparing EC and EC+X enrolees versus those 
not enrolled in EC phases despite being eligible, no differences were observed (see primary outcome manuscript supplementary appendix no. 
4).161  When inverse probability weights were used to account for non-enrolment in sensitivity analyses of the primary and secondary 
outcome, no changes were observed compared with the primary outcome analysis (see primary outcome manuscript appendix no. 7).161 
3.Setting
Score: 4 
Rationale: The study was done in Botswana HIV treatment clinics that were purposively chosen to be representative of HIV care and 
treatment clinics in Botswana (see manuscript appendix no. 1).161  However, Botswana is considered a higher middle-income setting, unlike 
most other countries in Africa which are low- or middle-income.  
4.Organization
Score: 5 
Rationale: A highly pragmatic trial would aim to slot the intervention into 
usual care.  Because the SOC arm represents true SOC, and because the 
intervention is a package of health system strengthening interventions 
combined with Xpert rollout, results represent impact of inserting the 
intervention package (TB screening, retention and Xpert) on top of SOC 
compared with true SOC. 
Score 1: 
Rationale:  Because both phases (EC and EC+X) were quite strictly 
controlled to ascertain impact of Xpert within a strengthened 
health system, the organization score reflects this weighting 







Rationale: A perfectly pragmatic trial would allow health clinics to design 
the “how” of TB screening, retention, and Xpert implementation without 
investigator influence. In the EC+X phase, because the intervention 
package was designed by investigators with central Ministry of Health 
leadership, some of whom worked in the clinics, and in accordance with 
national guidelines, a score of 3 on the “pragmatism scale” is proposed. 
 
Score 1: 
Rationale:  Because both phases (EC and EC+X) were quite rigidly 
controlled to ascertain impact of Xpert within a strengthened 





Rationale: Although the intervention implementation was closely 
monitored to assess adherence to implementation, this approach to 
monitoring was part of the intervention package.  
Score 1: 
Rationale:  Because in both phases (EC and EC+X) adherence to 
procedures was quite rigidly controlled to ascertain impact of 
Xpert within a strengthened health system, the flexibility score 




Rationale: Although mortality outcomes were rigorously ascertained, in 
the SOC phase this was done retrospectively, with no chance that 
telephonic outreach or home visits could have averted 6-month ART 




Rationale:  Because in both phases (EC and EC+X) active tracing 
was implemented within a strengthened health system, the 
follow-up score reflects this weighting towards “explanatory”, 








Because the analysis was intention-to-treat, the primary analysis score is weighted towards pragmatic. 
 
Total 38/45 28/45 
Abbreviations: PRECIS-2, Pragmatic-Explanatory Continuum Indicator Summary 2; ART, antiretroviral therapy; SOC, standard of care; 






As described in Table 8.2 above, the nested stepped-wedge trial design is the explanatory 
component of the XPRES trial.  The purpose of the nested stepped-wedge trial was to 
assess, as a secondary study question, whether, within a strengthened health system, 
Xpert has additional impact on mortality over smear microscopy. 
 
Contributions from XTEND, XPRES, and other Xpert impact trials  
Based on our Xpert impact literature review,146 and after reviewing information in the 
most recent critique of Xpert impact trial designs by Ochodo et al,148 XTEND is arguably 
the best pragmatic trial to answer the question of whether in a standard LMIC health 
system, replacing sputum smear microscopy with Xpert can independently drive mortality 
reductions among persons being investigated for TB.  Simultaneously, XPRES, along with 
other Xpert impact trials, helps to answer the question of whether Xpert introduced into a 
stronger health system can independently drive mortality reductions.  So far the answer 
to both study questions is that Xpert appears to have no easily detectable impact on 
mortality compared with smear microscopy, although there may be a modest impact 
more feasibly detected in large meta-analyses among PLHIV,204 or in sub-groups of PLHIV 
with advanced HIV disease.200 
 
How feasible are the XPRES health system strengthening interventions? 
The XPRES health system strengthening interventions to improve TB screening and case 
finding and ensure retention in TB-HIV care were associated with reductions in early ART 
mortality.  As noted above, we believe these findings are generalizable to other LMIC 
settings.  However, one question raised by this trial finding is whether it is feasible to 
implement the health systems strengthening package in LMIC, including SSA, to achieve 
the mortality reductions we observed in XPRES.  Although additional targeted investments 
are needed, XPRES showed that scale-up of the health system strengthening interventions 
was feasible, and well-supported by existing healthcare personnel and management, 
national guidelines, and WHO guidelines.161  In addition, several recent papers agree that 




retention cascades in LMIC is an important contemporary priority.16,163,184,186  Similarly, 
many large global funding bodies are investing in this area with an increasingly large 
percentage of annual investments directed to health system strengthening interventions 
that have proven sustainable impact.205,206  In addition, findings from XPRES, which 
showed feasibility and impact of cascade strengthening interventions on TB case finding, 
retention, and mortality outcomes, have been used to inform national investment profiles 
in countries in sub-Saharan Africa since the primary trial findings were released in 2018.207  
In retrospect, an economic analysis of the XPRES intervention would have been a valuable 
addition to the study, and a retrospective economic analysis has been proposed to fill this 
gap. 
 
8.2.3. The importance of implementing sensitive screening tools versus need for new 
sensitive diagnostic tests 
 
XPRES, as well as the seven other Xpert impact trials among presumptive TB patients or 
PLHIV that have evaluated impact of Xpert on all-cause mortality,68,69,71,72,82,165,200 showed 
that if clinicians implemented ICF and retention cascades in trial arms using microscopy, 
mortality outcomes were not different to well-implemented screening and retention 
cascades using Xpert.  A key observation was that across the seven prior Xpert impact 
trials evaluating mortality impact, TB treatment initiation rates were similar between arms 
or phases in six trials and only significantly higher in the Xpert arm in one trial.71  While 
participants in the Xpert arms had higher rates of microbiologically confirmed TB, higher 
rates of empiric TB treatment in microscopy arms balanced overall TB treatment initiation 
rates between arms in most trials.  Our systematic review and other papers showed that 
empiric TB treatment of culture-positive smear-negative TB patients in the microscopy 
arms largely removed any potential for observed Xpert impact.151,208  For example, in the 
TB-NEAT study,68 of the 68% of patients with smear-negative tuberculosis in the 
microscopy arm that were later correctly detected by Xpert, 93% were treated empirically 




rule to prompt clinicians to “think TB” versus the need for a sensitive TB diagnostic test.151  
This concept was the reason behind development of the new clinical TB screening score 
and is discussed in depth in section 8.2.5. below. 
 
Screening tools for detecting early ART mortality risk 
In a similar vein, the importance of a screening tool to prompt a clinician’s assessment of 
overall mortality risk prior to starting ART is important especially given the findings from 
the REALITY trial which shows that supportive and prophylactic packages of care can 
reduce early ART mortality.53  However, as noted by the authors of the REALITY trial, and 
as acknowledged by the WHO advanced HIV disease guidelines, up to 50% of those with a 
CD4 count <100 cells/µL could be classified as having WHO stage I or II and therefore 
missed by an advanced HIV disease eligibility guideline relying on WHO stage alone.44,53  
However, most PLHIV starting ART in LMIC do not have access to rapid on-site or near-site 
CD4 testing that would facilitate implementation of the WHO advanced disease 
management guidelines.102  Although there are calls to action to increase access to rapid 
CD4 testing across LMIC clinics, in most cases this scale-up needs to await release of 
inexpensive CD4 tests (e.g., lateral flow assays), and significant investments in scaling up 
these tests.102  In the meantime, many PLHIV continue to start ART or re-initiate ART with 
advanced disease that is missed because of lack of access to CD4 testing.  This insight was 
the foundation for the early ART care intensification analysis presented in the thesis. 
 
8.2.4. New tools to inform who needs intensification of early ART care 
 
Our CD4-independent and -dependent clinical scores, which to our knowledge are the first 
externally validated clinical scores to inform early ART care intensification developed for 
sub-Saharan Africa, have some advantages over the WHO advanced HIV disease eligibility 
criteria.  These advantages include: (1) the CD4-independent score was nearly twice as 
sensitive as WHO stage used alone to detect risk of early ART mortality and could be 




near-site CD4 testing capacity is very limited, (2) both the CD4-independent and -
dependent scores improved specificity compared with the full WHO advanced HIV disease 
eligibility criteria (CD4 <200/µL or WHO stage III/IV), indicating the opportunity to increase 
efficiency of advanced HIV disease differentiated care models, (3) both scores provide 
flexibility for programme managers to choose cut-offs that might increase feasibility and 
affordability of differentiated care algorithms to maximize impact of available resources, 
and (4) by creating three risk groups, further differentiation of models of care is possible.84 
 
Compared with other clinical scores 
Our clinical scores are more appropriate for sub-Saharan Africa and other LMIC settings 
than the scores generated for resource-rich settings (VACS, VACS 2.0, and EuroSIDA) for 
several reasons, which are discussed in more depth in the literature review section of 
Chapter 2.3.4., and only briefly summarised here.  Firstly, our score uses fewer, less 
complex, and more easily available scoring variables, with five routinely available variables 
needed for the CD4-independent and six variables needed for the CD4-dependent risk 
scores compared with 11 variables needed for VACS, 15 variables for VACS 2.0, and 10 
variables for EuroSIDA.  Secondly, the VACS, VACS 2.0, and EuroSIDA scores were 
generated among cohorts of PLHIV with very different demographic, clinical, and 
contextual factors compared to cohorts in LMIC.  Thirdly, the VACS, VACS 2.0, and 
EuroSIDA scores have never been validated in sub-Saharan Africa or other LMIC settings as 
valid predictors of early ART mortality.    
 
In addition, our scores are arguable better suited for sub-Saharan Africa, and possibly 
other LMIC clinic settings, than the Haiti score, which was generated using methodology 
with several important limitations as described in Chapter 2.3.4, and which has not been 
externally validated in sub-Saharan Africa or other LMIC.  Firstly, while the Haiti score was 
generated from six non-representative clinics in Haiti and validated in one non-
representative Haitian clinic with a small sample size, our scores were generated from 22 




clinics in Botswana and were externally validated in a trial dataset from South Africa (TB 
Fast Track).  Secondly, while over 35% of study participants in the Haiti study had missing 
covariate data, only 7% of XPRES prospective trial participants were excluded from the 
analysis because of one or more missing covariates.  Thirdly, in the Haiti study, the 
primary outcome of ART mortality was not well-ascertained, with 1-year vital status data 
in the derivation and validation datasets missing for 21.6% and 45.3%, respectively.  In 
contrast, in XPRES the primary mortality outcome was almost perfectly ascertained with 
<1% of prospective trial participants lost to follow-up. 
 
Next steps to validate use in contemporary routine programme LMIC clinic settings 
Ideally at least two next steps are needed to further strengthen the evidence base for 
rollout of the CD4-dependent and CD4-independent scores: (1) in the short term, further 
external validation of the early ART care intensification scores in a currently available 
dataset of adult PLHIV starting ART in sub-Saharan Africa under test-and-treat (i.e., 
universal ART eligibility) guidelines is needed and ongoing, and (2) a study to assess 
impact of the scores and associated algorithms of care on early ART mortality is needed. 
 
The first step of external validation in a currently available dataset is needed to address 
outstanding questions of how well the score discriminates risk in the current general ART 
enrolee population in sub-Saharan Africa.  Notably, the TB Fast Track trial external 
validation dataset consisted of persons with homogenously advanced HIV disease and low 
CD4 count (CD4 <150/µL).  The fact that the CD4-dependent and -independent scores and 
proposed cut-offs provided reasonable sensitivity in detecting early ART mortality risk 
compared to WHO advanced HIV disease eligibility criteria (i.e., 88-95% vs. 100%), and 
significantly superior specificity (20-27% vs 0%), indicates the ability of the score to 
differentiate risk even within a very homogenous population, which is a tougher test of 
discriminatory capacity compared with ability to discriminate risk in a more representative 
and heterogenous ART enrolee population.  Therefore, we would expect, but need to 




accuracy in a contemporary dataset than was observed through external validation efforts 
in the TB Fast Track trial dataset. 
 
Once validated again on a regionally or nationally representative dataset, the CD4-
independent score might be considered ready for use in some settings of sub-Saharan 
Africa lacking access to CD4 count testing, because of the very low sensitivity associated 
with trying to use WHO stage alone to discriminate early ART mortality risk (48% 
sensitivity among XPRES ART enrolees in our analysis).  However, ideally impact and 
feasibility of both the CD4-independent and CD4-dependent screening tools would be 
prospectively evaluated as part of a trial to inform subsequent programmatic rollout.  
 
Trials to improve early ART mortality risk assessments and differentiated care are still 
needed in sub-Saharan Africa despite rollout of new treat-all ART guidelines since 2015, 
because the percentage of PLHIV starting ART with advanced HIV disease remains 
persistently high in the region at about 15-30%, partly because many clients continue to 
cycle in and out of ART care.11,38   
 
To inform policy makers trying to choose between use of the CD4-independent or -
dependent scores rather than WHO advanced HIV disease care intensification criteria 
(CD4 <200/µL or WHO stage III/IV), a range of trials could be designed depending on the 
most pressing priorities. 
 
In those settings lacking CD4 testing access, where the CD4-independent score might 
replace the use of WHO stage alone in determining early ART mortality risk and access to 
an advanced HIV disease care package such as that recommended by WHO (i.e., 
cotrimoxazole prophylaxis, TB screening with subsequent TB treatment or TB preventive 
therapy, cryptococcal antigen (CrAg) screening with pre-emptive therapy for eligible CrAg-




cluster-randomised trial could evaluate the potential impact of the CD4-independent 
score on early ART mortality.   
 
In addition, both the CD4-independent and CD4-dependent clinical scores could inform 
new differentiated care packages, and this combination of clinical score plus new 
differentiated care might be superior and cost-effective compared with WHO ART care 
intensification criteria and packages for the following reasons.  Firstly, a score-informed 
care package might be superior to current WHO advanced disease eligibility and care 
guidelines by (a) improving access to early ART care packages through improved sensitivity 
of composite scores, and (b) use of additional interventions for the highest risk patients 
determined by the clinical score approach.84  The score-informed care package would 
have a good chance of remaining cost-effective while achieving additional impact on early 
ART mortality compared with standard of care, because of improved specificity of the 
scores compared with WHO advanced disease eligibility criteria. 
 
8.2.5. New tools and approaches to TB screening among PLHIV 
 
While the WHO four-symptom screening score is simple, widely known, recommended by 
WHO since 2011, and if implemented correctly can drive increases in case finding and 
associated mortality reductions among PLHIV starting ART, as was shown by the XPRES 
trial,161 our TB screening score has some advantages that mean it should be considered for 
scale-up in sub-Saharan Africa.  Below comparative advantages of our clinical TB screening 
score over (a) the WHO four-symptom TB screening rule, (b) the WHO-recommended 
approach to supplement WHO four-symptom TB screening with chest radiography where 
possible, and (c) other TB screening clinical scores are discussed.  Drawing lessons learned 
from XPRES, suggested next steps for scale-up so that the TB screening clinical score is 
actually implemented are proposed.  In addition, additional research that might support 
thoughtful scale-up plans to facilitate reaching ambitious TB preventive therapy goals 
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among PLHIV by 202192 and overall TB case finding, treatment, and prevention goals by 
2030, is proposed.88 
Comparative advantage of TB clinical score over WHO four-symptom TB screen 
As described in the most recent meta-analysis of accuracy of the WHO four-symptom 
screening rule by Hamada et al, and as described in the TB screening rule literature review 
section of this thesis (Chapter 2.4.1.), an inherent weakness of the WHO four-symptom TB 
screening rule is its inability to detect asymptomatic TB.  While this appears to have been 
a relatively small limitation at the time the screening rule was developed in 2011, when a 
much smaller percentage of PLHIV were taking ART, in 2020, when the majority of PLHIV 
in care are taking ART, this is a more important limitation.61  As described in the literature 
review, asymptomatic active TB as a proportion of total active TB cases is relatively more 
common among PLHIV stable on ART than ART-naïve PLHIV for at least two important 
reasons: (1) PLHIV who are stable on ART are often pre-screened, which progressively 
reduces the relative prevalence of untreated symptomatic versus untreated asymptomatic 
TB,60 and (2) PLHIV stable on ART are better able to control TB disease and are more likely 
to have indolent disease, possibly with intermittent symptoms.61,90,91   
In the Hamada et al meta-analysis, among PLHIV on ART, sensitivity of the WHO four-
symptom screening rule was only 51% compared with 89% among PLHIV who had not yet 
started ART.61  At a time when global health donors have committed to reaching over 13 
million PLHIV on ART with TPT by 2021,92 low sensitivity of the WHO four-symptom 
screening rule for active TB among PLHIV on ART is driving consideration of more sensitive 
screening approaches.16  In addition, asymptomatic active TB can be present among PLHIV 
with advanced HIV disease,38,94 and among pre-ART patients without advanced disease in 
high prevalence settings,96 among whom missing asymptomatic active TB can have 




Key advantages of our TB clinical score over the WHO four-symptom screening rule 
include that it can be used to prioritise sensitivity and NPV by choosing cut-offs that 
prioritise these features.  Scenarios where high sensitivity and NPV should be prioritised to 
“rule out” active TB disease include: (1) prior to TB preventive therapy prescription and (2) 
at HIV care or ART enrolment in sub-Saharan Africa when prevalence of active TB is high 
and intensified TB case finding and treatment can reduce morbidity and mortality.16  As 
reported in Chapter 7, choosing a clinical score cut-off of ≥2 increased the sensitivity by 3-
15% and NPV by 0.3-1.7% compared with the WHO four-symptom screening rule across 
the four study populations (XPRES, XPHACTOR, TBFT, and Gugulethu cohorts).  Notably, 
when the XPHACTOR dataset was restricted to clients on ART for >3 months, the 
improvement in clinical score sensitivity at cut-off ≥2 (80%) versus WHO four symptom 
screening rule sensitivity (69%) was more pronounced than in the unrestricted mixed ART-
naïve and ART-experienced XPHACTOR dataset (87% screening sensitivity at cut-off ≥2 
versus 80% with WHO 4-symptom screen), indicating the potential usefulness of the TB 
clinical score to increase sensitivity among PLHIV on ART, in situations where sensitivity in 
detecting TB disease needs to be prioritized.  In addition, in the XPRES cohort, among HIV-
TB patients who died by 6 months after enrolment, screening sensitivity of the TB score 
was 94% compared with 79% using the WHO four-symptom screen, indicating the 
potential utility of the clinical score in diagnosing asymptomatic TB earlier before ART 
initiation, with associated reductions in morbidity and possibly mortality.209   
 
At the same time, among PLHIV stable on ART who have received a course of TB 
preventive therapy, the clinical score can be used to prioritize specificity and PPV, 
reducing the NNS to a level that remains cost-effective in a patient population at low risk 
of incident TB disease and death from incident TB disease.54,89      
 
Although increases in NPV by using a clinical score cut-off of ≥2 instead of the WHO four-
symptom TB screen are modest, ranging from 0.3% to 1.7% in our analysis, use of the 




PLHIV92 could potentially avoid 39,000 to 221,000 PLHIV with active TB being prescribed 
TPT.  Recent 2018 WHO TB screening and TB preventive therapy guidelines for PLHIV,88 
and most global experts,16 acknowledge the need for increased sensitivity and NPV in a TB 
screening tool prior to TB preventive therapy prescription due to the risk of fuelling 
emergence and possible spread of drug-resistant TB, and missed active TB which has 
associated morbidity and mortality implications.16   
 
Comparative advantage of TB clinical score over WHO four-symptom TB screen plus 
chest radiography 
To achieve, the needed increase in sensitivity and NPV of the TB screening rule, WHO 
advises use of chest radiography where available to supplement the four-symptom TB 
screen, especially among PLHIV on ART, based on data from the Hamada et al meta-
analysis.88  In the Hamada et al meta-analysis, among PLHIV on ART, adding chest 
radiography to the four-symptom TB screening rule increased sensitivity in detecting 
microbiologically confirmed TB from 51.0% to 84.6%, with an associated increase in NPV 
of 0.2% (at TB prevalence of 1% which was about the TB prevalence among ART-
experienced PLHIV in the meta-analysis) but with a major loss of specificity from 70.7% to 
29.8%.61  Because of the marginal impact, the WHO guideline committee recommends 
that chest radiography should only be added as an additional investigation if it does not 
pose a barrier to the provision of preventive treatment for people living with HIV.88   
 
As described in our manuscript, compared with the WHO four-symptom TB screen, our 
clinical TB score at ≥2 improved sensitivity among PLHIV on ART (from 69% to 80%) and 
NPV (by 0.3% at 3% TB prevalence), with some loss in specificity (from 72% with the WHO 
four-symptom screen to 60% with our TB clinical score cut-off).  Given the similar 
improvements in sensitivity and NPV achieved with our TB clinical score compared with 
WHO’s recommended approach of adding chest radiography to the four-symptom TB 
screen, and given the relative simplicity of our TB clinical score, our TB clinical scoring 
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approach is arguably much more feasible and less costly and could better facilitate global 
TB preventive therapy scale-up and End TB goals. 
Significant challenges facing widespread use of chest radiography for TB screening in 
LMIC 
Although, with the advent of filmless or digital radiography and the validation of computer 
assisted diagnosis (CAD) software that can perform as well as trained clinicians in 
detecting both symptomatic and asymptomatic pulmonary TB disease,210,211 and although 
increasing costing data suggesting that a chest radiograph, interpreted through CAD 
software, could be affordable (e.g., $5-10/PLHIV screened) once infrastructure is in place 
and human resources trained,211,212 there remain many significant barriers to widespread 
rollout of chest radiography for TB screening in the near-term (e.g., to meet 2021 TB 
preventive therapy scale-up targets),92 and even over the next 10 years in the lead up to 
End TB 2030 goals.  
These barriers to scale-up of radiography for TB screening purpose are reported in a 
recent WHO situational assessment and include: (1) intra-reader and inter-reader 
variability, (2) no abnormalities are definitive of TB and therefore specificity is low, (3) a 
universally accepted reporting system is lacking, (4) patients are exposed to ionizing 
radiation although this is decreasing as advances are made, (5) special equipment with 
constant source of electricity needed, (6) trained personnel are needed to operate the 
machine, (7) chest radiography is usually not available outside district referral hospitals in 
sub-Saharan Africa and most LMIC, and (8) out-of-pocket expenses for patients are often 
high.213 
While barriers 1-3 are increasingly ameliorated by digital radiography advances and use of 
CAD, barriers 4-8 make widespread radiography rollout in LMIC settings, especially in sub-
Saharan Africa, a notable challenge.  Each barrier 4-8 is discussed below, with a brief 





Firstly, although the ionizing radiation associated with one chest radiograph is low (0.1 
millisieverts (mSv)), which is equivalent to 10% of the annual accepted dose of ionizing 
radiation for the general public, and therefore the risk of poor outcomes such as cancer 
from repeat exposure to the ionizing radiation associated with repeat chest radiographs is 
extremely small, the WHO review reports that when a large number of individuals are 
exposed to repeat chest radiography, “the associated risks may still constitute a public 
health issue.213  The WHO report also notes that children and pregnant women are 
especially vulnerable to ionizing radiation, with special considerations needed for these 
populations.213  Notably, pregnancy was common at ART initiation in the XPRES cohort 
(16-32% across the XPRES phases) and continues to be relatively common in most 
countries of sub-Saharan Africa.21,161 
 
Secondly, equipment maintenance in most sub-Saharan health facilities is a challenge 
since most health systems in sub-Saharan Africa do not receive the needed government 
health system spending due to competing priorities.214  A recent review of government 
health sector spending found that most African governments have deprioritized health in 
government budgets.214  Similarly, many countries in sub-Saharan Africa lack stable 
electricity supplies.  For example, in Malawi, only 59% of HIV clinics are connected to the 
electricity grid and unscheduled power outages are a daily problem affecting almost all 
health facilities.215  Similarly, most countries in sub-Saharan Africa have severe shortages 
of skilled healthcare workers.216,217  Given the limited infrastructure and human resources 
for health most PLHIV would have to travel to the nearest location with radiography 
services with significant out-of-pocket expenses, increasing the risk of dropping out of the 
TB-HIV care cascades.163  While mobile radiography units can bring chest radiography 
services closer to PLHIV receiving routine care, an upfront investment would be needed to 
buy the purpose-built mobile units, a recurring investment would be needed to maintain 
them, and a large number of mobile units would be needed because many health centres 




TB screening algorithms could increase the barrier to scale-up of TB preventive therapy 
and access to TB diagnostics and treatment.16  While some authors have suggested that 
chest radiography might facilitate immediate empiric TB treatment in the absence of a 
microbiological diagnosis, similarly, the TB clinical score could be used to define cut-offs 
above which the PPV is sufficiently high that immediate empiric TB treatment might be 
warranted.117 
  
Therefore, our TB clinical score, that incorporates six simple score components, is careful 
to use variables easily available already in a LMIC clinic, requires limited training to 
complete the score, includes objective data points that should limit inter-operator 
variability, and which carries the same screening accuracy improvements of adding more 
expensive radiography to WHO four-symptom TB screening and also allows opportunities 
for differentiated TB-HIV care algorithms, represents a more feasible approach to 
improving TB case finding and facilitating TB preventive therapy scale-up among PLHIV.   
 
Comparative advantage of TB clinical score over other clinical scores 
As described in the literature review, six studies and six TB clinical scores for PLHIV were 
reviewed, but all had limitations.118,120-123,218  Firstly, only three TB clinical scores, the 
Thailand score,119 Vietnam score,120 and TBScore from Guinea Bissau,122 represented a 
clinical score used as the first step of TB screening (as opposed to the second step after 
the WHO four-symptom screen completion among those who initially screened TB 
symptom positive).  Therefore, only these three scores could potentially serve to increase 
TB screening sensitivity and NPV compared with the WHO four-symptom screening rule.  
In addition, none of these three clinical scores (and none of the six TB clinical scores 
reviewed) had been externally validated.  Of the three first step scores, several other 
limitations limit their use compared with our TB clinical score.  Additional weaknesses of 
the Thailand score include the potentially biased derivation study population (since all 
those in the study were already suspected of having TB as described in the Chapter 2 




Vietnam score include use of CD4 and chest radiograph as potential variables in the 
combination score and inability to generate categories of TB risk that could inform 
differentiated care.120  Additional limitations of the TBScore study from Bissau include use 
of a complex 13-level score, and inclusion of more subjective variables (auscultation and 
anaemic eyes) in the score.122 
 
Summary contribution to the literature 
Therefore, our study is the first to derive and externally validate a clinical score for active 
TB among both ART-naïve and ART-experienced PLHIV that does not rely solely on WHO 
TB symptom screening, and allows flexibility in choosing the desired sensitivity, specificity, 
NPV, PPV, and NNS across a range of cut-offs, depending on the setting, use-case scenario, 
and population served.  Similarly, the screening tool’s differentiation of three risk groups 
can be used to inform differentiated care in LMIC clinic settings, which could improve 
efficiency and potentially impact morbidity and mortality.  Given the potential advantages 
of our TB clinical score over the WHO four-symptom screening approach with or without 
chest radiography and over other published TB clinical scores, our clinical score should be 
evaluated further in multiple settings to generate more data about its potential utility.  
Some potential evaluation approaches are described in the paragraph below.  
 
Next steps to build the TB clinical score evidence base 
Given the potential advantages of the TB clinical score over existing WHO 
recommendations for TB screening approaches, the screening tool should be further 
evaluated in the near term to establish its potential utility to facilitate TB case finding and 
TB preventive therapy scale-up.  Even if further evaluations demonstrate that there are 
important advantages of our TB clinical score over current WHO-recommended 
approaches, basic health system strengthening (i.e., ensuring healthcare workers have 
time to complete the score, training, checklists, job aids, and mentoring and supervision) 
would all be needed to ensure the clinical score is actually implemented as well as 




implementation of the score would be to incorporate the score in national electronic 
medical records (EMR) capturing data for PLHIV in care.  Even in the most resource-limited 
settings, sustainable EMR solutions with power requirements that can be met by widely 
available battery and simple inexpensive solar solutions are increasingly available.207  For 
example, in Malawi, incorporating routine WHO four-symptom TB screening into the 
point-of-care, touchscreen EMR that supports care for 70% of PLHIV across the country 
helped increase completion of the TB screening step.219  However, routine monitoring and 
quality checks will be needed to ensure the score is being actually completed, rather than 
rushed through or left blank as was observed in a large Kenyan programme supported by 
EMR.169    
 
Additional research to validate the screening accuracy of the score prospectively and 
evaluate effectiveness is needed.  For example, a parallel-group, pragmatic cluster-
randomised trial could compare standard of care (i.e., use of the WHO four-symptom 
screening rule and case finding algorithms) with our TB clinical score and differentiated TB 
management algorithms, in terms of impact on patient-important outcomes like morbidity 
and mortality.  If paired with a costing study, this evaluation could inform understanding 
of cost-effectiveness.  Given the continued challenge of obtaining sputum samples from 
40–50% of patients who screen positive for TB, and given the Xpert trial evidence of the 
importance of empiric TB treatment, such a trial could help evaluate empiric TB treatment 
approaches that are differentiated by TB risk.117  Differentiated TB care algorithms 
informed by the TB clinical score could help clinicians by: (1) helping to standardize when 
to use TB diagnostics (such as on-site or off-site Xpert use),220 (2) prompting empiric TB 
treatment in patient groups where PPV of active TB is sufficiently high and the patient is 
unable to produce sputum or delays in accessing a TB test are considered unacceptably 
long,221 and (3) by facilitating optimal completion of empiric TB treatment guidelines such 
as prompting further investigation for non-TB causes of illness if there is no response to 





8.2.6. Machine learning as an important tool in prognostic research if understand 
strengths and weaknesses 
 
A recent Institute of Medicine report concluded that a diagnostic error will be made in the 
care of nearly every patient in the course of his or her lifetime,224 and receiving the right 
diagnosis is critical to receiving appropriate care.128  Because of its potential to improve 
diagnostic decision-making in general, use of machine learning technology in medicine 
continues to be a point of great optimism and significant research.128,225  Given the recent 
speculation that artificial intelligence can transform the way medicine is practiced, some 
recent authors have cautioned the medical community to avoid the “hype” of inflated 
expectations, focus thoughtfully on the real strengths that machine learning can bring to a 
particular medical challenge in a particular setting.226  In this section, I describe how use of 
machine learning in generating the TB clinical score conservatively maximized the 
strengths of machine learning compared with traditional generalised linear regression 
models, while also controlling for its weaknesses, and represents a novel contribution to 
the TB screening literature.  In addition, a short paragraph on the broader implications of 
machine learning in TB diagnostic and treatment research is provided to further 
contextualize our contribution. 
 
Contribution of our machine learning approach to TB screening literature 
Few studies have attempted to use machine learning algorithms to generate TB screening 
approaches and none, based on a literature review, use machine learning to generate a 
simple clinical score for use among PLHIV in LMIC clinic settings.  One recent analysis by 
Melendez et al, combined 14 clinical features with a chest radiograph computer-assisted 
diagnosis score of >60 to generate a predictive model for patients suspected of having TB 
regardless of HIV status to predict culture-confirmed TB, but this was a second step 
screening approach among symptomatic patients (98.5% had cough), not focused on TB 
screening among PLHIV, and was reliant on availability of a computer-run algorithm and 




analyses, which are a type of supervised machine learning, to generate decision trees for 
TB investigation in emergency departments,228 in-patients,229 and among smear-negative 
persons suspected of having TB.230  However, none of these decision trees were specific 
for PLHIV, one included the need for chest radiography as part of the algorithm,229 one 
required pre-screening with radiography before entering the decision tree algorithm,230 
and one included the need for point of care ultrasound.228  No study had yet used a 
random forest machine learning approach to investigate importance of predictors for a 
simple clinical TB screen among PLHIV in LMIC, and the approach presented in this thesis 
contributes to the growing body of literature examining the role of machine learning in 
global health.231  
 
Maximizing strengths and controlling for weaknesses of machine learning 
As described in Chapter 7, a key strength of our approach was to use random forest 
machine learning to assess variable importance in discriminating TB risk because of the 
unique ability of machine learning approaches to detect potentially important non-linear 
relationships between covariates and outcomes.127  Among machine learning models, 
random forest models are particularly strong at predicting categorical outcomes like our 
TB outcome.158  As was described in the manuscript, BMI was identified as an important 
predictor via the random forest variable importance analysis.  Although BMI as a 
multifractional polynomial transformed continuous term was eliminated from the 
backwards stepwise regression, BMI was retained in the final model because of the 
importance of BMI in discriminating prevalent active TB using the mean decrease in Gini 
analysis.  This analysis indicated the importance of BMI in its ability to accurately split 
groups of patients into those who have or do not have prevalent active TB across the 
1,000 decision trees examined in our random forest model.  The high ranking of BMI 
according to mean decrease in Gini indicates the significant decrease in average, weighted 






Our approach also used rigorous traditional generalised linear regression modelling 
approaches and stringent external validation approaches to account for a common 
problem faced by machine learning prediction models, namely over-fitting on the training 
dataset with limited external generalizability.128,225,226  Firstly, the generalised linear 
regression approach, while is less likely to generate prognostic models that fit perfectly to 
the training dataset due to relative dependence on assumptions of average linear or 
transformed linear associations between covariates and outcome, is also more likely to 
generate prognostic models with improved external generalizability.225  The opposite 
characteristics were evident with the machine learning approach where we observed 
extremely high discrimination of the random forest model on the training data and a 
significant drop in discrimination on the validation data.   
 
Secondly, our novel approach highlights the importance of a stringent validation approach 
for any predictive model, but especially those derived using machine learning.127  At the 
analytic design stage, we purposefully split the dataset into northern and southern clinics 
in Botswana with a 50%:50% split, which is in line with more stringent validation 
approaches that help better assess generalizability of predictive models.124,127  In 
reviewing the machine learning literature, most widely available training resources and 
publications use a random 75%:25% split to create training and validation datasets for 
random forest models,232 and hopefully our analysis and approach increases awareness of 




Other and future uses of machine learning in TB diagnostic and treatment research 
By far the most common use to date of machine learning in TB diagnostics or treatment 
research, has been in developing chest radiograph interpretation algorithms.233  In a 
recent systematic review of machine learning approaches, 53 papers that used machine 
learning to develop or validate chest radiograph interpretation algorithms were included, 
293 
with 40 papers focused on algorithm development and 13 on external validation of the 
algorithms.233  Secondly, a systematic review of machine learning for infectious disease 
clinical decision support included nine studies that developed automated, computer-
driven algorithms to inform clinician decision-making about TB diagnosis and treatment, 
but none of these algorithms were documented to have been used or validated in real-
world clinic settings.234  Of all 60 machine-learning decision-support tools for infectious 
disease care identified in the systematic review, only three had documentation of use and 
evaluation in the real-world clinical setting.234  Other uses of machine learning for TB 
diagnosis and treatment include in drug discovery,235 predicting phenotypic drug 
resistance from genotypes,236 and evaluation of antigens in serum as predictors of active 
TB in attempts to develop non sputum-based diagnostic tools.237   
Summary of current usefulness of machine learning in TB diagnostics 
While the long-term future might hold promise for machine learning diagnostic support 
for TB and new treatment identification, in the short term, utilizing the strengths of 
machine learning to help with simple prognostic scores, immediately applicable in LMIC 
settings, may be the most practical way to use the power of machine learning to improve 
patient-centred care in the reality of LMIC clinic settings. 
8.2.7. Simple screening tools needed for precision public health plus strong health 
systems that implement them 
Three over-arching principles that emerge from this thesis include (1) the need for 
development and validation of new and improved screening tools to detect which patients 
are at risk of outcomes such as early ART mortality and active TB disease, (2) the largely 
untapped potential for stratified risk scores to inform risk-appropriate differentiated 
service delivery models, and (3) the need to strengthen health systems to implement the 




fundamental to public health approaches for care delivery in resource-constrained 
settings, this thesis showed many low-hanging fruits for improvement in these areas. 
 
Firstly, the thesis shows that both WHO eligibility criteria for early ART care intensification 
and the four-symptom TB screening rule can be improved by thoughtful development of 
clinical scores using easily available variables in LMIC clinic settings.  Notably, clinical 
scoring systems have not yet been carefully considered in the WHO guideline 
development process for either early ART care intensification or recent WHO TB screening 
guidelines.44,88  The clinical screening tools developed in this thesis and the data provided 
suggest such tools should be considered in future WHO guideline development processes. 
 
Secondly, opportunities to tailor simple care algorithms to stratified risk categories 
identified by clinical scores have not yet been explored widely in the area of early ART 
care intensification or differentiated TB-HIV care.  For example, only one algorithm-guided 
TB case finding and treatment approach suitable for LMIC clinic settings has been 
evaluated by Grant et al,117 compared with eight clinical trials examining potential impact 
of the Xpert diagnostic device.146,161,200  In the case of advanced HIV disease guidelines, no 
approach to stratify risk groups into low-, moderate-, and high-risk, with associated risk-
appropriate care packages has yet been evaluated.  Differentiating care according to 
holistic risk categories has the opportunity to increase impact of the limited available 
resources through a precise public health approach.238,239 
 
Thirdly, investments in health system strengthening to implement recommended TB 
screening approaches and retaining clients in TB-HIV care was shown to have significant 
impact on patient-important outcomes.161  This thesis provides further insight that “leaky” 
TB screening and TB-HIV care cascades might be the driving force behind unacceptably 
high rates of HIV mortality due to undiagnosed TB or TB diagnosed late, while also 




improve completion of these TB screening and TB-HIV care cascades in sub-Saharan 
Africa.161 
  
8.3. Limitations and strengths 
 
In addition to the limitations and strengths described in the manuscripts (Chapters 5, 6, 
and 7), the following section describes efforts at thoroughly evaluating the potential for 
biases and residual confounding, which can affect internal validity, and the generalizability 
of study findings (i.e., external validity). 
 
8.3.1. Evaluation of thesis limitations 
 
Healthcare access or referral filter bias, a type of selection bias 
The internal validity of a trial can be affected by several biases, which should be 
considered at the design stage.240  At the time XPRES enrolled patients, national guidelines 
recommended ART initiation for PLHIV at CD4 count <350/µL, WHO stage III/IV, or for 
pregnant women regardless of CD4 count or WHO stage.152  Some of the HIV clinic 
enrolees at the five large district hospitals included in XPRES, and to a lesser extent at the 
remaining 17 XPRES primary healthcare clinics, were referred for HIV treatment initiation 
after a period of CD4 count monitoring during pre-ART care at smaller health posts, with 
referral for ART initiation when the eligibility threshold was reached. 
 
This means that a section of the XPRES study enrolee population represents a population 
that should have been pre-screened for TB.  In some papers this is referred to as 
healthcare access bias or referral filter bias;240 in the case of XPRES it raises the need to 
consider how XPRES HIV clinic enrolees might be different to all PLHIV at the point of HIV 
diagnosis and how findings might be different if the study population had not been pre-
screened at all.  For example, in XPRES 359 (4%), 44 (2%), and 122 (3%) of SOC, EC, and 




arrival at the study clinic.  Ultimately, an additional 129 (1%), 86 (5%), and 244 (6%) 
enrolees in the SOC, EC, and EC+X phases were newly diagnosed with TB and started TB 
treatment before ART initiation or during the first 6 months of ART after study clinic 
enrolment.161   
 
In terms of potential impact on the primary manuscript outcome findings, we might have 
observed an even higher impact of the TB screening and case finding intervention in a 
population of PLHIV that was previously completely unscreened for TB symptoms.200  In 
terms of impact on the screening sensitivity of the WHO four-symptom TB screen, we 
might have observed a higher screening sensitivity (79%-89% according to the Getahun 
and Hamada meta-analyses), than the sensitivity we did observe in XPRES at the HIV clinic 
enrolment visit (73%).60,61  However, our study and other studies show that TB symptom 
screening is generally done poorly in LMIC clinic settings.161  In addition, if the whole 
population of XPRES had been thoroughly pre-screened for TB symptoms we would have 
expected sensitivity of the four-symptom TB screen to be even lower (41% according to 
the Getahun meta-analysis) than what we observed (73%).60  Therefore, the data suggest 
the impact of any pre-screening might have been minimal on the key trial findings.       
 
Survivor bias, a type of selection bias 
Notably, because of the delay between HIV diagnosis and ART initiation due to ART 
eligibility guidelines in place at the time of study enrolment (2010–2014), our population 
of XPRES study enrolees represents those who had survived and been retained in the pre-
ART time period after HIV diagnosis, with the need to consider the possibility of survivor 
bias in terms of the characteristics of patients enrolled versus characteristics of PLHIV at 
the point of HIV diagnosis.240  However, each study population (SOC, EC, and EC+X) would 
have been equally affected by any survivor bias, which means comparisons between 
phases in the primary outcome paper (Chapter 5) remain internally valid to the population 
studied, but care should be taken to generalize findings to PLHIV populations at the time 






Inherent to all Xpert impact trials is that clinics and healthcare workers where the study 
was being implemented were aware that Xpert is a more sensitive diagnostic test for 
detecting culture-positive TB than smear microscopy since this was the rationale for WHO 
and national guidelines for Xpert rollout.18,77  Knowledge of this superior diagnostic 
accuracy may have increased the rates of empiric TB treatment in the EC phase and 
decreased rates of empiric TB treatment in the EC+X phase, which could be considered a 
type of Hawthorne effect.151,240  However, it seems likely that any potential imbalance in 
likelihood of empiric TB treatment between situations where microscopy is the TB 
diagnostic and Xpert is the TB diagnostic would persist in the real-world,241 and therefore 
the finding of no sizable impact of Xpert versus smear microscopy in reducing mortality 
among PLHIV is generalizable to real-world settings in sub-Saharan Africa.146,151  In other 
words, if there had been feasible and ethical way to blind clinicians to which diagnostic 
test was being used, the study could have eliminated the potential for this particular 
observer bias, but then lost external validity (i.e., the ability to generalize findings to the 
real world).  In addition, by blinding the clinician to which diagnostic was used, rates of 
empiric TB treatment might have been higher in both phases with clinicians erring on the 
side of caution and assuming that smear microscopy was the diagnostic test being used.     
 
Contamination bias 
Contamination bias occurs when the intervention affects the standard of care comparison 
group or standard of care affects the intervention group.  In XPRES, none of the ART 
enrolees in the last six months of the SOC phase would have received the TB screening 
and retention intervention, because this was administered by the study nurse for study 
enrolees only.  However, all healthcare providers at study clinics received a training on TB 
case finding at EC phase initiation and this may have benefited a few SOC enrolees who 
screened positive for TB symptoms during their follow-up which overlapped with the EC 




symptoms in the EC+X phase during study follow-up, may have benefited from Xpert.  
Therefore, we implemented several pre-specified sensitivity analyses to assess the 
potential for this contamination, firstly by censoring follow-up time at the crossover in 
phases, and secondly by assigning follow-up time to the phase in which it occurred.  For 
the SOC versus EC+X comparison, there was no change in effect size or direction when 
implementing this sensitivity analysis suggesting there was no contamination bias 
affecting our primary intervention effect analysis.161   
 
However, for the EC vs. EC+X comparison, within the stepped-wedge portion of the trial, 
we did observe some changes in effect size, although 95% confidence intervals around the 
adjusted hazard ratios always included 1.0.  For example, 6-month mortality rates were 
similar between the EC (6.5/100 person-years) and EC+X phases (6.3/100 person-years) in 
the pre-specified primary analysis where all follow-up time was assigned to the phase in 
which the patient started ART (AHR 1.13, 95% CI, 0.63-2.03).  However, in sensitivity 
analyses comparing EC vs. EC+X 6-month mortality rates, the AHR was 0.90 (95% CI 0.42-
1.95) when EC enrolee follow-up time was censored at the time of EC+X cross-cover, and 
0.79 (95% CI 0.41-1.50) when EC enrolee follow-up time in the EC+X phase was assigned to 
the EC+X phase using a time-dependent variable.  As stated in the discussion section of 
Chapter 5, this might indicate a modest Xpert impact on 6-month ART mortality that our 
study was not powered to detect161 and which might be more feasibly detected in large 
meta-analyses.204   
 
In addition, when possible, sputum samples were sent for culture in both EC and EC+X 
phases to help answer the second co-primary objective (not reported in this thesis), which 
was to compare sensitivity of the microscopy- versus Xpert-based TB diagnostic 
algorithms.  However, only 12 (0.7%) of 1,768 EC enrolees and 16 (0.4%) of 4,215 enrolees 
in the EC+X phase received a TB diagnosis based on culture alone, suggesting any impact 






As described in the primary outcome analysis, a key limitation of the trial design is that the 
observed reduction in all-cause mortality between SOC and subsequent EC and EC+X 
phases represents a pre- versus post-comparison, rather than a randomised comparison, 
and is therefore at risk of residual confounding.240  Multivariable proportional hazards 
regression was used to account for measured confounders, however we cannot exclude 
the possibility that there were unmeasured confounders affecting the pre- versus post-
comparison.240,242  Therefore, the retrospective SOC phase is both a weakness (because 
there was no randomised comparison and limited ability to change what covariates were 
collected from the retrospective phase for comparison with the prospective phase), but 
also a strength because it allows comparison of the intervention package with a true 
standard of care to allow estimation of effectiveness in the real-world.203   
 
Potential impact of changing ART guidelines on generalisability  
As described in the manuscript, our study enrolment occurred prior to adoption of 
universal test-and-treat guidelines which were adopted in Botswana in 2016 and have 
been implemented in most of sub-Saharan African since 2016, with gradual increases in 
median CD4 count at ART initiation.161  As stated in the manuscript (Chapter 5), the 
absence of an interaction between CD4 count at ART initiation and intervention package 
effect size suggests that ICF and retention interventions are still important for all new HIV 
clinic enrolees, not just those with more advanced disease.28,44  Therefore, the main trial 
findings still support current WHO recommendations that high quality implementation of 
TB screening and case finding and retention interventions remain important for all HIV 
clinic enrolees, even in the era of test-and-treat.161  
 
 




An important limitation of the early ART mortality risk scores is that they have not yet 
been validated in a cohort enrolled under HIV test-and-treat guidelines, something which 
is planned in the near future.   
 
Another limitation of both the early ART mortality risk scores and TB risk score is the fact 
that while the gender variables are relevant in sub-Saharan Africa and many resource-
limited settings, the association of male gender with early ART mortality risk and TB is not 
generalizable to cohorts in resource-rich settings like the U.S. and Europe, where males 
often have better outcomes than female ART enrollees.243   
 
For the early ART mortality risk scores, these screening tools were validated in trial 
cohorts that received relatively intensive TB screening and treatment services, and 
therefore those that died did so despite access to these services.161  Evaluation of early 
ART risk score screening accuracy in cohorts of adult ART enrollees starting HIV treatment 
in the current era of “treat all” would help evaluate this limitation. 
 
Feasibility of risk scores 
Although the specificity of the early ART mortality risk scores is superior to the WHO 
advanced disease eligibility criteria, still a substantial percentage of ART enrollees (36-38% 
in the XPRES cohort) would be screened into receiving an advanced disease care package, 
which would require a pilot with an associated monitoring system to assess 
implementation fidelity and feasibility.  
 
For the TB risk score, if the cut-off is set at ≥2, the goal is to increase sensitivity in 
detecting asymptomatic TB, with a resulting loss of specificity.  Such a cut-off would be 
suitable for a population of PLHIV starting ART or immediately prior to TB preventive 
therapy prescription.61  In these scenarios, the volume of patients requiring a TB test, 
probably with Xpert, would increase compared with a screening approach using the WHO 




to be evaluated.61  Arguably, by using a cut-off of >10 for those PLHIV stable on ART who 
have already received TB preventive therapy, this differentiated approach discussed in 
Chapter 5 will help improve feasibility and cost-effectiveness of the proposed TB clinical 
score by reducing the number of TB tests needed in this stable and low risk population 
compared with the WHO four-symptom TB screen, but this approach needs to be 
evaluated. 
 
Outcome ascertainment error 
For the early ART mortality risk score analysis, there was almost perfect ascertainment of 
the all-cause 6-month ART mortality outcome in both XPRES and TB Fast Track, so 
outcome ascertainment error would not have affected the early ART mortality risk score 
development. 
 
However, within the TB risk score analyses, (1) TB case finding approaches were different 
across the four cohorts and (2) for the XPRES and XPHACTOR cohorts, a clinical definition 
of TB was included in the TB outcome definition, whereas for TBFT and Gugulethu cohorts, 
results of enrollment sputum collection for TB culture and Xpert were used to define the 
TB outcome. However, model results and risk score screening accuracy did not change 
significantly when we restricted the TB outcome in XPRES and XPHACTOR datasets to 
microbiologically confirmed TB. 
 
Risk score effectiveness assessments needed 
As described in the recommendation section below (8.3), even if screening accuracy of the 
risk scores is shown to be superior to the WHO-recommended standard of care, 
effectiveness of the risk scores and associated care algorithms on patient-important 
outcomes like mortality is needed to inform future scale-up. 
 





Many of the study strengths have been described in the published manuscripts and in 
previous sections of the thesis and these are briefly summarized below. 
 
External validity – generalisability 
As described in section 8.1.2, we believe most study features allow the study findings to 
be broadly generalizable to other settings in sub-Saharan Africa, with these features 
including: (1) purposive selection of study sites to be representative of HIV clinics in 
Botswana, (2) inclusive eligibility criteria for the trial with minimal exclusion criteria to 
ensure the study population was representative of the real-world HIV clinic patient 
population, (3) a census approach to trial recruitment (i.e., the aim was to enrol all eligible 
trial enrolees to obtain a representative study population), (4) no discernible difference 
between those enrolled versus not enrolled in the study, (5) no effect of inverse 
probability weighting approaches to account for non-enrolment on primary study 
outcomes, (6) the practical nature in which the intervention was designed and 
implemented, (7) the way outcomes were compared between intervention phases and an 
untouched historical standard of care phase, and (8) using an intention-to-treat analysis. 
 
Accurate ascertainment of primary outcome, complete data, large sample size 
Other study strengths include: (1) novel trial design to fill knowledge gaps not addressed 
by other Xpert impact trials as discussed in section 6.2.2., (2) large sample size, (3) almost 
perfect ascertainment of the primary outcome (early ART mortality), and (4) nearly 
complete data for key covariates so that adjustment could be conducted without loss of 
power and without introducing risk of differential measurement error. 
 
Clinical score analyses validated externally 
Key strengths of the clinical score analyses include many of the same strengths above as 
well as the extensive external validation of clinical score screening accuracy in datasets 
from South Africa, and use of both established and new analytic techniques to generate 






8.4. Reflective commentary and practical lessons learned 
 
8.4.1. Reflective commentary 
 
Like many clinicians working in sub-Saharan Africa during the early 2000’s, the experience 
of caring for and losing patients to preventable and treatable diseases like HIV and TB has 
been a motivating factor for subsequent research and public health work.  Although XPRES 
study planning began in 2011, its intervention design was informed both by prior clinical 
work in South Africa during 2003–2007, and observational studies conducted in sub-
Saharan Africa between 2007 and 2011.28  By 2011, many considered Xpert to be a game 
changer for TB-HIV care with the estimation that hundreds of thousands of lives would be 
saved as Xpert was scaled up across Southern Africa.81  Experience from clinical work 
helped provide insight into prevalent health system weaknesses in LMIC, with clinicians 
often forced to limit the length of clinical care interactions to get through the volume of 
patients seeking care.244  For example, from a meta-analysis of data from 67 countries, 
about 50% of primary care interactions last less than 5 minutes, with national averages as 
low as 2 minutes/patient consultation in Malawi and 48 seconds/patient consultation in 
Bangladesh (Figure).244  The length of the consultation is directly correlated with both the 














Both the clinical insight gained from working in LMIC clinic settings, and the operational 
research which showed persistently incomplete performance of basic care functions like 
completing a four-symptom TB screen in sub-Saharan countries trying to expand TB-HIV 
care,62,98,99 informed the rationale behind the health system strengthening component of 
the XPRES TB screening and retention package.  The thesis findings have helped highlight 
the importance of health system strengthening, which, depending on the public health 
problem being addressed in LMIC, might need to be prioritised ahead of, or at least 
combined with, scale-up of any new technology. 
 
Another reflection from both clinical work, prior operational research, and this thesis is 
the importance of prompting busy clinicians to “think TB” as part of a differential 
diagnosis, due to the protean manifestations of this disease in clinical practice, especially 




those at high risk of having active TB even if a microbiological diagnosis is not possible.  
This thesis provides new tools to potentially enable more accurate TB screening, and new 
methods to facilitate screening tool implementation in LMIC clinic settings. 
 
8.4.2. Practical lessons learned 
 
A key practical lesson learned in conducting this research, is the difficulty associated with 
conducting research using sputum-based diagnostics in LMIC clinic settings.  As was 
described in Chapter 5, although the percentage of enrolees screening positive for at least 
one TB symptom who provided one or more sputum samples increased from 38% in the 
SOC phase to 46% and 55% in the EC and EC+X phases, respectively, collection of sputum 
samples remained a challenge even in the EC phases despite intensive interventions.18  In 
retrospect, I might have suggested inclusion of sputum-independent TB tests, such as 
either testing for urinary lipoarabinomannan (LAM) (e.g., with the Alere Determine TB-
LAM Antigen test) or Xpert testing of urine if I had better anticipated the challenge 
obtaining sputum samples from symptomatic patients.  However, inclusion of this 
additional intervention would have made it more challenging to fully understand which 
part of the intervention package impacted mortality.  In addition, other studies such as 
the STAMP trial, although conducted purely among hospitalised patients, have shown the 
value of these urinary diagnostics and have changed WHO guidelines.245      
 
Another practical lesson learned was how challenging it was to implement a large trial in 
routine LMIC settings, from the conceptualization and protocol writing process,18 through 
training of study nurses and health facilities involved, data entry and management tool 
development, monitoring implementation both in-country and remotely, preparation of 
quarterly progress reports for funders, tracking expenditure of available funds and 
applying for additional funding to complete the trial, painstaking review of central 




writing.161  However, the experience also highlighted the importance of trials to solidify 
the evidence base for changes that need to occur to improve care for patients.        
 
8.5. Summary recommendations 
 
The table below provides a summary of key findings, insights and recommendations 




Table 8.3. Summary of key recommendations in this thesis 




1. HIV-TB programmes should prioritise health system strengthening interventions to improve 
completion of TB screening, case finding and TB-HIV retention cascades to reduce all-cause, early 
ART mortality in sub-Saharan Africa. 
2.2., 5, and 
8.2.1. 
1.1. Tracing all PLHIV who missed an appointment during the first 6-12 months of ART was a 
feasible and effective retention intervention to reduce rates of loss to follow-up by 82-95% and 
should be considered for scale-up as standard of care in LMIC settings. 
Needed 
research 
1.2. Cost-effectiveness analysis of implementing the health system strengthening 
interventions compared with standard of care.  




2. HIV programmes and regulatory bodies such as the WHO should consider clinical scores as one 
approach to inform who needs early ART care intensification in future guideline development 
processes. 
2.3., 6, and 
8.2.4. 
2.1. Health facilities in sub-Saharan Africa lacking access to rapid on-site or off-site CD4 count 
testing should consider initially validating and then using the CD4-independent clinical score, 
instead of WHO advanced HIV disease eligibility criteria, to inform who needs intensification of 
early ART care.  Potential advantages of the clinical score include: (1) a nearly two-fold increased 
sensitivity in detecting early ART mortality risk compared with using WHO stage alone, (2) 
improved specificity compared with the full WHO advanced HIV disease eligibility criteria, and (3) 
improved ability to differentiate risk into low-, moderate-, and high-risk groups. 
2.2. Health facilities in sub-Saharan Africa that have access to rapid on-site or off-site CD4 
count testing should consider initially validating and then using the CD4-dependent clinical score, 
instead of WHO advanced HIV disease eligibility criteria, to inform who needs intensification of 
early ART care.  Potential advantages of the clinical score include: (1) similar or improved 
sensitivity in detecting early ART mortality risk, (2) improved specificity compared with the full 
WHO advanced HIV disease eligibility criteria, and (3) improved ability to differentiate risk into 






2.3. External validation of the CD4-dependent and -independent clinical score in currently 
available datasets including PLHIV starting ART after rollout of “treat all” WHO guidelines. 
2.4. Trial to assess early mortality impact and cost-effectiveness of using the CD4-independent 
and -dependent scores instead of WHO advanced HIV disease criteria to inform who needs:  
(a) the current standard of care for early ART care intensification (i.e., the WHO advanced HIV 
disease care package), and, 




3. HIV-TB programmes in sub-Saharan Africa should consider initially validating and then using the 
TB clinical score instead of the WHO four symptom TB screen to facilitate TB case finding and 
preventive therapy scale-up.  Potential advantages of the clinical score include: (1) flexibility to 
choose cut-offs depending on the population and use-case scenario (e.g., prioritising increased 
sensitivity and NPV among new HIV clinic enrolees and among PLHIV prior to TB preventive 
therapy initiation and prioritising specificity and PPV among PLHIV stable on ART who have 
already received TB preventive therapy), (2) increased ability to detect asymptomatic TB, and (3) 





3.1. Research to validate the screening accuracy of the score prospectively in a direct 
comparison with the WHO recommended four-symptom screen with and without chest 
radiography. 
 
3.2. Trial to assess impact on patient important outcomes of using the TB clinical score instead 
of the WHO four-symptom screening rule to implement TB case finding, differentiated TB-HIV 
care for moderate-, and high-risk categories, and TB preventive therapy for those who screen 
negative. 
 
Abbreviations: TB, tuberculosis; WHO, world health organisation; PLHIV, people living with HIV; LMIC, low- and middle-income 






Leaks in the TB screening and TB-HIV care cascades appear to be the biggest drivers of HIV-
related mortality due to undiagnosed TB or TB diagnosed late in sub-Saharan Africa.  Health 
system strengthening to address these leaks should be prioritised by clinicians, TB-HIV 
programme managers, governments, and global health funders in the field of TB and HIV.  In 
XPRES, interventions to support TB screening and active tracing for patients missing clinic 
appointments drove increased TB case finding and reduced loss to follow-up with associated 
reductions in early ART mortality.   
 
The CD4-independent and -dependent risk scores are the first externally validated clinical scores 
for ART care intensification generated for sub-Saharan Africa.  Sensitivity of the CD4-
independent risk score with cut-off set at ≥4 was nearly twice that of WHO stage in predicting 6-
month mortality and could be used in settings lacking CD4 testing to inform ART care 
intensification.  Compared with the WHO advanced HIV disease eligibility criteria, the CD4-
independent clinical score also had higher specificity and would screen 8-26% fewer ART 
enrollees into intensified care pathways, suggesting the screening tool could also increase 
efficiency of investments in differentiated service delivery models for advanced HIV disease.   
 
In those settings where CD4 is available, using the CD4-dependent clinical score with a cut-off 
score of ≥5 could increase both sensitivity and specificity over WHO advanced disease eligibility 
criteria, with the potential to both reduce early ART mortality and improve efficiency of 
differentiated service delivery algorithms.  Therefore, both the CD4-independent and -
dependent clinical scores should be considered for scale-up to facilitate early ART care 
intensification in sub-Saharan Africa, with the potential for reductions in early ART mortality. 
 
Advantages of the TB clinical score over the WHO four-symptom TB screen are that it has 
capacity to detect asymptomatic TB, has screening accuracy characteristics that indicate 




choosing the desired sensitivity, specificity, NPV, PPV, and NNS across a range of cut-offs, 
depending on the setting, use-case scenario, and population served, and can differentiate three 
risk groups, which can be used to inform differentiated care in LMIC clinic settings, with the 
potential to improve efficiency and potentially impact morbidity and mortality. 
 
Overall, the literature reviews including the Xpert systematic review, the XPRES trial, and the 
risk score analyses highlight the importance of considering the operational capacity of HIV and 
TB clinics in sub-Saharan Africa, where most clinics are under-resourced and operate within 
weak health systems.  Within these under-resourced clinic environments, interventions to (1) 
strengthen the health system to do the basics right, and (2) provide simple, feasible, accurate 
screening tools, can potentially have a bigger impact on mortality than introducing new 
diagnostic tools, which might not be tailor-made for LMIC settings.  Simple innovations to 
screening tools, through improving the clinician’s understanding of holistic risk, and informing 
differentiated early ART and TB management algorithms, can maximize impact of available 
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10.1. Appendix 1. Published XPRES protocol
STUDY PROTOCOL Open Access
Implementation of a pragmatic, stepped-
wedge cluster randomized trial to evaluate
impact of Botswana’s Xpert MTB/RIF
diagnostic algorithm on TB diagnostic
sensitivity and early antiretroviral therapy
mortality
Andrew F. Auld1*, Tefera Agizew2, Sherri Pals1, Alyssa Finlay2,3, Ndwapi Ndwapi4, Rosanna Boyd2,3,
Heather Alexander1, Anikie Mathoma2, Joyce Basotli2, Sambayawo Gwebe-Nyirenda2, James Shepherd2,5,
Tedd V. Ellerbrock1 and Anand Date1
Abstract
Background: In 2012, as a pilot for Botswana’s national Xpert MTB/RIF (Xpert) rollout plans, intensified tuberculosis
(TB) case finding (ICF) activities were strengthened at 22 HIV treatment clinics prior to phased activation of 13 Xpert
instruments. Together, the strengthened ICF intervention and Xpert activation are referred to as the “Xpert
package”.
Methods: The evaluation, called the Xpert Package Rollout Evaluation using a Stepped-wedge design (XPRES), has
two key objectives: (1) to compare sensitivity of microscopy-based and Xpert-based pulmonary TB diagnostic
algorithms in diagnosing sputum culture-positive TB; and (2) to evaluate impact of the “Xpert package” on all-cause,
6-month, adult antiretroviral therapy (ART) mortality. A pragmatic, stepped-wedge cluster-randomized trial design
was chosen. The design involves enrollment of three cohorts: (1) cohort R, a retrospective cohort of all study clinic
ART enrollees in the 24 months before study initiation (July 31, 2012); (2) cohort A, a prospective cohort of all
consenting patients presenting to study clinics after study initiation, who received the ICF intervention and the
microscopy-based TB diagnostic algorithm; and (3) cohort B, a prospective cohort of all consenting patients
presenting to study clinics after Xpert activation, who received the ICF intervention and the Xpert-based TB
diagnostic algorithm. TB diagnostic sensitivity will be compared between TB culture-positive enrollees in cohorts A
and B. All-cause, 6-month ART-mortality will be compared between cohorts R and B. With anticipated cohort R, A,
and B sample sizes of about 10,131, 1,878, and 4,258, respectively, the study is estimated to have >80 % power to
detect differences in pre-versus post-Xpert TB diagnostic sensitivity if pre-Xpert sensitivity is ≤52.5 % and post-Xpert
sensitivity ≥82.5 %, and >80 % power to detect a 40 % reduction in all-cause, 6-month, ART mortality between
cohorts R and B if cohort R mortality is ≥13/100 person-years.
(Continued on next page)
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Discussion: Only one small previous trial (N = 424) among ART enrolees in Zimbabwe evaluated, in a secondary
analysis, Xpert impact on all-cause 6-month ART mortality. No mortality impact was observed. This Botswana trial,
with its larger sample size and powered specifically to detect differences in all-cause 6-month ART mortality,
remains well-positioned to contribute understanding of Xpert impact.
Trial registration: Retrospectively registered at ClinicalTrials.gov: NCT02538952.
Keywords: Xpert MTB/RIF, Diagnostic accuracy, Sensitivity, Antiretroviral therapy, People living with HIV, Mortality,
Stepped-wedge cluster randomized trial, Botswana
Background
In Botswana, as in the rest of sub-Saharan Africa,
undiagnosed tuberculosis (TB) or TB diagnosed late in
the course of disease is thought to be the most common
cause of death among persons living with HIV (PLHIV),
whether they are receiving antiretroviral therapy (ART)
or not, with TB accounting for about 40 % of deaths ac-
cording to a recent meta-analysis of pathological autopsy
studies [1]. Although antiretroviral therapy (ART) re-
duces risk of all-cause mortality among PLHIV, early
mortality in the first 3–6 months after ART initiation re-
mains high in sub-Saharan Africa and is commonly due
to undiagnosed TB or TB diagnosed late [2–4].
Reasons for failure to diagnose TB early among PLHIV
can be categorized as patient-related or health facility-
related. Patient-related reasons include: (1) failure to
present to a health facility when symptoms arise, which
may be due to poor access to health care or cultural
norms that delay health-seeking behavior [5], and (2)
absence of TB symptoms among late presenters with
advanced immune suppression because TB symptoms
are dependent on both bacillary burden and immune
response [6].
Healthcare facility-related reasons for missed or late
TB diagnoses among PLHIV include: (1) failure of
healthcare workers (HCW) to screen for TB symptoms
[7–9]), (2) failure of HCWs to request sputum or other
diagnostic samples from symptomatic patients [10], (3)
inability to collect high quality sputa or other appropri-
ate diagnostic samples from symptomatic patients [11],
(4) insensitive TB diagnostics, with smear microscopy
alone having a sensitivity of about 45 % in diagnosing
culture-positive disease among PLHIV [12], (5) inability
to diagnose drug-resistant TB timeously [13], and (6)
long turn-around times for some TB diagnostic tests or
failure to return results to clinicians and patients [14].
In 2009, the commercial release of the Xpert MTB/
RIF assay (Xpert) for the GeneXpert platform repre-
sented an important breakthrough in TB diagnostics.
With features including sensitivity of about 79 % in diag-
nosing culture-positive TB from sputum samples among
PLHIV [15], significantly superior to smear microscopy
[12], ability to detect rifampicin resistance-conferring
mutations, capacity to run the test on sputum samples
within 100 min after brief sample processing, and minimal
laboratory training requirements, Xpert significantly ad-
vanced TB diagnostic capability for clinicians managing
PLHIV, especially in resource-limited settings (RLS) [16].
However, Xpert on its own, cannot solve all the facility-
level challenges to diagnosing TB [17]. Strengthening of
the entire TB symptom screening and diagnostic algo-
rithm is needed for Xpert to have maximum impact on
patient health outcomes in most RLS [17].
Therefore, in 2012, the Botswana Ministry of Health
(MOH) and the United States Centers for Disease
Control and Prevention (CDC), designed a package of
intensified TB case finding (ICF) interventions to be
rolled out prior to, and in coordination with, the phased
activation of 13 Xpert devices in support of 22 HIV care
and treatment clinics.
The package of ICF interventions included: (1) ensur-
ing the 22 HIV care and treatment clinics adopted the
World Health Organization (WHO)-recommended four-
symptom TB screen for adults (>12 years old as defined
by the HIV care and treatment program); (2) situating
trained TB case-finding nurses in all 22 facilities to im-
plement the screening and diagnostic algorithms; and (3)
training TB case-finding nurses and other health facility
personnel in both smear-microscopy-based and Xpert-
based TB diagnostic algorithms for adults and children.
The combination of the ICF interventions and rollout of
the Xpert device is referred to as the “Xpert package” in
this report.
To evaluate the accuracy of the new MOH-proposed
Xpert diagnostic algorithm and also the impact of the
whole Xpert package on patient outcomes, a pragmatic,
stepped-wedge cluster-randomized trial (CRT), referred
to as the Xpert Package Rollout Evaluation using a
Stepped-wedge design (XPRES), was initiated. In this
paper, the protocol-specified key study objectives, design
rationale, sample size, key procedures, and analytic
approaches are described. In addition, the evolution of
power estimates over time as real-time study enrollment
numbers became available, and key amendments to
study procedures, which were needed to adapt to oper-
ational challenges, are described.




The first objective of the evaluation is to determine
whether the new MOH-recommended Xpert-based pul-
monary TB diagnostic algorithm (including Xpert testing
of sputum samples for all patients screening positive
(i.e., presumptive TB patients) and chest x-ray for Xpert-
negative presumptive TB patients) is more sensitive than
the pre-Xpert smear-microscopy-based algorithm (smear
microscopy and chest x-ray for smear-negative presump-
tive TB patients) in diagnosing culture-positive TB dis-
ease among adult PLHIV. Although it is expected that
the Xpert-based TB diagnostic algorithm will be both
more sensitive and more specific than the pre-Xpert al-
gorithm, superiority of the Xpert algorithm has not yet
been demonstrated in Botswana and thorough evalu-
ation of the accuracy of the new diagnostic algorithm is
important to guide future investments [18, 19].
The second objective is to evaluate the impact of the
whole Xpert package on all-cause mortality during the
first six months of ART, among adult PLHIV. With an
estimated 40 % of early ART deaths due to undiagnosed
TB or TB diagnosed late, the Xpert package could con-
ceivably reduce all-cause, 6-month ART mortality by en-
suring: (1) that all ART enrollees are appropriately
screened for TB symptoms before and during ART, and
(2) that presumptive TB patients have access to a sensi-
tive TB test (Xpert) and early TB treatment where war-
ranted [20]. Only one small trial (N = 424) in Zimbabwe
has previously aimed to examine the impact of Xpert-
versus microscopy-based TB diagnostic algorithms on 6-
month ART mortality [21]; no difference in early ART
mortality was noted between study arms, however, the
small sample size and high rates of empiric TB treat-
ment in both study arms limit study findings.
Study design rationale
A pragmatic stepped-wedge CRT design was chosen be-
cause: (1) Xpert device activation was most feasibly
achieved for an entire district TB laboratory, which often
served more than one health facility; this fact made an
individual randomized controlled trial (RCT) design less
desirable [19], (2) according to WHO guidance [22] and
MOH guidelines [23], the Xpert device was expected to
be beneficial for both patients and providers, and there-
fore it was considered ethically sub-optimal to imple-
ment a parallel group CRT, where certain district TB
labs and their associated clinics were denied access to
Xpert for an extended period of time [12, 24], (3) the
phased rollout of Xpert provided logistical advantages,
because it meant that a single site activation team, in
charge of training and activation of the Xpert device,
could sequentially initiate all study sites [24], (4) the
need for only a single site activation team reduced
projected study cost, (5) program managers and funders
were interested in assessing accuracy of the Xpert diag-
nostic algorithm in a real-world environment rather than
trying to assess accuracy in a tightly controlled research
environment, with limited external validity [25], (6) in a
real-world setting, the sequential rollout of an interven-
tion allows lessons learned during earlier steps to be ap-
plied during later steps, and (7) a stepped-wedge design
provides analysis options that allow for the control of
trends over time [26, 27].
Study design description
Figure 1 summarizes the study design. This step-wedge
design involved enrollment of three cohorts: (1) retro-
spective cohort (R), shaded in red in Fig. 1, (2) prospect-
ive cohort A (enrolled pre-Xpert device rollout), shaded
in yellow in Fig. 1, and (3) prospective cohort B (en-
rolled post-Xpert device rollout), shaded in green in
Fig. 1. For cohort R, all patients who initiated ART at
one of the 22 HIV clinics for the first time in the
24 months before study start (i.e., before July 31, 2012),
were eligible for enrollment. For cohort A, all patients
who attended one of the 22 HIV clinics for the first time
after study start (July 31, 2012), but before Xpert device
rollout, were eligible for enrollment. For cohort B, all pa-
tients who attend one of the 22 HIV clinics for the first
time after Xpert device rollout were eligible.
To answer the first primary study question, sensitivity
of the pre-Xpert TB diagnostic algorithm in prospective
cohort A will be compared with the post-Xpert algo-
rithm sensitivity in prospective cohort B. Figure 2 de-
scribes the differences in TB diagnostic algorithms
between cohorts A and B and how sensitivity propor-
tions will be determined.
To meet the second key study objective (comparison
of pre- versus post-Xpert package all-cause ART mortal-
ity), all-cause 6-month ART mortality rates will be com-
pared between the retrospective cohort (cohort R) and
the post-Xpert prospective cohort (cohort B). Since the
cohorts being compared (cohorts R and B) do not over-
lap in a phased manner that would allow for controlling
for secular trends according to analytic approaches rec-
ommended by Moulton et al [26] or Hussey & Hughes
[27], this analysis approach is best characterized as a be-
fore and after comparison. However, secondary analyses,
comparing 6-month ART mortality, and other ART out-
comes, between cohorts A and B will make use of the
stepped-wedge portion of the trial and analytic ap-
proaches recommended by Moulton et al [26] and
Hussey & Hughes [27] to control for secular trends.
Interventions
As described above, Fig. 2 illustrates the differences be-
tween the microscopy-based algorithm used in cohort A
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(pre-Xpert device rollout), and the Xpert-based algo-
rithm used in cohort B (post - Xpert device rollout).
For the second key question, comparing all-cause 6-
month ART mortality in cohort R with cohort B, Table 1
summarizes the differences between cohort R and B in
terms of TB case finding and patient management activ-
ities. Notably, in addition to implementing ICF activities,
study nurses were responsible for tracing prospectively
enrolled patients (patients in cohorts A and B) who were
≥1 day late for a clinic appointment through up to five
telephone calls and two home visits to return patients to
HIV care. Indicators measuring compliance with all in-
terventions, including implementation of the appropriate
TB diagnostic algorithm and the tracing intervention,
will help inform discussions of causal pathways during




The main reason for selecting the 22 facilities in Table 2
is that they are considered by study investigators and
MOH to be representative of facilities in Botswana in
terms of TB case finding capacity and ART service deliv-
ery. Study facilities consist of five district hospitals and
17 primary healthcare clinics (PHCs). Other advantages
of choosing these facilities are: (1) on average they had
anticipated high patient enrollment rates (at 33 patients/
month/clinic), which helped meet the desired study
power (see below), (2) one clinic (Gantsi, in Western
Botswana) is estimated to have high prevalence of multi-
drug resistant TB among HIV clinic enrollees and so
could benefit from early rollout of the Xpert device per
WHO recommendations [22], and (3) all 22 clinics had
at least one year’s experience in providing ART services
by the time of study start. Table 2 summarizes the study
facilities chosen for XPRES.
Study patients
For the retrospective cohort, all patients starting ART in
the 24 months before study start, except for prisoners,
were eligible for chart abstraction to estimate all-cause
ART mortality rates. For the prospective cohorts (A and
B), all patients, who met consent requirements, register-
ing for HIV care for the first time at the facility in the
19 months after study start, were eligible for enrollment,
except for prisoners. Prisoners were excluded because it
would be difficult to obtain comprehensive retrospective
cohort data for cohort R, due to frequent unscheduled
prisoner movement during incarceration, and difficult to
retain prisoners in cohorts A and B for the study’s dur-
ation. Children (<12 years of age) were eligible for pro-
spective enrollment, if their assent and guardian’s
consent were provided, because secondary study ques-
tions aim to estimate Xpert algorithm sensitivity for chil-
dren and its impact on pediatric ART outcomes.
Randomization procedures
Because some of the clinics use the same TB diagnostic
facility, Xpert activation was simultaneous for these
clinic consortiums (Table 2). For scheduling purposes
and because clinic staff rotations occurred at the end of
Fig. 1 Study design for the Xpert package rollout evaluation using a stepped wedge design (XPRES)
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Fig. 2 Comparison of pre-X pert and Xpert-based TB diagnostic algorithms in adults
Auld et al. BMC Infectious Diseases  (2016) 16:606 Page 5 of 14
341
calendar months, each step in the stepped-wedge design
needed to be equivalent to one calendar month. In
addition, because the MOH and partners wanted the 13
Xpert devices to be operational and serving patients in
nine months rather than 13 months, there was a need to
initiate two Xpert devices during a single step for four of
the nine steps. Taking into consideration constraints in
Xpert device assignments to clinics (see Table 2 and
Fig. 1), there were 9! (362,880) possible permutations of
the order of Xpert rollout. The study statistician ran-
domly selected one of these permutations [28].
Sample size and power—first key objective
Funding availability limited the prospective enrollment
duration to 19 months at the 22 study facilities. MOH
monitoring data reported an average of 23 new ART-
eligible patients enrolling in each facility per month and
investigators estimated there were 10 new ART-
ineligible patients enrolled per month at each facility
(i.e., potentially 33 study-eligible patients/month/clinic).
To be conservative with sample size estimates, we as-
sumed that only 70 % of study-eligible patients would
agree to prospective enrollment in the study (i.e., 23
study patients/month/clinic), giving anticipated cohort A
and B sample sizes of 3,266 and 6,348, respectively (N =
9,614). Since the vast majority of patients (>99 %) at
these study clinics were adults (≥12 years old), for the
purpose of sample size calculations, we assumed all
9,614 prospective enrollees would be adults.
Based on a published meta-analysis, we estimated that
about 49 % of new adult HIV clinic enrollees would
screen positive for TB [29], and that about 33 % of those
screening positive would have culture-confirmed TB,
giving an overall active TB prevalence among adult study
enrollees of about 16.2 % [30–35]. Our literature review
suggested true active TB prevalence among adult PLHIV
entering HIV care ranged from 7.1 % in Ethiopia [34] to
31.5 % in South Africa [33]; since Botswana has a higher
TB case notification rate (about 470/100,000 population)
than Ethiopia (about 224/100,000 population) but a
lower TB case notification rate than South Africa (about
860/100,000 population), our estimate of adult active TB
prevalence of 16.2 % at HIV care entry in Botswana was
considered reasonable [36–38]. Further literature review
suggested that the pre-Xpert, microscopy-based TB diag-
nostic algorithm sensitivity might be as high as 62.5 %
Table 1 Comparison of TB case finding and patient management interventions for PLHIV in the retrospective and prospective cohorts
Retrospective (R) Prospective pre-Xpert (A) Prospective post-Xpert (B)
TB screening algorithm for
adults
1. Cough of any duration
2. Fever of any duration
3. Shortness of breath
4. Chest pain
5. Haemoptysis
6. Loss of appetite









3. Loss of weight
4. Night sweats
Number of sputa collected
from patients suspected of
having TB
2 spot sputa 4 (2 spot sputa on day 1, 1 morning
sputum on day 2, and one spot sputum
on day 2)
4 (2 spot sputa on day 1, 1 morning




Estimated to be low High High
Specialized TB case finding
nurses support TB case
finding activities
No Yes Yes
Regular training for clinic




Microscopy + chest X-ray for
smear-negative suspects
Microscopy + chest X-ray for smear-
negative suspects
Xpert + chest X-ray for Xpert-negative
suspects
Gold standard TB
diagnostic test (MGIT) at
national TB reference
laboratory (NTRL)
Infrequent utilization of MGIT
liquid TB culture at NTRL
MGIT liquid TB culture for all patients
suspected of having TB. Prior to culture,
fluorescent microscopy was conducted
at NTRL.
MGIT liquid TB culture for all patients
suspected of having TB. Prior to culture,
fluorescent microscopy was conducted
at NTRL.
TB drug resistance Infrequent requests for TB drug
resistance tests.
All positive MGIT TB cultures received: (1)
LPA, (2) Phenotypic culture-based DST.
All positive MGIT TB cultures received: (1)
LPA, (2) Phenotypic culture-based DST.
Patient tracing
interventions in place
Irregular attempts to trace
patients late for clinic
appointments through telephone
calls and home visits.
Tracing of patients late for clinic
appointments through telephone calls
and home visits.
Tracing of patients late for clinic
appointments through telephone calls
and home visits.
Abbreviations: ICF intensified TB Case Finding, TB tuberculosis, MGIT mycobacteria growth indicator tubes, LPA line probe assay, DST drug susceptibility testing
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[34], and that Xpert algorithm sensitivity among symp-
tomatic PLHIV could be about 82.5 % based on data
from a recent multi-country Xpert accuracy study [12].
To estimate power, data were simulated according to the
stepped-wedge design, using the beta-binomial model to
induce the intra-cluster correlation coefficient. One thou-
sand datasets were simulated and a mixed model appropri-
ate for the stepped-wedge design fit to the data, as
described by Hussey and Hughes [27], that included fixed
effects for time and intervention condition (0 for time
points before Xpert implementation and 1 afterward), and
a random effect for the clinic, to take into account
between-clinic variability. For protocol-specified sample
sizes (N = 9,614), and assuming culture-positive TB preva-
lence of 16.2 % at study entry, and pre-versus post-Xpert
sensitivity comparisons of 62.5 % vs. 82.5 %, we had 99.6 %
power. In multiple simulations, pre-Xpert sensitivity was
varied from 55 % to 62.5 % and post-Xpert sensitivity from
70 % to 82.5 % and the study had >80 % power to detect
the intervention effect across all simulated scenarios.
After study initiation, monitoring data, prepared by
study nurse supervisors during supervision visits, re-
vealed that actual monthly HIV clinic enrollment
numbers were lower than expected (about 21 pa-
tients/clinic/month instead of 33 patients/clinic/
month). In addition, study nurses were only able to
enroll about 72 % of study-eligible patients at the
clinic, mostly because patients were not willing to
wait while the study nurse completed enrollment of
other patients, a process which took about 1 h/enrol-
lee. Therefore, prospective enrollment occurred at about
15/month instead of the protocol-specified 23/month. In
addition, the proportion of adult patients screening posi-
tive for TB at prospective cohort enrollment was lower
than expected (24 % instead of 49 %), and the proportion
of those screening positive, who were diagnosed with
culture-positive TB, was lower than expected (17 % in-
stead of 33 %), giving a much lower culture-positive TB
prevalence at enrollment than was originally expected
(about 4 % instead of 16 %).
Table 2 Selected study sites for the Xpert package rollout evaluation using a stepped-wedge design (XPRES)
District Fixed consortiums Clinic names Pre-study estimates of no.
new ART patients/month
Xpert location
Ngami (Maun) fixed triplet Letsholathebe II Memorial Hospital 36 1 × Lab Xpert
Ngami (Maun) Boseja Clinic 28
Ngami (Maun) Maun Clinic 28
Gaborone fixed pair Brodhurst Traditional Clinic 35 1 × Lab Xpert
Gaborone Bontleng Clinic 45
Francistown fixed pair Botswelelo Clinic 22 1 × Lab Xpert
Francistown Area W Clinic 22
Francistown single facility Nyangabgwe Referral Hospital 18 1 × Lab Xpert
Kweneng East-Molepolole fixed quadruplet Borakalalo Clinic 9 1 × POC Xpert
Kweneng East-Molepolole Kgosing Clinic 8
Kweneng East-Molepolole Molepolole Central Clinic 8
Kweneng East-Molepolole Phuth-kobo Clinic 8
Kweneng East-Mogoditsane single facility Nkoyaphiri Clinic 46 1 × POC Xpert
Palapye fixed pair Ext 3 Clinic 20 1 × POC Xpert
Palapye Lotsane Clinic 20
Bobirwa single facility Bobonong Primary Hospital 38 1 × Lab Xpert
Kanye single facility SDA Hospital 22 1 × Lab Xpert
Gantsi single facility Gantsi Clinic unknown* 1 × Lab Xpert
Kgatleng single facility Deborah Memorial Hospital 26 1 × Lab Xpert
Lobatse single facility Athlon Clinic 18 1 × Lab Xpert
Serowe District fixed pair Kadimo Clinic 12 1 × POC Xpert
Serowe District Serowe Clinic 12
Total (22 clinics) 479 13
Average per clinic 23
Abbreviations: POC point of care, Xpert Xpert MTB/RIF, lab laboratory, ART antiretroviral therapy
*Routine monitoring data on rate of enrollment of antiretroviral therapy patients was not available at the time of study initiation for this clinic
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Lower numbers of culture-positive TB cases/clinic/
month (1/clinic/month instead of 4/clinic/month)
resulted in inability to fit the stepped-wedge model
to all simulated datasets. Therefore, the power esti-
mation approach was simplified and Fisher’s Exact
Test for comparing two proportions (pre-and post-
Xpert) in SAS version 9.2. software (SAS Institute
Inc., Cary, NC) was used to estimate study power.
Power estimates were then adjusted for the expected
design effect to account for intra-cluster correlation.
For design effect calculations, an intra-class correl-
ation of 0.05 was assumed [28]. Input estimates for
TB prevalence at HIV care enrollment and TB diag-
nostic sensitivity were varied to understand impact
on study power (Fig. 3). As illustrated in Fig. 3,
sample size and TB prevalence shortfalls meant we
only had about 75.4 % power to detect the protocol-
specified difference in sensitivity (62.5 % vs. 82.5 %)
if active TB prevalence at enrollment was 4 %. How-
ever, we would have >80 % power to detect pre-
versus post-Xpert TB diagnostic sensitivities at a
culture-positive TB prevalence of 4 % if pre-Xpert
sensitivity was ≤52.5 % and post-Xpert sensitivity
≥82.5 % (Fig. 3). Because available National TB
Reference Laboratory (NTRL) monitoring data sug-
gested pre-Xpert TB diagnostic sensitivity was
≤52.5 % and Xpert sensitivity ≥82.5 %, the study was
considered still well powered to answer the first key
study question at quarterly reviews conducted by the
study sponsor.
Sample size and power—second key objective
To estimate power for the comparison of all-cause 6-
month mortality in the retrospective cohort (cohort R)
versus the post-Xpert prospective cohort (cohort B), the
approach of Moulton et al, suitable for stepped-wedge
trial designs, was chosen because these power estimates
were more conservative than those derived from a pre-
post sample size calculation [26]. Per this approach,
published formulae for the comparison of two rates in
an unmatched parallel group CRT [39] were adapted to
the stepped-wedge design as follows:
Zβ ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
c−1ð Þ rc−rtð Þ2




where Zβ is the standard normal deviate corresponding
to the upper tail probability of β and β is the probability
of a Type II error; c is the number of clusters (study fa-
cilities) per arm, where, since this is a stepped-wedge
trial involving 22 clinics, 22/2 was used [26]; rc is the es-
timated true 6-month ART mortality rate in the pre-
intervention control phase (cohort R); rt is the estimated
true mortality rate in the post-intervention phase (co-
hort B); yc is the average number of person-years (PYs)
per clinic in the control phase, estimated as the average
retrospective cohort size per clinic (552) divided by two
since each patient commits 6 months of follow-up time
to the analysis; yt is average number of PYs per clinic in
the intervention phase, conservatively estimated as
the harmonic mean of PYs contributed by each study
Fig. 3 Figure showing power to detect a difference in TB diagnostic algorithm sensitivity pre- versus post-Xpert over a range of culture-positive
TB prevalence rates at study enrollment according to actual prospective cohort sample size (N = 6,136)
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site in cohort B, again assuming 6 months of follow-
up time per participant [26]; k is the estimated
between-cluster coefficient of variation of the true
rates in both the control and intervention phases, es-
timated as 0.2 [26]; Za/2 is the standard normal devi-
ate corresponding to the upper tail probability of a/2
where a is the probability of a Type I error.
Since a log-rank test statistic for intervention effect
calculated for a simulated stepped-wedge trial (ZSW) will
generally always be lower than the corresponding statis-
tic (ZE) for a parallel group trial, because allocation ra-
tios of patients to intervention or control status for
parallel group trials remain equal while for stepped-
wedge trials they are usually unequal, except at the mid-
point of the stepped-wedge design, the z-score in the
stepped-wedge trial formula (Zβ above) was divided by a
published estimate of ZE/ZSW (i.e., 1.2) prior to extrapo-
lating the z-score to a power estimate [26]. Similarly, for
Type 1 error of 5 %, instead of assuming a Zα/2 of 1.96,
an inflated estimate of 2.352 was used, per published
precedent [26].
Prior to study start, available data from Botswana sug-
gested that the documented all-cause early mortality
rates in the first 6 months of ART among adults were
about 15 deaths per 100 PYs [40], which was similar to
estimates from a meta-analyses of 18 programs in RLS
with active tracing programs (14.7/100 PY) [41]. Since
Botswana data, and available meta-analyses suggested
about 40 % of deaths among PLHIV were due to undiag-
nosed TB or TB diagnosed late, and given that interrupt-
ing ART during the first 6 months of therapy by missing
clinic appointments increases mortality risk [42, 43], it
was considered reasonable that the Xpert package plus
the tracing intervention might reduce mortality by about
40 % [2, 44]. According to protocol-specified sample
sizes, the study had >80 % power to detect a difference
in 6-month all-cause ART mortality between cohorts R
and B of 40 % if cohort R mortality was ≥10/100 PYs
(Fig. 4). According to anticipated actual sample sizes, the
study has >80 % power to detect a difference in 6-month
all-cause ART mortality between cohorts R and B of
40 % if cohort R mortality is ≥13/100 PYs (Fig. 4).
Study procedures related to first key objective
For prospective cohort enrollment, all new HIV clinic
enrollees were informed about the study, and if inter-
ested, offered the opportunity to enroll following the
Institutional Review Board (IRB)-approved consent
process. An enrollment questionnaire collected import-
ant baseline demographic and clinical information, and a
patient locator form was used to document telephone
numbers and home addresses for patient retention activ-
ities. Adult patients screening positive for TB were asked
to provide four sputa, two collected simultaneously the
day of enrollment (referred to as “spot” sputa), and two
the following day. Of the two sputa provided the second
day, one was a morning sputum prepared by the patient
soon after waking up, and the other a spot sputum pro-
vided upon arrival at the clinic. Additional file 1 shows a
poster used by study nurses to inform the patient how
to produce a good sputum. The poster also illustrates
important infection control precautions (e.g., preparing
Fig. 4 Power to detect a 40 % and 50 % difference in all-cause 6-month ART mortality between pre-Xpert retrospective and post-Xpert prospective
cohort enrollees over a range of pre-Xpert mortality rates
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spot sputa in a well-ventilated, but still private, “cough
spot” outside the clinic). If a patient screening positive
for TB was unable to spontaneously produce sputa,
MOH-recommended sputum-induction procedures were
encouraged if there were no contra-indications [23]. For
children <12 years old, who were unable to produce
sputa spontaneously and were too young for induction
(i.e., <5 years old), naso-gastric tube aspirates were rec-
ommended per MOH guidelines [23]; however, very few
children <5 were expected to enroll in the study.
Spot sputa numbers one and three were sent to the
on-site or peripheral district TB lab for: (1) smear mi-
croscopy, and (2) Xpert, if the Xpert device had been ac-
tivated by that time. Spot sputum 2 and the morning
sputum were sent to the NTRL for: (1) fluorochrome
acid fast bacilli (AFB) smear microscopy on concen-
trated specimens, (2) liquid culture in mycobacteria
growth indicator tubes, (3) confirmation of any myco-
bacterial growth as Mycobacterium tuberculosis (MTB)
or non-tuberculous mycobacteria through Ziehl-Neelsen
staining, blood agar plate, and immunochromatographic
assays, (4) line probe assay testing for isoniazid and ri-
fampicin resistance on MTB-positive cultures, and (5)
phenotypic culture-based drug susceptibility testing on
MTB-positive cultures. All test results were returned to
study nurses with recommended maximum turnaround
times from the time of sample collection to result return
to the nurse being four days for smear microscopy at the
peripheral lab, 10 days for flourochrome smear micros-
copy at the NTRL, two days for Xpert testing regardless
of Xpert location, and 49 days for liquid culture results
from the NTRL. Nurses were encouraged to inform pa-
tients of positive TB diagnoses the same day via phone,
although, if the patient was unreachable by phone, the
patient was informed at the next scheduled clinic
appointment.
For the first 17 months of study conduct, all prospect-
ively enrolled patients consented to 12 months of
follow-up but this was shortened to 6 months of follow-
up in December 2013 (17 months into study enroll-
ment), in an attempt to reduce burden on study nurses.
Study procedures related to second key objective
Enrollment of the retrospective cohort (cohort R) was
through chart abstraction of eligible patients who started
ART in the 24 months before study initiation at one of
the 22 study clinics. Chart abstraction procedures were
similar to procedures described in previous studies [45].
Data on important demographic and clinical characteris-
tics were abstracted to maximize opportunities to ex-
plore and control for confounding, when estimating
impact of the Xpert package on all-cause mortality.
Since loss to follow-up (LTFU) from ART can account
for as much as 75 % of all attrition (death plus LTFU) in
ART programs, and because incidence of death follow-
ing LTFU ranges from 20 % to 60 % and failure to adjust
mortality estimates for death among LTFU patients
could bias estimates of intervention effect [40, 46], tra-
cing patients LTFU was considered essential to answer
the second key question. Tracing for mortality ascertain-
ment purposes, was conducted through two methods in
all cohorts. Firstly, up to five telephone calls and two
home visits were used to determine outcomes of patients
LTFU; in the retrospective cohort this occurred follow-
ing documentation that the patient was >90 days late for
a scheduled appointment, whereas in the prospective co-
hort this tracing started the day following a missed ap-
pointment. Secondly, all patients that remained LTFU
following telephonic and home visit tracing activities
were searched for in Botswana’s national mortality
database.
Since about 2,429 (28 %) of 8,565 patients eligible for
the prospective cohort did not enroll due to logistical
constraints (see above), a protocol amendment was ap-
proved in April 2014, that allowed retrospective chart
abstraction of the missed prospective patients. By
abstracting key baseline data (e.g., baseline CD4 count)
and outcome data (e.g., vital status) on the 2,429 missed
patients, investigators will be able to: (1) estimate if the
prospective cohort is truly representative of new HIV
clinic enrollees at the 22 study sites during study con-
duct, and (2) use appropriate methods to explore effect
of non-response [47].
Analytic methods
For the first key study question, we will employ a mixed-
model approach similar to that presented by Hussey and
Hughes (2007) [27]. A generalized linear mixed model
will be fit to the data. The dependent variable is dichot-
omous, indicating whether the diagnostic algorithm de-
tected TB or not (only those with true TB detected by
liquid culture will be included in the sensitivity analysis).
A fixed effect for time will be included in the analysis to
adjust for any time trends that might bias the pre-post
comparison. A fixed effect for intervention condition (0
before Xpert implementation, 1 afterward) will also be
included and is the test of the intervention effect. A ran-
dom effect for clinic will be included to adjust for
between-clinic variation. The intervention effect will be
judged significant at p < 0.05 with a two-tailed test.
For the second key question, crude and multivariable
Cox proportional hazards regression models, accounting
for study design, will be fit to the data with a fixed effect
specified for intervention status, and random effect for
clinic [28]. Since there are three levels to the interven-
tion, with cohort R receiving standard of care, cohort A
receiving the ICF intervention, and cohort B receiving
the ICF intervention plus the Xpert diagnostic
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algorithm, intervention effect will be coded as a three-
level variable to represent the three study phases. Al-
though the protocol-specified primary question aims to
compare 6-month mortality in cohort R versus cohort B,
investigators will examine for any dose-response effect
across cohorts R, A, and B, which could add data to in-
form interpretation of causal pathways [48]. Importantly,
the analysis will need to control for trends over time.
Several reports from RLS, including Botswana [49], have
reported improvements in baseline health status at ART
initiation (e.g., higher median CD4 counts) and lower in-
cidence of 6-month ART mortality over successive an-
nual cohorts of ART enrollees. As described earlier,
because cohorts R and B do not overlap during the
stepped-wedge portion of this trial, a comparison of 6-
month mortality rates in cohorts R and B cannot make
use of the stepped-wedge design to control for secular
trends [26]. However, since most variation in 6-month
ART mortality over successive annual ART cohorts is
accounted for by changes in health status of ART enrol-
lees (e.g., changes in baseline CD4 count), incorporation
of these known risk factors for 6-month ART mortality
into the multivariable model may fully account for secu-
lar mortality trends [7, 50].
In a secondary analysis, that excludes cohort R, we will
compare 6-month ART mortality rates between cohorts
A and B using analytic methods described by Moulton
et al, fitting Cox proportional hazards models to the data
with the underlying time frame being time since July
2012 (initiation date for the stepped-wedge component
of the trial), fixed effect for intervention arm (Xpert de-
vice activation), and a random effect for clinic [26, 51].
We will also explore an alternate analytic approach, rec-
ommended by Hussey & Hughes, which utilizes a Poisson
model, including fixed effect for intervention and time
interval, and a random effect for cluster [27].
Ethical considerations
This research study was reviewed and approved by the
CDC IRB C, the Health Research and Development
Division of the Human Resource Development Council
(HRDC) in Botswana, and the University of Pennsylvania
IRB No.4. XPRES is registered at ClinicalTrials.gov (trial
registration no. NCT02538952).
Trial status
Prospective cohort enrollment started in July, 2012 and
was completed by the end of March 2014. Retrospective
cohort chart abstraction was complete by December
2015. Data entry is estimated to be complete by the end
of September 2016. Data analysis for the primary study
questions has not yet begun. Trial data will be reported
according to published guidelines for cluster-randomised
trials (Additional file 2).
Discussion
The over-arching purpose of this project is to improve TB
diagnostic and care services at 22 HIV care and treatment
clinics through phased rollout of (1) strengthened ICF sys-
tems, and (2) 13 Xpert devices, while simultaneously an-
swering important implementation science questions,
concerning Xpert operationalization and impact.
The stepped-wedge study design was chosen for a
number of reasons related to ethical, operational, and
analytic needs, as described in the method’s section.
During the course of study implementation, the oper-
ational advantages of the phased implementation ap-
proach have been particularly notable. In our RLS of
Botswana, the phased implementation approach has
allowed the limited human and financial resources to be
focused on smaller, more manageable pieces of the
whole project, one step at a time, rather than be spread
thinly across study sites, as would be required in a paral-
lel group CRT [19]. Analytically, the stepped-wedge de-
sign allows multiple opportunities for controlling trends
over time [26]. Potential disadvantages, when compared
with a parallel group CRT, include: (1) moderately lower
ability to assign causality to the intervention, and (2)
higher sample size requirements in most circumstances,
because of unequal allocation ratios for most of the dur-
ation of stepped-wedge trials [19]. The ethical, oper-
ational, and analytic advantages may help explain the
increasing popularity of the stepped-wedge evaluation
design, especially in RLS [24].
During trial conduct, several operational challenges
were experienced, mainly related to lower than expected
clinic enrolment rates, human resource constraints that
reduced ability to enroll all study-eligible patients in the
prospective cohort, and lower than expected prevalence
of culture-positive TB at clinic enrollment. The declining
HIV clinic enrolment rates probably reflect success of
the HIV treatment program in reaching HIV-infected
persons in prior years (i.e., during 2002–2011) [49], de-
clining HIV incidence rates [52], and expanding num-
bers of alternate HIV clinics at which patients can
receive care [49]. The study team probably over-
estimated the willingness of patients to wait at the clinic
for their turn to enroll in the study. However, in
response to the observation that 28 % of potentially
study-eligible patients were not being enrolled in the
prospective cohort, the study team wrote a protocol
amendment that allowed retrospective chart abstraction
for the missed prospective patients, which will allow
investigators to quantify any potential selection bias in-
curred by non-response. The lower than expected preva-
lence of culture-positive TB at HIV clinic enrollment
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needs further investigation once all study data are avail-
able for analysis. Fueled by the HIV epidemic, TB case
notification rates in Botswana increased from about 202/
100,000 population in 1990 to about 600/100,000 in
1998, plateaued at this level during 1998 through 2007,
and have since declined to about 470/100,000 in recent
years [36]. Increased ART coverage among HIV-infected
persons might again explain declining national TB inci-
dence and the lower-than-expected TB prevalence
among HIV clinic enrollees in this study [53]. In retro-
spect, the protocol-specified large sample sizes and
resulting high pre-study power to answer the first two
primary study questions, were important precautions in
place to ensure any sample size shortfalls did not result
in trial futility.
Although, several Xpert impact studies have been pub-
lished after this trial started, the two key study questions
have not yet been answered. Firstly, data validating the
Botswana Xpert diagnostic algorithm have not yet been re-
ported, and this is an important program evaluation activity
[54]. Secondly, among six trials that have compared all-
cause mortality outcomes of study enrollees between
microscopy and Xpert arms [17, 21, 54–57], none have ob-
served Xpert impact on either morbidity or mortality out-
comes, and only one was conducted exclusively among
ART enrollees (Mupfumi et al) [21]. Certain study limita-
tions of the trial by Mupfumi et al, including small sample
size (N = 424) and powering the study to detect differences
in a composite outcome (death or TB) between study arms,
mean that XPRES, with its larger sample size (N = 16,267)
and powered to detect Xpert impact on 6-month mortality
rates specifically, is still positioned to provide a valuable sci-
entific contribution. In addition, the intervention in XPRES
is different from interventions employed in previous Xpert
impact trials [17, 21, 54–59]—it represents a package of
strengthened ICF interventions, activation of the Xpert de-
vice, and improved tracing for patients late for ART clinic
appointments. In real-world settings, ICF interventions are
often implemented at a sub-optimal level of quality and
consistency due to health system weakness [9], and
strengthening health systems to improve ICF compliance is
arguably as important as the rollout of a new TB diagnostic
device [17]. In addition, preventing treatment interruptions
or LTFU during early ART through the tracing interven-
tion, could contribute to reductions in all-cause, 6-month
ART mortality rates [42, 43].
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10.2. Appendix 2. Data collection and consent forms for XPRES 
10.2.1. Information and consent form – prospective adult enrolees (>18 years old at time 
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[Title of the study]: Evaluating Performance, Impact, and Operational Challenges of GeneXpert use for TB 
Case Finding among HIV-infected Persons in Botswana during 2011-2013. 
[Introduction]: 
Hello, my name is………….I am a trained health care provider working with the Ministry of Health of 
Botswana and the United States Centers for Disease Control and Prevention or CDC. I am responsible for 
checking whether you might have the sickness called tuberculosis.  There is also a research study at this 
clinic and I am responsible for managing the research study.  I will explain the research study, but first let 
me tell you about the sickness called TB. 
TB is caused by a germ which is too small to see.  The germ usually lives in a person’s lungs. Coughing is 
one sign that a patient might have TB.  TB is a common disease especially in people living with HIV.  It is 
also a common cause of death amongst people with HIV. Once TB is detected, it can be treated in most 
patients.  Treatment helps patients to feel better and live longer.  However, detecting which people have TB, 
is difficult. 
Recently, a new TB test was developed.  The new test is called “Gene Xpert”.  Gene Xpert is a machine that 
can detect TB germs in a person’s cough sputum.  Sputum is the liquid that a person produces when they 
cough .  The test can be done in less than 24 hours.  GeneXpert is better than TB tests which rely on 
microscopes (microscopes are tools which help people to look at very tiny things like TB germs).   
We are doing a research study to find out the best way to use GeneXpert to detect TB in people living with 
HIV in Botswana.  We think that if we can find the best way to use GeneXpert, we can detect TB infection 
earlier, treat TB earlier and make people healthier.  
The CDC has paid for this research study.  CDC and the Ministry of Health are partners in this study. 
[Reason for Asking the Patient to be Part of the Study] 
We are going to ask if you want to be part of this study.  The reason we are asking you, and not all patients 
at this clinic is that we need patients visiting the clinic for the first time to be in the study.  We think about 
10,000 people will be enrolled in the study in total.  About 500 of these people might be children less than 18 
years old. 
[Procedures] 
If you agree to be in the study, your part in the study will start today.  We will do the following today and 
tomorrow.: 
1. Ask you to sign this paper, showing that you agree to be part of the study.
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2. Ask you some questions like “What is your age?” and “Are you married?”
3. Ask you some questions about whether you are coughing, sweating at night, losing weight, or have a
fever.
4. Review your records prepared by the doctor to get information like your weight, height, and health
history.
5. Ask you for contact details (telephone numbers) so that we can contact you or a friend or a family
member if you miss a future clinic visit.  Note that this is standard practice recommended by the Ministry
of Health and is not something specific to this study.
6. Ask you for your omang number to help us with data collection from your medical records.
7. If you have one of the signs of TB, we will ask you to cough sputum into two cups for us today.  If you
are unable to cough, we may need to assist you by advising you how to produce sputum.
8. Once you have produced the cough sputum, we will ask you to return tomorrow to the clinic.  We will
give you a container to cough into when you wake up tomorrow morning and will ask you to bring the
container with you to the clinic tomorrow.
9. When you arrive at the clinic tomorrow, we will ask for a fourth cup of cough sputum.
10. All sputa will go to laboratories for TB tests, including TB microscopy and culture.
If the GeneXpert test has been set up at the TB lab at the time we collect your sputum, we will test the 
sputum with the GeneXpert device.  (Note that all patients attending the clinic will have access to the 
GeneXpert device, after its set up, even if they are not part of the study). Any left-over sputum at the lab will 
be discarded according to government guidelines.  However, if TB germs are identified, these germs will be 
studied to identify their type and, if you agree, may be used in future studies.  After tomorrow, we will contact 
you by telephone if we find that you have TB and will ask you to come back to the clinic as soon as possible 
to start TB treatment. If you do not have TB, we will ask you to visit with me (the study nurse), each time you 
come to the clinic to see the doctor treating you for HIV.  The clinic visit schedule varies depending on 
whether the doctor recommends you start HIV treatment with drugs called antiretrovirals or not.  If you don’t 
start antiretrovirals, clinic visits will be according to the schedule provided by your doctor.  If you do start 
antiretrovirals, clinic visits will be at 2 weeks, 1 month, 2 months, 3 months and then 3 monthly thereafter.  
At each clinic visit, after you have seen the doctor, you will come to see me (the study nurse) and we will: 
1. Make sure you have the results, which are ready, from your previous sputum tests.
2. Explain the results to you.
3. Ask additional questions about your health.
Record additional data from you medical record. 
Most of the procedures we have just described would occur even if you did not enroll in the study.  However, 
the following procedures will occur only because you agree to be in this study: (1) interview at each clinic 
visit, (2) collection of data from your medical record, (3) 4 instead of 2 sputa collected if you have TB 
symptoms, and (4) testing of your sputum for a drug resistant form of TB. 
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[Time Commitment] 
If you agree to the study, today we will need about an extra hour of your time, in addition to the time you 
would have needed to spend at the clinic if there were no study. 
At each subsequent visit, we will need about half an hour to an hour of your time for the study. 
Your part in the study will end 6 months from the time you agreed to be part of the study, or, if you start TB 
treatment during the next 6 months, and TB treatment ends more than 6 months from now, your part in the 
study will end at the end of TB treatment. 
[Confidentiality] 
As part of the study, we will collect your name and telephone number so that we can contact you if you miss 
an HIV clinic appointment.  However, everything we write down about you will be kept confidential as far as 
possible.  We will store the paper questionnaires in sealed brown envelopes and in locked steel cabinets 
here at the clinic.  When transporting the paper questionnaires to Gaborone, sealed boxes will be used.  The 
questionnaires will be stored in Gaborone in locked steel cabinets and entered into a computer protected by 
a password.  We will not use your name in any printed reports for the study. 
[Risks/Discomfort] 
We do not anticipate any additional health risks due to enrolment in the study.  However, there is small risk 
of loss of privacy.  For example, if you miss a clinic visit, and we cannot reach you by phone, we would like 
to visit your home to find out if there is a problem preventing you attending the clinic.  We will only visit your 
home if you have missed the clinic appointment by more than 7 days and we are unable to reach you or a 
friend by phone. 
[Benefits for You] 
There may be additional health benefits for you due to enrolment in the study because if you have 
symptoms of TB, as part of the study, we will test the sputum for drug resistant TB, a test not routinely 
offered to all patients with TB symptoms.  This might help to identify and treat this form of TB early which 
could improve your health. 
[Benefits for the Program] 
By taking part in the study, you will be helping the Ministry of Health and CDC find the best ways to use 
GeneXpert.  For example, the study may show that GeneXpert works best in district laboratories rather than 
in small peripheral clinics.  This finding would direct future use of GeneXpert in Botswana maximizing the 
usefulness of GeneXpert for future patients. 
[Your Rights] 
You can choose not to take part in the study.  If you choose not to take part in the study, we will still give you 
the standard of care recommended by the Ministry of Health.  There will be no penalties for choosing not to 
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take part. You will also be able to leave the study at any time, without penalty. You may take a copy of the 
consent form with you.  Now, or at any time in the future, you can ask any member of the study team any 
questions about the study.    
[Contact Persons for Additional Information] 
If you have any questions about this study now, please ask us now. 
If you have any questions about this study in the future, please contact.  
 [Dr James Shepherd Principal Investigator at 367-2430]  
If you feel that you have been harmed by this study, please contact [Chawangwa Lesedi Study 
Coordinator at 367-2534 CDC Botswana]  
If you have any concerns about your rights in this study, please contact [Mr. Pilate Khulumani, Health 
Research Development Committee - Ministry of Health at 3632775] 
[Consent] 
If you agree to the following statements, please sign your name below: “I agree to be in this study. The 
information in this consent form has been explained to me.  I have been given a chance to ask questions. I 
feel that all of my questions have been answered.  I know that being in this study is my choice.  I know that 
after choosing to be in this study, I may leave the study at any time.  If I wish to leave this study, I will 
contact the study nurse at my clinic. If I leave this study, I will continue to get regular medical care at this 
clinic or hospital. 
I understand that I will receive a copy of this signed and dated consent form.  By signing and dating this 
consent form, I have not waived any of the legal rights that I would have if I were not a participant in the 
study.” I have read or heard this form read to me.  
By signing below, I consent to join this study.   
By ticking this box  I also agree to let the researchers use any TB germs for future studies. 
____________________________ ____________________________ 
Name of participant Signature or thumb print of participant 
Date: //   [DD/MM/YYYY] 
I verify that the consent form has been read and explained accurately by a member of the study staff. 
____________________________                                ____________________________ 
Name of witness                                                    Signature of witness 
Date: //   [DD/MM/YYYY]      
 Study Staff Administering Consent _____________________________ 
Date: //   [DD/MM/YYYY] 
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10.2.2. Information and consent form for guardians of minors (<18 years) 
Instructions for study nurse only: 
1. The statement should be read to legal guardians of eligible enrolees aged <18 years old.
2. Only read the non-italicized parts.
3. Throughout the process of obtaining consent, it is important that you are patient and allow
the respondent to ask questions and to consider the decision. Never rush or otherwise
pressure the respondent to give consent.
4. Offer a copy of this consent script to all guardians whether they consent to enrolment of the
child in their care or not.
5. Keep the other copy in the consent form folder, locked in a cabinet, at the clinic. (Flesch-
Kincaid Grade Level: 7.7)
See next page for consent form 
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[Title of the study]: Evaluating Performance, Impact, and Operational Challenges of GeneXpert use for 
TB Case Finding among HIV-infected Persons in Botswana during 2011-2013. 
[Introduction]: 
Hello, my name is………….I am a trained health care provider working with the Ministry of Health of 
Botswana and the United States Centers for Disease Control and Prevention or CDC. I am responsible for 
checking whether patients might have the sickness called tuberculosis or TB. .  There is also a research 
study at this clinic and I am responsible for managing the research study.  I will explain the study, but first 
let me tell you about the sickness called TB. 
TB is caused by a germ which is too small to see.  The germ usually lives in a person’s lungs. Coughing is 
one sign that a patient might have TB.  TB is a common disease especially in people living with HIV.  It is 
also a common cause of death amongst people with HIV. Once TB is detected, it can be treated in most 
patients.  Treatment helps patients to feel better and live longer.  However, detecting which people have 
TB, is difficult. 
Recently, a new TB test was developed.  The new test is called “GeneXpert”.  GeneXpert is a machine 
that can detect TB germs in a person’s cough sputum.  Sputum is the liquid that a person produces when 
they cough.  Young children sometimes do not cough up sputum.  Instead, young children often swallow 
it.  The GeneXpert test can be done in less than 24 hours.  GeneXpert is better than TB tests which rely 
on microscopes (microscopes are tools which help people to look at very tiny things like TB germs).   
We are doing a research study to find out the best way to use GeneXpert to detect TB in people living with 
HIV in Botswana.  We think that if we can find the best way to use GeneXpert, we can detect TB infection 
earlier, treat TB earlier and make people healthier. 
The CDC has paid for this research study.  The CDC and the Ministry of Health are partners in this study. 
[Reason for Asking the Patient to be Part of the Study] 
We are going to ask if you will allow the child in your care to be part of this research study.  The reason we 
are asking for your child to be enrolled in the study, and not all patients at this clinic, is that we need 
patients visiting the clinic for the first time to be in the study.  We think about 10,000 people will be 
enrolled in the study in total.  About 500 of these people might be children less than 18 years old. 
[Procedures] 
If you agree for the child in your care to be in the study, the child’s part in the study will start today.  We 
will do the following today and tomorrow: 
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1. Ask you to sign this paper, showing that you agree for the child in your care to be part of the study.
2. Ask you some questions like “What is your child’s age?”
3. Ask you some questions such as whether your child is coughing, sweating at night, losing weight, has
a fever, or has reduced playfulness.
4. Review your child’s records, prepared by the doctor, to get information like your child’s weight, height,
and health history.
5. Ask you for contact details (telephone numbers) so that we can contact you or a friend or a family
member if your child misses a future clinic visit.  Note that this is standard practice recommended by
the Ministry of Health and is not something specific to this study.
6. Ask you for your child’s omang number to help us with data collection from medical records.
7. If your child has one of the signs of TB, we will ask your child to cough sputum into two cups for us
today.  If your child is unable to cough, we may need to advise and encourage your child to cough, or
we may need to use a tube to suck swallowed sputum out of your child’s stomach.
8. Once your child has produced the cough sputum, we will ask you and your child to return tomorrow to
the clinic.  If your child can cough, we will give you a container for the child to cough into when your
child wakes up tomorrow morning.  We will then ask you to bring the container with you to the clinic
tomorrow.  If your child cannot cough, we will collect two sputa tomorrow when you get to the clinic.
9. If your child is <=12 years old, even if he/she has no TB symptoms, we will ask your child to cough in
one sputum container today and one container tomorrow.  If your child is unable to cough, we may
need to advise and encourage your child to cough, but we will not use a tube to suck swallowed
sputum out of your child’s stomach, if he/she has no symptoms of TB.
10. All sputa will go to laboratories for TB tests.
If the GeneXpert test has been set up at the TB lab at the time we collect your child’s sputum, we will test 
the sputum with the GeneXpert device.  (Note that all patients attending the clinic will have access to the 
GeneXpert device, after its set up, even if they are not part of the study).Any left-over sputum at the lab 
will be discarded according to government guidelines.  However, if TB germs are identified, these germs 
will be studied to identify their type and, if you agree, may be used in future studies.   After tomorrow, we 
will contact you by telephone if we find that your child has TB and will ask you and your child to come back 
to the clinic as soon as possible to start TB treatment. If your child does not have TB, we will ask you and 
your child to visit with me (the study nurse), each time you and your child comes to the clinic to see the 
doctor treating your child for HIV.  The clinic visit schedule varies depending on whether the doctor 
recommends your child starts HIV treatment with drugs called antiretrovirals or not.  If your child does not 
start antiretrovirals, clinic visits will be according to the schedule provided by your doctor.  If your child 
does start antiretrovirals, clinic visits will be at 2 weeks, 1 month, 2 months, 3 months and then 3 monthly 
thereafter.  At each clinic visit, after you have seen the doctor, you and your child will come to see me (the 
study nurse) and we will: 
11. Make sure you have the results, which are ready, from your child’s previous sputum tests.
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12. Explain the results to you and your child.
13. Ask additional questions about your child’s health.
14. Record additional data from your child’s medical record.
Most of the procedures we have just described would occur even if your child did not enroll in the study.  
However, the following procedures will occur only because you agree for your child to be in this study: (1) 
interview at each clinic visit, (2) collection of data from your child’s medical record, (3) 4 instead of 2 sputa 
collected if your child has TB symptoms, (4) testing of your child’s sputum for a drug resistant form of TB. 
[Time Commitment] 
If you agree to the study, today we will need about an extra hour of your time, in addition to the time you 
and your child would have needed to spend at the clinic if there were no study. 
At each subsequent visit, we will need about half an hour to an hour of your time and your child’s time for 
the study. 
Your child’s part in the study will end 6 months from the time you and your child agreed to be part of the 
study, or, if your child starts TB treatment during the next 6 months, and TB treatment ends more than 6 
months from now, your child’s part in the study will end at the end of TB treatment. 
[Confidentiality] 
As part of the study, we will collect your name and telephone number and your child’s name so that we 
can contact you and your child if your child misses an HIV clinic appointment.  However, everything we 
write down about you and your child will be kept confidential as far as possible.  We will store the paper 
questionnaires in sealed brown envelopes and in locked steel cabinets here at the clinic.  When 
transporting the paper questionnaires to Gaborone, sealed boxes will be used.  The questionnaires will be 
stored in Gaborone in locked steel cabinets and entered into a computer protected by a password.  We 
will not use your name or your child’s name in any printed reports for the study. 
[Risks/Discomfort] 
We do not anticipate any additional health risks due to enrolment in the study.  However, there is a small 
risk of loss of privacy.  For example, if your child misses a clinic visit, and we cannot reach you by phone, 
we would like to visit your home to find out if there is a problem preventing you and your child attending 
the clinic.  We will only visit your home if your child has missed the clinic appointment by more than 7 days 
and we are unable to reach you or a friend by phone.  If your child does not have TB symptoms, this does 
not guarantee that your child does not have TB.  By collecting 2 sputa samples from your child, we will 
help to rule out the possibility of TB, but this may cause some discomfort, especially if sputum needs to be 
suctioned.  Currently the Ministry of Health guidelines do not recommend collection of sputa from children 
if they have no TB symptoms, but we want to assess whether these guidelines are correct.  By allowing 
your child, who does not have TB symptoms, to provide sputa, you and your child will help the Ministry of 
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Health to decide on the best way to find TB in children. 
[Benefits for You] 
There may be additional health benefits for you due to enrolment in the study because: if your child has 
symptoms of TB, as part of the study, we will test the sputum for drug resistant TB, a test not routinely 
offered to all patients with TB symptoms.  This might help to identify and treat this form of TB early which 
could improve your child’s health. 
[Benefits for the Program] 
By taking part in the study, your child will be helping the Ministry of Health and CDC find the best ways to 
diagnose TB in children using GeneXpert.  For example, the study may show that GeneXpert works best 
in district laboratories rather than in small peripheral clinics.  This finding would direct future use of 
GeneXpert in Botswana maximizing the usefulness of GeneXpert for future patients. 
[Your Rights] 
You and your child can choose not to take part in the study.  If you choose for your child not to take part in 
the study, we will still give your child the standard of care recommended by the Ministry of Health.  There 
will be no penalties for choosing not to take part. You will also be able to leave the study at any time, 
without penalty.  You may take a copy of the consent form with you.  Now, or at any time in the future, you 
can ask any member of the study team any questions about the study.    
[Contact Persons for Additional Information] 
If you have any questions about this study now, please ask us now. 
If you have any questions about this study in the future, please contact.  
 [Dr James Shepherd Principal Investigator at 367-2430]  
If you feel that you or your child has been harmed by this study, please contact [Chawangwa Lesedi 
Study Coordinator at 367-2534 CDC Botswana]  
If you have any concerns about your rights in this study, please contact [Mr. Pilate Khulumani, Health 
Research Development Committee - Ministry of Health at 3632775] 
[Consent] 
If you agree to the following statements, please sign your name below: “I am the legal guardian of the 
child.  I agree for the child in my care to be in this study.  The information in this consent form has been 
explained to me.  I have been given a chance to ask questions.  I feel that all of my questions have been 
answered.  I know that allowing my child to be in this study is my choice and my child’s choice.  I know 
that after choosing to allow my child to be in this study, my child and I may leave the study at any time.  If I 
wish for my child and I to leave this study, I will contact the study nurse at my clinic. If my child and I 
leave this study, we will continue to get regular medical care at this clinic or hospital.  I understand that I 
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will receive a copy of this signed and dated consent form.  By signing and dating this consent form, I have 
not waived any of the legal rights that I or my child would have if my child were not a participant in the 
study.” 
I have read or heard this form read to me. By signing below, I consent for my child to join this study.   
By ticking this box  I also agree to let the researchers use any TB germs for future  studies. 
____________________________ 
Name of participant (child) 
____________________________         ____________________________ 
Name of Guardian    Signature or thumb print of participant 
Date: //   [DD/MM/YYYY] 
I verify that the consent form has been read and explained accurately by a member of the study staff. 
____________________________                                             ____________________________ 
Name of witness                                                                  Signature of witness 
Date: //   [DD/MM/YYYY] 
Study Staff Administering Consent _____________________________ 
Date: //   [DD/MM/YYYY] 
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10.2.3. Information and assent form for minors aged 13-17 
Instructions for study nurse only: 
1. The statement should be read to eligible child enrolees aged 13-17 years old. The assent
form should only be read if the guardian provided consent for enrolment.
2. Only read the non-italicized parts.
3. Throughout the process of obtaining assent, it is important that you are patient and allow
the child to ask questions and to consider the decision. Never rush or otherwise pressure the
child to give assent.
4. Offer a copy of this assent script to all guardians whether the child assented to enrolment or
not.
5. Keep the other copy in the assent form folder, locked in a cabinet. (Flesch-Kincaid Grade
Level: 6.5)
See next page for consent form. 
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[Title of the study]: Evaluating Performance, Impact, and Operational Challenges of GeneXpert use for 
TB Case Finding among HIV-infected Persons in Botswana during 2011-2013. 
[Introduction]: 
Hello, my name is………….I am a trained nurse.  I need to check whether you have a sickness called 
tuberculosis.  I am also managing a research study at this clinic.  I will explain the research study, but first 
let me tell you about the sickness called TB. 
TB is caused by a germ which is too small to see.  The germ usually lives in a person’s lungs. Coughing is 
one sign that someone might have TB.  TB is common.  It can cause death. If we find TB we can treat it 
most of the time.  Treatment helps patients feel better and live longer.  However, finding which people 
have TB, is difficult. 
Recently, a new TB test was developed.  The new test is called “Gene Xpert”.  Gene Xpert is a machine.  
GeneXpert is better than TB tests which rely on microscopes (microscopes are tools which help people to 
look at very tiny things like TB germs).  GeneXpert tests sputum for TB germs.  Sputum is the liquid that a 
person produces when they cough .  We are doing a research study to find out the best way to use 
GeneXpert to find TB.  If we find the best way to use GeneXpert, we can make sick people healthier. 
The CDC has paid for this research study.  CDC and the Ministry of Health are partners in this study. 
[Reason for Asking the Patient to be Part of the Study] 
We are going to ask if you want to be part of this study.  The reason we are asking you, and not all 
patients at this clinic is that we need patients visiting the clinic for the first time to be in the study.   
[Procedures] 
If you agree to be in the study, we’ll start today.  We will do the following today and tomorrow: 
1. Ask you to sign this paper, showing that you agree to be part of the study.  Your
mother/father/aunt/uncle/(other____) [choose correct word for guardian] has already given consent for
you to join the study if you agree.
2. Ask you and your mother/father/aunt/uncle/(other____) [choose correct word for guardian] some
questions like “What is your age?”
3. Ask some questions about whether you are coughing, sweating at night, losing weight, or have a
fever.
4. Review your records prepared by the doctor.
5. Ask for your mother’s/father’s/aunt’s/uncle’s/(other____) [choose correct word for guardian] telephone
number so that we can contact you if you miss a future clinic visit.
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6. Ask your mother/father/aunt/uncle for contact details (telephone numbers) so that we can contact you
or a friend or a family member if you miss a future clinic visit.  Note that this is standard practice
recommended by the Ministry of Health and is not something specific to this study.
7. Ask you for your omang number to help us with data collection from your medical records.
8. If you have one of the signs of TB, we will ask you to cough sputum into two cups for us today.
9. Once you have produced the cough sputum, we will ask you to return tomorrow to the clinic.  We need
two more sputa from you tomorrow.
10. If you have no signs of TB, we will still collect one cup of sputum today and one cup tomorrow, to help
rule out the possibility that you have TB.  If you have no signs of TB, and cannot cough, we will
encourage you to cough, but will not use a tube to suck sputum from your stomach.
11. All sputa will go to laboratories for TB tests.
12. If you are unable to cough, we may need to advise you how to cough, or use a tube to suck sputum
from your stomach.  These are normal clinic tests and would be needed even if you did not enroll in
the study.
13. If the GeneXpert test has been set up at the TB lab at the time we collect your sputum, we will test the
sputum with the GeneXpert device.  (Note that all patients attending the clinic will have access to the
GeneXpert device, after its set up, even if they are not part of the study).After the TB tests, we will
discard any left-over sputum.  However, if TB germs are identified, these germs will be studied to
identify their type and, if you agree, may be used in future studies.
After tomorrow, we will contact you if you have TB.  We will ask you to come back so you can start TB 
treatment.  If you do not have TB, we will ask you to visit with me (the study nurse), each time you come to 
the clinic to see the doctor treating you for HIV.  At each clinic visit, we will: 
14. Make sure you have the results of your tests.
15. Explain the results to you.
16. Ask you questions about your health.
17. Look at your medical record.
[Time Commitment] 
We need about an extra hour of your time at this clinic visit and every future clinic visit for about 1 year.  
The number of future clinic visits with me depends on whether the doctor recommends you start HIV 
treatment with drugs called antiretrovirals or not.  If you don’t start antiretrovirals, clinic visits will be 
according to the schedule provided by your doctor.  If you do start antiretrovirals, clinic visits will be at 2 
weeks, 1 month, 2 months, 3 months and then 3 monthly thereafter. 
[Confidentiality] 
As part of the study, we will collect your name and your mother’s/father’s/aunt’s/uncle’s/(other____) 




HIV clinic appointment.  We will keep your information as secret as possible.  We will not use your name 
in any printed reports for the study. 
 
[Risks/Discomfort] 
We do not anticipate any additional health risks due to enrollment in the study.  However, there is a small 
risk of loss of privacy.  For example, if you miss a clinic visit, and we cannot reach you by phone, we 
would like to visit your home to find out if there is a problem preventing you attending the clinic.   
 
[Benefits for You] 
There may be additional health benefits for you due to enrolment in the study because we will test your 
sputum, as part of the study, for a dangerous form of TB which is resistant to standard treatment. This is 
not routinely available for all persons with TB symptoms and the test could help to improve your health 
sooner. 
 
[Benefits for the Program] 
By taking part in the study, you will be helping the Ministry of Health and CDC find the best ways to use 
GeneXpert.  For example, the study may show that GeneXpert works best in district laboratories rather 
than in small peripheral clinics.  This finding would direct future use of GeneXpert in Botswana maximizing 
the usefulness of GeneXpert for future patients. 
[Your Rights] 
You can choose not to take part in the study.  If you choose not to take part in the study, we will still give 
you the standard of care recommended by the Ministry of Health.  You will also be able to leave the study 
at any time, without penalty.  You may take a copy of the assent form with you.  Now, or at any time in the 
future, you can ask any member of the study team any questions about the study.        
 
[Contact Persons for Additional Information] 
If you have any questions about this study now, please ask us now. 
If you have any questions about this study in the future, please contact.   
 [Dr James Shepherd Principal Investigator at 367-2430]  
If you feel that you have been harmed by this study, please contact [Chawangwa Lesedi Study 
Coordinator at 367-2534 CDC Botswana]  
If you have any concerns about your rights in this study, please contact [Mr. Pilate Khulumani, Health 
Research Development Committee - Ministry of Health at 3632775] 
 
[Assent] 
If you agree to the following statements, please sign your name below: “I agree to be in this study. The 




feel that all of my questions have been answered.  I know that being in this study is my choice.  I know 
that after agreeing to be in this study, I may leave the study at any time.  If I wish to leave this study, I will 
inform my mother/father/uncle/aunt [choose correct word for guardian] and we will contact the study 
nurse at my clinic. If I leave this study, I will continue to get regular medical care at this clinic or hospital.  
I understand that I will receive a copy of this signed and dated assent form.  By signing and dating this 
assent form, I have not waived any of the legal rights that I would have if I were not a participant in the 
study.” 
I have read or heard this form read to me. By signing below, I agree to join this study.  
By ticking this box  I also agree to let the researchers use any TB germs for future  studies. 
 
____________________________   ____________________________ 
Name of participant (child)    Signature or thumb print of participant 
Date: //   [DD/MM/YYYY] 
I verify that the assent form has been read and explained accurately by a member of the study staff. 
____________________________                                ____________________________  
Name of witness                                                    Signature of witness 
Date: //   [DD/MM/YYYY] 
Study Staff Administering Consent _____________________________ 






10.2.4. Prospective cohort enrolment form for EC and EC+X enrolees 
 
XPRES Enrolment Questionnaire for Consenting New HIV Clinic Enrolees 
Instructions for Study Nurse:  
1. Complete a separate form for each consenting patient at Prospective Study Enrolment.   
2. Some questions require interview responses.  Others require review of the patient’s medical record and others 
require patient measurement 
A. Patient Study Identification 
1. Name of Facility __________________________________________ 
2. Name of staff completing the form:  __________________________________________ 
3. Date of form initiation: //   [DD/MM/YYYY] 
4. Time of form initiation:  :  [HH (24hr format) : min] 
5. Patient Clinic Registration number __________________________________________  
6. Patient Serial Log Number          --- 
7. Patient Study Identification number          --- 
B. Demographics 
8. Is the patient male or female?   Male  Female 
9. What is your age?      (Years)                    Refused to Answer 
                                                        Unknown    
10. What is your date of birth? //                Unknown 
[Nurse]:  Either age or date of birth or both must be recorded. 
11. What is your current marital status (check  one):           




 Refused to 
Answer 
12. What is the highest level of school you attended: 
primary, secondary, higher? 
  None 
  Primary 
  Secondary 
 Higher         
 Refused to 
Answer           
[Nurse]:  If “None”, skip to question 14. 
13. How many years of schooling have you 
completed?            Years   
 Refused to Answer           
 Unknown 
14. Are you employed?   Yes  No 
[Nurse]:  If “No”, skip to question 16. 





16. Which of the following options best describes your 
living arrangements? 
 Live in a house/apartment we own 
 Live in a house/apartment we rent 
 Am homeless 
 Refused to answer 
[Nurse]:  If “Am homeless”, skip to question 19. 
17. Please indicate which of the following 
is present in your home? 
Electricity Yes No 
Running water from a tap Yes No 
Brick wall (or modern wall) Yes No 
Mud walls (or traditional walls e.g. reeds) Yes No 
A fridge Yes No 
A television Yes No 
A radio      Yes No 
Refused to answer Yes No 
18. How many people live in your home?         Refused to answer      Unknown 
19. [Skip this question if enrolee is <13 
years old] How many biological children 
do you have?  
        Refused to answer      Unknown 
20. [Skip this question if enrolee is >18 
years old] How many siblings do you 
have?  
        Refused to answer      Unknown 
21. a. How many kilometres away from the 
clinic do you live?    Refused to answer  Unknown 
21.b. How do you travel to the clinic? 
 By taxis 
 In my own car 
 In a friend’s or relative’s car 
 By foot (walking) 
 Refused to answer  Unknown 
22. How long does it take you to reach the 
clinic from home? 
h mins    Refused to answer  
                                                    Unknown 
23. How much does it cost you to reach the 
clinic from home 
Pula       Refused to answer  
                                                    Unknown 
[Nurse]:  If “patient is <12, skip to Q 26] 
24. Have you told a close family member or friend about your HIV status? 
 Yes  No 
[Nurse]:  If “No”, skip to question 26. 
25. If yes, who have you told 
 Husband/wife  Boyfriend/girlfriend 
 Friend 
 Family member other than 
spouse 
 Other________ 





[Nurse]:  If “patient is >18, skip to Q 27] 
26. Is the child aware of his/her HIV status? 
 Yes  No 
C. HIV Clinic Visit Information 
27. What date did you first test HIV-
positive?     //                Unknown 
  Adults Children (<12) 
28. WHO stage?  
 
1.Measure and cross 
check with medical 
record.  
 
2.Record all relevant 
conditions 
experienced in the 
past or presently 
 
3.WHO stage cannot 
improve with time 
(e.g.from IV to III) 
 Stage I 
 Asymptomatic HIV infection     
 Persistent, generalized 
lymphadenopathy    
 Asymptomatic HIV infection     
 Persistent, generalized 
lymphadenopathy    
 Stage 
II 
 Moderate weight loss (<10% of body 
weight). 
 Recurrent respiratory infections, 
sinusitis, tonsillitis, otitis media and 
pharyngitis 
 Herpes zoster                                                  
 Sores/cracks around lips 
 Recurrent mouth ulcers 
 Itchy skin rash (papular pruritic 
eruptions) 
 Itchy, scaly skin condition 
(seborrhoeic dermatitis) 
 Fungal nail infections of fingers   
  Unexplained persistent 
hepatosplenomegaly  
 Papular pruritic eruptions 
 Extensive wart virus infection 
 Extensive molluscum contagiosum 
 Recurrent oral ulcerations 
 Unexplained persistent parotid 
enlargement 
 Lineal gingival erythema 
 Herpes zoster 
 Recurrent or chronic upper respiratory 
tract infections (otitis media, otorrhoea, 
sinusitis, tonsillitis) 
 Fungal nail infections 
 Stage 
III 
 Unexplained severe weight loss 
(>10% of body weight)  
 Unexplained chronic diarrhea (> 1 
mo)  
 Unexplained  persistent fever (> 1 
mo)      
 Oral candidiasis   
 Oral hairy leukoplakia       
 Pulmonary TB (current) 
 Severe bacterial infection (e.g., 
pneumonia, empyema, pyomositis, bone 
or joint infection, meningitis or 
bacteremia) 
 Severe painful oral ulcers (i.e., acute 
necrotizing ulcerative stomatitis, 
gingivitis, or periodontitis) 
 Unexplained anaemia (<8 g/dl), 
neutropenia (<0.5 X 109 per litre) or 
chronic thrombocytopaenia (<50 X 109 
per litre)                                               
Unexplained moderate malnutrition not 
adequately responding to standard therapy 
Unexplained persistent diarrhoea (14 
days or more) 
Unexplained persistent fever (above 37.5 
degrees C, intermittent or constant, for 
longer than one month) 
Persistent oral Candidiasis (after first 6 
weeks of life) 
Oral hairy leukoplakia 
Acute necrotizing ulcerative 
gingivitis/periodontitis 
Lymph node TB 
Pulmonary TB 
Severe recurrent bacterial pneumonia 
Symptomatic lymphoid interstitial 
pneumonitis 
Chronic HIV-associated lung disease 
including bronchiectasis 
Unexplained anaemia (<8.0 g/dl), 
neutropenia (<0.5x109/L3) or chronic 
thrombocytopenia (<50 x 109/L3) 
 Stage 
IV 
  HIV wasting syndrome (> 10% wt 
loss and > 1 mo diarrhea and > 1 mo 
fever) 
  Pneumocystis pneumonia (P. 
jiroveci)                    
  Recurrent severe bacterial 
pneumonia  
  Chronic herpes simplex (> 1 mo)        
  Oesophageal candidiasis                     
  Extrapulmonary TB  
  Kaposi’s sarcoma                                   
  CNS toxoplasmosis                               
  HIV encephalopathy          
  Cytomegalovirus infection  (retinitis 
Unexplained severe wasting, stunting or 
severe malnutrition not responding to 
standard therapy 
Pneumocystis pneumonia 
Recurrent severe bacterial infections 
(e.g. empyema, pyomyositis, bone or joint 
infection, meningitis, but 
excluding pneumonia) 
Chronic herpes simplex infection; 
(orolabial or cutaneous of more than one 







or infection of other organs, excluding 
liver, spleen and lymph nodes) 
 Extrapulmonary cryptococcosis 
including meningitis 
  Other stage 4 diagnosis.   
 Disseminated nontuberculous 
mycobacteria infection 
 Progressive multifocal 
leukoencephalopathy 
 Chronic cryptosporidiosis 
 Chronic isosporiasis 
 Disseminated mycosis 
(histoplasmosis, coccidiomycosis) 
 Recurrent septicaemia (including 
nontyphoidal Salmonella) 
 Lymphoma (cerebral or B cell non-
Hodgkin) 
 Invasive cervical carcinoma 
 Atypical disseminated leishmaniasis 
 Symptomatic HIV-associated 
nephropathy or HIV-associated 
cardiomyopathy 
Oesophageal candidiasis (or candiadisis 
of trachea, bronchi or lungs) 
Central nervous system toxoplasmosis 
(after the neonatal period) 
HIV encephalopathy 
Cytomegalovirus (CMV) infection; retinitis 
or CMV infection affecting another organ, 
with onset at age more than 1 month 
Extrapulmonary cryptococcosis including 
meningitis 
Disseminated endemic mycosis 
(extrapulmonary histoplasmosis, 
coccidioidomycosis, penicilliosis) 









HIV-associated cardiomyopathy or 
nephropathy 
29. Weight [measure]  .      kg   
30. a. Height/Length [measure]     cm   
30.b.Mid upper arm circumference 
for children aged < 5     mm 
30.c. Is the child assessed as 
having developmental delay 
(children <12 only)? 
Yes                                                      No 
31. Heart rate [measure]     per min   
32. Respiratory rate [measure]    per min   
33. Blood Pressure [measure] /  in   mmHg         
34. Temperature [measure] .    Degrees Celsius  Oral   Axillary   
[Nurse]:  Review the patient’s medical record for these values.  If lab test results are not in the patient 
medical record, check that the tests have been done, and get the results when they return. 
35. Date of current clinic visit // [DD/MM/YYYY] 
36. a. Current CD4 count 
  cells/ul                   .  % (for children 
<5)    
Date blood was taken: //                                   
36.b. Current Viral Load 
 copies/ml 
Date blood was taken: //       




Date blood was taken: //
 Not done     
38. Current ALT
 IU/L
Date blood was taken: //
 Not done 
39. Current AST
 IU/L
Date blood was taken: //
 Not done
40. Current Creatinine
 mg/dL  Not 
done 
Date blood was taken: //
 Not done





 Dapsone Start //
 Neither Co-trimoxazole nor Dapsone started 
[Nurse]: If patient is male or <13 years old, skip to (Q 46).  For other patients, If these data are missing 
from the patient’s medical record, ask the patient.    
42. Is the patient pregnant?
 Yes EDD//
 No [If no, skip to 46] 
43. If the patient is pregnant, has she been
prescribed PMTCT antiretrovirals?
 No    
 Yes, the following antiretrovirals:_______________________ 
Date started: // 
44. Has this female patient previously
taken antiretrovirals for PMTCT?
 No 
 Yes, the following antiretrovirals:_______________________ 
Date started: // 
Date completed: //
[Nurse]:  If “patient is >12, skip to Q 46] 
45. Was the child exposed to PMTCT
antiretrovirals after birth?
 No 




46. Is the patient eligible for ART?  Yes                                   No   [If “No”, Skip to 50] 
47. If yes, on what criteria is the patient 
ART eligible? [Can check more than 1] 
Adult/child (>5 years old) Children <5 years old 
 WHO Clinical Stage 
IV other than TB 
 WHO Clinical Stage 
III other than TB  
 
 CD4 count <350 
cells/uL 
 Diagnosis of TB 
 <2year old 
 >2year old with Stage III other 
than TB 
 >2year old with Stage IV other 
than TB 
 24-59 months with 
CD4%<25% or CD4<750 
 Diagnosis of TB 
48. If ART-eligible, did the patient start 
ART?      
No  
[Nurse]:  If no, skip to 
Q 50]      
 Yes, Started on 
// 
49. If the patient started ART, what 
regimen was started? 
 TDF/FTC/EFV 
 TDF/FTC/NVP 
 TDF/3TC/ EFV 
 TDF/3TC/ NVP 
 TDF/ABC/LPV/r 













D. Past Medical History 
50. Have you been 
treated for TB before? 
 Yes, on  occasions 
 No   [Nurse, If “No”, Skip to 52] 
51. If yes, when did 
TB treatment start and stop? 
Dates of start and stop of episodes of TB Outcome 
1st: Started 
on// 
Pulmonary      Extra-Pulmonary          
 Cured                     
Complete        
 Failure                    Default        
 Transfer out          Unknown      
  Treatment ongoing 
1st: Ended on  
// 
Pulmonary      Extra-Pulmonary          
2nd: Started on  
// 
Pulmonary      Extra-Pulmonary          
 Cured                     
Complete        
 Failure                    Default        
 Transfer out          Unknown       
 Treatment ongoing 
2nd: Ended on 
// 
Pulmonary      Extra-Pulmonary          
3rd: Started on   
// 
Pulmonary      Extra-Pulmonary          
 Cured                     
Complete        
 Failure                    Default        
 Transfer out          Unknown      
  Treatment ongoing 





Pulmonary      Extra-Pulmonary          
52. Has anyone living in your 
home received TB treatment in past 24 
months? 
 Yes                         Started on// 
 No      Refused to answer   Don’t know       
53. Have you been in contact with 
someone, who lives outside your home, who 






 Yes                         Date (most recent) // 
 No      Refused to answer   Don’t know       
54. In the past 24 months have 
you received medicines to prevent Tuberculosis 




 Yes                         
Started on// 
Ended// or, 
 Currently taking INH 
 No      Refused to answer   Don’t know       
55. In the past 6 months, has 
your sputum been tested for Tuberculosis? 
 Yes                         Date // 
 No      Refused to answer   Don’t know       
56. Are you currently taking 
medicines besides antiretrovirals, co-
trimoxazole, dapsone, and INH? 
 Yes                               No [Nurse, If “No”, skip to 
58]   
57. Besides antiretrovirals, co-
trimoxazole, dapsone, and INH, which other 








E. TB Screening Questions 
58. Do you currently 
have a cough?  
 Yes                               No [If “No”, skip to 61]   
59. When did the cough 
start?  days ago or  years ago  
60. Since the cough 
started, have you coughed up blood? 
 Yes                               No  
61. Do you have a 
fever? 
 Yes                               No [If “No”, skip to 63]   
62. When did the fever 
start?  days ago or  years ago 
63. Do you have 
drenching sweats at night? 
 Yes                               No [If “No”, skip to 65]   
64. When did the night 




65. Have you lost 
weight? 
 Yes                               No [If “No”, skip to 68]   
66. When did the weight 
loss start?  days ago or  years ago 
67. How have you 
noticed the weight loss? 
 Observed weight loss as measured by a scale 
 Clothes fit less tightly 
 Observed my physical appearance changing 
 Others observed my physical appearance changing 
 Other________________________________ 
[Nurse, examine the patient to answer this 
question]  
68. Does the patient 
have asymmetric lymphadenopathy? 
 Yes                                Cervical        armpit       groin      
  other,__________________________ 
 No                                
F. Potential Risk Factors for Poor Outcomes 
[Nurse, skip to 79 if <10 years old]  
69. Do you drink 
alcohol? 
 Yes                               No [If “No”, skip to 72]                              
70. How often do you 
drink alcohol? 
 Every day                      5-6 times per week 
 3-4 times per week       1-2 times per week     
 <1 times per week           
71. When you drink, on average, how many units do you 
drink?  One unit is equivalent to one beer, one glass of wine, or one shot 
of spirits. One whole Chibuku is equivalent to 3 units.  One glass of 
Chibuku is one unit. 
 units  
 
72. Have you ever 
smoked cigarettes? 
 Yes                               No [If “No”, skip to 76] 
73. Are you a current 
smoker or an ex-smoker? 
 Current smoker          Ex-smoker 
74. When you 
smoke/smoked, how many cigarettes 
do/did you smoke per day on 
average? 
 <1 per day              1-5 per day              6-10 per day                  
 11-20 per day         21-30 per day          >30 per day           
75. For how long have you been 
smoking? [or for how long did you smoke if an ex-
smoker] 
 years 
76. Are you currently, or 
have you ever been, a miner? 
 Yes                               No [If “No”, skip to 79] 
77. What do/did you 
mine? 
 Diamonds                   Gold 
 Coal                             Copper 
 Other________________________________ 
78. For how long have 
you been/were you  a miner?  years 








each occasion you 
were hospitalized, 
for how long were 
you hospitalized? 
Duration Date Diagnosis 
1st 
days // ________________ 
2nd 
days // ________________ 
3rd 
days // ________________ 
4th 
days // ________________ 
5th 
days // ________________ 
6th 
days // ________________ 
81. Does the patient 
currently work in a health facility or 
has the patient ever worked in a 
health facility? 
 Yes, currently 
working in a health 
facility                   
Describe:_____________________________ 
 Yes, worked in a 
health facility in the 
past                   
Describe:_____________________________ 
 No  
82. Does the patient work in a prison?  Yes                             No   
83. Does the patient work in a TB lab?  Yes                             No   
84. Has the patient been in contact with someone 
who is being treated or has been treated for drug resistant TB? 
 Yes                             No   
G. Questions Specific for Children (<12 years old).  Address interview questions to the 
guardian. [Skip to 96 if >12 years old] 
85. What was the child’s birth 
weight?  grams                   Unknown 
86. What was the child’s 
APGAR score?                        Unknown   
87. Has the child been 
assessed as having developmental 
delay?[Review the medical record for this 
information] 
 Yes                  No                   Unknown   
88. Did the child receive a 
BCG vaccination? 
 Yes                  No                   Unknown 
89. Is the child’s vaccination schedule up 
to date? [Review Immunization Card] 
 Yes                  No                  
90. Please describe the growth curve in 
the last 3 months. 
 Child has lost weight 
 Child has not gained weight 
 Child has gained some weight 
91. Does the child have any 
enlarged lymph nodes (>1cmx1cm)? 
 Yes                   
 Cervical        armpit       groin      
  other,______________________ 
 No  
92. Have you noticed reduced 
playfulness of the child? 
 Yes                  No      [If no, skip to 94]            
93. When did the reduced 
playfulness start?  days ago   





95. What grade at school is 
the child attending? 
___________________________  Unknown 
H. TB Diagnostic Tests Performed 
96. Did the patient screen positive 
for TB? 
 Yes                  No              
Instructions for Specimen Collection: 
 Adult (>12 years old) Child <=12 years old 
Screened positive for one or more TB symptoms Collect 4 sputa Collect 4 sputa 
Screened negative for all TB symptoms Collect 0 sputa Collect 2 spot sputa 
97. How many sputum specimens 
were collected in total?  specimens  [If zero sputa specimens go to Q.99] 
98. For 
each specimen 








Y   N Y   N S   M 
// 
Time: hmin 
Y   N Y   N S   M 
// 
Time: hmin 
Y   N Y   N S   M 
// 
Time: hmin 
Y   N Y   N S   M 
99. Was the patient referred for X-Ray 
 
 
 Yes                          No  
If yes please ensure the CXR form is completed 
100. Were any other TB diagnostic specimens taken?  Yes                          No [ if no skip to Q 102] 
101. Other Specimens 
Date and Time Acquired by 
Nurse 













102. What is the date of the next appointment after the 
appointment today (date of enrollment)? 
// 
[DD/MM/YYYY] 
103. Was the 
patient diagnosed as 
having TB 
 Yes                          No 
If yes, please specify:  Pulmonary TB 
                                     Extra-Pulmonary TB 





Form has been completed by the Study Nurse and checked for quality and 
completeness: (Signature) ______________________________     
Date: // 
DATA ENTRY CHECK (to be completed by data entry clerks in Gaborone) 
First data-entry completed:________________   Date: //
Second data-entry completed:_______________Date: //
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10.2.5. Patient locating information – kept by study nurse for tracing purposes 
Patient Locating Information 
Instructions For Study Nurse: 
1. Complete a separate form for each consenting patient at Prospective Study Enrolment.
2. Questions require interview responses.
A. Patient Study Identification
1. Name of Facility __________________________________________ 
2. Name of staff
completing the form:
__________________________________________ 
3. Date of form




4.1. Omang Number __________________________________________  Missing
4.2. If Omang missing, 
list Passport/ birth 
certificate / resident 
permit number 
__________________________________________  Missing
Passport     Resident permit  Birth certificate 
5. Patient Name
6. Patient Serial Log
Number   ---
7. Patient Study










who will know where
you are if we can’t




11. Family/friend’s 1. Name:_________________________________
380 
residential addresses 
who will know where 
you are if we can’t 
reach you (someone at 
the address must be >= 





Form is complete and has been reviewed by the Study Nurse:  _____________________ 
Date: //
DATA ENTRY CHECK 
    Study Nurse Completed Data Entry:  _______________________________  
Date: //
381 
10.2.6. Prospective study register to facilitate appointment tracking 


















surname)  Tel # 











































__/__/____ __/__/____ __/__/____ __/__/____ __/__/____ __/__/____ 
__/__/____ __/__/____ __/__/____ __/__/____ __/__/____ __/__/____ 
__/__/____ __/__/____ __/__/____ __/__/____ __/__/____ __/__/____ 
__/__/____ __/__/____ __/__/____ __/__/____ __/__/____ __/__/____ 
__/__/____ __/__/____ __/__/____ __/__/____ __/__/____ __/__/____ 
__/__/____ __/__/____ __/__/____ __/__/____ __/__/____ __/__/____ 
__/__/____ __/__/____ __/__/____ __/__/____ __/__/____ __/__/____ 
__/__/____ __/__/____ __/__/____ __/__/____ __/__/____ __/__/____ 
__/__/____ __/__/____ __/__/____ __/__/____ __/__/____ __/__/____ 
__/__/____ __/__/____ __/__/____ __/__/____ __/__/____ __/__/____ 
*If a study nurse works at more than one study site, this nurse will have one register per site.
Creation of study ID:  A 1 0 0 0 S H R N 















PAGE 2 FOR A GROUP OF 10 PATIENTS 







































































__/__/____ __/__/____ __/__/____ __/__/____ __/__/____ __/__/____ __/__/____ __/__/____ __/__/____ __/__/____ 
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10.2.7. Follow-up questionnaire for prospective EC and EC+X cohorts 
XPRES Follow-up Questionnaire 
Instructions for Study Nurse: 
1. Complete a separate form for each consenting patient returning for Prospective Study Follow-up.
2. Some questions require interview responses.  Others require review of the patient’s medical record and
others require patient measurement
A. Patient Study Identification
1. Name of Facility __________________________________________ 
2. Name of staff completing
the form:
__________________________________________ 
3. Date of form completion: // [DD/MM/YYYY]
4. Time of form completion:  :  [HH (24hr format) : min]
5. Patient Clinic Registration
number
__________________________________________ 
6. Patient Serial Log
Number   ---
7. Patient Study
Identification number   --- 
B. Updated Demographics
[Nurse: If enrolee is <13 years old, skip to Q10] 
8. Since the last clinic visit, have you told a close
family member or friend about your HIV status?
 Had disclosed 
status by time of 




[Skip to Q 
11] 
9. If yes, who have you told
 Husband/wife  Boyfriend/girlfriend 
 Friend  Family member other than spouse 
 Other________ 
 Refused to answer  
 Unknown 
[Nurse: If enrolee is >18 years old, skip to Q11] 
10. Is the child aware of his/her HIV status?
 Yes, Was aware 
of HIV status at time 
of enrolment 
 Yes  No 
C. HIV Clinic Visit Information
C.1. Outcomes
11. What was the scheduled
appointment date? // [DD/MM/YYYY]
12. What is the actual visit
date? // [DD/MM/YYYY]
13. Based on question 11
and 12, is the patient
late for his/her
 On time: Attended clinic on scheduled date [Nurse: If checked skip 
to Q15]  
 Late for scheduled visit [Nurse: If checked, ensure that a tracing 
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appointment? form was completed] 
14. If the patient is late, did
the patient return to the
clinic due to the active
tracing of the study
team?
 Yes – returned because of tracing interventions.  Please check how 
patient was reached: 
 Phone call 
 SMS 
 Home visit to patient 
 Home visit to patient’s friend/neighbour 
 Other___________________________________________ 
 Patient returned on his/her own accord (was never reached by the 
study team)  
14.b. What was the
reason for the missed






14.c. If the reason for




 Transport problems 
 Work responsibilities 
 Childcare responsibilities 
 Hospitalized 
 Forgot about 
appointment 
 Spouse did not allow clinic 
attendance 
 Significant social event (e.g. 
funeral) 
 Unsatisfied with quality of care 




Date of hospitalization: 
//
Reason:______________________ 
C.2. Clinic Visit Data






















 Stage I 
 Asymptomatic HIV infection     
 Persistent, generalized lymphadenopathy 
 Asymptomatic HIV infection     
 Persistent, generalized lymphadenopathy 
 Stage 
II 
 Moderate weight loss (<10% of body 
weight). 
 Recurrent respiratory infections, sinusitis, 
tonsillitis, otitis media and pharyngitis 
 Herpes zoster     
 Sores/cracks around lips 
 Recurrent mouth ulcers 
 Itchy skin rash (papular pruritic eruptions) 
 Itchy, scaly skin condition (seborrhoeic 
dermatitis) 
 Fungal nail infections of fingers 
  Unexplained persistent hepatosplenomegaly 
 Papular pruritic eruptions 
 Extensive wart virus infection 
 Extensive molluscum contagiosum 
 Recurrent oral ulcerations 
 Unexplained persistent parotid enlargement 
 Lineal gingival erythema 
 Herpes zoster 
 Recurrent or chronic upper respiratory tract 
infections (otitis media, otorrhoea, sinusitis, 
tonsillitis) 
 Fungal nail infections 
 Stage 
III 
 Unexplained severe weight loss (>10% of 
body weight)  
 Unexplained chronic diarrhea (> 1 mo) 
 Unexplained  persistent fever (> 1 mo)  
 Oral candidiasis   
 Oral hairy leukoplakia     
 Pulmonary TB (current) 
 Severe bacterial infection (e.g., 
pneumonia, empyema, pyomositis, bone or 
joint infection, meningitis or bacteremia) 
 Severe painful oral ulcers (i.e., acute 
necrotizing ulcerative stomatitis, gingivitis, or 
periodontitis) 
 Unexplained anemia (<8 g/dl), 
Unexplained moderate malnutrition not 
adequately responding to standard therapy 
Unexplained persistent diarrhoea (14 days or 
more) 
Unexplained persistent fever (above 37.5 oC, 
intermittent or constant, for longer than one 
month) 
Persistent oral Candidiasis (after first 6 weeks 
of life) 
Oral hairy leukoplakia 
Acute necrotizing ulcerative 
gingivitis/periodontitis 






IV to III) 
neutropenia (<0.5 X 109 per litre) or chronic 
thrombocytopaenia (<50 X 109 per litre)     
Severe recurrent bacterial pneumonia 
Symptomatic lymphoid interstitial pneumonitis 
Chronic HIV-associated lung disease 
including bronchiectasis 
Unexplained anaemia (<8.0 g/dl), 
neutropenia (<0.5x109/L3) or chronic 
thrombocytopenia (<50 x 109/L3) 
 Stage 
IV 
  HIV wasting syndrome (> 10% wt loss 
and > 1 mo diarrhea and > 1 mo fever) 
  Pneumocystis pneumonia (P. jiroveci)  
  Recurrent severe bacterial pneumonia 
  Chronic herpes simplex (> 1 mo)     
  Oesophageal candidiasis     
  Extrapulmonary TB  
  Kaposi’s sarcoma     
  CNS toxoplasmosis     
  HIV encephalopathy     
  Cytomegalovirus infection  (retinitis or 
infection of other organs, excluding liver, 
spleen and lymph nodes) 
 Extrapulmonary cryptococcosis including 
meningitis 
  Other stage 4 diagnosis. 
 Disseminated nontuberculous 
mycobacteria infection 
 Progressive multifocal 
leukoencephalopathy 
 Chronic cryptosporidiosis 
 Chronic isosporiasis 
 Disseminated mycosis (histoplasmosis, 
coccidiomycosis) 
 Recurrent septicaemia (including 
nontyphoidal Salmonella) 
 Lymphoma (cerebral or B cell non-
Hodgkin) 
 Invasive cervical carcinoma 
 Atypical disseminated leishmaniasis 
 Symptomatic HIV-associated 
nephropathy or HIV-associated 
cardiomyopathy 
Unexplained severe wasting, stunting or 
severe malnutrition not responding to standard 
therapy 
Pneumocystis pneumonia 
Recurrent severe bacterial infections (e.g. 
empyema, pyomyositis, bone or joint infection, 
meningitis, but 
excluding pneumonia) 
Chronic herpes simplex infection; (orolabial or 
cutaneous of more than one month’s duration, 
or visceral at any site) 
Extrapulmonary TB 
Kaposi sarcoma 
Oesophageal candidiasis (or candiadisis of 
trachea, bronchi or lungs) 
Central nervous system toxoplasmosis (after 
the neonatal period) 
HIV encephalopathy 
Cytomegalovirus (CMV) infection; retinitis or 
CMV infection affecting another organ, with 
onset at age more than 1 month 
Extrapulmonary cryptococcosis including 
meningitis 
Disseminated endemic mycosis 
(extrapulmonary histoplasmosis, 
coccidioidomycosis, penicilliosis) 
Chronic cryptosporidiosis (with diarrhoea) 
Chronic isosporiasis 
Disseminated non-tuberculous mycobacterial 
infection 
Cerebral or B cell non-Hodgkin lymphoma 
Progressive multifocal leukoencephalopathy 




 Able to work (play for children) 
 Ambulatory (Mobile, for children) 
 Bed ridden 
17. Weight [measure]  .      kg
17.1. Mid-upper arm 
circumference for 
children (< 5years old) 
   mm
17.2. Is the child 
assessed as having 
developmental delay 
(children <12 only)? 
Yes  No
18. Height/Length [measure]     cm
19. Heart rate [measure]     per min
20. Respiratory rate
[measure]    per min
21. Blood Pressure
[measure] /  in   mmHg
22. Temperature [measure] .    Degrees Celsius  Oral Axillary 
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[Nurse]:  Review the patient’s medical record for these values.  If lab test results are not in the 
patient medical record, check that the tests have been done, and get the results when they return. 
23. Current CD4 count
  cells/ul .  % (for children <5)
Date blood was taken: //
 Not done          
23.b. Current viral load
 copies/ml




Date blood was taken: //
 Not done 
25. Current ALT
 IU/L




Date blood was taken: //
 Not done
27. Current Creatinine
 mg/dL  Not done 
Date blood was taken: //
 Not done
28. Is the patient currently
taking Cotrimoxazole or
Dapsone?
 Co-trimoxazole Start //
 Dapsone Start //
 Neither Co-trimoxazole nor Dapsone started 
[Nurse]: If patient is male or <13 years old, skip to Q 31.  For patients >13, if these data are missing 
from the patient’s medical record, ask the patient.   
29. Is the patient pregnant?
 Yes EDD//
 No [If no, skip to 31] 
30. If the patient is pregnant,
has she been prescribed
PMTCT antiretrovirals?
 No    Yes, the patient is currently taking ART for her own health  
 Yes, the patients was prescribed the following PMTCT  





Date started: // 
31. Has the patient already
started ART?
 No [If no, skip to 34]    
Yes, Date started: //
32. Did the doctor change
the patient’s initial
regimen?
 Yes     No 




 TDF/3TC/ EFV 








 other [specify below] 
Drug 1:       
__ __ __ __    
Drug 2:       
__ __ __ __ 
Drug3:       
__ __ __ __ 
34. If not yet started on ART,
is the patient newly
eligible for ART at this
visit?
 Yes   No   [If “No”, Skip to 38] 
35. If yes, on what criteria is
the patient newly ART
eligible? [Can check
more than 1]
Adult (>5 years old) Children <5 years old 
 WHO Clinical Stage IV other 
than TB 
 WHO Clinical Stage III other 
than TB  
 CD4 count <350 cells/uL 
 Diagnosis of TB 
 <2year old 
>2year old with Stage III
>2year old with Stage IV
24-59 months with
CD4%<25% or CD4<750 
36. If newly ART-eligible, did
the patient start ART?
Yes, Started on // 
 No [Skip to 38] 





 TDF/3TC/ EFV 








 other [specify below] 
Drug 1:       
Missing
__ __ __ __    
Drug 2:          
Missing
__ __ __ __ 
Drug3:        Missing
__ __ __ __ 
D. TB Outcomes 
38. Were you tested for
Tuberculosis at the last
clinic visit?





















_ _/_ _/_ _ _ _ _ _/_ _/_ _ _ _ 
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Xpert 
 MTB detected 
 MTB not 
detected 
 MTB invalid 
 MTB 
indeterminate 
 MTB error _ _/_ _/_ _ _ _ _ _/_ _/_ _ _ _ 
 RIF Resistance 
Detected 
 RIF Resistance 
Not Detected 










_ _/_ _/_ _ _ _ _ _/_ _/_ _ _ _ 
Culture 
 MTB growth 
detected 
 Mycobacterium 
other than TB 
(MOTT) 
detected_______ 
 No growth 
detected 
 Contamination 
_ _/_ _/_ _ _ _ _ _/_ _/_ _ _ _ 
Spot #3 
Microscopy 





_ _/_ _/_ _ _ _ _ _/_ _/_ _ _ _ 
Xpert 
 MTB detected 
 MTB not 
detected 
 MTB invalid 
 MTB 
indeterminate 
 MTB error _ _/_ _/_ _ _ _ _ _/_ _/_ _ _ _ 
 RIF Resistance 
Detected 
 RIF Resistance 
Not Detected 











_ _/_ _/_ _ _ _ _ _/_ _/_ _ _ _ 
Culture 
 MTB growth 
detected 
 Mycobacterium 
other than TB 
(MOTT) 
detected_______ 
 No growth 
detected 
 Contamination 




+ve  NR 
-ve




+ve  NR 
-ve
_ _/_ _/_ _ _ _ _ _/_ _/_ _ _ _ 
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X-ray result: Suspect TB      
 TB not suspected    
 No 
41. Did Patient start TB
treatment?
 Yes 
Start date: // 
Pulmonary TB   Extra-pulmonary TB:  (Site of 
extra-pulmonary TB:_______________________) 
 No 
42. Was TB drug resistance
detected?
 Yes 
INH       RIF       PYZ       ETH     
other___________________________ 
date: //
 No [If “No”, Skip to 44] 
43. Which test(s) detected
resistance? [Tick all that
apply]
 Xpert   Line Probe Assay   Drug Susceptibility test 
44. Which TB drug regimen
was started?


























P-aminosalicylic acid (PAS) #
Levofloxacin
Streptomycin
E. Other Outcomes 
45. Has the patient been
diagnosed as having (1)
an opportunistic infection
(OI) (other than TB) or,









as the patient 
been hospitalized 
since the last 
clinic visit? 
 Yes on  occasions
 No [If no, skip to 48] 
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47. F
or each occasion 
you were 
hospitalized, for 
how long were 
you hospitalized? 
Duration Date Diagnosis 
1st  days // ________________ 
2nd  days // ________________ 
3rd  days // ________________ 
F. TB Risk Factors 
48. Has anyone living 
in your home received TB treatment 
since your last clinic visit? 
 Yes    Started on//
 No     Refused to answer   Don’t know    
49. Have you been in 
contact with someone, living 
outside your home, who is receiving 
TB treatment, since your last clinic 
visit? 
 Yes    Date (most recent) //
 No     Refused to answer   Don’t know    
50. Have you started 
medicines to prevent Tuberculosis 
(TB) called INH (or IPT) since the 
last clinic visit? 
 Yes    
Started on// 
Ended// or, 
 Currently taking INH 
 No     Refused to answer   Don’t know      
51. Are you taking 
medicines besides antiretrovirals, 
co-trimoxazole, dapsone, and INH? 
 Yes     No [If “No”, skip to 53]  
52. Besides 
antiretrovirals, co-trimoxazole, 
dapsone, and INH, which other 








G. TB Screening Questions 
53. Do you 
currently have a cough?  
 Yes     No [If “No”, skip to 56]  
54. When 
did the cough start?  days ago or  years ago
55. Since 
the cough started, have 
you coughed up blood? 
 Yes     No 
56. Do you 
have a fever? 
 Yes     No [If “No”, skip to 58]  
57. When 
did the fever start?  days ago or  years ago
58. Do you 
have drenching sweats 
at night? 
 Yes     No [If “No”, skip to 60]  
59. When 
did the night sweats 
start? 
 days ago or  years ago
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60. Have 
you lost weight? 
 Yes     No [If “No”, skip to 63]  
61. When 
did the weight loss start?  days ago or  years ago
62. How 
have you noticed the 
weight loss? 
 Observed weight loss as measured by a scale 
 Clothes fit less tightly 
 Observed my physical appearance changing 
 Others observed my physical appearance changing 
 Other_________________________________ 
63. [Exami
ne the patient to answer 
this question] Does the 
patient have asymmetric 
lymphadenopathy? 
 Yes    
 Cervical        armpit       groin 
 other,__________________________
 No    
64. Has the patient been in contact with 
someone who is being treated or has been treated for 
drug resistant TB? 
 Yes     No  
Questions Specific for Children (<12 years old).  Address interview questions to the guardian. [Skip 
if >12 years old] 
65. Is the child’s 
vaccination schedule up to 
date? [Review Immunization 
Card] 
 Yes     No    
66. Please 
describe the growth curve in the 
last 3 months. 
 Child has lost weight 
 Child has flat growth (i.e. has not gained or lost weight) 
 Child has gained some weight 
67. Does the child 
have any enlarged lymph nodes 
(>1cmx1cm)? 
 Yes    
 Cervical        armpit      groin 
 other,______________________ 
 No 
68. Have you 
noticed reduced playfulness of 
the child? 
 Yes     No      [If no, skip to 70]    
69. When did the 
reduced playfulness start?  days ago  
70. Is the child 
going to school? 
 Yes     No      [If no, skip to 72]    
71. What grade at 
school is the child attending? 
___________________________  Unknown 
TB Diagnostic Tests Performed 
72. Did the patient 
screen positive for TB at this clinic 
visit? 
 Yes     No    
Instructions for Specimen Collection during follow-up: 
Adult (>12 years old) Child <=12 years old 
Screened positive for one or more TB symptoms Collect 4 sputa Collect 4 sputa 
Screened negative for all TB symptoms Collect 0 sputa Collect 0 sputa 
73. How many sputum 
















Y   N Y   N S   M 
// 
Time: hmin
Y   N Y   N S   M 
// 
Time: hmin
Y   N Y   N S   M 
75. Was the patient referred for X-Ray
 Yes                          No  
[If yes, make sure x-ray form is completed] 
76. Were any other TB diagnostic specimens
taken?
 Yes     No  [If No, go to Q78] 
77. Other
Specimens









78. What is the date of the next appointment after
the appointment today (date of interview)? // [DD/MM/YYYY]
79. Was the patient
diagnosed as
having TB
 Yes    
 No
If yes, please specify:  Pulmonary TB 
 Extra-Pulmonary TB 
   (Site of extra-pulmonary TB_ 
________________________________________) 
   Form is complete and has been reviewed by the Study Nurse:  _____________________    
Date: __________ 
    First data-entry completed:         ________________      Date: ___________ 
    Second data-entry completed:    ________________      Date: ___________  
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10.2.8. TB treatment chart abstraction form 
TB Patient Chart Abstraction Instrument 
To be abstracted from ETR.net/Paper Chart at TB Clinic 
1. TB and HIV patient information
1. Name of Facility __________________________________________ 
2. Name of staff completing
the form:
__________________________________________ 
3. Date of form initiation: //   [DD/MM/YYYY]
4. Patient Clinic Registration
number __________________________________ 
5. Patient Serial Log Number  --- 
6. Patient Study Identification
number  --- 
7.a. Was the study nurse
able to access the
patient’s TB chart at the
TB clinic?
Yes  
No:  Specify reason (E.g. distance >60klm to
TB clinic):____________________________________ 
__________________________________________
7.b. Date of TB registration //   [DD/MM/YYYY] Missing
8. TB register number




ame of clinic where s/he 
received TB treatment:  
TB clinic in the study clinic
Other TB clinic (specify)
____________________________________________    Missing 
10. W
as patient referred for TB 
treatment from an HIV 
care and treatment facility? 
Yes   No Missing
11. I
f yes, what was the name 




id the patient start ART at 
any time before or during 
TB treatment?  
Yes   No Missing 
13. I
f yes, what was the date of 
ART start? 
//   [DD/MM/YYYY] Missing 
14. D
id the patient start Yes   No Missing 
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Cotrimoxazole prophylaxis 
at any time before or 
during TB treatment?  
15. I
f yes, what was the date of 
Cotrimoxazole start? 
//   [DD/MM/YYYY] Missing 
16. D
isease diagnosis site: 
 Sputum-smear positive pulmonary TB
 Sputum-smear negative pulmonary TB
 Sputum-Xpert positive pulmonary TB
 Sputum-Xpert negative pulmonary TB
 Smear or Xpert not done, pulmonary TB
 Culture positive pulmonary TB
 Culture negative pulmonary TB





reatment in Intensive 
Phase:  
 Category I  - 2HRZE/4HRZ 
 Category II - 2HRZES/1HRZE/5HRE 
 Unknown 
 Other (specify)___________________ Missing 
18. S
putum results for follow-up 
of TB treatment (Sputum 
Smear Microscopy): 
Month: 0  Date:  //   [DD/MM/YYYY] Missing 
Result:    Neg. Actual ____  1+    2++    >3+++ Missing
Month: 2  Date:  //   [DD/MM/YYYY] Missing   
Result:    Neg. Actual ____  1+    2++    >3+++ Missing
Month: 3  Date:  //   [DD/MM/YYYY] Missing 
Result:    Neg. Actual ____ 1+    2++    >3+++ Missing
Month: 5  Date:  //   [DD/MM/YYYY] Missing 
Result:    Neg. Actual ____  1+    2++    >3+++ Missing
Month: 6  Date:  //   [DD/MM/YYYY] Missing 
Result:    Neg. Actual ____  1+    2++    >3+++ Missing
Month: 8  Date:  //   [DD/MM/YYYY] Missing 




  Cured      
Missing 
  Completed Treatment 
  Died      
  Treatment failure 
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  Defaulted/Lost-to-follow-up/missing     
  Transferred out    
  Treatment not completed before the end of the study follow-
up 
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10.2.9. Study exit form for EC and EC+X enrolees 
Study Exit Form 
Complete one of these forms for every patient enrolled in the prospective or retrospective cohorts (Cohort A or 
B or R), when they leave the study 
A. Patient Identification Information
1. Name of Facility __________________________________________ 
2. Name of staff completing the form: __________________________________________ 
3. Date of form initiation: //   [DD/MM/YYYY]
4. Patient Clinic Registration number __________________________________ 
5. Patient Serial Log Number ---
6. Patient Study Identification number ---
7. Date of study enrollment //  [DD/MM/YYYY]
B. Outcomes
8. What was the
patient’s final
outcome?
  Completed Follow-up. If yes: 
End of 6 months of follow-up 
End of TB treatment which was 
>12
  months after enrollment 
Date follow/up completion 
(last study visit): 
//
[DD/MM/YYYY] 
 Transferred to another clinic. If yes, 
why?: 
 Patient migrated from study area  
 Patient transferred to a clinic closer 
to 
  home 
 Patient transferred to another clinic  
  because not ART eligible 
Other_________________________ 
Date of transfer: 
//
[DD/MM/YYYY] 
 Patient lost to follow-up (>90 days late 
for their next scheduled appointment) 
Date last attended clinic: 
//
Date of missed visit: 
//
Date of study exit: 
//
 Unable to attend further clinic visits.  
Give 









 Unwilling to attend further clinic visits 





Date of study exit: 
//
[DD/MM/YYYY] 
   Investigator decides to end study 







Date of study exit: 
//
[DD/MM/YYYY] 
   Patient died (Complete 
Appendix 9.2 as well).   
Date of last clinic visit: 
//
[DD/MM/YYYY] 
Date of death: 
 DD   unknown  
 MM   unknown
 YYYY unknown     
9. If patient died, did
patient die in
hospital?
  Yes (if yes, enter date)    
  No   
Date of hospital admission: 
 DD   unknown  
 MM   unknown
 YYYY unknown     
Form has been completed by the Study Nurse and checked for quality and 
completeness: (Signature) ______________________________     
 Date: 
// 
DATA ENTRY CHECK (to be completed by data entry clerks in Gaborone) 
First data-entry completed:________________   Date: //
Second data-entry completed:_______________Date: //
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5c. Did the patient consent to being called by 
phone by the clinic if needed? 
 Yes  No   Missing 
5d. Has patient disclosed status to family  Yes  No   Missing 
5e. Has patient disclosed status to partner  Yes  No   Missing 
5f. Has partner been tested for HIV  Yes  No   Missing 
5g. HIV status of partner  Positive   Negative   Missing 
Employment and Treatment Support Information 
6a. Was the patient 
employed at ART 
initiation?  
 Yes Check “Yes” if there is documentation of any of: Occupation, Employer, 
work address, or work telephone number 
 No, patient 
unemployed      
Check “No” if the patient is documented to be unemployed. 
 Missing  Check “Missing” if there is no documentation of whether the patient is 
employed or unemployed 
6b. Occupation (main activity) __________________________   Missing 
7. Does the patient have one or more treatment
supporters?
 Yes  No   Missing 
8. Is the patient a member of a support group  Yes  No   Missing 
B. HIV DIAGNOSIS
9. Date patient first tested HIV-positive?   /   /   Missing  
 D    D      M   M    Y    Y    Y   Y 
10. Was this patient transferred in?  Yes (if yes, record date of transfer-in below)  
 /         /                      Missing date
D    D     M   M      Y    Y    Y    Y
 No  
11. If patient is documented to have
transferred in, is there a documented date
of ART initiation at a previous facility?
 Yes, date of ART start at 
previous facility:      
 /         /  
D    D     M   M      Y    Y    Y    Y
 Patient transferred in but 
there is no date of ART start 
at a previous facility      
 Patient is 
not a transfer 
in 
C. TIME LINE
12. Date of ART initiation at this facility.  /    /    (cannot be missing) 
D    D    M   M    Y    Y    Y    Y 
13. Date of most recent visit to this facility.  /    /    (cannot be missing) 
 D    D    M   M    Y    Y    Y    Y 
D. ART INITIATION VISIT
14. WHO stage at ART initiation  I   II   III   IV  Missing 
15. Functional Status at ART initiation  Ambulatory   Working   Bedridden  Missing 
16. Weight at ART initiation _  _ .  _      kg  Missing
17. Was patient pregnant at time of
initiation of ART?
 Yes  No   Missing   N/A (male) 
18. CD4 count at ART start _  _  _  _   cells/mm3   Missing   /   / D  
D    M   M    Y    Y    Y    Y
19. Has the patient had previous PMTCT
antiretrovirals?
 Yes  No   Missing   N/A (male) 
20. Has the patient had previous ART?  Yes  No   Missing  
21. Prescribed Cotrimoxazole
(CTX)/Dapsone?
 Yes  No  
22. Is there documentation the patient had
TB prior to ART start?
 Yes  No  
E. TB SCREENING AND DIAGNOSIS INFORMATION AT OR PRIOR TO ART START
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23. Has the recommended TB screening
form been completed?
 Yes (could be part of another form)    
 No  (cannot find form or form is not completed) 
 N/A  (there is no recommended TB screening form) 
24. What is the date of the earliest (1st) TB
screen
 /   /  Missing
D    D    M   M    Y    Y    Y    Y
25. Which of the following
symptoms screened positive at the
earliest (1st) visit?
Symptom Yes No Missing 
Cough >=2 weeks 
Current cough (any duration) 
Fever (any duration) 
Night Sweats(any duration) 
Loss of appetite 
Loss of Weight (any duration) 
Malaise (any duration) 
Shortness of breath (any duration) 
Any chest pain? (any duration) 
Hemoptysis (coughing blood) (any 
duration) 
26. What is the documented TB screening result at
the earliest (1st) visit?
 positive   negative   Missing 
27. Was patient tested for
active TB?
Test Test done? Result? 
Sputum smear? Yes No   pos  neg  missing 
Sputum culture? Yes No   pos  neg  missing 
Chest X-ray Yes No  pos  neg  missing 
Other________ (e.g. Biopsy) Yes No   pos  neg  missing 
28. Was the patient
diagnosed as having TB?
 Yes       
If Yes: 
Date of TB treatment start:  __ __ /__ __ /__ __ __ __    (D D / M  M /  Y  Y  Y  Y) 
 Pulmonary TB 
 Extra-Pulmonary TB  
[Note: Remember to complete App. 8.2 for each documented episode of 
TB treatment]      
 No  
29. Was the patient taking TB treatment at ART start?  Yes  No  
30. Was the patient prescribed IPT?  Yes  /     / 
  D    D    M   M    Y    Y    Y    Y
 No  
F. ANTIRETROVIRAL THERAPY REGIMEN
31. Indicate if one of the following









 TDF/FTC/EFZ (ATRIPLA) 
 TDF/FTC/NVP 
 other (see below) 
32. If ”other”, please describe the regimen
used (write 3 or 4 letter code: e.g. AZT for
zidovudine, LPV/r for Lopinavir ritonavir):
Drug 1:   Missing
__ __ __ __ 
Drug 2:   Missing
__ __ __ __ 
Drug3:   Missing
__ __ __ __ 
NRTI NNRTI PI’s and Boosted PI’s FDC 
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 Zidovudine (AZT) 
 Lamivudine (3TC) 
 Stavudine (d4T) 
 Abacavir (ABC) 
 Didanosine (Videx, ddl)
 Tenofovir (TDF) 
 Nevirapine 
(Viramune, NVP)
 Efavirenz (EFZ) 
 Lopinavir (Lop) 
 Nelfinavir (NFV) 
 Indinavir (IND) 
 Saquinavir (Saq) 
 Lopinavir/ritonovir(Lop/r) 
 Nelfinavir/ritonovir (Nfv/r) 
 Indinavir/ritonovir (Ind/r) 
Saquinavir/ritonovir (Saq/r) 
 Virolans (d4T/3TC/Nevirapine) 
 Combivir (AZT/3TC) 
 Triomune (d4T/NVP/3TC)  
 TZV (ABC/3TC/ZDV) 
 Other, specify:_______ 
 Missing 
G. MOST RECENT VISIT
33. Date of most recent clinic visit  /    /    (cannot be missing) 
D    D     M   M      Y    Y    Y    Y
34. WHO Stage recorded  I   II   III   IV   Missing 
35. Functional status  Ambulatory   Working   Bedridden  Missing 
36. Weight _  _ .  _   kg  Missing
37. If Female, did she ever become pregnant
since ART initiation?
 Yes 
  /   /   Missing  
D    D     M   M      Y    Y    Y    Y     date  
 No pregnancy documented 
 N/A (male) 
38. Most recent CD4 count _  _  _  _   cells/mm3   Missing        /          /      D   
D     M   M      Y    Y    Y    Y  
39. Prescribed Cotrimoxazole or Dapsone?  Yes  No documentation of this  
40. Date of next appointment?       /          /       Missing
D    D     M   M      Y    Y    Y    Y  
H. KEY EVENTS DURING ART
41. As of today, since ART initiation, the
patient is…. 
 (choose one, except if patient stopped 
and/or restarted ART ): 
Note any additional comments here:  
__________________________________ 
__________________________________ 
[Note: Remember to complete App. 8.3 – 
the Exit Form - for each patient who is 
known to have died, stopped ART, or 
transferred to another clinic].       
[Note: Remember to complete App.9 if the 
patient is late for next appointment (see 
Q.40) or thought to be LTFU]
 Retained; patient is alive and 
on ART 
Date of most recent visit (either to see 
clinician or pick up medication)  
       /         /       
D    D     M   M      Y    Y    Y    Y
  Stopped ART A) /  /  
D    D     M   M      Y    Y    Y    Y   UNTIL 
B) /  / No restart
  Transferred out (officially 
documented) 
 /    /  
D    D     M   M      Y    Y    Y    Y
  Died  /    /  
D    D     M   M      Y    Y    Y    Y
  Been lost to follow up
(Last visit >90 days ago) (LTFU) 
 /    /  
D    D     M   M      Y    Y    Y    Y 
42. If patient died, what was the cause of
death documented?
 N/A, patient did not die 
 Respiratory (not pulmonary TB)  
 Acute diarrhea       Chronic diarrhea 
 TB (pulm + extra pulm)       IRIS 
 Other………………….   Unknown 
I. DRUG CHANGES
43. If the antiretroviral medications changed during treatment, please indicate the new drugs, the date of change and the
reason for change (1= Immunologic failure, 2=Virologic failure, 3=Clinical Failure, 4 = Neuropathy, 5 =  Anemia, 6 =
Hepatitis, 7 = toxicity (other than neuropathy and anemia), 8 = pregnancy, 9 = presumed pregnancy , 10 = active TB, 11 =
stock-out of medicine, 12 = new medication available, 13 = other, please specify___________).
 No change in ARVs 
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Change Antiretrovirals Reason DD   /  M M  / Y Y 
1st _ _ _    /   _ _ _   /   _ _ _  /   /  Missing __________(1-13)  Missing 
2nd _ _ _    /   _ _ _   /   _ _ _  /   /  Missing __________(1-13)  Missing 
3rd _ _ _    /   _ _ _   /   _ _ _  /   /  Missing __________(1-13)  Missing 
4th _ _ _    /   _ _ _   /   _ _ _  /   /  Missing __________(1-13)  Missing 
5th _ _ _    /   _ _ _   /   _ _ _  /   /  Missing __________(1-13)  Missing 
6th _ _ _    /   _ _ _   /   _ _ _  /   /  Missing __________(1-13)  Missing 
7th _ _ _    /   _ _ _   /   _ _ _  /   /  Missing __________(1-13)  Missing 
8th _ _ _    /   _ _ _   /   _ _ _  /   /  Missing __________(1-13)  Missing 
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10.3. Appendix 3. IRB approvals for XPRES 
10.3.1. CDC IRB C approval 
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10.3.2. Botswana national ethics committee approval (HRDC) 
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10.3.4. London School of Hygiene & Tropical Medicine ethics approval 
